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Abstract 
Quantitative one-dimensional proton NMR metabolomics is performed on growth medium 
samples gathered at up to ten time-points during the in vitro culture of P. falciparum in 
human red blood cells. From this study, exchange fluxes between the parasite-host 
complex and the growth medium are calculated for glucose, lactate, glycerol, glutamine, 
hypoxanthine, valine, leucine, isoleucine, alanine, tyrosine and phenylanaine. 
Carbon-source exchange fluxes are added as constraints to a new model of malaria 
metabolism — built using my published MetNetMaker software — consisting of 249 
reactions, 143 genes and a novel experimentally derived biomass function. 
Analysis of this network including by flux-balance analysis and flux-variability analysis are 
projected onto a live map of the network providing the most accessible view of malaria 
metabolism to date. This model reproduces key phenotypes of the malaria parasite such as 
the unusual branched TCA cycle, and accurately predicts internal fluxes through the 
pentose-phosphate cycle and the low oxygen-dependence of the parasite’s metabolism 
during its erythrocytic life stages. The model is carbon balanced and accurately predicts 
the parasite’s growth-rate at measured glucose uptake rates. Furthermore, it accurately 
reproduces measured amino acid and purine-source exchange fluxes at the optimal 
solution and implies that the parasite digests 30% of its red blood cell host’s haemoglobin 
but incorporates just 40% of the resulting freed amino acids into its proteome. Lethal 
single and double gene deletions are predicted and suggest potential drug and vaccine 
targets. 
The metabolic model is available in MetNetMaker format for easy editing, SBML format 
including constraints for metabolic modelling and the independent reproduction of the 
reported results, and cytoscape format with metadata for visualisation of both the 
network and the results of simulations performed on it. 
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Introduction 
Metabolic networks 
 
 
 
 
 
 
 
Metabolism - the chemical processes that occur within a living organism in order to 
maintain life. 
The Oxford English Dictionary 
 
 
 
 
 
 
 
 
This thesis is an attempt to more fully understand the chemical processes that make up 
the metabolism of the parasite Plasmodium falciparum, the cause of malaria in humans. 
Let us start at the beginning.  
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Life as a controlled network of chemical reactions 
For the greater part of human history the realms of the living and the dead were 
considered to be largely separate. Greek philosophers, and many who followed, believed 
that the chemistry of animals and plants was inspired by a force greater than what drove 
reactions between minerals.  
In 1828, Friedrich Wöhler began to dismantle the barrier between the living and the non-
living by showing that urea could be made without the intervention of a living organism. 
The discovery that a compound found in the urine of animals could be made from two 
solutions not associated with life marked the birth of organic chemistry. 
Meanwhile, in the fields of agriculture and biology, the increasing population of the world 
was quickly approaching the limits of the soil to produce food. In highest demand by 
farmers were the nitrites and similar nitrogenous compounds required for the production 
of proteins by plants. At this time, humanity had only one primary renewable source for 
these compounds; leguminous plants such as peas and beans which were known to 
accumulate nitrates in their roots. In 1888 Martinus Beijerinck had isolated and studied 
the bacteria that lived in the root nodules of these plants1 and noted that they produced 
nitrites from the hydrogen and the nitrogen in the air but the mechanism of the reaction 
remained unknown. The limited amount of nitrogenous fertiliser, from manure, guano, or 
saltpetre mines in South America risked defining the limit of human population. 
With such a constraint on production the price of nitrites grew ever higher and much 
attention was turned to performing for ourselves the same reaction that bacteria had 
mastered millennia before. The development of the Haber process in 1908 was the 
achievement of that goal. And yet it was striking that industrial production of nitrites 
required a temperature of 300°C and a pressure of 100 atmospheres whilst the same 
reaction in bacteria operates at ambient temperature and pressure. Although we had 
learned to mimic a reaction that bacteria had mastered it was clear that we still had a lot 
to learn from bacteria in the emerging field of biochemistry. 
In this genomic era of biology we have moved beyond mimicking reactions that bacteria 
already perform and started to use bacteria for our own purposes. Insulin, a hormone 
produced by the pancreas, helps regulate blood sugar levels in humans. In patients with 
diabetes insulin is not produced properly by the patient but blood sugar levels can still be 
controlled by injecting insulin from an external source. For decades the only source of 
insulin was by isolating it from the pancreas of an animal an expensive and dangerously 
unsterile procedure. It was clear that it would be a great advantage to be able to 
synthesise pure insulin — a molecule over 300 times as large and enormously more 
3 
 
complex than ammonia — from basic materials but the existing chemistry was not up to 
the task. 
The solution arrived at by Herbert Boyer in 1978 was to add a gene encoding insulin to a 
bacterium and let the intricately evolved and interoperable systems of life deal with the 
complexity of the synthesis. This application of biochemistry is now often called 
biotechnology and it is probably the fastest growing discipline in all of science. Today we 
are turning to biotechnology to solve problems in fields as diverse as medicine, 
environmental protection and energy supply.  
In less than 200 years we have moved from single reactions between minerals to hijacking 
the thousands of controlled and overlapping reactions that let bacteria live to our own 
ends. Wöhler opened the world of organic chemistry to us with a single reaction. Haber 
developed a process that not only permitted a more difficult reaction but also linked 
together several reactions. Boyer harnessed the set of regulated reactions within bacteria 
to produce a chemical product of unprecedented industrial complexity, but he did so by 
using, not understanding, the complex systems of the E. coli bacterium. The future of 
biotechnology lies in extending our ability to harness the existing set of regulated 
reactions within an organism to shaping that metabolism to our own needs. Before we can 
do this we must first more fully understand the process of metabolism. 
The chemical reactions we know to exist in the living world are no different to ones we 
could perform in isolation without the intervention of life. What makes life special is that it 
has evolved not to perform these reactions in isolation but rather to perform them 
together and most importantly to perform them as part of a controlled network with 
reactants and products separated and allowed to mix as and when required. The scale on 
which these networks operate and the variability and harshness of the conditions they are 
able to tolerate is astounding and it will take decades to understand them fully. However, 
even at this early stage it seems clear that much of the function and the resilience of the 
metabolic networks that maintain life can only be understood in terms of the relations 
between all the components of the network. 
The gene-protein-reaction relationship and the importance of enzymes 
Some of the reactions within a living organism occur spontaneously at a rate sufficient to 
permit life, and perhaps more frequently at a rate sufficient to cause death. Depending on 
how you look at it we should be either frustrated or grateful then, that the majority of 
reactions require the intervention of one enzyme or more to take part in the processes of 
life. It would be hard to make much progress in describing metabolism without first 
describing what has become known as the central dogma of molecular biochemistry.  
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Figure 1: Simplified depiction of the central dogma of molecular biochemistry  
(Daniel Horspool – Wikimedia Commons under license: CC BY-SA 3.0). 
The central dogma, as shown in figure 1, is that DNA is transcribed to RNA by RNA 
polymerase and then translated to a protein by a ribosome. In this simple model, the unit 
of transcription is the gene, with each gene directly related to one strand of RNA and each 
strand of RNA directly related to one protein. If the protein is an enzyme — and in study of 
metabolism almost all proteins of interest will be — then this enzyme catalyses a single 
reaction. This gene-protein-reaction (G-P-R) relationship, where the proteins act as 
enzymes, is at the core of studying metabolism.  
In reality the links between gene and protein are complicated by alternative splicing, post-
transcriptional modification and post-translational modification. Similarly the link 
between protein and reaction is often more complex than simply linking a single enzyme 
with a single chemical reaction. Nevertheless, the underlying concept of the central dogma 
and its application to the study of metabolism as a set of G-P-R relationships is valid and in 
the case of simple bacteria, unencumbered by many of the complexities of higher orders of 
life, can give a remarkably accurate representation of an organism. 
Now that we know where they come from, let us turn to considering what enzymes do. 
We can break enzyme function down into three parts. They speed up slow reactions, they 
allow reactions to occur that would otherwise take place so infrequently that they might 
as well be considered impossible and they let an organism control when and where 
reactions occur. Let’s deal with these three features of enzymes in turn. 
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Enzymes speed up reactions 
The rate at which a reaction proceeds is overwhelmingly governed by two factors, 
activation energy and temperature, as formalised in Arrhenius’ law. 
           
  reactions second,   constant,    activation energy,   gas constant,   temperature in  elvin 
The simplest way to speed up reactions is thus to increase the temperature and as a rule of 
thumb Arrhenius’ law tells us that the rate of a reaction doubles for every 10°C increase in 
temperature. For industrial processes, increasing temperature is rarely a problem. Life on 
the other hand is restricted by both the temperature of its surroundings and the physical 
properties of water and even the hardiest bacteria cannot survive in boiling water for long.  
Once the option of raising temperature to speed up reactions is exhausted*lowering a 
reaction’s activation energy is the most effective alternative. Enzymes are the direct 
equivalents of the catalysts — typically made of heavy metals and often effective only at 
high temperatures — we use industrially for this purpose.  In comparison, enzymes have 
evolved to operate in the conditions provided by the host organism and only occasionally 
incorporate rare metallic atoms to improve their effectiveness.  
Enzymes and catalysts speed up reactions not by changing the equilibrium concentrations 
of the reactants and products or the free energy difference between them but rather by 
reducing the activation energy required for the reaction to proceed. 
Enzymes permit extremely unlikely reactions 
A naïve interpretation of the second law of thermodynamics can show life to be impossible 
in that it frequently appears to build order from disorder and structure from individual 
compounds. The flaw in this line of argument is that the Earth is not a closed system but 
rather driven by the heat and light delivered by the Sun. Still, it is essential to consider the 
mechanism by which the Sun is able to drive all the chemical processes of life on Earth 
given that only a tiny fraction of the reactions in a tiny fraction of the organisms on the 
planet are able to photosynthesise and thus directly harness the energy that the sun 
provides. These photosynthetic organisms are able to convert electromagnetic radiation 
into compounds with a large amount of easily accessible energy, usually adenosine tri-
phosphate (ATP), frequently stored in a more stable form such as glucose for conversion 
back to ATP, or similar, as required. Compounds like ATP, with large amounts of available 
free energy, are what allow hundreds of other key enzyme-mediated metabolic reactions 
                                                             
* few warm-blooded animals exceed a body temperature of 40°C. 
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to occur. More specifically, ATP permits reaction to occur in a direction that would not 
otherwise satisfy the second law of thermodynamics. 
 
Figure 2: KEGG reaction R04479, catalysed by enzyme 2.7.1.11, typically proceeds in the direction shown in part a. 
It can be considered a combination of two reactions, b and c with opposite energetically favoured directions. 
KEGG reaction R04479, shown in figure 2, is a good example of this property. The reaction 
shown in part b; β-D-Fructose-6P to β-D-Fructose-1 ,6P2  through the addition of a 
phosphate ion, is not energetically favourable and at equilibrium the population of β-D-
Fructose-6P will be much higher than the population of β-D-Fructose-1 ,6P2. Similarly, but 
in the other direction, the equilibrium concentration of ATP is extremely low compared 
with the equilibrium concentration of ADP. 
Because an enzyme ensures that both components of the desired reaction R04479 take 
place at the same time and in the same place it can also ensure that the free energy 
released by the dissociation of ATP and the high energy phosphate group can be used to 
phosphorylate the β-D-Fructose-6P molecule. Furthermore, although the natural reaction 
rates of reactions b and c are much higher than the natural reaction rate of reaction a, the 
presence of the enzyme 2.7.1.11 specific to reaction a means that as long as ATP is 
supplied to the system, β-D-Fructose-1 ,6P2 is produced more quickly than it is consumed 
by reaction b. For this reason we can, in the presence of the correct enzyme, draw reaction 
R04779 just as in figure 2a.  
For almost all of this thesis this simplified picture will serve us adequately and all the 
analysis I have performed assumes that an enzyme-mediated reaction takes place only in 
the presence of the enzyme facilitating it. In all but a few cases I have ignored the kind of 
spontaneous decay shown in figure 2b and c. Nevertheless, it is important to appreciate 
the limitations of the simplification of all three sections of figure 2 to just the part shown 
in section a and be wary of situations where this simplification is no longer valid. 
Enzymes let an organism control when and where a reaction takes place 
The third key advantage to life of making use of enzyme-catalysed reactions is that the 
presence and location of these enzymes can be set to allow certain reactions to occur only 
at certain times within the life-cycle or within certain organelles and internal 
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compartments. Although this property is useful in bacteria and other prokaryotes it is 
particularly important to the functioning of mitochondria within eukaryotic cells. 
Mitochondria can only function because particular reactions occur in separate 
compartments with limited permeability between them. The inclusion of compartments 
within a metabolic model for P. falciparum is similarly essential as I will show later. 
Metabolism is highly conserved 
Now that we have seen how genes, enzymes and reactions are related and how enzymes 
thus govern the chemical reactions that make up metabolism, let us turn to what I 
consider one of the most beautiful results in all of science. 
That the machinery of the central dogma of biochemistry is shared across all living 
organisms is magnificent evidence for the common ancestry of all life on Earth and it is 
this common language of DNA, RNA and proteins that lets us express human genes in 
bacteria. And yet I see absolutely no reason to extrapolate from this that the products of 
that machinery, the enzymes that govern the chemical reactions that make up our 
metabolism, should be as deeply shared. Figure 3 shows the collection of reactions that 
form the Glycolysis I metabolic pathway — the key link in the conversion of glucose to 
lactate that sports scientists call anaerobic respiration — in humans and in E. coli. It is 
striking in this image that the two pathways, despite around three billion years of separate 
evolution, are almost exactly the same. And not only are the reactions the same but the 
amino acid sequence of each pair of enzymes in this pathway is so similar that the DNA 
sequence of each enzyme-coding gene in E. coli can be found, albeit with a few 
modifications, in every human’s genome.  
In some ways it should not surprise us that some core pathways, and their component 
reactions (and thus enzymes and genes) are conserved. The process of evolution works in 
small steps, not in great leaps, and thus a successful system, even an imperfect one, is 
likely to be retained in future species. And yet in the 3-4 billion years since life began there 
has been plenty of time for changes to occur and for the different species, and certainly the 
different kingdoms, of life to diverge and find different enzymes, perhaps even different 
pathways, to perform identical roles. For this reason I think the finding of Peregrin-
Alvarez et al.2 that “half of the metabolic enzymes have homologs in all domains of life” is 
particularly beautiful. To someone like myself who entered the field of biochemistry after 
studying physics it is also surprising. 
8 
 
 
Figure 3: Visual representations of the Glycolysis I Pathway in E. coli (left) and Human (right) in Biocyc 15.1 
The widely shared homology of metabolic enzymes has enormous practical benefits. It 
means that as long as we have the genome sequence of an organism — an increasingly 
affordable thing to discover — we can immediately find a significant proportion of its 
enzymes just by searching that genome for sequences homologous to known genes. In this 
way an enzyme whose associated gene and reaction has been discovered in one organism 
can be found in all other organisms where there is a homolog. 
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Existing ontologies in systems biology 
KEGG LIGAND contains our knowledge on the universe of chemical substances 
and reactions that are relevant to life. 
- First sentence of the KEGG LIGAND site at www.genome.jp/ligand 
In order to define a set of chemical reactions we must first define a single reaction. This is 
not as easy as it sounds. 
Identical reactions almost always have many different names and a single name is not 
guaranteed to refer to a single reaction. Furthermore, each compound making up a 
reaction will almost always have many different names and again a single name is not 
guaranteed to refer to a single compound. Clearly, in order to construct a metabolic 
network these naming problems have to be overcome and a single naming system must be 
defined. This defined naming system is called an ontology and within systems biology 
there are two leading ontologies that define both reactions and compounds, MetaCyc and 
KEGG. 
MetaCyc 
The MetaCyc ontology3 is maintained by Peter Karp’s group at SRI International 
(previously Stanford Research Institute) and is available as a collection of flat-files for free 
to both academics and industry and as part of Pathway Tools for free to academics. It is 
tightly coupled to the Biocyc pathway/genome database collection and the pathway tools 
software package available from SRI International. As of 2011, MetaCyc contained a 
description of 9460 unique reactions and 9188 Compounds. 
MetaCyc reactions and compounds are linked as part of a well-defined hierarchy stored by 
Pathway Tools in object-orientated structures written in the LISP programming language. 
This has the advantage of providing extensive links between entities within the ontology 
but the drawback that the data structure is extremely complex. Access to the MetaCyc 
ontology is available directly via Pathway Tools and via Java and Perl APIs for Pathway 
Tools all of which represent a steep learning curve for those new to the field. The ontology 
is also available as a collection of flat-files in a variety of formats although the structure of 
these files is necessarily complex to represent the extensive links between component 
entities. 
KEGG LIGAND 
The LIGAND ontology4 is part of the larger Kyoto encyclopedia5 of genes and genomes 
(KEGG) and was maintained until recently by its founder within the Kanehisa group. 
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Financial pressures mean that access is now provided via a non-profit organisation, NPO 
Bioinformatics Japan. Currently the ontology is mostly free to academics and industry* and 
looks likely to remain so but recent developments mean that access may become more 
difficult in the future. As of 2011, LIGAND describes 8146 unique reactions and 14762 
Compounds (some deprecated, some similar). 
The ontology is available directly on the internet and via the KEGG API with the complete 
ontology available in flat files. Each compound is given a unique ID starting with a C and 
followed by 5 digits (C00001 = water, C00002 = ATP, etc...) and each reaction is given a 
unique ID starting with an R and following by 5 digits (R00004 = diphosphate 
phosphohydrolase, R00028: maltose glucohydrolase, etc…). Although it is hard to find, 
KEGG provides a file named compound.inchi which provides International Chemical 
Identifier (InChI) codes — text strings that uniquely describe all chemical compounds — 
for all KEGG compounds. 
LIGAND vs MetaCyc 
With the exception of some notable efforts to link the two major ontologies of metabolism, 
some of which I mention later, they remain effectively incompatible. Therefore it is 
regrettably necessary to make a choice before embarking on a considerable effort in a 
given area. To this end I took the advice of many different people including my supervisor 
David Westhead, others in the lab including John Whitaker and Elizabeth Edwards and 
Markus Herrgard. Additionally, I attended a two-day workshop on Pathway Tools at King's 
College London in 20086. The opinions I formed then, and since, on the differences 
between the two ontologies are summarised below in two parts. 
Ontology take-up and completeness 
Biocyc currently contains 1129 pathway/genome databases all based on the MetaCyc 
ontology of which 4 are intensively curated with almost all genes having been identified by 
an expert and the corresponding reaction assigned by that person. Thirty-two pathways 
are mildly curated with a computational model having been improved by an expert in the 
metabolism of the organism or in metabolism generally. The remaining metabolic 
networks have been created by computational annotation only. 
KEGG currently contains 1536 pathway/genome databases all based on the LIGAND 
ontology the vast majority of which were assembled using computational annotation 
                                                             
* Direct internet and API access is unrestricted and can feasibly supply the whole ontology. Bulk 
downloads of the ontology as flat-files via FTP is now restricted to paid licensees as part of a larger 
package of services  EGG provides. 
11 
 
alone. The extent of manual curation on those pathways claiming to have been manually 
curated is extremely variable. 
Both ontologies are widely used and capable of accurately representing a metabolic 
network. In fact both had been used for metabolic network reconstructions of Plasmodium 
falciparum, MetaCyc by Yeh et al.7 and LIGAND by Ginsberg8, before I started my PhD. 
Ontology complexity 
Although it is unwise to judge a scientific tool on its appearance, the best place to start 
comparing the complexity of the two ontologies is to look at the default representation of a 
single compound. In figure 4 and figure 5 on the following pages a condensed version of 
the compound descriptions for ATP in each of the ontologies is shown. Whilst both 
definitions uniquely define the compound there is a stark contrast between the LIGAND 
representation, three pages of simple but ordered information, and the MetaCyc 
representation, seventeen pages of extensive and well linked but cluttered information. 
A closer inspection of these figures shows a key advantage of MetaCyc over LIGAND. In 
both ontologies compounds are well linked with reactions and pathways in addition to 
information on the physical properties of the compound. MetaCyc goes a step further by 
linking compounds with other compounds, a property of the ontology’s structure that is 
extended to reactions. In the ATP example we see that ATP belongs to various nested 
classes of compounds, “a purine phosphate” which is a member of “a ribonucleoside 
triphosphate” which is a member of “a nucleoside triphosphate” and so on. This extra 
linking offers some attractive features. For example ambiguities in a metabolic network 
can be represented more simply and more flexibly within this system.  
In my experience this contrast in styles extends across the full extent of both ontologies. 
LIGAND’s use of unique IDs makes using the ontology simpler and easier to apply 
computationally and in my use there are only a few areas where the more complex 
hierarchical structure of MetaCyc makes sacrificing that simplicity worthwhile*. It is 
further worth noting that the ambiguities that the MetaCyc ontology permits in metabolic 
networks must be resolved; the subject of a fascinating talk9 by Jeremy Zucker of the 
Broad institute at the NeSC metabolic modelling workshop at the National eScience Centre, 
Edinburgh, 07/04/2010. 
In summary then, my slight preference is for the LIGAND ontology. This is a particularly 
sensible choice because the most extensive manual curation of malaria metabolism to date 
— the malaria metabolic pathways database (MPMP)10 — uses the LIGAND ontology.  
                                                             
* Work by Mark Poolman and David Fell at Oxford Brookes University using the MetaCyc compound 
and reaction names within a simplified framework suggests that this trade-off is avoidable. 
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Figure 4: The KEGG LIGAND compound entry for ATP, shortened from 3 pages. The simplicity of the ontology 
appeals to me. 
Entry 
C00002                      Compound                          
       
 
Name ATP; 
Adenosine 5'-triphosphate 
Formula C10H16N5O13P3 
Exact mass 506.9957 
Mol weight 507.181 
Structure 
 
 
Remark Same as:  
D08646 
 
Reaction R00002 R00076 R00085 R00086 R00087 R00088 R00089 R00104  
R00105 R00124 R00126 R00127 R00128 R00129 R00130 R00137  
                     … plus many more … 
Pathway ko00190   Oxidative phosphorylation 
ko00195   Photosynthesis 
… plus many more … 
 
Enzyme 1.2.1.30        1.2.1.31        1.3.7.8         1.13.12.7        
1.14.99.19 (C)  1.17.4.1 (C)    1.17.4.2        1.17.4.2 (C)     
                     … plus many more … 
Other DBs CAS:  
56-65-5 
PubChem:  
3304 
ChEBI:  
15422 
KNApSAcK:  
C00001491 
3DMET:  
B01125 
NIKKAJI:  
J10.680A 
KCF data 
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Figure 5:The MetaCyc compound entry for ATP, shortened from 17 pages. The extensive linking within the ontology 
has many advantages but is intimidating to work with.  
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Other ontologies of note 
Although KEGG and MetaCyc are the dominant ontologies for defining metabolism there 
are other ontologies that serve useful complementary functions which are worth 
describing briefly. 
ChEBI 
The chemical entities of biological interest database11, ChEBI, is in its own words “a freely 
available dictionary of molecular entities focused on 'small' chemical compounds”. In aim this is no 
different to the compound databases found in MetaCyc, LIGAND or other competitors and 
its focus on compounds limits its usefulness for my purposes. 
Despite this drawback, ChEBI has two distinct advantages. Firstly, its stated aim to stay 
completely free makes it a safer platform on which to build tools. Secondly, ChEBI is in my 
experience the best linked compound database with almost all compounds linking directly 
to international chemical identifiers (InCHI) codes and KEGG compound IDs amongst 
other identifiers. 
ChEBI is of further note because the combined yeast model assembled at the 2007 Yeast 
Jamboree12 — one the most comprehensive metabolic models assembled to date — used 
ChEBI identifiers as the preferred compound description format. 
EC numbers 
All the previous ontologies I have discussed deal with the reaction part of the gene-
protein-reaction relationship. The enzyme commission’s nomenclature for the 
classifications of enzymes13, EC numbers*, are different in that they primarily describe the 
protein’s function. 
An EC number consists of four numbers separated by a full-stop with the first number 
describing the action of the enzyme in very general terms and each number to the right 
describing a more detailed subset of that action. As an example, the enzyme involved in 
the reaction 6-phosphofructokinase, as shown in figure 2, is defined in the top part of 
figure 6. 
                                                             
* often referred to by the backronym enzyme classification numbers. 
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Figure 6: The tree structure of the EC number definition for 6-phosphofructokinase and the 10 KEGG reactions 
related to 2.7.1.11. 
An EC number could perfectly define of a reaction if it were unambiguous but in this, and 
many other cases, the single EC number 2.7.1.11 describes no fewer than ten separate 
KEGG reactions, each defined in terms of four of the twelve compounds present across all 
ten reactions. Whilst these reactions are very similar, when building a metabolic network 
where reactions must link exactly, very similar is not good enough. 
Figure 6 shows us that the complexities of the real world and the requirement for an 
ontology to remove ambiguity means that the naïve model of metabolism, where EC 
numbers uniquely define both protein function and a single associated reaction, is 
insufficient. Still, EC numbers are probably the single most universally applicable 
descriptor of metabolism and an extremely valuable resource for linking genes and 
reactions. 
Beyond the ontology: a rigorous reconstruction framework 
The described ontologies are an important unambiguous vocabulary for describing the 
components of metabolic models. And yet in order to build functional models upon which 
we can perform analysis and simulations we need to assemble these components, usually 
from multiply ontologies, into models in a regular, unambiguous and structured way. In 
the absence of a generally accepted term I have called this system of assembly a 
reconstruction framework.  
As part of my attempts to explore the requirements of such a framework I created the 
videos14 from which figure 7 and figure 8 are taken. 
2 = Transferase
  .7 = Transferase, transferring Phosphorous-containing groups
     .1 = Transferase, transferring Phosphorous-containing groups, with an alcohol group as acceptor
        .11 = Transferase, transferring Phosphorous-containing groups, with an alcohol group as acceptor, 6-phosphofructokinase
2.7.1.11 = R00756 ATP:D-fructose-6-phosphate 1-phosphotransferase
R00767 CTP:D-fructose-6-phosphate 1-phosphotransferase
R00769 UTP:D-fructose-6-phosphate 1-phosphotransferase
R00770 ITP:D-fructose-6-phosphate 1-phosphotransferase
R01843 ATP:Sedoheptulose 7-phosphate 1-phosphotransferase
R03236 ATP:D-tagatose-6-phosphate 1-phosphotransferase
R03237 CTP:D-Tagatose 6-phosphate 1-phosphotransferase
R03238 UTP:D-Tagatose 6-phosphate 1-phosphotransferase
R03239 UTP:D-Tagatose 6-phosphate 1-phosphotransferase
R04779 ATP:D-fructose-6-phosphate 1-phosphotransferase*
*R00756 and R04779 are not identical, R04779 acts on the β form of the fructose
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Figure 7: The LIGAND reaction R01600 labelled with the key components required to define a reaction within a 
reconstruction framework. This is a still frame from the “Framework Video” on my project website14. 
 
Figure 8: The key components required to define a reaction within a reconstruction framework. This is a still frame 
from the “Framework Video” on my project website14. 
Figure 7 breaks down a single reaction within a reconstruction framework into 
components with each component colour co-ordinated as in figure 8. The stoichiometries, 
compounds (both IDs and names), reaction (both ID and name), and the associated 
pathway (both ID and name) are taken from the LIGAND ontology and fully define the 
reaction. Additionally, EC numbers associated with the reactions are included to provide a 
link to the enzyme. A gene could additionally be assigned to this reaction to complete the 
GPR definition. When further reactions are added to a model it is essential that they 
conform to this same structure and are defined according to the same ontologies in order 
to avoid confusion or ambiguity. 
For the definition of metabolic models suitable for analysis two further properties are 
required for each reaction: compartment and kinetics. Since any given reaction can occur 
within different cellular compartments — the cytosol, mitochondria, nucleus, etc… — a 
compartment must be defined for each reaction to ensure it is unique and to ensure that 
its reactants and products are properly separated from those in other compartments. 
Kinetic properties are essential to creating a valid metabolic model upon which 
simulations can be run and in the scope of this thesis the only kinetic properties provided 
are limited to simple flux constraints. 
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The seven components of a reconstruction framework as shown in figure 8 are a guide 
rather than a prescription. As long as a rigorous framework is adhered to, each component 
of that framework could derive from a separate ontology. For the rest of this thesis the 
LIGAND ontology and the EC system, in addition to custom naming of compartments and 
arbitrary kinetic parameters, are used. 
SBML: the standard for network exchange 
A metabolic network can at its simplest be represented simply as a list of reactions on the 
condition that those reactions are properly defined somewhere as part of a rigorous 
framework. The first metabolic networks were thus lists, or, more usually, spreadsheets 
containing lists of reactions with additional information on each reaction contained in 
extra columns. Whilst this approach is perfectly adequate when a model is used within a 
single group using a single reconstruction framework it presents problems when models 
need to be shared. In these cases reactions are frequently not accompanied by a full 
definition of the stoichiometries and compounds from which they are formed leading to 
ambiguity in the metabolic model. Furthermore, without a standard for model interchange 
the order and meaning of entries in different columns of a spreadsheet are variable and 
unclear. 
In April 2000, as this problem of model interchange within systems biology was becoming 
clear, “The 1st Workshop on Software Platforms for Systems Biology” was held at the 
California Institute of Technology15 and by 2003, the proposed solution, the systems 
biology markup language, SBML16, had been finalised. This was followed in 2004 by the 
biological pathways exchange language, BioPAX17, proposed by a group including Peter 
Karp at SRI and joined that year by PSI MI18, the Proteomics Standards Initiative’s 
molecular interaction XML format. Other interchange formats have been proposed but in 
the field of metabolic modelling SBML and BioPAX are the only two in wide enough use for 
me to have encountered them in the last four years. 
Although SBML and BioPAX are far easier to convert between than LIGAND and MetaCyc it 
is still easiest to choose one when starting a large project and for this reason they must be 
compared. I can give no better a summary of the comparison between these two formats 
than that published in 2005, 
“SBML is better on simulation-related properties [whilst] BioPAX provides the richest and most general 
representation. The richer hierarchy of BioPAX, which is a benefit with respect to representation of data, 
has a price with respect to computational complexity.” 
From the conclusion of “Representations of molecular pathways: an evaluation of SBML, PSI MI 
and BioPAX”19 by Lena Strömbäck and Patrick Lambrix. 
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Since 2005, the scope of both SBML and BioPAX has increased as the standards have 
matured. Higher levels — currently at level 3 in both specifications20–22 — have been 
added to allow a more complete description of the modelled system. 
Choosing between these standards is difficult and many people in the systems biology 
community have very strong views on the subject. The hierarchy and flexibility of BioPAX 
means that almost every imaginable aspect of a model can be contained within the format 
but I have found the cost in terms of usability too high. SBML is much simpler to work with 
and in almost all cases it is good enough. 
It seems that others agree with me and as of June 2011 the SBML software matrix lists 225 
tools compatible with the format. To further prove the dominance of SBML, Pathway Tools 
— a project with close ties to the BioPAX working group — now supports SBML export of 
models in addition to the longer-standing option for BioPAX export. The interoperability 
of models afforded by SBML is an outstanding achievement and its value should not be 
underestimated. As long as the format is maintained and updated as rapidly as it is 
currently it will remain, as many argue it currently is23, the lingua franca of biological 
modelling. 
SBO (systems biology ontology) 
The systems biology ontology24, SBO, project is different to the other ontologies I have 
described in that it aims not to define the physical contents of a metabolic model but 
rather the mathematical properties of that model: what I called kinetics in figure 8. 
Currently models can be exchanged using SBML but there is no standard way to define 
things like enzyme properties, reaction kinetics or any of the more complex features of a 
mathematical model. This makes it difficult for one group to repeat simulations, and thus 
verify the results obtained by another group, performed on metabolic networks. This in 
turn makes it difficult for existing models to be expanded and adapted to future modelling 
techniques. 
SBO is developed at the European Bioinformatics Institute and, although it can be used to 
mathematically define models in any format, it is tightly coupled with the maintenance 
and extension of the SBML standard. As the modelling techniques applied to metabolic, 
and other, models increases SBO is likely to become an increasingly important part of the 
SBML specification. 
A less adventurous effort to standardise metabolic models with the goal of making their 
simulated behaviour reproducible  is the MIRIAM25 (minimum information required in the 
annotation of models) project which I discuss further at the end of this thesis. 
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Visual representations of metabolic networks 
An intuitive feel for the process of metabolism can best be gained from a visual 
representation of it. For example, the visual representation in figure 3 is easily 
understandable to someone with some experience of chemistry and requires no special 
explanation. By comparison, the mathematical model underlying the visualisation would 
not be widely understood. 
I strongly believe that visualisation techniques are essential to the wider understanding of 
metabolic models and the results of their analysis and I develop this idea throughout this 
thesis. To help with that it is important to define some basic principles of visualisation.  
Networks of nodes (objects) connected by edges (lines) are called graphs and their study 
is called graph theory. As shown in figure 9, there are essentially three different types of 
graphs that can be used to display metabolic networks. 
 
 
Figure 9: (top/a) Reaction-centric graph. (left/b) Compound-centric graph. (right/c) Combined graph. These are all 
equivalent representations of the first six reactions in the glycolysis pathway. ATP and ADP nodes are aliased. 
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Reaction-centric graph 
In this type of graph, reactions are placed as nodes which are then connected by edges 
representing the compounds passed between reactions. In graph theory this is called a 
simple graph or a directed graph if a preferred direction for the compound flow is 
specified. 
Compound-centric graph 
Much more commonly the compounds in a metabolic network are chosen as the nodes 
connected by reactions shown as edges. Many visual representation of metabolism are 
compound-centric graphs such as those already shown in figure 3 and figure 7. Even 
though all reactions are reversible a preferred direction of each reaction is defined to 
ensure the correct coupling of reactants and products. At first it might be tempting to 
consider the compound-centric graph a directed graph within graph theory but in fact it is 
more like the combined graph below but with the reactions nodes omitted and instead 
used to label a group of edges representing the reaction. 
Combined graph 
A bipartite directed graph treats both compounds and reactions as nodes, with the edges 
showing only how compounds connect to each reaction. This is the graph type that most 
usefully represents a metabolic network although the increased complexity means that 
graphs like this can be confusing on a large scale. 
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Mathematical representations of metabolic networks 
Visual representations of network are essential to our understanding of them but the true 
power of representing metabolic networks as graphs is the symmetry that these 
representations have with much more powerful mathematical representations. 
Figure 10 shows us how we can represent a metabolic network mathematically by forming 
a stoichiometric matrix. 
 
Figure 10: (left) A visual representation of a small reaction network. (right) The equivalent     stoichiometric matrix 
(S matrix) that completely defines the network. Reaction IDs and compound IDs and names are added as labels to 
the matrix. 
We can best understand this stoichiometric matrix (S matrix) by inspecting its rows and 
columns separately. 
Let us take as an example the fifth row of the S matrix. We see that α-D-Glucose-6P 
(C00668) is not involved in three of the six reactions, a single molecule is consumed by the 
forward direction of the reactions R02739 and R02740 and a single molecule is consumed 
by the forward direction of reaction R01786.  
Inspecting a row of the S matrix is equivalent to inspecting the edges connected to that 
compound’s node in the compound-centric visual representation shown in Figure 9b. 
Likewise, inspecting a single column of the S matrix is equivalent to inspecting the edges 
connected to a reaction’s node in the reaction-centric visual representation shown in 
Figure 9a. 
Completing the symmetry between the rows/columns of the S matrix and the different 
possible visual representations we see that the combined graph in Figure 9c is equivalent 
to considering the nodes represented by the rows and columns of the S matrix at the same 
time. 
α-D-Glucose  β-D-Glucose 
 β-D-Glucose-6P α-D-Glucose-6P 
 β-D-Fructose-6P
 β-D-Fructose-1 ,6P
2
ATP 
ADP 
ATP 
ADP 
ATP 
ADP 
R01600 R01786 
R02739
R03321
R02740
R04479
 β-D-Glucose 
ATP 
ADP 
α-D-Glucose 
 β-D-Fructose-1 ,6P
2
 β-D-Fructose-6P
α-D-Glucose-6P 
 β-D-Glucose-6P 
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SBGN: an emerging standard for network visualisation? 
In March 2010 I attended the “Systems Biology of Microorganisms” conference at the 
Institut Pasteur in Paris. At the poster sessions of the meeting I took photos of 28 visual 
representations of biological networks. It was striking that the information in all 28 forms 
was conveyed in a completely different way. Whilst it was possible to understand each 
poster it took a long time to see what was being shown and it was almost impossible to 
make comparisons between similar systems shown in different ways. I thought that there 
had to be a better way to represent models and in fact the reason why the leading 
proposed solution was not yet being used was that it was less than a year old and had not 
yet been finalised. 
The systems biology graphical notation26 — SBGN — was proposed and promoted by 
much of the same group, led by Kitano and Hucka, that have worked on SBML for the last 
ten years. SBGN aims to standardise the major elements of the visual representation of 
metabolic models in the same way that SBML has standardised the major elements of their 
mathematical description. I think that the SBGN initiative is a worthwhile venture and 
many people, including myself, have already adopted elements of it.  
A visualisation of a biological network is inherently more variable and more open to 
personal interpretation than the underlying structure of the network. It is also harder to 
build tools to create and interpret visual networks.  
For these reasons I doubt SBGN will achieve the same universal acceptance as SBML. 
Nevertheless I have already noticed that some of its design elements and conventions are 
becoming more widely applied and I have adopted many for my own visualisation tool in 
this thesis. For example, my own visualisation efforts draw heavily on SBGN’s insistence 
on the use of the combined graph visual style, the use of rounded nodes for compounds 
and rectangular nodes for reactions, and the insistence that aliased compounds be 
represented differently to non-aliased compounds.  
In time I’m sure that the efforts of the SBGN group will make visual representations of 
biological networks much clearer than they are now and I suspect that this — rather than 
the widespread adoption of their precise standard — was always their main aim. 
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The malaria parasite 
 
 
 
 
 
 
 
 
Malaria is like no other disease, it isolates communities, people simply don’t go 
there. It violates Adam Smith’s precept of freedom of movement as being essential 
for economic growth. It sits on the people. It protects them from intruders but also 
denies them access to the world economy. I think that’s probably the most 
important element of economic growth in Africa… 
Interview with Prof Andrew Spielman, Professor of Tropical Public Health, Harvard School of 
Public Health 27. 
 
 
 
 
The background to some of the information in this section comes from the ninth, tenth and 
eleventh episodes of a podcast by Vincent Racaniello and Dickson Despommier called This 
Week in Parasitism, the tenth episode in particular is well worth listening to. Much of that 
material is in turn based upon Despommier’s two books on the subject28,29. An exceptional 
account of mosquito-borne diseases, including large sections on malaria, can be found in 
the excellent book Mosquito by the late Professor Andrew Spielman30 a fascinating 
interview with whom can be found with the Vega Science Trust27 from which the quote at 
the start of this section was taken.  
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Human impact 
Malaria is a major cause of human suffering around the world with between one and three 
million directly attributable deaths each year. Direct deaths are principally the result of 
infection with Plasmodium falciparum and occur primarily in the young and in pregnant 
mothers. The secondary affects, caused primarily by the temporary inability of affected 
people to work, and the associated fear of travel and trade, but possibly extended into 
many other areas such as reduced IQ31, impose considerable economic costs and thus 
hamper projects to reduce malaria infection rates. 
Perhaps the most significant long-term impacts of malaria are caused by its rapid 
evolution and the resulting specificity of acquired immunity. People growing up in a single 
affected village acquire immunity to the local variant of the malaria parasite with those 
who survive into their teens continually re-infected but with symptoms usually no worse 
than mild flu. Such is the variation of the parasite — and the specificity of their acquired 
immunity — that even travelling a distance on the order of ten miles can result in a 
debilitating or even deadly infection from a variant to which they have no immunity. In 
this way, sharing of goods and ideas, and even the establishment and maintenance of 
nations is cripplingly frustrated by malaria. 
Malaria, alongside other mosquito-borne diseases, has critically shaped the course of 
human history. Malaria was a key part of the failure of the first Panama Canal project by 
the French and placed a huge burden on Egyptian, Greek and Roman empires. Quinine, the 
first drug to combat malaria, was first given by, and later stolen from, native South 
Americans when they came into contact with Europeans and remained an important 
treatment until over-use in the 20th century made it increasingly useless against resistant 
parasites. Derivatives of quinine32 that for a while proved more resilient to resistance are 
now unable to treat malaria in many parts of the world and there are worrying signs33 that 
resistance to the last universally effective anti-malarial drug artemisinin may be emerging. 
At one time in the 1970s it seemed as if malaria could be eradicated in the developing 
world as it had been in the developed world. This belief was so prevalent that much 
research into the parasite was stopped and many Universities greatly reduced the 
importance of the parasites in their teaching of both microbiologists and doctors. In 
addition to distributing bed nets, DDT was sprayed to target the mosquito vector whilst 
anti-malarial drugs were given as soon as symptoms emerged with the aim of both curing 
the illness and the parasite’s spread. Despite early successes the discovery that DDT 
remained active in ecosystems far longer than predicted, notably in Rachel Carson’s book 
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Silent Spring, and the corresponding reduction in its use marked the end of our last 
attempt, nearly 40 years ago, to rid the world of malaria. 
The characteristics and life-cycle of the parasite 
The primary host of parasites in the genus Plasmodium are mosquitoes, typically of the 
genera Anopheles or Culex. Over two hundred species of Plasmodium have been identified 
to date, with each usually specific to a given non-insect host and at least a specific genus of 
the insect host. Although further parasite species have not been classified, it is likely that 
many more mammal, reptile and bird species with territories overlapping a suitable 
mosquito vector play host to at least one corresponding Plasmodium parasite. 
Humans are afflicted by five species of Plasmodium, most frequently by falciparum but also 
by vivax, ovalae, malariae, and occasionally by the long-tailed macaque specific species 
knowlesii. Of these, P. falciparum reaches the highest population within the body and 
causes the most severe symptoms including severe anaemia and unconsciousness: 
frequently called cerebral malaria. By comparison P. malariae has far milder symptoms 
but can persist asymptomatically for decades. P. vivax and P. ovalae are distinguished by 
the persistence of hypnozoites in the liver stage which can later cause the recurrence of 
acute symptoms. 
The complex life-cycle of Plasmodium is best understood in a diagram as shown in figure 
11 on page 27 and described below. 
Life stages within the human blood stream (erythrocytic stages) 
1 – The merozoite, regardless of its source, attaches and induces the red blood cell to 
produce extra membrane and, enclosed in this membrane, enters the red blood cell. 
2 – Early-stage trophozoites appear ring-shaped under Giemsa stain34 and are easily 
recognised by clinicians for diagnosis. This is frequently called the ring-stage. 
3 – Late-stage trophozoites grow to fill the host cell. In infections by Plasmodium 
falciparum these trophozoites induce the production of a histidine-rich protein (Pf HRP II) 
which causes red blood cells to clump around an infected cell and block capillaries35. This 
coagulation ultimately causes unconsciousness called cerebral malaria*, making treatment 
and patient maintenance extremely difficult and thus greatly increasing the risk of death 
                                                             
* Many textbooks still explain that cerebral malaria is caused when clumped red blood cells induce 
the expression of tumor necrosis factor in the capillary walls. This in turn induces nitric acid 
production leading to unconsciousness. Newer evidence increasingly suggests that nitric acid 
frequently protects brain function212 in stressed conditions and that it can also protect against 
cerebral malaria213. Current consensus seems to be shifting towards…  (continued overleaf) 
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4 – Mitotic nuclear division takes place to form a schizont full of merozoites ready to enter 
the blood stream upon cell lysis.  Toxic haemozoin — the crystallised accumulation of the 
haem groups left as a by-product of the parasite’s haemoglobin digestion — is left in the 
lysed blood cells upon lysis. 
5 and 6 – Microgametocytes (5, male) and Macrogametocytes (6, female) form from 
ring-stage parasites and remain inside un-lysed red blood cells in circulation. They are 
rarely seen in parasite cultures and the mechanism governing gametogenesis versus 
schizogeny is not fully understood. 
Life stages within the mosquito 
7, 8 and 9 – Any parasites ingested by a female mosquito taking a blood meal are digested 
except for microgametocytes and macrogametocytes which are released from their 
surrounding red blood cell and activated by the mosquito’s digestive tract. For the female 
gamete this activation is simple and the activated macrogametocyte becomes a 
macrogamete (9). At this point the activated microgameteocyte begins a process known 
as exflagellation, producing a free-living microgamete (8) capable of fertilising the 
macrogamete at which point the combined diploid organism is called the zygote. 
10 – The zygote matures to become the mobile ookinate which embeds itself in the 
mosquito gut wall. Although exact details remain unclear it is likely that the zygote is the 
only diploid form of Plasmodium 36 with meiosis occurring during its maturation into the 
ookinate. 
11 – The embedded ookinate matures into the oocyst.  
12 and 13 – The oocysts divide asexually until individual sporozoites are mature. 
14 – The sporozoites lyse the host cell and circulate within the mosquito until reaching 
the salivary gland where they settle, ready to be injected when the mosquito takes it next 
blood meal. 
Life stage within the human liver (exoerythrocytic stages) 
15 – Sporozoites injected into the human blood stream settle in the liver where they infect 
hepatocytes. At this stage the parasites are almost invisible to clinicians and are thus 
referred to as cryptozoites. In P. vivax and P. malariae these liver-stage parasites can 
become hypnozoites, capable of staying asymptomatically in the liver for months or years 
before continuing their life-cycle and causing a recurrence of acute malaria. 
                                                                                                                                                                                  
cerebral malaria being caused by the breakdown of the blood-brain barrier and the ability of 
clumped rosetted red blood cell groups to enter the brain214,215. 
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16 – Hepatic schizonts form, the direct equivalent of the schizonts in red blood cells. 
17 – The lysis of hepatic schizonts releases merozoites into the blood stream to 
commence the red-blood cycle. 
 
Figure 11 : The multiple life stages and host cells of Plasmodium. Parasite nuclei are shown in dark purple, cytosol 
as a lighter purple, as under Giemsa stain. Partially adapted from Dr. Wiser’s malaria course at Tulane University, 
FL, USA37. 
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Methods of study 
Cell culture of erythrocytic stages 
Human malaria parasites had proved impossible to culture until 1976 when Trager and 
Jenson realised that the low oxygen environment of coagulated red blood cells (RBCs) 
within the capillaries was essential to the progression of the P. falciparum life-cycle38. Just 
a year later the technique had advanced to a system we would recognise today whereby 
frozen parasitised red blood cells could be thawed and grown in washed human RBCs in 
RPMI medium fortified with human serum all within culture flasks kept with a low oxygen 
internal environment39. At the time the low oxygen environment was provided by burning 
a candle at the entrance of the culture flask to lower the oxygen concentration. Modern 
improvements to these methods have improved reproducibility; low-oxygen gas of known 
composition replaced candles and a standard culture medium of RPMI+AlbuMAX has 
largely replaced the variable composition of human serum40. 
 
Figure 12 : The life-cycle red blood cell stage Plasmodium parasites with representative images of Giemsa stained 
infected red blood cells on thin blood smears. All images are my own. 
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The techniques I have used to manipulate P. falciparum cultures are detailed in the 
experimental methods chapter of this thesis. Additional methods of study that I have not 
conducted but which are worthy of a brief mention are, 
Cell culture of liver stages 
Limited success in cultivating liver stages of Plasmodium vivax and malariae  to study their 
ability to persist as hyponozooites has been achieved41,42. Furthermore, recent advances 
with Plasmodium falciparum are making it possible to culture the liver stages of the 
parasite in human liver cell lines43. These techniques are currently very difficult but may 
offer a way to study the organism’s metabolism more fully and may allow the development 
of new types of drugs, both prophylactic and as treatment, that target the liver-stage of the 
parasite’s life cycle. 
Other in vitro methods of study 
Studies into Plasmodium continue in bird species, rats (berghei) and long-tailed macaques 
(knowlesii) as well as in the mosquito primary host and may provide valuable insights into 
human malaria. It is also possible to study the human species in vivo by infecting 
splenectomised, and thus immunodeficient, chimpanzees although these studies are both 
extremely expensive and ethically questionable. 
Unique challenges to the study of P. falciparum 
Although it is now relatively straightforward to culture erythrocytic life stages of 
P. falciparum, it remains more difficult than the culture of many other pathogens. Daily 
attention to cultures is usually required and unexplained culture death is not unusual. 
Furthermore, since only a third of the parasite’s life cycle occurs in human RBCs the 
current life-cycle coverage of in vitro study remains low. 
Although some initial efforts at gene silencing through RNA interference appeared 
successful in reducing growth-rate44 further studies have shown that P. falciparum lacks 
the genetic machinery required for general application of RNAi45. 
The intracellular nature of the parasite means that direct manipulation typically involves 
lysing the host RBCs and conducting experiments on freed and thus dying parasites 
outside of their normal environment46. 
The genome of P. falciparum was published in 200247 and many hoped it would simplify 
the study of the parasite. By building a metabolic network of P. falciparum, based 
principally on its genome, and integrating it sufficiently with supporting experimental 
data we might reasonably expect to construct a model that would reproduce the inner 
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workings of the organism. Unfortunately the genome47 presented many problems. 
Assembling the fragments from shotgun sequencing had been hard because the genome 
was known to be A-T rich but at 80.6% A-T, with around 90% A-T in introns and 
intergenic regions. The genome remains to my knowledge the most A-T rich genome ever 
sequenced. This unusual nucleotide composition presents further difficulties. Homology 
searches find fewer genes than expected making metabolic network reconstruction 
difficult and very few restriction enzymes are specific enough to perform genetic 
modifications on the genome. 
A final impediment to creating an accurate metabolic reconstruction of the parasite is a 
result of it being an intracellular parasite and thus able to rely on its host, and even induce 
its host, to fill gaps in its own metabolism. Homology searches of the parasite genome will 
not identify these genes and the gaps must be filled with knowledge of red blood cell 
(RBC) metabolism.  
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Network analysis 
 
 
 
 
 
 
 
 
We’ve got the human genome sequenced, we’ve got the parasite genome 
sequenced, we’ve got the mosquito genome sequenced. Somehow you should be 
able to work out some way of controlling everything… 
Dickson Despommier, TWiP Episode 10 
 
 
 
 
 
 
 
 
 
Flux-balance analysis is the primary metabolic analysis technique I will use in this thesis. 
It is well described in a book on the subject by Bernhard Palsson48 — one of the early 
users of the technique — and in four papers charting the development of the technique 
over the last fifteen years49–52 most recently in a summary published by J. Orth in 201053.   
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A note on Wikipedia 
In 2010 the clearest academically published description of FBA was published in Nature 
Biotechnology53 and, despite adding little to the field, was cited nearly fifty times in the 
following year. At this time, in frustration at the lack of an openly available, linkable and 
updatable resource describing FBA I decided to write what remains the current Wikipedia 
page on the subject.  
The work on that page, including all figures, is almost completely my own and has been 
reviewed, graded and commented on by notable academics in the field, including Kieran 
Smallbone at the University of Manchester. Some sections are repeated in the following 
pages without citation because they were written by me. 
In the eight years since I started as an undergraduate I have had numerous candid, and 
usually negative, discussions about Wikipedia. These have ranged from markers failing my 
lab reports for no other reason than they referenced Wikipedia, through lecturers 
instructing me to mark as errors in lab reports any reference to Wikipedia.. I have listened 
to, considered and engaged in the debates on whether knowledge should be open or 
correct and ultimately concluded that we can have both. I do not think that the current 
“solution” to the phenomenon of free and open information: rephrasing Wikipedia text 
and then — without reading the source — citing that text’s reference, is in interest of 
scientific advance or education. 
For this reason I will in this section focus on the basics of FBA, in addition to the 
requirements, scope and limitations of the technique. The version online is both more 
complete and will already be more current than the limited version I reproduce here. It is 
reflective of the approach that academic institutions have taken to Wikipedia that in all the 
written guidance* given to PhD students and supervisors at the University of Leeds, the 
word does not occur once. I hope that my use of, and contribution to, this resource is in 
keeping with the requirements of the University of Leeds. 
  
                                                             
* Research Student Handbook 2010-2011, Ordinance and Regulations and Programmes of Study for 
Research Degrees 2010-2011, Guide for Research Degree Supervisors 2010-11, Guidance on Ethesis 
Preparation, Copyright and Publication, General Academic Regulations. 
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Recognising the limitations of metabolic network reconstructions 
Armed with the genome of an organism it is a relatively simple task to search for genes 
homologous to those in reference databases such as refseq54. More advanced software 
such as SharkHunt55 and RAST56 can make this process even easier and more effective. 
Yet no matter what technique is employed to find genes, and thus reactions, describing an 
organism’s metabolism there are still significant limitations on these automated 
techniques. Just four of these limitations are, 
 We haven’t found all the enzymes required to build a complete set of reference 
sequences and we cannot search a genome for enzymes we don’t yet know exist. 
 We don’t know the properties of most enzymes or their location or concentration 
within their host organism.  
 We cannot predict the effect that small changes in mostly homologous proteins 
may have on their properties. 
 We cannot predict how an enzyme’s properties will change in a different organism. 
Steps can be taken to improve the quality of a metabolic network by filling gaps in the 
automated annotation and I will discuss those in detail later. For now let’s deal with 
another approach to dealing with incomplete metabolic networks; making simplifications 
when analysing them. 
Techniques for the analysis of metabolic networks can be split as by Poolman et al.57 into 
two groups: structural and kinetic. To this I add a further type, local analysis, which was 
considered too basic to be included in Poolman et al. and is arguably not true network 
analysis. 
Local analysis (chokepoint analysis) 
The first published metabolic network reconstruction and analysis for P. falciparum was 
conducted by Yeh et al.7 in 2004. Their core technique was chokepoint analysis where they 
define a chokepoint as “a reaction that either uniquely consumes a specific substrate or uniquely 
produces a specific product” and finding that 21 out of 24 known drug targets (enzymes coding 
for reactions disrupted by a drug) were chokepoints. 
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Figure 13: Cellular overview of P. falciparum network used for chokepoint analysis from Fig 2 in Yeh et al7. Reactions 
(edges) shown in grey are not present in the model. 
Inspecting an overview of the reconstructed network, figure 13, to which chokepoint 
analysis was applied it becomes clear why the technique was adopted. Because of the large 
number of gaps in the reconstructed network an analysis technique that considered the 
flow of metabolites through the network could not be used. Since chokepoint analysis 
considers each reaction in turn it can deal with this problem with the associated downside 
that every reaction before and after a gap in the network is by definition a chokepoint. 
In fact in the analysis of this basic network 216 out of 303 (71%) core metabolic enzymes 
were found to catalyse reactions that were chokepoints making it unsurprising that 21 out 
of 24 (87.5%) known drug targets were also chokepoints. The complexity of the network 
description — typical of a reconstruction in Pathway Tools — and the many reactions 
excluded from the chokepoint analysis ultimately make the results of this paper difficult to 
quantify and utility of chokepoint analysis unclear. 
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Structural analysis 
Structural analysis differs from local analysis in two connected ways. Firstly, it examines 
reactions not in isolation but rather as a collection. Secondly — and partly as an extension 
of the first point — it operates not only on the metabolic network of a system but also on 
the interaction between that system and its surroundings; a key part of structural analysis 
is that there is some input and some output. In the examples of glycolysis shown back in 
figure 3 these are as simple as β-D-Glucose-6P as an input and pyruvate as an output. On 
the whole-organism scale, as represented in figure 14, the inputs are the metabolites 
absorbed from the environment and the outputs are both the metabolites excreted back to 
the environment and the metabolites used for growth and reproduction. 
 
Figure 14: a. A metabolic network on its own cannot simulate life. b. A metabolic network that is able to exchange 
metabolites with a growth medium and provide molecules for growth as part of a biomass function can. 
Because structural analysis requires inputs and outputs it invokes the concept of 
metabolites flowing through the network from input to output and for this reason it 
cannot operate on networks with key missing reactions. This requirement makes 
networks more difficult to prepare for structural analysis than for local analysis. 
Flux-balance analysis (FBA) 
A key form of structural analysis is FBA, which can be explained most concisely in 
mathematics as the solution to the flux-balance problem, where   is the stoichiometric 
matrix and  ⃗  is the vector describing the collection of fluxes through the reactions in the 
network. 
   ⃗    
The result of multiplying the stoichiometric matrix with a vector of fluxes through each 
reaction in this way is a vector representing the rate of change in the concentration of all 
the compounds within the system. The condition that this is equal to zero is equivalent to 
the homeostatic condition, that the internal concentrations of compounds within a living 
organism stay constant over time. 
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Additional constraints on the minimum and maximum fluxes, either from thermodynamic 
considerations or experimental results, can be defined to ensure the model is realistic. 
               
The constrained model, which will still usually have a large null space, is then solved to 
find the optimal solution according to some sensible optimisation goal. Typically this is 
biomass production, a single reaction,     representing the consumption of metabolites in 
the correct proportion to represent growth of the organism. 
   
 ⃗ 
                   ⃗    
Whilst the mathematical description of FBA is accurate it can be hard to comprehend and a 
purely mathematical understanding of the technique does not express the impressive 
ability of the technique to make insights into metabolism. Thankfully, as I showed earlier, 
mathematical and visual representations of metabolic networks can be completely 
equivalent and FBA can be best explained visually.  
In figure 15 we see the process of preparing a metabolic network, in this case the first six 
reactions of the glycolysis pathway, for FBA. The process involves adding reactions to 
allow α-D-glucose, β-D-glucose, ATP and ADP to enter and leave the system from an 
infinite external pool. A biomass objective function is added to remove β-D-Fructose-1-
6P2 from the system with this removal simulating growth in this highly simplified example. 
 
Figure 15: The first six reactions in glycolysis prepared for FBA through the addition of an objective function (red) and 
the import and export of nutrients (ATP, ADP, BDG, ADG) across the system boundary (dashed green line). The full 
version* shows the stoichiometric matrix both before and after the model is prepared for FBA.  
                                                             
* http:  en.wikipedia.org wiki File:Prepare_for_FBA_maths.png 
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The result of performing FBA on the network shown in Figure 15 with constraints on the 
maximum uptake of glucose at 50 arbitrary units are shown both as a vector and 
represented pictorially in figure 16. In this representation the width of the edges 
representing each reaction is proportional to the calculated flux through that reaction. 
Applied constraints are represented as red bars limiting the flux on the entry of α-D-
glucose and β-D-glucose to the system. 
 
Figure 16 : A metabolic network before (left) and after (right) flux-balance analysis. The 'after' picture conveys the 
optimal flux from the nutrient source to the biomass function as the weight of the lines representing each reaction. 
These weights correspond to the reaction flux vector, v, shown below in its transposed orientation v'. A constraint on 
the glucose uptake flux of 50 arbitrary units is shown as a pair of red bars constraining flux through these reactions. 
There is nothing surprising in this result and indeed it, or something similar, could be 
drawn without calculation by anyone familiar with the technique. FBA is important 
because it easily scales to large networks where human intuition on metabolite flows is 
useless.  The efficiency of the technique is also a major advantage with analysis of a 1000 
reaction network taking under a second on a desktop computer. This in turn allows 
further techniques such as studying the effect on network fluxes of simulated deletions of 
all single, and all pairs of, reactions to be carried out within minutes. 
Flux-balance analysis of whole organism metabolic networks of P. falciparum have been 
used to predict essential reactions and thus drug targets58,59 and I will discuss these results 
in more detail later. 
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Elementary modes analysis 
The solution to the flux-balance problem, the null-space of the stoichiometric matrix, is not 
singular. All solutions are made up of some linear combination of a set of basic solutions 
we call elementary modes which I have drawn for the example system used so far in figure 
17. 
Of these, solutions 1-4 that are valid solutions to the problem    ⃗    whilst also 
satisfying the objective function to produce biomass. Solutions 6 and 7 are valid solutions 
to     ⃗    but do not satisfy the objection function. Solution 5, is an example of an 
internal cycle which although a valid solution to the problem    ⃗    is of limited 
informative value and can be confusing when interpreting results. 
Elementary modes are important because they help us understand how FBA works but 
also because they help us find and eliminate unwanted features of a network. The type of 
elementary mode that we call internal cycles are almost never biologically representative 
and can be eliminated by enforcing constraints on some of the components. For example, 
enforcing a forward direction on reactions R03321 and R02740 eliminates this cycle and 
is a sensible thermodynamic constraint to add to the model in this system. Beyond being 
of interest in their own right, elementary modes are key components of further analytic 
techniques such as extreme pathways60 and minimal flux modes61. 
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Figure 17 : The seven elementary modes of the example system. Solutions 5,6 and 7 are equally valid in both directions.
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Kinetic modelling 
Structural modelling techniques like FBA are an advantage over local modelling 
techniques like chokepoint analysis because they consider the whole network and thus 
interactions between all parts of the network. This advantage brings with it the associated 
disadvantage of requiring a network with no gaps in the chain of reactions between 
nutrient uptake and the production of compounds required for growth. 
Kinetic modelling is an advantage over structural modelling techniques because it 
considers how the concentrations of compounds within a system evolve over time but 
requires a network even more complete than that required for structural analysis. 
The key of FBA is that compounds are assumed to remain at a constant concentration 
within the organism. We wrote this earlier as     ⃗    with the right-hand side of the 
equation representing a zero vector of equal dimension to the number of unique 
compounds in the system. In kinetic modelling we no longer make the constant 
concentration assumption and this zero vector has in each position a differential equation 
describing the evolution of that compound’s concentration with time. 
   ⃗  
(
 
 
 
 
 [ ] 
  
 [ ] 
  
 
 [ ] 
  )
 
 
 
 
 
The exact form of these differential equations may be simplified but would most 
realistically consist of linked Michaelis-Menten kinetic equations with the metabolic 
products of one equation being the substrate of one of more other equations. These 
formulae require not only a good guess of each compound’s initial concentration but also 
knowledge of the kinetic parameters for each enzyme. This is particularly difficult because 
the kinetic properties of enzymes are poorly predicted from homology and vary 
considerably in different conditions. 
Once the metabolic model has been expanded to contain these required details solutions 
can be found by solving the fuller problem using software such as COPASI62. 
To date kinetic modelling has been used mostly to study small subsystems within 
organisms. Attempts have been made on a larger scale and in 2010 an extremely 
impressive study of E. coli showed that kinetic modelling was able to reproduce many 
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complex behaviours of bacterial metabolism that had previously been thought to require 
sensing and regulation at a higher level63. 
Kinetic modelling can offer a more accurate description of an organism’s metabolism than 
FBA but at the same time it is substantially more difficult.  This difficulty means there is a 
larger scope for errors when constructing kinetic models and finding errors can take a 
long time. Furthermore, large problems can become computationally expensive and the 
resulting systems are frequently unstable and give results that are difficult to trust.  
Kinetic modelling is a technique best applied either to small, simple or extremely well 
studied systems and I do not think it is currently suitable for malaria research. 
Extensions of FBA 
Many extensions have been built on top of FBA aimed at more deeply analysing the system 
being studied or attempting to mediate the limitations of the technique. Of these I will 
discuss the three of most interest to me and this thesis, flux-variability analysis (which I 
perform later), dynamic FBA (which I have not performed) and attempts to model the 
regulation of metabolism (which I discuss again in the final chapter as a possible extension 
of my work). 
Flux variability analysis 
The optimal solution to the flux-balance problem is rarely unique, with many possible and 
equally optimal, solutions existing. Flux variability analysis (FVA), as described by 
Mahadevan and Schilling64, returns the boundaries for the fluxes through each reaction 
that can, when combined with the right combination of other fluxes, produce an optimal 
solution.  
An example of the result of FBA performed on the top six reactions of the glycolysis 
pathway as shown in previous figures is shown in figure 18. 
Reactions which can support a low variability of fluxes are likely to be of a higher 
importance to an organism and FVA is a promising technique for the identification of 
reactions that are highly important despite being non-essential. In this example we see 
that the essential reactions, R04779, ADP exchange and ATP exchange have no associated 
variability.  Furthermore, once R01786 has been deleted we see that other reactions, 
notably R01600, that previously had an associated variability now have none, indicating 
the essentiality of these reactions within the new reduced network. 
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Figure 18 : Visual representation, with FBA and FVA solution vectors below, of flux-variability analysis (FVA) 
performed on the top six reactions of glycolysis. R03321 and R02740 were only allowed to run forwards to avoid an 
internal cycle. Constraint on R04779 of 50 units as shown places an upper limit on biomass production. Variability of 
fluxes (in light grey) shown at four times width with chevrons noting possible direction of flow. 
(left) Full network. (right) With non-lethal deletion of R02740. 
Dynamic FBA 
Dynamic FBA, as first described in Varma et al. 199465 and later expanded in Mahadevan 
et al. 200266, attempts to add the ability for models to change over time, thus avoiding the 
strict homoeostatic condition of pure FBA but without requiring kinetic parameters for 
each reaction. Typically the technique involves running an FBA simulation, changing the 
model based on the outputs of that simulation, and rerunning the simulation. By repeating 
this process an element of feedback is achieved over time. I have not performed dynamic 
FBA in this thesis but it is a technique that I think could be applied to the model I have 
ultimately produced. 
Regulation of metabolism 
Finally, let me introduce one of the most interesting directions in which FBA is moving and 
a key area where improvements in its predictive power can be made. I mentioned at the 
beginning of this chapter that life is a controlled network of chemical reactions and yet I 
have barely discussed the element of control. Metabolism is not a fixed process and 
organisms must adapt to their changing surroundings or changing roles by changing how 
they live. 
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The ways that metabolism adapts to different conditions are varied. At the simplest 
conceptual level allosteric feedback loops within networks can increase or decrease flux 
through certain reactions. Referring back to Figure 18 we can imagine that if β-D-
Fructose-6P bound to the enzyme catalysing reaction R01600 in such a way as to reduce 
the enzyme’s effectiveness the network would limit its own use of β-D-Glucose and thus 
the organism’s growth-rate. We can similarly imagine that β-D-Fructose-6P might bind to 
the enzyme catalysing reaction R03321 in such a way as to increase the enzyme’s 
effectiveness and the network would increase the flux through that reaction at the expense 
of R02739 and R02740. 
Complex networks of allosteric interactions can produce systems that adapt extremely 
well to changes in conditions, often frustrating attempts to disrupt metabolic networks 
with pharmaceuticals. Similarly — as we can see from the complexities of drug design — 
the effects of small molecules on enzymes are extremely difficult to predict and the huge 
diversity of chemistry combined with the variability of enzymes makes experimental 
screening of libraries of small molecules against target enzymes extremely expensive and 
often unsuccessful. This extremely difficult problem means that exhaustive lists of the 
small molecules and enzymes involved in allosteric regulation of metabolism are not 
available for anything larger than small systems within model organisms and even then 
are subject to substantial changes caused by small changes in conditions. 
A more promising avenue for understanding the regulation of metabolism is via the more 
conceptually difficult but experimentally more accessible mechanism of gene regulation. 
Within the GPR relationship I have described, it follows logically that if the gene is not 
expressed, the protein is not synthesised and the reaction does not occur. Thus by turning 
genes on and off an organism can drastically change its metabolism. The mechanism of 
this gene regulation and the adaptability it allows is explained extremely well in Nessa 
Carey’s book, “The Epigenetics Revolution”67 but a brief explanation can give an idea of 
how we can improve FBA with this knowledge. 
Gene expression data is primarily gathered in one of two ways. The more established 
technique is to use a micro-array with different DNA molecules (probes) attached at 
different grid positions. The contents of a growing cell are extracted and the mRNA 
isolated and reverse transcribed to cDNA, and then placed on the micro-array. cDNA 
sequences with sufficient complimentarity to a probe bind to it, with the amount of cDNA 
bound to each probe signified by the intensity of the fluorescence at that position. The 
advent of much cheaper next-generation sequencing techniques now offers us a far more 
powerful way to measure the transcriptome (the set and quantity of transcribed genes), 
with the cDNA strands created by reverse transcription of the organism’s mRNA and 
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sequenced directly. This technique, called RNA-seq, has the advantage of giving 
information for the whole transcriptome rather than just the parts for which probes were 
designed and placed on the micro-array. In addition to these techniques for measuring the 
transcriptome, techniques for measuring the collection of proteins, often called the 
proteome, exist. Methods based around mass spectrometry such as peptide mass 
fingerprinting are particularly useful when studying eukaryotes where transcribed genes 
and translated proteins are subject to a variety of post-transcriptional and post-
translation modifications. 
Whatever the method used to measure the transcriptome or the proteome the obvious 
applications to the study of metabolism are similar. By comparing the transcriptome or 
the proteome in different conditions we can see the set of reactions that are active within 
the organism in each condition. This approach extends to further studies of variation, for 
example seeing active metabolic reactions in different human cell types, seeing active 
metabolic reactions in different P. falciparum life stages or seeing how P. falciparum 
responds to known inhibitors68. 
Several transcriptome and proteome studies69–73 have measured which genes are 
transcribed or which proteins are present at different life stages in P. falciparum with the 
most notable probably being Bozech et al.74. The work on P. falciparum by Huthmacher 
et al.59 integrates this life-stage specific gene-expression/transcriptome data into their 
flux-balance analysis to simulate metabolism and predict metabolic fluxes at different life 
stages. This integration is achieved* by setting each gene to either “expressed” or “not 
expressed” depending on whether the gene-expression is above or below a defined 
threshold. The flux optimisation problem is then changed such that it seeks to maximise 
biomass production at each stage whilst minimising contradictions between whether flux 
flows through a reaction catalysed by a gene that is not expressed or does not flow 
through a reaction catalysed by a gene that is expressed. The results of this approach are 
interesting, with some evidence that the predicted metabolic variations at different life 
stages accurately represent changes in metabolism as measured by known exchanges of 
metabolites between the parasite and the RBC host. Despite this success, I think that this 
type of model is often more explanatory than it is predictive and the last extension of FBA I 
want to mention is an attempt to improve upon that. 
The variable expression of the genes that largely determines the state of metabolism is 
itself governed by a network of molecules, usually proteins, called transcription factors 
which affect which genes are transcribed. Individual transcription factors increase or 
                                                             
* The last page of their paper explains this more precisely. 
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reduce the expression of a number of genes, often with related roles. For highly curated 
metabolic models such as E. coli and S. cerevisiae these gene-transcription factor networks 
have been painstakingly reconstructed and can be used to predict the effects of 
perturbations to the network, either in growth conditions of the organism or as a result of 
a knock-out of metabolic genes or transcription factors. The probabilistic regulation of 
metabolism (PROM) model proposed by Chandrasekaran and Price75 is better able to 
predict the phenotype in response to varied perturbations of E. coli and Mycobacterium 
tuberculosis than other models by moving beyond the Boolean (express/not-expressed) 
gene regulation model in Huthmacher et al. towards a probabilistic model of gene 
regulation where the expression of a gene has a certain probability of being linked to a 
transcription factor. In this system the penalty paid for allowing flux to flow through a 
reaction linked to a non-expressed gene (and vice-versa) is proportional to the probability 
it was not expressed. 
The collection of multi-layered and highly connected networks that explain the regulation 
of metabolic networks is hard to understand but it also gives good results as reported in 
Chandrasekaran and Price.  
I’ll finish this chapter by mentioning an example of where this multi-layered system of 
regulation explains a complex system very beautifully as reported in Kotte et al. 76 for 
E. coli metabolism.  The paper shows that the ability of E. coli to sense and adapt to 
different carbon sources (acetate and glucose) can be explained, without specific sensing 
of the carbon sources, using a metabolic model of just “4 TFs, 17 transcriptional regulations and 
28 enzymatic regulations”. The achievements in that paper are beyond the scope of this thesis 
but I hope that it shows what will one day be possible in other organisms and eventually in 
P. falciparum. 
  
46 
 
MetNetMaker 
 
 
 
 
 
MetNetMaker is a great program with a user-friendly interface that allows non-
programming-literate people like me to enter the world of SBML. 
Melinda Griffiths, MetNetMaker user creating SBML models of algae metabolism at the University 
of Cape Town 
 
 
 
 
 
 
A paper on the subject of the software described in this section was published in 
Bioinformatics in 2010 as follows, 
T. Forth, G. A, McConkey, D. R. Westhead. MetNetMaker: A free and open-source tool for 
the creation of novel metabolic networks in SBML format. Bioinformatics (Oxford, 
England). 2010:2-3. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20671147. 
The software can be downloaded at www.metnetmaker.com  — both packaged as an 
installer with the Microsoft Access Runtime or as a standalone *.accdr runtime database 
(changeable to *.accdb to open with the full version of Access) — where tutorial videos 
are available and some frequently asked questions are answered. The tutorial videos and 
examples show all the key features described in this chapter and replace formal 
documentation.  
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Lessons learned from initial reconstruction attempts 
My first attempt at building an SBML model of P. falciparum metabolism used results from 
an automated annotation of the raw genome by the SharkHunt77 software previously 
developed in the group. This first effort selected those EC numbers returned by SharkHunt 
with a high confidence — which I defined as those with an   -             — and looked 
up the KEGG reaction most closely linked to that EC number using the KEGG web API.  
My software was written completely in Perl and output an SBML file containing the list of 
reactions as defined in the KEGG LIGAND ontology. Whilst this software produced a valid 
SBML file, the network contained a lot of holes (gaps in an otherwise complete series of 
reactions) and orphans (individual or small groups of reactions not linked to other 
reactions) and had a number of shortcomings that would not be present in a complete 
network. Some of these shortcomings were as follows. 
 Reactions were not defined within pathways and so were difficult to link together. 
 Pathways known from other sources to exist fully had missing reactions and 
orphaned reactions were common. Despite their frequency these problem were 
hard to spot as there was no way to see the network. 
 The model was not compartmentalised and all reactions occurred in the cytosol of 
the parasite. 
 The network could not be changed or added to except by direct manipulation of 
the SBML file. 
 Information contained in the literature and in other manual annotations was not 
integrated into the network. 
Overall then, my first attempt to create a metabolic network was a useful introduction to 
SBML, the KEGG database and the project in general but was far too simplistic a base on 
which to build a whole-network reconstruction. It was clear that I would need to use — or 
build — a more powerful system for tracking my metabolic network reconstruction and 
building it piece by piece. 
Evaluation of existing solutions 
The paucity of existing software for metabolic network reconstruction was summed up in 
“A protocol for generating a high-quality genome-scale metabolic reconstruction”78 
published in 2010 by Thiele & Palsson in which they list only Simpheny79 as a suitable 
“reconstruction software package”. Whilst their assessment is both slightly biased and 
overly pessimistic, it is probably not far from the truth.  
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In the search for another option I spent a considerable amount of time researching 
existing methods for constructing whole-organism metabolic networks. This process 
included exchanging a number of emails with Markus Herrgard, discussing options with 
Elizabeth Edwards (Webb) and attending a training event with Peter Karp on Pathway 
Tools. I include a brief overview of my findings and conclusions below. 
Simpheny 
Elizabeth Edwards had spent several months prior to my arrival at Leeds working in 
Bernhard Palsson’s group at UCSD and had constructed a small model of central carbon 
metabolism in P. falciparum using the Simpheny™ software package. Information on this 
software suite is hard to come by; the only published material is a single page abstract in a 
2005 list of grantees produced by the genomics science program of the US department of 
energy 79. Bernhard Palsson is currently listed as a “Board Observer” and a co-founder of 
Genomatica, the private company who develop and distribute the software. In 
conversations with former PhD students of his including Nathan Price, Ines Thiele and 
Markus Herrgard it has been suggested that Prof. Palsson is able to ensure free or cheap 
access to the Simpheny platform to researchers with personal affiliations to him as long as 
their use of the software does not compromise the interests of Genomatica. 
My understanding is that Simpheny did not historically enforce a particular ontology — 
the many arbitrary reaction and compound names in Elizabeth Edwards’s reconstruction 
reinforce this — but that the software has since evolved to use an ontology completely 
compatible with MetaCyc. Examining recent metabolic reconstructions made using the 
software it now seems that Simpheny has fully adopted the MetaCyc ontology. Simpheny 
has the advantage of being the only tool to allow all steps of the metabolic network 
reconstruction, analysis and visualisation process to occur within a single piece of 
software. Reactions can be added to a network either by choosing them from a list of pre-
existing reactions or by independent definition. These reactions can then additionally be 
represented graphically in user-editable graphs. Flux-balance analysis can be performed 
within the programme and the results projected onto the edges of the network graph. 
Given the work already done by Elizabeth Edwards in Simpheny and her opinion that it 
was a useful programme I contacted Genomatica in June 2008 with the hope of using their 
software for my project. I was quoted a fee of $13,000 per year for use of the software, 
with additional fees for extra users and a worrying suggestion that Genomatica may retain 
certain rights to the metabolic network and simulation results produced using the 
software. Clearly we would have to find another solution. 
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Pathway Tools 
The Pathway Tools software80, at version 15.1 as of June 2011, is maintained by Peter 
 arp’s group at Stanford Research International (SRI) and is available to academics free of 
charge. It continues to be well promoted and developed and is closely linked to the 
MetaCyc ontology maintained by the same group at SRI and described in the introduction. 
The software is used for the curation of a groupe of networks all of which end with “cyc”, 
including the P. falciparum network, plasmocyc, that we have already seen in relation to 
choke-point analysis. Pathway Tools includes tools for visualising networks and finding 
and filling gaps within networks, courtesy of the Pathologic module. When I originally 
investigated using the software it did not allow SBML export of models, nor did it allow 
flux-balance analysis to be performed on models. Both these features have now been 
added. 
In the end my decision not to use Pathway Tools for my metabolic reconstruction was 
based on its extremely confusing user interface, its lack of features and flexibility, and its 
worrying tendency to revert to a LISP command-line interpreter at the first sign of trouble. 
That the software was only able to use the MetaCyc ontology was a further issue. 
CellDesigner/Payao 
CellDesigner81, and its collaborative online implementation Payao82, are interesting 
because they are primarily visual methods of creating valid SBML format metabolic 
models. As such, they can be a big help in creating joined up models without making errors 
and should be a good introduction for researchers looking to build their first models. 
The promise of CellDesigner is rather let down by its implementation which is at the same 
time too complex — with an extremely cluttered user interface — and too simple; no 
ontology or reconstruction framework is offered or enforced. My experience with 
CellDesigner has been much like Markus Herrgard’s who told me via email in July 2008 
that, “I’ve also used CellDesigner a bit, but it seems a bit too clumsy for my liking”. 
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Building MetNetMaker 
 
 
 
Obviously, the more you can automate generating the input files the easier things 
will be. 
Markus Herrgard’s advice, July 2008 via email. 
 
 
 
Having evaluated the available existing software, I decided that the best way to progress 
with my project was to build my own solution capable of six key tasks. 
1. Store the LIGAND ontology* offline within a rigorous reconstruction framework. 
2. Allow the user to generate new reactions not defined in the LIGAND ontology and 
insert them into this framework. Non-defined reactions are generally transfer 
reactions, spontaneous reactions, biomass reactions or simplifications of complex 
groups of reactions.  
3. Help the user to re-use commonly custom-defined reactions, such as hydrogen ion 
transport across the cell membrane. 
4. Output metabolic networks in SBML format complete with relevant constraints, 
optimisation objectives and kinetic properties for use with the COBRA toolbox, 
probably the most widely-used tool for flux-balance analysis. 
5. Remain flexible and expandable enough to accommodate additional information. 
Amongst other things this additional information could consist of Gene-Protein-
Reaction relations (GPRs), the chemical formulae of compounds, or references to 
evidence supporting the inclusion of a given reaction in a network. 
6. Have an interface that makes creating new reactions, viewing existing reactions and 
adding reactions to a metabolic network extremely quick, easy, and reliable. 
In the process of developing, publishing and updating MetNetMaker it has acquired a 
further key feature; the production of visual representations of the network being 
reconstructed.  
                                                             
* My reasons for choosing  EGG over MetaCyc are explained in the introduction. 
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Application structure 
The structure of MetNetMaker version 1.0, as shown in figure 19, was my solution to these 
design challenges. MetNetMaker is built around a central reaction database which holds a 
rigorous reconstruction framework as described in the introduction. This database is 
initially populated by selected parts of the LIGAND ontology as parsed and imported by a 
comprehensive parsing script called the LIGAND loader which I describe later.  Within 
MetNetMaker the reaction creator is used to create new reactions to add to the central 
database and the reaction picker is used to insert reactions from the central database into 
the selected reactions table in order to build up a metabolic network. 
 
Figure 19: Representation of key parts of the application structure of MetNetMaker as published in Forth et al.83 
Excel spreadsheets are used to hold lists of selected reactions and can be considered 
MetNetMaker’s internal file format. Multiple pathway files in Excel format can be joined 
within MetNetMaker and can additionally be exported as SBML files with extra markup for 
easy analysis in the COBRA toolbox. 
The software can thus be considered in four main parts, the database structure, database 
population (ligand loader), database addition (reaction creator) and network assembly 
(reaction picker). 
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Software implementation 
MetNetMaker is written using visual basic for applications (VBA) for the user interface 
elements and structured-query language (SQL) queries for database manipulation. These 
two elements of the design are brought together within the Microsoft Access Runtime 
which manages the central reaction database. The source code for the application (though 
not of the runtime) is available from within the full version of Microsoft Access. 
Decision to use Microsoft Access 
Since it has been the subject of much discussion let me briefly explain my decision to write 
MetNetMaker in Microsoft Access. 
I made preliminary efforts to write my software as a webservice using html, css and 
javascript for the user interface and php scripts linked to a MySQL database to manage the 
data. This was unacceptable to me because of the complexity of installation if run locally 
and the poor responsiveness if run remotely. 
I attempted to use the opensource database module of openoffice.org as the basis for 
MetNetMaker but quickly realised that the poor documentation and limited user interface 
tools available in openoffice.org would make this a very slow process. 
Although at the time I was reluctant to write software that I knew could only be used on 
Windows I am extremely happy with the outcome. The software is extremely easy to 
install, completely portable and will be supported without any intervention on my part for 
at least ten years.  
Database structure 
A further advantage of using Microsoft Access was that the entity relation diagram I 
designed, figure 20, could be verified graphically as in figure 21. This made it much easier 
to add links between tables to ensure that additions and deletions of compounds and 
reactions to and from the reconstruction framework were handled correctly. 
The entity relation structure ensures that each compound is referred to uniquely by a 
single ID and that each reaction — also referred to by a single ID — is built only of those 
compounds.  Synonym tables mean that a reaction can be searched for using any 
combination of multiple names, metabolic pathways, associated EC numbers, or 
constituent compounds whilst retaining a single unique ID. 
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Figure 20: The Entity Relation Diagram of the central database in MetNetMaker is central to implemented a rigorous reconstruction framework. 
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Figure 21: The Entity Relation Diagram of the central database in MetNetMaker as represented within Microsoft Access.
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Database population 
MetNetMaker’s central database is populated with a parsed version of the LIGAND 
ontology, obtained either through direct download* of the following files, 
 reaction from ftp://ftp.genome.jp/pub/kegg/ligand/reaction/ 
 compound from ftp://ftp.genome.jp/pub/kegg/ligand/compound/ 
 glycan from ftp://ftp.genome.jp/pub/kegg/ligand/glycan/ 
or via the KEGG API available at http://www.genome.jp/kegg/soap/. 
Prior to version 1.5.2 these files were automatically downloaded and parsed on the first 
run of MetNetMaker but due to licensing changes by KEGG MetNetMaker now ships pre-
populated with the last freely available (July 2011) version of the ftp-derived LIGAND 
ontology. This information — and subsequent ontology updates — could still be obtained 
legally using the KEGG API but would require some changes to be made to the scripts used 
to parse the ontology. 
The parsing algorithm is written in Perl and notably makes fewer parsing errors than the 
kegg2sbml algorithm written for conversion of KEGG pathways to SBML84. For 
convenience this perl script is compiled as a Windows executable file 
(parsescript.exe) for distribution with MetNetMaker so that the installation process 
has absolutely no dependencies but is also included uncompiled (parsescript.pl) with 
the standalone version of MetNetMaker (without installer) for inspection and re-use. 
Since the structure and purpose of the glycan flat file is identical to the compound flat file, 
the approach to parsing the three input files from LIGAND (REACTION, COMPOUND and 
GLYCAN) can be explained in two parts. In figure 22 I show how a section of the 
REACTION flat file corresponding to reaction R00014 (pyruvate:thiamine diphosphate 
acetaldehydetransferase (decarboxylating)) is parsed and a summary of the total length 
and destinations of the files produced is shown below as table 1. 
                                                             
* Access to the FTP site is currently only available to paid subscribers. 
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Table 1: The purpose of text files produced by parsing the LIGAND REACTION file. 
 
The equivalent parsing approach for the COMPOUND and GLYCAN files is shown in figure 
23 for C00022 (pyruvate) the first reactant of R00014 and a summary of the total length 
and destinations of the files produced is shown in table 2. 
 
 
Table 2: The purpose of text files produced by parsing the LIGAND COMPOUND and GLYCAN files. 
 
A final text file (reactionbalancedcheck.txt) is created by the parsing script and is 
shown in figure 24. This file is slightly different from the other parsing outputs as it 
contains information that is calculated — rather than merely extracted — from the 
LIGAND flat files. The chemical formula information for compounds held in the 
preferredcompoundname.txt file is split into counts for each atom. These atom counts 
are then combined according to the compounds and stoichiometries for each reaction as 
given in the reactants.txt and products.txt file. By counting atoms on each side of 
the mass-balancing of each LIGAND reaction is checked and any violations are marked in 
the balanced column of the reactionbalancedcheck.txt file. Of the 8134 reactions 
imported from LIGAND, this methodology reports 6269 to be balanced. 
Text file Length Purpose/Destination within MetNetMaker 
parseKEGGreactionfileOUT.txt 8137 lines Used to check for errors in the parsing algorithm. 
multiplereactionpathways.txt 10781 lines Imported to MRP table. 
multipleECnumbers.txt 7626 lines Imported to EC-REACTIONS LINK table. 
preferredreactionpathway.txt 8137 lines Created but not used. 
preferredECnumber.txt 6836 lines Created but not used. 
multiplereactionnames.txt 8280 lines Imported to MRN table. 
preferredreactionname.txt 8137 lines Imported to REACTION table. 
reactants.txt 16821 lines Imported to REACTIONS-REACTANTS LINK table. 
products.txt 17358 lines Imported to REACTIONS-PRODUCTS LINK table. 
 
Text file Length Purpose/Destination within MetNetMaker 
multiplecompoundnames.txt 17798 lines Imported to MCN table. 
preferredcompoundname.txt 10874 lines Imported to PREFERRED COMPOUND NAME 
table. 
reactionbalancedcheck.txt 8136 lines Calculated for each reaction rather than parsed 
directly from LIGAND.  
Imported to BALANCED table. 
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Difficulties with mass and charge balance 
It must be noted that although checking that reactions are balanced in this way is useful 
and avoids obvious mistakes, it is by no means perfect.  
Mass balancing is made especially difficult where imprecise definitions of polymers are 
given such as the addition or subtraction of a single glucose molecule from starch in KEGG 
reaction R01790 (Starch + H2O <=> alpha-D-Glucose + Starch). Another common area for 
problems in the LIGAND ontology is that most reactions involving RNA are also 
unbalanced, for example R00435 (ATP + RNA <=> Diphosphate + RNA).  
Usually problems with mass balance can be resolved quite easily but resolving problems 
with charge-balance is typically much more difficult. Since metabolism mostly takes place 
in aqueous solutions, compounds can freely exchange protons and electrons with the 
solvent. Depending on the pH, many compounds will have different ionisation states from 
their defined state. LIGAND reactions are remarkably well balanced with respect to 
protons but electrons are not considered at all when counting atoms. For most pathways 
this is unimportant but in key areas, especially close to the electron transport chain, it is 
extremely important to check if reactions are properly balanced and avoid internal cycles 
capable of creating electrons from nowhere. It is perhaps fortunate that the electron 
transport chain plays such a minor role in P. falciparum metabolism that I have been able 
to omit this pathway from my reconstruction. The reasons for this simplification are given 
later. 
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Figure 22: (top) Colour coded entry from the LIGAND database REACTION file for R00014. (bottom) The tables 
produced from parsing this entry and then used to populate tables in MetNetMaker’s central database. 
///
ENTRY       R00014                      Reaction
NAME        pyruvate:thiamin diphosphate acetaldehydetransferase (decarboxylating)
DEFINITION  Pyruvate + Thiamin diphosphate <=> 2-(alpha-Hydroxyethyl)thiamine 
diphosphate + CO2
EQUATION    C00022 + C00068 <=> C05125 + C00011
COMMENT     2-oxoglutarate dehydrogenase complex: pyruvate dehydrogenase (see R01699), 
subsequently R03270
            TPP-dependent enzymatic reaction (see R00006), subsequently R03050
            TPP-dependent enzymatic reaction (see R00226), subsequently R04672
            TPP-dependent enzymatic reaction (see R00224), subsequently R00755
            TPP-dependent enzymatic reaction (see R08648), subsequently R04673
RPAIR       RP00074  C00068_C05125 main
            RP02918  C00022_C05125 trans
            RP05698  C00011_C00022 leave
ENZYME      1.2.4.1         2.2.1.6         4.1.1.1
PATHWAY     rn00010  Glycolysis / Gluconeogenesis
            rn00020  Citrate cycle (TCA cycle)
            rn00290  Valine, leucine and isoleucine biosynthesis
            rn00620  Pyruvate metabolism
            rn00650  Butanoate metabolism
            rn01100  Metabolic pathways
            rn01110  Biosynthesis of secondary metabolites
            rn01120  Microbial metabolism in diverse environments
ORTHOLOGY   K00161  pyruvate dehydrogenase E1 component subunit alpha [EC:1.2.4.1]
            K00162  pyruvate dehydrogenase E1 component subunit beta [EC:1.2.4.1]
            K00163  pyruvate dehydrogenase E1 component [EC:1.2.4.1]
            K01568  pyruvate decarboxylase [EC:4.1.1.1]
            K01652  acetolactate synthase I/II/III large subunit [EC:2.2.1.6]
            K01653  acetolactate synthase I/III small subunit [EC:2.2.1.6]
            K11258  acetolactate synthase II small subunit [EC:2.2.1.6]
///
Reaction ID Name Definition Eqaution Pathway
R00014 pyruvate:thiamin diphosphate 
acetaldehydetransferase 
(decarboxylating)
Pyruvate + Thiamin diphosphate <=> 2-
(alpha-Hydroxyethyl)thiamine 
diphosphate + CO2
C00022 + C00068 <=> 
C05125 + C00011
rn00010  Glycolysis / 
Gluconeogenesis
parseKEGGreactionfileOUT.txt
Reaction ID Kegg Pathway
R00014 Glycolysis / Gluconeogenesis
R00014 Citrate cycle (TCA cycle)
R00014 Valine, leucine and isoleucine biosynthesis
R00014 Pyruvate metabolism
R00014 Butanoate metabolism
R00014 Metabolic pathways
R00014 Biosynthesis of secondary metabolites
R00014 Microbial metabolism in diverse environments
multiplereactionpathways.txt multipleECnumbers.txt
Reaction ID Name Source
R00014 pyruvate:thiamin diphosphate acetaldehydetransferase(decarboxylating) KEGG
multiplereactionnames.txt
preferredreactionname.txt
Reaction ID EC number
R00014 1.2.4.1
R00014 2.2.1.6
R00014 4.1.1.1
Reaction ID Compound ID Stoichiometry
R00014 C05125 1
R00014 C00011 1
products.txt
Reaction ID Compound ID Stoichiometry
R00014 C00022 1
R00014 C00068 1
reactants.txt
preferredreactionpathway.txt
preferredECnumber.txt
Created but not used
59 
 
 
Figure 23: (top) Colour-coded sample entry from the LIGAND database COMPOUND file for C00022. (bottom) The 
tables produced from parsing this entry and then used to populate tables in MetNetMaker’s central database. 
///
ENTRY       C00022                      Compound
NAME        Pyruvate;
            Pyruvic acid;
            2-Oxopropanoate;
            2-Oxopropanoic acid;
            Pyroracemic acid
FORMULA     C3H4O3
MASS        88.016
REACTION    R00006 R00008 R00014 R00195 R00196 R00197 R00198 R00199 
            R00200 R00203 R00205 R00206 R00207 R00208 R00209 R00210 
...
            R08660 R08667 R08686 R08698 R08714 R09048 R09088 R09238 
            R09254 R09366
PATHWAY     ko00010  Glycolysis / Gluconeogenesis
...
            ko00900  Terpenoid backbone biosynthesis
            map01060  Biosynthesis of plant secondary metabolites
            ...
            map01070  Biosynthesis of plant hormones
            ko01100  Metabolic pathways
...
            ko04930  Type II diabetes mellitus
ENZYME      1.1.1.27        1.1.1.28        1.1.1.38        1.1.1.39        
            1.1.1.40        1.1.1.83        1.1.2.3         1.1.2.4         
            ...
            4.4.1.13        4.4.1.15        4.4.1.16        4.4.1.24        
            4.4.1.25        4.4.1.-         4.5.1.2         4.6.1.1 (C)     
            6.4.1.1
DBLINKS     CAS: 127-17-3
            PubChem: 3324
            ChEBI: 32816
            LIPIDMAPS: LMFA01060077
            LipidBank: DFA0385
            KNApSAcK: C00001200
            PDB-CCD: PYR
            3DMET: B00006
            NIKKAJI: J2.015J
ATOM        6
            1   C1a C    12.6924  -17.4300
            2   C5a C    13.9049  -16.7300
            3   C6a C    15.1173  -17.4300
            4   O6a O    16.3318  -16.7288
            5   O5a O    13.9049  -15.3302
            6   O6a O    15.1173  -18.8300
BOND        5
            1     1   2 1
            2     2   3 1
            3     3   4 1
            4     2   5 2
            5     3   6 2
///
Compound ID Compound Name
C00022 Pyruvate
C00022 Pyruvic acid
C00022 2-Oxopropanoate
C00022 2-Oxopropanoic acid
C00022 Pyroracemic acid
multiplecompoundnames.txt
preferredcompoundname.txt
Compound ID Compound Name Formula
C00022 Pyruvate C3H4O3
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Figure 24: Table produced during parsing to test whether reactions are mass balanced. 
  
Reaction ID Reactant Atoms Product Atoms Balanced
R00014 C15 H23 N4 O10 P2 S1 C15 H23 N4 O10 P2 S1 True
reactionbalancedcheck.txt
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User interface 
A key aim for me when writing MetNetMaker was that it should be usable by someone 
with a limited knowledge of metabolic network design. Ideally this would include people 
who spent a majority of their time in the wet lab performing experiments on the organism 
they were studying. A key part of achieving this goal was to have a friendly and familiar 
user interface capable of performing all tasks without ever presenting the user with a 
command line prompt. My decision to build features around the user interface, rather than 
the other way round, means that there are some useful features missing from 
MetNetMaker. This lack of features is a reasonable criticism of my software but I think my 
software fills a valuable niche below much more complex programmes like Metannogen85 
and I have been greatly encouraged by the feedback I have received from all around the 
world. 
The user interface of MetNetMaker can be considered in two main parts, the reaction 
picker and the reaction creator, all tied together by the ribbon user-interface (UI). The 
ribbon — now common in modern Windows programmes — contains frequently used 
controls within the user interface. 
Reaction Picker 
The reaction picker, shown in figure 27 on page 64, is the immediately visible part of 
MetNetMaker and is itself divided into a number of subsections. 
Reaction Filters 
This section gives the user the chance to search for a reaction within the database by 
specifying reactants and/or products (by either full or partial name or ID), associated 
pathway, associated EC number and reaction name (including partial names). All of these 
parameters can be searched for in any combination. 
Reaction Chooser 
This section provides the user with a list of reactions that fit the search parameters chosen 
in the “Reaction Filters” section. In figure 27 the reaction chooser only shows reactions 
associated within the LIGAND ontology with the EC number 1.2.4.1. Reaction R00014 has 
been selected. Double-clicking on a selected reaction within the reaction chooser opens 
the relevant page of the LIGAND website with the most recent full description of the 
reaction. 
Three additional buttons allow the user to delete existing reactions, open the reaction 
creator to create a new reaction from scratch, or edit an existing reaction by pressing the 
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“Edit Reaction” button. Selecting a reaction and pressing “Edit Reaction” opens the 
selected reaction within the reaction creator. 
Reaction Viewer 
Clicking on a reaction in the “Reaction Chooser” opens it for inspection in the “Reaction 
Viewer” section so that the user can be sure that they are ready to add the correct reaction 
to their metabolic network. Additional information is shown for each reaction, including 
whether it is balanced or not. Double-clicking on any compound within the reaction 
viewer opens the relevant page of the LIGAND website with the most recent full 
description of the compound. 
Reaction Picker 
In this area the user chooses which compartment they want the reaction to take place in 
and the kinetic type of the reaction. Possible kinetic types are transfer, reversible (with 
varying maximum fluxes), forward, backward, special (if a user has defined the reaction 
themselves in the reaction creator they are prompted to choose this) and biomass. By 
clicking on the “Add Reaction ==>” button the reaction that is currently selected in the 
reaction chooser section is added to the “Selected Reactions” section with the relevant 
compartment and kinetic type attributes added to it. A selection of common compartments 
is pre-populated but non-standard custom compartments — such as the food vacuole in 
P. falciparum — can be added where necessary. 
Selected Reactions 
The selected reactions area shows the user a scrollable list of all the reactions that are 
currently in their metabolic network. Items can be deleted and edited from within this list 
to allow the user to build up a metabolic network. The selected reactions table can be 
detached, as shown in figure 25, and moved separately from the main window of 
MetNetMaker allowing changes to be made more easily. Additional columns of the selected 
reactions table leave space to tweak the composition of a model’s objective biomass 
function, add information on the associated KEGG Pathway (Map Number) of each 
reaction, add information on a gene associated with each reaction and choose to reverse 
the preferred direction of the reaction during export. 
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Figure 25: Detachable window for the selected reactions list within MetNetMaker 1.5.2. 
A further notable feature of the selected reactions table is the option to see dead-end 
compounds — the lists of compounds that only enter, or only leave the network — for the 
currently loaded set of reactions. Since this calculation requires knowledge of the 
preferred direction of each constituent reaction in the network any reactions known to be 
operating in the reverse of their default direction need to be reversed by selecting the 
“Rev” tickbox in the selected reactions table. The resulting dead-end compounds table, as 
shown in figure 26, can be extremely useful in solving small errors in a network such as 
missing inter-compartment transfer reactions. 
A full description of the algorithm used to calculate the dead-end compounds within a list 
of selected reactions is included as appendix I. 
 
Figure 26: Dead-end compounds report for an example set of reactions in the selected reactions table.
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Figure 27: Reaction Picker window within MetNetMaker 1.5.2. Reaction R00014 is currently highlighted. The ribbon UI at the top is always present.
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Reaction Creator 
The reaction creator, as shown in figure 28 on page 67, performs two functions. Firstly, it 
protects the reaction database and reconstruction framework from the user, and secondly it 
helps the user make additions to the reconstruction framework without creating inconsistencies 
or duplications. Like the reaction picker it can be considered in different subsections. 
Compound Picker 
Here the user can search — by either a partial or complete name or compound ID — for the 
compound they would like to add to the reaction. Because a single compound may have multiple 
names each compound may appear more than once in the possible compounds list, as in the 
example in figure 28. 
Custom compounds, typically generic compounds such as “lipid” or “any tRNA”, can be added to 
the list of compounds here and are marked within the PREFERRED COMPOUND NAME table as 
being user generated so they can be exported by pressing the “Backup User Reactions” button in 
the ribbon UI. These exported custom compounds can be restored at a later date or transferred 
to other version of MetNetMaker as required. 
Add Record 
The user selects whether the compound selected in the compound picker is a reactant or a 
product and defines which, if any, compartment it is in. By clicking on the “Add New Record” 
button this compound is added to the selected compounds area. At this stage ambiguities from 
the compound picker area are removed and only the unique compound ID and its associated 
preferred name is added to the selected compound area. 
Selected Compounds 
This section holds lists and details of all the compounds in the reaction being created or edited. 
In figure 28 the reaction R00014 is being edited and the relevant reactants and products and 
their associated stoichiometries are present and editable in the selected compounds area. 
Similar Reactions 
The application checks that the reaction that is being defined has not already been created by 
warning of similar reactions (those containing the same reactants and products). In this example 
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it is warning that R00014 is already present within the reaction database so that it not defined 
twice with different names. 
Reaction Naming 
Despite efforts to automate naming of new reactions I have decided to offer suggestions on 
naming conventions but ultimately leave the user to name them. In this section the user defines 
a long name and a reaction ID before the reaction is added to the central reaction database. 
Finalise and Create Reaction 
Clicking this button finalises the reaction and adds it to the database. User-added reactions are 
marked “User” instead of “ EGG” in the source column of the REACTION table. These custom 
reactions are exportable in the same way as custom compounds by using the “Backup User 
Reactions” button in the ribbon UI.
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Figure 28: Reaction R00014 being edited within the Reaction Creator window of MetNetMaker 1.5.2. The ribbon UI at the top is always present.
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Application outputs for further analysis 
The most frequently used controls in the ribbon are those related to the import and export 
of models.  Model export options are critical because further use of a model must take 
place in other programmes. MetNetMaker can export models to three destinations, Excel 
spreadsheets for internal saving, SBML files for sharing models, and Cytoscape86 sessions 
for visualisation. 
Excel spreadsheet import and export 
Since MetNetMaker is written in Microsoft Access it is simple to export a list of reactions 
accumulated in the selected reactions table as an Excel spreadsheet using the “Export 
Excel” button. In this way, small sections of a complete network can be built over time and 
saved and shared easily. 
These sets of reactions can later be loaded into MetNetMaker using the “Import Excel” 
button. Importing multiple sets of reactions into a single selected reactions table within 
MetNetMaker automatically joins them and in this way large networks can be quickly 
assembled from pre-prepared components. 
SBML export 
MetNetMaker offers two options for SBML export of the reactions currently defined in the 
Selected Reactions table. Files exported as level 2 version 1 have been fully tested to work 
with COBRA toolbox 1.3.3 and this option is retained for compatibility. Exported networks 
using the level 2 version 4 export button have been validated using the SBML validator at 
sbml.org/facilities/validator and are known to work with a wide variety of tools including 
CellDesigner81, SurreyFBA87 and Cytoscape (SBML import). 
Cytoscape export 
Any valid SBML network can easily be imported into Cytoscape for visualisation. This 
would be a good method of network visualisation both for verification of the network 
during reconstruction and to view the results of analysis except for one problem. For 
useful visualisation of a network frequently occurring compounds need aliasing to allow 
the network to take a proper shape and neither SBML nor the cytoscape SBML import 
function provide a mechanism for defining and aliasing these currency metabolites. For 
this reason MetNetMaker includes a dedicated button to “Visualise in Cytoscape” which 
prompts the user to select which metabolites to alias before opening the network in 
cytoscape. 
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Since a metabolite may be a currency metabolite only in some parts of a complete network 
a related feature the “Merge .xgmml visualisations” lets the user merge separate visual 
representations of networks in the same way as they merge separate excel files in the 
selected reactions table. This helps the user manually layout a large network in small 
pieces whilst specifying different currency metabolites for each section. 
 
Figure 29: The cytoscape output form in MetNetMaker 1.5.2 
Final structure and additional features 
Because networks within MetNetMaker are stored as Excel spreadsheets they can easily 
be opened, edited and appended outside of MetNetMaker and then re-imported later. This 
flexibility is the key behind the evidence lookup process I have developed to help with my 
reconstruction of a metabolic network for P. falciparum. A key advantage of this approach 
is that organism-specific information is kept separate from the general reconstruction 
thus allowing a complete reconstruction without unnecessary complexity. 
A thorough example of the reconstruction process, including all parts of the complete 
process diagram shown in figure 30, is contained in the next chapter of this thesis.
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Figure 30: Representation of key parts of the application structure of MetNetMaker 1.5.2 as currently available from www.metnetmaker.com and an overview of associated tools for further analysis of 
networks.  
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Visualisation and Network 
Reconstruction 
visit www.tomforth.co.uk/pfalnetwork for the network. 
 
The case for manual curation: 25% of 4711 enzymatic activities are orphan 
reactions and 26% of Pfam* families are of unknown function. 
Monica Munoz-Torres at ISB2012†  
 
Why visualisation and network reconstruction in the same chapter? 
I have shown in the introduction that a visual representation of a metabolic network is 
directly equivalent to the mathematical representation we can use for calculations and 
simulations. Previous reconstructions of the P. falciparum metabolic network have 
strongly focused on either the mathematical representation — Yeh et al.7, Hutchmacher 
et al.59 and Plata et al.58 — or the visual representation as in Ginsburg et al.10.  
Another limited visual reconstruction is shown as figure 33 and is an extract from 
Olszewski et al.88. No computational model of this network exists although my final model 
largely follows its template. 
The focus on the mathematical approach to network reconstruction is likely to have 
contributed to some of the errors found in the Huthmacher and Plata models, evidence of 
which is shown in figure 31 and figure 32, These errors are easily visible to humans when 
drawn but, as described in Gregorvyan et al.89, are often difficult to uncover 
mathematically. Also described in Gregorvyan et al. are errors, such as unconserved 
metabolites, that are difficult to see but that can be discovered computationally and which 
I will return to later. 
The visualisations of the networks in figure 31 and figure 32 use two different techniques 
to show a number of non-connected/orphan reactions. Since these network visualisations 
                                                             
* The Pfam database is a large collection of protein families, each represented by multiple sequence 
alignments and hidden Markov models (HMMs) – as defined at pfam.sanger.ac.uk. 
† Biocuration 2012. The Conference of the International Society for Biocuration, April 2-4, 2012, 
Washington DC, USA. 
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have no aliased compounds these reactions are completely redundant and serve no 
possible purpose within the final networks. Visualisation lets us see these obvious errors 
but we must also consider that there are likely to be further orphan reactions, or non-
orphan but incorrect reactions that are included in error within both models. The orphan 
reactions in both models provide good reasons why I think that network visualisation is a 
vitally important part of network reconstruction. 
 
Figure 31: P. falciparum metabolic model from Huthmacher et al.59 as visualised in SharkView90 with no compound 
aliasing. Squares represent reactions and circles represent compounds. The outline colour of each compound 
denotes the compartment it is found in. Isolated reactions are not connected to the network. 
 
Figure 32: P. falciparum metabolic model from Plata et al.58 as visualised in cytoscape86 with no compound aliasing. 
Red lines show compounds entering a reaction, green lines show compounds leaving a reaction. Compounds and 
reactions are arranged around the perimeter of the circle. Isolated reactions at the top-left are not connected to the 
network.  
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Figure 33 : The simplified map of carbon metabolism from Olszewski et al.88shows the unusual role of the 
mitochondrial TCA cycle in P. falciparum metabolism and the unusual role of the apicoplast in lipid synthesis and 
manipulation. Some of the visual simplifications are highly misleading, for example the reaction Glu => 2OG 
(glutamate => oxoglutarate) and the reaction OAA <=> Asp (oxaloacetate <=> aspartate) are actually the same 
reaction and their linked behaviour radically changes the structure of the network. My final model on page 94 (figure 
47) retains some of the design features of this model without making this important oversimplification. 
 
KEGG projector and Cytoscape: one problem, two approaches 
I have explained the general principles of metabolic network visualisation in the 
introduction and I have tried many techniques to implement those ideas. In the end I have 
largely settled for two network visualisation techniques which I have implemented in 
versions of MetNetMaker greater than v1.6. Access to both the KEGG projector and 
cytoscape visualisation techniques are shown in the user interface excerpt in figure 34. 
Both visualisation techniques are used widely in the rest of this thesis and it makes more 
sense to refer to later figures in this chapter as examples than to include them in this 
section out of context. 
 
Figure 34 : The visualisation section of the ribbon in MetNetMaker v1.6+ includes new options for visualising 
reactions in the selected reactions table. These methods rely either on my KEGG projector tool (the two buttons on 
the left) or Cytoscape for visualisation. 
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KEGG projector: a visual tool for immediately gauging the extent of a network 
KEGG projector relies on the KEGG markup language (KGML) global map available from 
the KEGG ftp site and described at www.kegg.jp/kegg/xml/ where an xml version of the 
global map can be downloaded. This xml file describes the KEGG global map91 in the 
scalable vector graphics (SVG) format and as such the visual map can be easily read by 
humans and manipulated by simple computer programmes called scripts. 
The KEGG projector tool — available from within MetNetMaker and also at 
www.tomforth.co.uk/keggprojector — shows the reactions described by a list of KEGG 
reaction IDs or EC numbers projected onto the KEGG global map. An example of this for all 
the reactions for which I have found any evidence of existence in P. falciparum is shown on 
page 88 as figure 42. I have found the KEGG projector to be a very powerful tool because 
the KEGG global map is widely recognisable to people working in metabolism and because 
the maps are generated in seconds from basic input and without the need for any manual 
intervention. 
There are some drawbacks to this very quick approach to visualisation. One is that the 
KGML global map only has 2048 edges, much fewer than the current 8135 active reactions 
and 6742 EC-linked reactions in the KEGG LIGAND ontology. This means that many 
different reactions correspond to the same edge within the visualisation and some 
reactions do not refer to any edge at all. A further problem arises as a side-effect of the 
simplifications made to create the KGML global map whereby only major connections 
between nodes are shown. Clearly currency metabolites need to be removed from this 
kind of visual overview, but at the level of simplification used in KGML important 
connections between major metabolites are also frequently omitted. An example of these 
simplifications is shown in context on page 83 as figure 39 where the addition of 18 
reactions to a network is projected as just 7 extra paths, one of which appears — wrongly 
— to be orphaned from the other reactions in the network. 
These and other limitations mean that KEGG projector is mostly useful to get a quick 
overview of a metabolic network and whilst I have written an extension of the tool that 
allows the thickness of each path to be weighted by calculated fluxes from FBA, the 
inherent disjointedness of the visualisation makes this a poor tool for visualising fluxes in 
a metabolic network. 
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Cytoscape: precise network display and flux projections 
Cytoscape visualisation makes none of the simplifications that make the KEGG projector so 
easy to use and it therefore retains much more power and flexibility.  Cytoscape 
visualisations have an extra advantage because they can contain a very large amount of 
metadata, allowing each node and edge to be precisely defined. The powerful model 
structure used by cytoscape allows this metadata to govern how data is displayed on the 
network using customisable and interchangeable Vizmaps. I have defined Vizmaps for 
showing fluxes (page 199, figure 98), flux constraints (page 204, figure 99), flux 
variabilities (page 216, figure 107) and essential reactions (page 218, figure 109). 
Figure 35 shows how cytoscape visualisation can recreate — as a fully editable cytoscape 
session — the static representations in MPMP. These visual representations require 
currency metabolites to be defined during creation within MetNetMaker and then require 
manual layout making them manageable for no more than thirty reactions. Large visual 
models can be built up from these small networks by combining xgmml (extensible graph 
markup and modelling language) format files* representing each subnetwork. A script to 
merge *.xgmml metabolic networks is included in MetNetMaker v1.6+ and is available as 
the “merge .xgmml visualisations” button. 
A key advantage of cytoscape visualisations is that they show all the reactions and 
metabolites within a model and the layout options make dead-ends and orphan reactions 
easy to see during model construction. The greatest strength of cytoscape visualisation is 
to provide a global map — like the one in figure 46 on page 94 — of the final model 
containing sufficient metadata to allow the projection of the results of simulations directly 
onto the model. This approach allows considerable insights into the system being studied.  
                                                             
* Cytoscape files (.cys) can be exported to xgmml files without loss of information from within 
cytoscape. Manipulated xgmml files can be reimported to cytoscape after merging. This round trip 
and merge retains all information within the network. 
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Four elements of my P. falciparum reconstruction 
Whilst both the Huthmacher et al. model59 and the Plata et al. model58 have been published 
since I started my reconstruction, the majority of my reconstruction was complete and my 
reconstruction process developed before I was aware of these efforts. I have not used any 
significant elements from these reconstructions, largely because I did not need to but also 
because of difficulties re-using these models. At the end of this chapter I describe how I 
have learned from the problems I had trying to re-use these published models to make my 
model easier to re-use. In this section I will explain the four principal methods I used to 
complete my metabolic reconstruction, reusing and correcting MPMP, using existing 
sources of curated data, gap filling with literature and defining custom reactions. 
Reusing and correcting MPMP 
The malaria parasite metabolic pathways (MPMP) project10 remains one of the best 
sources of information on P. falciparum metabolism but the raw data is available only as 
linked pictures like the one shown in figure 35 alongside the accompanying digitised 
pathway. Digitising these drawings is cumbersome but could have been completed quickly 
using the advanced searching features in MetNetMaker were it not for a second problem. 
 
Figure 35 : (left) depiction of glycolysis from MPMP8 (right) equivalent diagram within Cytoscape, created from a 
corrected version of the MPMP network using the ‘Visualise in Cytoscape’ button in MetNetMaker. 
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In large part because it is assembled and defined graphically, MPMP is full of errors. As I 
digitised and corrected these errors I noted and categorised them according to severity. 
Counting these errors after model assembly showed there to be, 
 62 minor errors such as currency metabolites being wrongly defined or mass not 
being conserved for a single reaction. These problems could be fixed quickly. 
 57 serious errors such as mass and/or charge not being conserved across a larger 
set of reactions or required reactions within a pathway being omitted. A few of 
these problems could typically be fixed in a day, especially where information from 
other sources was available. 
 22 very serious problems that were difficult to resolve and were critical to the 
functioning of the network as a whole. These problems often required extensive 
simplifications or generalisations to be made to my network. 
The full list of errors and corrections may no longer be accurate as corrections are made to 
MPMP frequently but to more fully explain the problem I include — as table 3 —an 
example of the kind of issues found when digitising an MPMP pathway. 
Pyrimidine metabolism - MPMP digitisation issues 
Severity EC Number Note 
serious 4.2.1.1 and 6.3.5.5 Carbonic Acid issue needs looking into seriously. Here 
4.2.1.1 creates carbonic acid (H2CO3). This will 
disassociate by itself in solution to H+ and HCO3— which is 
then used by 6.3.5.5. I should add this dissociation 
reaction implicitly. 
minor 1.17.4.1 Extra H20 in KEGG reaction 
minor 2.7.4.14 KEGG reaction R02098 is a perfect match but has EC 
number 2.7.4.9 
serious 2.7.4.9 This reaction is already in the pathway one step above. In 
FBA this is useless so I've omitted it. 
minor 2.1.2.1 R00945 is a good match but produces an extra H20 
compared to MPMP. 
minor 1.8.1.9 (occurs 
twice, second 
occurrence omitted) 
R02016 is a good match but produces an extra H+ 
compared to MPMP. 
minor 1.17.4.1 R02023 is a good match but is much more complex than 
the MPMP reaction. 
minor 6.3.4.2 R00573 is a good match but has an extra H20 as a 
reactant. 
Table 3 : Issues encountered during the digitisation of MPMP’s depiction of pyrimidine metabolism. 
Updating or redefining deprecated KEGG reactions 
In the introduction I described how the simplicity of the KEGG LIGAND4 ontology played a 
large role in my decision to use it for this reconstruction but as I used it more I realised 
78 
 
that this simplicity comes at a price. As the ontology is updated some reactions are 
removed, often without a direct replacement. I first noticed this issue when manually 
entering reactions drawn in MPMP pathways which linked to numbered KEGG reactions 
that no longer existed. The issue came to light a second time when updating the first draft 
of my model two years after it was built. The first draft of my P. falciparum metabolic 
network was completed using MetNetMaker 1.0 in early 2010. Just over a year later seven 
reactions — R02086, R00415, R05919, R05921, R05922, R07461 and R07462 — that 
were valid at the time of reconstruction were no longer part of the updated KEGG LIGAND 
database. 
 
Figure 36: RO2086 as shown in MetNetMaker v1.0. This reaction is no longer present in current versions of LIGAND. 
No current LIGAND reaction involves C04256 but the compound remains in the ontology. 
 
Figure 37: R08193 as shown in MetNetMaker v1.5+. This reaction replaces R02086 but specifies the product as 
C04501 in place of C04256. The two compounds are isomers. 
It is somewhat reassuring that where reactions are removed from LIGAND their reaction 
numbers seem to be permanently retired so at least a reaction does not change across 
different versions of the ontology. The extent of this problem is unclear but with the 
current LIGAND reaction numbering system going up to R09052 and with only 8135 
distinct LIGAND reactions it seems likely that around 900 reactions have been removed 
from the LIGAND ontology since it was first published. 
At first inspection it seems as if a similar purging of the ontology occurs with compounds; 
in the version of LIGAND used in MetNetMaker 1.5+ compounds are listed up to C13782 
but there are only 10873 unique compounds. In considering this discrepancy we must 
remember that the compounds within the LIGAND database serve purposes greater than 
just defining reactions; they are also used to define drugs and inhibitors for example. In 
my experience no compounds that have ever been involved in a defined reaction are 
removed from the ontology, even if the reaction is removed. 
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A reaction that no longer exists within a model presents a problem. The ideal solution and 
the one I have used wherever possible is to update an outdated reaction to its modern 
equivalent. This often requires updating several reactions to ensure that the new reaction 
connects properly with its neighbours. 
Where replacing reactions has not been possible I have taken advantage of the consistency 
of the defined compounds to redefine legacy reactions in the new version of the ontology 
using the original reaction ID. Because these redefined reactions are stored within 
MetNetMaker as user-defined rather than KEGG-defined reactions they are included in the 
user’s custom reactions file if custom reactions are exported.  
This problem is one of many unexpected and frustrating discoveries I have made over the 
last four years and worked around. Because of  EGG’s decision to charge for access to the 
LIGAND ontology via its FTP service, all current and future version of MetNetMaker are 
pre-populated with the last free version of the ontology. This has the welcome side-effect 
that the problem I have just described is substantially reduced as compared to when each 
installation of MetNetMaker populated itself with the most up-to-date version of LIGAND 
when it was first run. 
Using existing sources of curated data 
SharkHunt77 was run on version 2.1.4 of the P. falciparum 3D7 genome available from the 
European Molecular Biology Laboratory (EMBL) and returned 289 protein hits with an E-
value under         (good) and 250 protein hits with an E-value under         (very 
good). These EC hits corresponded to 558 and 447 possible LIGAND reactions at each of 
the two confidence levels. SharkHunt returns more information than a list of EC hits 
including the sequence of each hit and the name of the reference sequence it was matched 
with but since this information is not required for network reconstruction I did not use it.  
The list of genes and associated EC numbers was downloaded for the KEGG pfa model 
from the organism section of  EGG’s FTP servers. This contained 616 genes corresponding 
to 646 unique EC numbers and 908 distinct possible LIGAND reactions. Initially I had used 
the output of KEGG2SBML84 on the KEGG pfa model to convert EC numbers of reaction IDs  
but it was clear that a number of EC numbers were missed in that parsing script. Using the 
EC Number-Reaction ID linking table in my ECinfo database — described on page 81 — 
gave much better results. 
The Braunschweig Enzyme Database (BRENDA) database92 contains 230 pieces of direct 
evidence, typically an experimentally isolated enzyme or experimentally confirmed 
reaction, covering 151 distinct EC numbers for enzymes that exist in P. falciparum. An 
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additional 451 distinct EC numbers are returned using the FRENDA text-mining method 
and 410 distinct EC numbers are returned using the AMENDA text-mining method. Hits by 
the three methods — direct evidence, FRENDA and AMENDA —overlap, meaning that in 
total BRENDA contains at least some evidence for 556 distinct EC numbers corresponding 
to 1053 distinct KEGG reactions. 
In addition to reporting on the presence of enzymes in P. falciparum BRENDA contains 
information on the localisation of some of those enzymes. A BRENDA localisation search 
returned 107 unique EC numbers with an associated cellular localisation of which 47 were 
from direct evidence in P. falciparum, 18 from direct evidence in other species of 
Plasmodium and 42 from FRENDA text-mining. These 107 unique EC numbers correspond 
to 295 compartmentalised reactions; there may be evidence for a single reaction occurring 
in more than one compartment. 
The version of PlasmoDB93 — a centralised database of Plasmodium genes — in the ECinfo 
database contains 813 distinct genes associated with 452 distinct EC numbers in turn 
associated with 1190 distinct LIGAND reactions. 
Extra reactions: gap filling with literature 
Carbon metabolism94–96, the role of the apicoplast97–99, and amino acid metabolism100–103 
are areas of metabolism where significant research has been conducted in Plasmodium 
and where ideas are still changing.  Fatty acid metabolism is also an area where the 
behaviour of P. falciparum is complicated and I have incorporated results from Mi-ichi 
et al.104 widely in this area. I have tried wherever possible to include information from 
these sources in my model. 
Defining custom reactions 
Sometimes reactions need to be added to metabolic models even when there is little or no 
evidence for their existence. There are seven reasons why these reactions may need 
defining. 
1. Transport between compartments within the model. These make up the largest 
number of custom-defined reactions and are largely included without evidence. 
2. Exchange reactions that move metabolites to and from the external pool of 
metabolites that simulates an inexhaustible growth medium. 
3. The biomass function. Strictly the biomass function is a reaction in that it appears 
in the SBML model as such. 
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4. Reactions defined for simplification. An example is in the fatty acid biosynthesis 
and elongation pathways where long series of elongation reactions are simplified 
to the creation of a single fatty acid which is then added to the biomass function. 
5. Balanced versions of reactions within LIGAND. In many cases unbalanced 
reactions in LIGAND can be fixed simply by defining a balanced equivalent. 
6. Reactions which occur in the host red blood cell and whose mechanism is beyond 
the scope of my model. 
7. Reactions added through necessity. Usually these reactions are strongly implied, 
for example where a single reaction is missing from a pathway that is known to be 
active.  
Combining evidence in the ECinfo database 
With evidence coming from many different sources it was a considerable challenge to join 
it together. The ECinfo database was my solution to this problem and it combines all the 
raw data used to create my final model. The structure of the database, as shown in figure 
38, is much looser than that for MetNetMaker because there are none of the same 
requirements to preserve the integrity of a reconstruction framework. The database 
structure collects information from all the sources described by EC number and links this 
to the LIGAND ontology which — like the reconstruction framework within MetNetMaker 
— is based on Reaction IDs and pathways. 
 
Figure 38: Entity relationship diagram for the ECinfo database as presented in Microsoft Access’s Relationships 
view. 
The Reaction ID – EC Number link 
The key task of the ECinfo database is providing a reliable link between KEGG Reaction IDs 
and EC numbers. This is a many-many relationship with the conversion table being 
created when the KEGG LIGAND database is parsed and imported into MetNetMaker. In 
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total this table contains 7533 entries referring to 6742 distinct KEGG Reaction IDs. 
Incomplete EC numbers, eg (2.4.1.-) are linked only to those reactions specified in the 
KEGG LIGAND ontology and not to all the possible reactions that could be linked to an EC 
number if the dash, or dashes, in the EC number were treated as wildcards. 
Additional information 
Beyond the other described sources of information, the ECinfo database contains 
information from KEGG on the preferred direction, if specified, of each reaction. As 
discussed in the introduction, all chemical reactions are theoretically reversible and since 
metabolism in general often uses the same reaction both anabolically and catabolically the 
preferred direction of a reaction is sometimes related to the pathway it is found in. In 
order to allow this specification the KEGG pathways associated with each reaction are held 
in a table within ECinfo and I have additionally created my own table linking the non-
standard MPMP pathways names to the KEGG pathway numbering/naming system. 
The ECinfo database also contains the same information on whether a LIGAND reaction is 
balanced as contained in MetNetMaker so that problems with known unbalanced 
reactions within a network are highlighted twice. 
Example reconstruction: nucleotide metabolism 
A description of the process for choosing each reaction within my final model would serve 
little purpose but since the process is shared across the whole network a small example is 
useful in explaining how the four main reconstruction elements described so far in this 
chapter are combined. In P. falciparum, an excellent place to choose such an example is 
nucleotide metabolism which is an interesting group of pathways for two main reasons. 
Firstly, because we know a great deal about both purine and pyrimidine metabolism, both 
in humans and in malaria parasites. Whilst humans can both salvage and synthesise de 
novo both purines and pyrmidines, it has been known for over three decades that 
P. falciparum parasites cannot perform de novo synthesis of purines105 and cannot salvage 
pyrimidines106. They must therefore rely on salvage of the host cell’s purines and de novo 
synthesis of pyrimidines for nucleotide synthesis. These gaps in malaria metabolism are 
especially good drug targets since human metabolism can use the redundant pathway if 
one of the two mechanisms of nucleotide synthesis is perturbed. The widely used 
prophylactic drug atovaquone — used in combination with proguanil and marketed as 
Malarone® by GSK — perturbs pyrimidine metabolism and the drugs Coformycin, 
Bredinin, Hadacidin, Allopurinol and the iminoribitol group of compounds target purine 
metabolism10. 
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Secondly — and surprisingly given the importance of nucleotide metabolism — MPMP 
seems to omit parts of the pathway with considerable evidence for occuring. To highlight 
this, the left side of figure 39 shows — using the KEGG projector tool — the reactions I 
created from correcting and importing MPMP’s drawings for nucleotide metabolism. 
When compared to the equivalent section of the consensus reactions projection at the top 
right of figure 43 it is clear that there are considerable gaps that can be filled from our 
existing knowledge. 
          
Figure 39: (left) The heavily shaded edges represent the 49 reactions of the nucleotide metabolism section of MPMP 
as projected onto the KEGG global map in KEGG projector (right) My reconstruction contains 17 more reactions but 
this is represented as only an additional 4 heavily shaded edges on the KEGG global map. 
The following example of how I improved on MPMP’s model of pyrimidine is considerably 
more ordered than what I actually did but it is a good representation of what I would do if 
I started my reconstruction now with the knowledge I have gained during my PhD studies. 
The results of the improvements I have made, as shown on the right side of figure 39 seem 
small in the KEGG projector view of the network but are more considerable than they 
appear. 
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Pyrimidine metabolism as an example of my reconstruction technique 
The starting point for my reconstruction is the list of reactions shown in table 4 and I 
assume that all reactions for which there is a consensus across all my data sources, as 
presented by the ECinfo database, are worthy of inclusion in my model. 
 
Table 4 : The 29 consensus reactions associated with pyrimidine metabolism (KEGG pathway 00240) from the 
ECinfo database. 
Using the ECinfo database’s information on each reaction we immediately see that five of 
these reactions are unbalanced.  
 R00377 and R00378 have both as reactants and products the generic compound 
DNA (C00039) and are the LIGAND ontology’s representation of DNA elongation 
using dCTP (C00458) and dTTP (C00459) respectively. These reactions can be 
deleted so long as dCTP and dTTP are included in the biomass function and that 
the biomass function returns to the cytosol, for each nucleotide consumed, a 
molecule of diphosphate. 
 R00442 and R00443 can be deleted for the similar reason that they refer to 
elongation of the generic compound RNA (C00046) from CTP and TTP bases 
respectively.  
 R00575 (2 ATP + L-Glutamine + HCO3— + H2O <=> 2 ADP + Orthophosphate + L-
Glutamate + Carbamoyl phosphate) is an unbalanced reaction; the atom counts 
calculated by MetNetMaker are shown in figure 40. After checking these atom 
counts by hand I added a hydrogen ion as a reactant in R00575 to create 
R00575_balanced and include this in my model instead. 
Reaction ID EC Number 
R00139 2.7.4.6 
R00156 2.7.4.6 
R00158 2.7.4.14 
R00377 2.7.7.7 
R00378 2.7.7.7 
R00442 2.7.7.6 
R00443 2.7.7.6 
R00512 2.7.4.14 
R00570 2.7.4.6 
R00571 6.3.4.2 
R00573 6.3.4.2 
R00575 6.3.5.5 
R00965 4.1.1.23 
R00969 3.6.1.17 
R01665 2.7.4.14 
R01867 1.3.3.1 
R01870 2.4.2.10 
R01876 2.4.2.3 
R01993 3.5.2.3 
R02016 1.8.1.9 
R02018 1.17.4.1 
R02024 1.17.4.1 
R02093 2.7.4.6 
R02094 2.7.4.9 
R02098 2.7.4.9 
R02100 3.6.1.23 
R02101 2.1.1.45 
R02326 2.7.4.6 
R02331 2.7.4.6 
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Figure 40 : The report from MetNetMaker on the atom counts for R00575 showing that the reaction is unbalanced. 
R00575_balanced replaces it in my final model. 
The next step in network reconstruction is to visualise the network and see whether there 
are any orphaned reactions. Selecting Pi (Orthophosphate), PPi (Diphosphate), H2O, O2, 
C02, PRPP (5-Phosphoribosyl diphosphate), ATP, ADP and H+ as currency metabolites in 
MetNetMaker’s cytoscape export dialogue and applying cytoscape’s circular layout to the 
resulting visualisation showed three reactions to be orphaned.  
 R00139 shares an EC number with R00156 which is not orphaned and is exactly 
equivalent except for the use of thioredoxin as the charge carrier in place of 
R00139’s ferrodoxin. With thioredoxin used elsewhere in the network I chose to 
delete R00139 and have used thioredoxin as the preferred charge carrier in similar 
reactions throughout my final network. 
 R01876 converts between Uracil (C00106)  + Pi (C00009) and Uridine (C00299) + 
alpha-D-ribose 1-P (C00620). Since we know from the literature that pyrimidines 
cannot be salvaged this is entirely expected and we can assume that the gene for 
this reaction is vestigial or serves another purpose. R01876 is deleted. 
 R02016 moves charge between thioredoxin and NADP and has no non-currency 
metabolites. This important reaction is kept since it only appears to be an 
orphaned reaction when NADP and thioredoxin are aliased and is actually well 
connected with the network. 
During visualisation I observed a dead-end compound which I chose to remove from the 
network by removing the reaction that creates it. R00969 combines two phosphorylated 
uracil bases to create UppppU (C06198) in the reaction UTP + UMP  <=> C06198 + H2O. 
This compound, shown in figure 41, is a dead-end that I am not including in my biomass 
function and whose known biochemical properties107 are beyond the scope of my model to 
simulate. 
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Figure 41 : The chemical structure of KEGG compound C06198, also called P1,P4-Bis(5'-uridyl) tetraphosphate or 
UppppU. 
At this point I turned to the digitisation of MPMP’s depiction of pyrimidine metabolism 
which I had previously manually converted into 24 reactions. Table 3, earlier in this 
chapter, summarised the issues I encountered during digitisation of this pathway but for 
this example we are only interested in the five reactions from the MPMP digitisation that 
were to this stage not in my model. 
 R00132 (4.2.1.1) has evidence for existence from both BRENDA text-mining and 
PlasmoDB and is necessary to provide HCO3- from carbon dioxide dissolved in 
water. I added this reaction to my model. 
 R01397 (2.1.3.2) provides N-Carbomyl-L-aspartate to R01993. The reaction did 
not appear in the consensus model because it is missing from BRENDA but it is 
present in all other sources and required for the pathway and so included in my 
model. 
 R00945 (2.1.2.1) is omitted from the consensus model for this pathway because it 
is defined within other pathways (specifically 00670, 00460, 00260, 01100 and 
00680) and in this case acts as a link to folate metabolism. It is added to my model. 
 R02023 (1.17.4.1). There is only evidence for this reaction from BRENDA and 
these are text-mining hits. The reaction does not occupy an essential position in 
the pathway and although the reaction is included in MPMP I have not included it. 
 R02325 (3.5.4.3). The only evidence for this reaction is from PlasmoDB but given 
the reliability of this source it seems safe to include it. Without inclusion, 
conversion between dUTP and dCTP is only possible if the nucleotides are first 
oxidised which lends weight to its inclusion given the number of other reactions 
that would otherwise be redundant. 
With these three reactions added, returning to the visual representation highlights a 
further problem. R00132 creates H2CO3 from carbon dioxide dissolved in water but the 
following reaction requires HCO3- which forms spontaneously in solution (H2CO3 <=> 
HCO3- + H+). Defining this reaction as CarbonicAcid_disoc and adding it to the network 
solves this problem.  
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The next stage in the reconstruction is to flag the compounds in the pathway to include in 
my biomass function. In the case of pyrimidine metabolism these are UTP (C00075) and 
CTP(C00063) for RNA synthesis and dTTP(C00459) and dCTP(C00458) for DNA synthesis.  
The last stage of reconstruction is to define exchange and transport reactions. For 
simplicity I have not modelled a separate nucleus or endoplasmic reticulum in the parasite 
which means that none of the compounds involved in pyrimidine metabolism need 
transport reactions between internal compartments defining. Exchange reactions 
simulating the entry and exit into the parasite of compounds are required.  
A good guideline to the nutrients available to P. falciparum is provided by the exchange 
reactions in the Leishmania major metabolic network of Chavali et al.108 which I examined 
closely. Further information on relevant exchange reactions is provided from a number of 
papers103,109–117, from necessity and from my experimental results on nutrient exchange. 
For this pathway I have defined exchange reactions for L-glutamate, L-glutamine, H2O, CO2, 
Orthophosphate, Diphosphate, L-aspartate. NH3, and H+. Where exchange reactions are 
required for multiple pathways they only need defining once and it should be remembered 
that the fluxes through many of these exchange reactions — particularly those of the 
amino acids and carbon sources — are restricted by experimental results at the modelling 
stage. 
 
The size of the task 
The techniques I have documented for pyrimidine metabolism are similar to those for 
other pathways, each with their own difficulties. The scale of the challenge of creating a 
reconstruction can be shown as the difference between figure 42, showing the reactions 
for which there is some evidence of existence within P. falciparum, and figure 43, the EC 
numbers for which there is a consensus of evidence across all sources.  
The challenge is thus to develop a model somewhere between these two extremes whilst 
adding the necessary transport and exchange reactions and any simplifications needed to 
keep the model functional when combined with experimentally measured fluxes. 
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Figure 42: Projection onto the KEGGML pathway map118 of all 1415 reactions with any evidence for existence in 
P. falciparum in my ECinfo database. 
 
Figure 43: Projection onto the KGML pathway map118 of all 363 reactions related to an EC number with a consensus 
of evidence for existence in P. falciparum. Nucleotide metabolism (dark pink, top-right) appears more populated than 
in figure 39 because EC numbers associated with multiple reactions are projected onto multiple edges. 
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The final model 
Model creation ended up being a two-step process. First I built a large model with nearly 
500 reactions which I have called the full model and whose properties are summarised in 
figure 44. I then began reducing it to a core network which I could usefully visualise and 
manually check to be free of errors. 
Notable simplifications in this model are, 
 All de novo fatty acid synthesis is reduced to a one-step creation of palmitic acid 
(16:0 fatty acid) in the apicoplast as a direct branch from glycolysis at 
phosphoenol pyruvate (PEP). 
 The simplification of all fatty acid elongation to the addition of a single C2H4 unit 
to a generic fatty acid. This process occurs in the apicoplast as a branch from de 
novo fatty acid synthesis. 
 The desaturation of all fatty acids is simplified to the desaturation of a generic fatty 
acid by a three step process in the cytosol. This step is thought to occur in the 
endoplasmic reticulum but from a modelling perspective moving it to the cytosol 
removes around a dozen reactions — without affecting the modelling results — 
and removes a compartment from the model. 
 GDP-L-fucose is selected as the only compound to represent all glycosylation 
within the model. 
 GDP-mannose is selected as the only compound to represent carbohydrate 
accumulation in the parasite. 
 The majority of non-core metabolic reactions are removed from the network, 
including all reactions ultimately producing compounds not incorporated into my 
biomass function such as spermidine and putrescine. 
 Thioredoxin replaces ferroredoxin as the charge carrier for all reactions where 
either can be used. 
 The electron transport chain is not included in the model even though it is known 
to be functional. This is justified because there is very strong evidence that it 
serves only to replenish ubiquinone levels to allow the synthesis of purines and 
not to provide energy via oxidative phosphorylation as per Painter  et al. 119, 
“erythrocytic stages of the human malaria parasite Plasmodium falciparum seem to maintain an 
active mitochondrial electron transport chain to serve just one metabolic function: regeneration of 
ubiquinone required as the electron acceptor for dihydroorotate dehydrogenase, an essential 
enzyme for pyrimidine biosynthesis”  
 Haemoglobin digestion in the food vacuole is substantially reduced in complexity 
to just five reactions; importing haemoglobin, releasing amino acids and forming 
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and exporting haemozoin. I took this decision because despite considerable 
study100,103,120–125 our understanding of the processes surrounding haemoglobin 
digestion remains unclear. 
 Hydrogen peroxide, H2O2 is produced in the cytosol by pyrimidine synthesis and in 
the food vacuole by haemoglobin digestion. In many organisms, catalase (1.11.1.6) 
converts hydrogen peroxide to water and oxygen but there is no evidence that this 
protein class is expressed in P. falciparum. Catalase from the RBC is known to be 
ingested along with haemoglobin and is active within the parasite’s food 
vacuole126. The acidity of the food vacuole reduces the catalase’s activity to about 
one third of its specific activity within the RBC127 and the catalase appears to be 
broken down by proteases within the parasite. This means that some hydrogen 
peroxide is exported to the parasite’s cytosol before being dealt with by catalase 
but I have not included this behaviour in my model. This behaviour could easily be 
simulated by forcing a flux of H2O2 from the vacuole to the cytosol and this reaction 
is included in the model for just this eventuality. 
This simplified model, which I call the final model, is summarised in figure 45, and at 249 
reactions and 143 genes is around half the size of the full model.  
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Figure 44 : Characteristics of the “full” metabolic network before reduction to form the final model. 
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Figure 45: Characteristics of the reduced “final” model used for flux-balance analysis. 
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Size vs accuracy 
My final model is small but I think it has significant advantages over other models. That 
the Plata et al.58 model contains 1001 reactions versus the 1812 for the combined parasite 
and red-blood cell model in Huthmacher et al.59 is not a basis for comparing their quality 
or usefulness and in my opinion both are much larger than they should be considering our 
rapidly changing understanding of P. falciparum metabolism. Taking the size vs. accuracy 
argument to an extreme we could take the 1415 reactions shown in figure 42 and add the 
relevant transport and exchange reactions to create the largest model of P. falciparum 
metabolism to date but it seems unlikely that we would learn anything from doing that. 
As discussed elsewhere in this thesis with reference to Olszewski et al. 201188 even the 
functioning of central carbon metabolism remains unclear in the most-studied life stage of 
the parasite. I think it is foolish to create an extremely large model and introduce further 
complexities at deeper levels when the basis of such a model is so unclear and those 
further levels would rest so heavily upon any errors at the core of the model. Likewise, it 
does not seem useful to define specific products of the metabolic network in the biomass 
function whilst it remains unclear what is produced by the parasite, not to mention where, 
when and how. 
In comparing the number of exchange and transport reactions in my models with many 
others it is essential to realise that I have removed fifty reactions from my network. I have 
achieved this without side-effect by not separating exchange reactions (transfers of 
compounds between the extra cellular space and a pool external to the modelled system) 
and cell membrane transport reactions (import from the extra cellular space to the 
cytosol). Separating these two types of reaction is useful if there are reactions that occur in 
the extra cellular space but in my models no such reactions occur. Because of this a single 
reaction can be defined that moves a metabolite from an external pool directly into the 
cytosol, halving the number of exchange reactions. 
Finally, when considering the size of my final model it is worth remembering the visibly 
redundant reactions shown in figure 31 and figure 32 for previously published 
P. falciparum metabolic models and considering that these and similar reactions increase 
the size of the network whilst adding nothing to — and sometimes diminishing — its 
quality. I am sure that my final network contains no completely disconnected reactions 
and I am almost certain it contains no similar internal errors. I think this level of 
confidence — combined with a powerful visualisation system — is essential to 
understanding the true functioning of a metabolic network. 
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Dynamic visualisation, compartments and fluxes 
One of the reasons I can be so confident in the quality of the model is that I have 
assembled it both mathematically and visually. The full visual representation is shown in 
figure 46 and additionally with annotations of key features and an example flux projection 
in figure 47. These maps are fully editable within cytoscape and are coupled to SBML 
models representing the same system mathematically. Results of FBA can be shown on the 
map within seconds, highlighting problems that would otherwise escape attention. 
 
Figure 46: Visual version of the final model ready for flux projection, as in figure 47. 
 
Figure 47 : Final model with live flux projections of the optimal flux distribution given measured constraints. 
Annotations in red show key pathways and features of the network. 
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Encouraging model re-use 
This final model is arguably the fifth such model to be created for P. falciparum and I have 
spent some time examining how well existing models are being re-used to try and 
understand whether effort is being wasted by not building on previous achievements. 
Plasmocyc7 was last updated in 2003 and is no longer relevant. The Huthmacher et al. 
model59 is being re-used by the Hoppe group internally but, despite being well cited, a 
search on Google scholar suggests it has not yet been re-used for published work. 
Similarly, the Plata et al. model58 has not, according to Google scholar, been re-used for 
published work outside of the group in which it was developed and the currently available 
model does not seem to incorporate some of the recent improvements published by the 
group. In fact, of all the existing models it is arguably the least easy to re-use, MPMP10, that 
has been most widely adopted. 
I have thought a lot about this and had useful discussions with Giancarlo Biaggini and 
Simon Wagstaff, who are currently building on my model at the Liverpool School of 
Tropical Medicine, to try and make my model easy to re-use in the following three ways. 
Using the most standard LIGAND ontology possible 
Because Plata et al. use the MetaCyc ontology, re-use is difficult in a field where much of 
metabolism has already been formalised using the LIGAND ontology.  The Huthmacher 
et al. model is an improvement in this regard but the widespread simplifications they 
make to the ontology make the model more difficult to re-use. For this reason I have used 
the LIGAND ontology for my reconstruction and deviated from it as infrequently as 
possible, even where this might mean making the model slightly less accurate. 
Providing the model in a variety of formats, both visual and mathematical and both 
as a complete network and in sections 
The MPMP model is drawn pathway by pathway meaning it can be visually examined in 
manageable amounts. The drawback of this approach is that the details of connections 
between pathways are not well represented. In comparison, Plasmocyc is available only 
within Pathway tools and the Huthmacher and Plata models are easily available only as 
SBML files of the whole model without any corresponding visual representation of the 
network. I think that the lack of a visual representation for the two newest models is a 
huge barrier to their further use and maintenance. 
For my model both individual pathways and pre-defined useful combinations are available 
in a variety of formats; as MetNetMaker-ready excel format spreadsheets, SBML files, 
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cytoscape visualisations and as KEGG projections. All of these files are accessible from a 
single website, currently www.tomforth.co.uk/pfalnetwork , and linked to from my 
published software’s main website at www.metnetmaker.com . 
Providing tools to easily edit and update the model 
Since MPMP is provided as a collection of hyperlinked images it is not possible to re-use 
and update computationally. In discussions with Carola Huthmacher at ICSB 2011, 
Mannheim she mentioned that Hagai Ginsburg provided her with a list of the reactions in 
MPMP and I have had similar discussions with the LAMP (Liverpool Library of 
Apicomplexan Metabolic Pathways) consortium in Liverpool. It is unclear why MPMP is 
not made available publicly in a more computationally accessible format alongside the 
visual representations but I suspect that the errors that I encountered when manually 
digitising the pathways may provide some explanation. 
The Huthmacher model was assembled from a spreadsheet using custom scripts written 
by Carola Huthmacher. There is no documented way to update the model except to work 
backwards from the SBML which itself is described in terms of a mostly undocumented 
ontology. 
The Plasmocyc model can only be edited in Pathway Tools and I have already expressed 
my reservations with this software. As a result the Plasmocyc model has not been updated 
since 2003.  
The Plata et al. model was built using Simpheny but the raw files are not provided and 
even if they were the software is not within the budget of most researchers. 
By comparison my models are distributed ready to edit in MetNetMaker and because they 
are divided into pathways in the same way as MPMP, the choice of pathways is familiar to 
people working on malaria metabolism. My models are already being reused in Liverpool 
and I have tried my best to give them a good chance of being used even more widely in the 
future. 
Links to MetNetMaker 
A final goal of mine in constructing my model was that all forms of it should contain as 
much information as possible. MetNetMaker Excel files of the model contain the full set of 
information and much of this is exported to the Cytoscape visualisation file but when using 
the publicly available version of MetNetMaker most of the extra information for each 
reaction is omitted from the SBML export. 
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I designed the structure of MetNetMaker (figure 19 on page 51) so that it would be 
completely independent of the model being reconstructed and there are therefore no 
direct links between it and the ECinfo database. A link between the two databases is 
provided by the evidence checker spreadsheet which adds columns to the metabolic 
reconstruction from the ECinfo database. Examples of this process for the pyrimidine 
metabolism reconstruction used as an example in this chapter are found as table 33 and 
table 34 in appendix II. 
A key feature of a MetNetMaker pathway file is that any number of extra columns can be 
added by the evidence checker spreadsheet and it remains readable. This means that 
adding evidence to pathways does not break the compatibility of the pathway files but it 
also means that the extra information cannot be exported from a normal version of 
MetNetMaker.  
Since some of the evidence I have added to my model is specific to P. falciparum I wrote a 
special version of MetNetMaker to export the information in the extra columns of each 
pathway file as part of the SBML output. This took about half a day and I include an 
example of the extra information in the SBML description of R00156 below as figure 48. 
 
Figure 48 : The portion of the SBML export produced by MetNetMaker for the top reaction in table 33 (appendix II), 
R00156, showing the mechanism for encoding additional information in SBML level 2 format within the <notes> tag 
for COBRA compatibility. 
<reaction id = "R00156_c" name = "ATP:UDP phosphotransferase" reversible = "true" >  
 <notes> 
  <html:p>GENE_ASSOCIATION: PF13_0349, PFF0275c</html:p> 
  <html:p>PROTEIN_CLASS: 2.7.4.6</html:p> 
  <html:p>SUBSYSTEM: 00240</html:p> 
  <html:p>SHARKHUNT_EVALUE: 4.2E-58</html:p> 
  <html:p>PRESENT_IN_PLASMODB: True</html:p> 
  <html:p>BRENDA_HIT: BRENDA</html:p> 
 </notes> 
 <listOfReactants> 
  <speciesReference species="C00002_c" stoichiometry ="1"/> 
  <speciesReference species="C00015_c" stoichiometry ="1"/> 
 </listOfReactants> 
 <listOfProducts> 
  <speciesReference species="C00008_c" stoichiometry ="1"/> 
  <speciesReference species="C00075_c" stoichiometry ="1"/> 
 </listOfProducts> 
 <listOfModifiers> 
  <modifierSpeciesReference species="EC_2_7_4_6__7"/> 
 </listOfModifiers> 
 <kineticLaw> 
  <listOfParameters> 
   <parameter id="LOWER_BOUND" value="-500" units="mmol_per_gDW_per_hr"/> 
   <parameter id="UPPER_BOUND" value="500" units="mmol_per_gDW_per_hr"/> 
   <parameter id="OBJECTIVE_COEFFICIENT" value="0"/> 
   <parameter id="FLUX_VALUE" value="0" units="mmol_per_gDW_per_hr"/> 
  </listOfParameters> 
 </kineticLaw> 
</reaction> 
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Keeping a model up to date 
At the end of this chapter I would like to make it clear that I have made a compromise in 
keeping the model up-to-date. Where experimental results and publications have 
improved our understanding of P. falciparum I have made sure to update my network 
accordingly and in these contentious areas my network includes data published as 
recently as the end of 2011. SharkHunt results and the KEGG pfa reconstruction are largely 
static and do not require updating but PlasmoDB and BRENDA are being constantly 
updated. I initially used data from these two sources from mid-2009 and updated this 
information most recently towards the end of 2010. 
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Experimental Methods 
In addition to precise details on the experimental techniques used in this thesis this 
chapter includes some discussion of the development and assessment of those techniques. 
Details of actual measurements taken and their analysis is contained within the chapter on 
experimental results. 
 
Malaria culture 
Preparing human red blood cells for culture 
Erythrocytes for parasite culture are isolated from rejected donations from the national 
blood service at St. James’ Hospital, Leeds. Blood is still thoroughly screened and 
donations have typically been rejected for being underweight or having too much or too 
little of a measured component such as fat, alcohol or salt. Before use, the RBCs must be 
separated from other blood components which would complicate culture or lead to 
variability in the nutrient content of the growth medium. White blood cells and platelets 
are removed using a filter provided with the blood as it is transferred from a donation bag 
into sterile glassware. In this state the blood partially separates as the serum rises and the 
RBCs sink. Washing these RBCs aims to isolate them whilst minimising the content of 
other components. 
1. 10ml of blood placed in a 50ml plastic conical tube (falcon tube). 
2. Falcon tube filled to 50ml with RPMI 1640 growth medium and shaken. 
3. Falcon tube centrifuged at 30-45k RPM in bench-top centrifuge for 5 minutes. 
4. A clear divide between the supernatant and compacted RBCs should be clear, the 
supernatant is removed and discarded. 
5. Repeat steps 2, 3 and 4: typically three times. 
6. Dilute the compacted RBCs (defined as being close to 100% haematocrit at this 
point) to double their volume with RPMI 1640 and store at 4°C labelled as “washed 
RBCs, 50% haematocrit” with the date of the initial blood stock.  
Culture maintenance 
Plasmodium parasites in culture typically require daily attention but this can be reduced 
to every other day if the percentage of red blood cells infected with parasites is kept low 
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(below 1%). A culture with a parasitemia below 1% left in a good condition on Friday 
night can be expected to be in a recoverable condition on Monday morning but cultures 
are unlikely to handle such neglect frequently and the following protocol for media change 
should ideally be completed daily, especially during experiments. 
1. Red blood cells are separated from the growth media by leaving the culture flask 
tilted within its tray and waiting for separation or, especially for larger cultures, by 
transferring to falcon tubes and centrifuging at 30-40k RPM for 5 minutes. 
2. The supernatant is removed. For analysis of used growth medium this is 
immediately frozen and labelled appropriately. 
3. Fresh growth medium, made as described below, is added back to the culture flask. 
4. Red blood cells are re-suspended in growth medium. 
Complete growth medium 
Complete growth medium is prepared by combining the following ingredients in sterile 
conditions and then filter-sterilising by passing through a filter with a pore size of 0.22µm. 
 45ml RPMI 1640 (Gibco) (optionally supplemented with 0.1g/L hypoxanthine). 
 5ml human serum. 
 0.1g sodium bicarbonate powder. 
 50µL gentamicin solution (10mg/ml stock). 
Fresh complete growth medium is a colour best described as salmon and is slightly cloudy. 
It keeps for one or two days in at 4°C before components of it oxidise, lowering the pH and 
changing it to a brighter pink colour.  By storing prepared medium in full containers with 
less available oxygen it can keep for twice as long.  
AlbuMAX I growth medium 
AlbuMAX I growth medium is prepared by combining the following ingredients in sterile 
conditions and then filter-sterilising by passing through a filter with a pore size of 0.22µm. 
 50ml RPMI 1640 (Gibco) (supplemented with 0.1g/L hypoxanthine). 
 0.25g AlbuMAX I powder. 
 0.1g sodium bicarbonate powder. 
 50µL gentamicin solution (10mg/ml stock). 
AlbuMAX I growth medium looks and behaves almost identically to complete growth 
medium and has the advantage of being identical across batches and thus more likely to 
give reproducible results across different experiments and laboratories. There are also 
some problems with using AlbuMAX I growth medium, notably that it moves the in vitro 
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system further away from the in vivo system we are aiming to reproduce. Evidence of this 
has been both in previous studies128 although no reduction in growth-rate was reported in 
the paper which first reported the use of AlbuMAX II growth medium40. The composition 
of AlbuMAX I is unknown and unspecified beyond being a lipid-rich fraction of bovine 
serum albumen (BSA).  
Note on maximum parasitemia and culture “crash” 
Cultures with a parasitemia higher than 8% tend to die. In some cases this occurs where 
glucose levels become critically low and in discussions with Giancarlo Biaggini at the 
Liverpool School of Tropical Medicine he has mentioned that parasites die in the absence 
of glucose within 20 minutes. Whilst low glucose levels cause culture death this can be 
avoided by supplementing the growth medium with glucose or changing the growth 
medium more frequently. Even where this is done cultures still crash at parasitemia 
greater than about 8% for unknown reasons; proposed mechanisms include toxin 
accumulation and even inter-parasite chemical communication/quorum sensing129,130,131. 
Note on the requirement for supplementary hypoxanthine 
Work on the requirements of a minimal growth medium for cultured Plasmodium 
falciparum by Geary et al.101,102,132 published in 1985 had already found that, 
 “hypoxanthine was the preferred purine source for the parasite over adenine, guanine, inosine, adenosine 
and guanosine although all supported growth equally.” 
Geary et al.101,102,132  
This finding was also reported in 199540 in the first paper on substitution of human serum 
for AlbuMAX where hypoxanthine was required for parasite growth in AlbuMAX growth 
medium and the addition of a small amount of hypoxanthine to some examples of human 
serum that would otherwise not support parasite growth allowed parasites to grow. 
“One important finding was the absolute requirement for hypoxanthine in RPMI-A [AlbuMAX II growth 
medium] to enable good parasite growth.” 
Cranmer et al. 199540 
There is a further discussion of the parasite’s uptake of hypoxanthine from the growth 
medium in the next chapter. 
Transition of cultures from complete medium to AlbuMAX I 
Mixtures of complete medium and AlbuMAX I medium are defined according to the 
percentage of the AlbuMAX I medium. For example, growth medium referred to as 50% 
AlbuMAX is half complete medium and half AlbuMAX I medium. For simplicity of 
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preparation, 90% AlbuMAX can be prepared by adding 0.5ml of human serum to prepared 
AlbuMAX growth medium. 
Immediately transitioning cultures from complete medium to 100% AlbuMAX I medium 
has been observed to slow parasite growth-rate and even cause the death of a culture. The 
reasons for this are unknown but can be avoided if the amount of human serum within the 
growth medium is reduced to nothing over the course of a week. The observations of 
Plasmodium falciparum cultures adapting to changing conditions over a period greater 
than a full life cycle seems bizarre. Beyond the set of transcribed genes and expressed 
proteins inherited by merozoites from their mother cell I can think of no good mechanism 
for what appears to be some signalling between generations in culture and yet this 
property of slowly adapting to new conditions is well known to occur. A good published 
example is of parasites recovering from being deprived of hypoxanthine in their growth 
medium. 
“It required weeks to months of meticulous culture for the parasites to adapt successfully and to restore 
good growth kinetics in the absence of hypoxanthine.” 
Cranmer et al. 199540 
Observing cultures 
Blood smears 
Cultures of P. falciparum are still observed in much the same way as Alphonse Laveran 
first observed the parasite in Algeria around twenty years before his discovery and 
subsequent work won him the 1907 Nobel Prize133.  
“Films of blood are stained by Leishman or Giemsa stains and the red cells are examined...” 
Medical Microbiology, G. Thomas, 1963134 
 
Figure 49: Thin blood smears are made from a single drop of blood pushed quickly across a glass slide. The red 
blood cells at the edge of the smear are one layer thick. 
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In our lab we take thin blood smears and use Giemsa stain, which binds specifically to the 
phosphate groups in the parasite’s DNA — red blood cells (RBCs) have no DNA — whilst 
being able to easily diffuse across multiple membranes to reach the parasite nucleus. The 
protocol for making blood smears is the same as for changing the growth medium and the 
two are usually performed at the same time. 
1. The culture flask is tilted and left until the RBCs have mostly separated from the 
growth medium. 
2. If the growth medium is being changed it is removed. 
3. The smallest possible drop of packed RBCs is removed from the flask and placed 
on a labelled glass slide. 
4. A second glass slide is used to quickly push the drop of blood out into a thin smear 
with only a single layer of RBCs towards the edges of the smear. 
5. Once dry, the smear is fixed in 100% methanol and can be stained immediately or 
left for staining later. 
6. The fixed slide is stained for 10 minutes in Giemsa’s stain, diluted 1 part in 5 parts 
Sorenson’s buffer. Slides are held upside-down in a staining tray so that any 
Giemsa crystals falling out of solution do not stick to the slide. 
7. Once staining is complete, slides are immediately de-stained under running water 
for as long as necessary, usually a few minutes. 
8. Dry slides are ready to be examined under an optical microscope. 
The parasitemia of a culture is defined as the number of parasites divided by the number 
of red blood cells in that smear. Under the oil-immersion microscope used in our lab (x100 
object lens magnification in series with an x6 magnification eyepiece lens = x600 total 
magnification) a tightly-packed monolayer of red blood cells contains approximately 250 
red blood cells. Usually ten fields are counted though more may be necessary to get an 
accurate reading at low parasitemias. For all reported parasitemias all slides were read 
blind, that is to say without knowledge of the expected parasitemia or life stages present. I 
found this invaluable in preventing a positive bias creeping into my results and it is a 
technique we have all adopted in the lab when taking measurements for analysis. 
Where it is necessary to count not only the number of parasites but also the number at 
each approximate life-stage the generalisations set out by Coatney in “The primate 
malarias”135 are generally adopted, These classifications are shown in figure 50 where 
drawings 1 through 26 might be interpreted as the progression of the parasite through 
equal time steps over the full 48 hour life cycle. Since each person counts differently these 
life-stage drawings can only be considered a guide and I report an accurate measurement 
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of my counting later in this chapter in the section on “objectively re-assessing sorbitol 
synchronisation”. 
 
Figure 50: Categories used to define the life stages of P. falciparum in the microscopy time course. 1: normal red 
cell. 2-10: early ring trophozoites. 11-18: late trophozoites. 19-26: schizonts. 27-30: gametocytes (not observed in our 
system of continuous culture). Image: Plate XLII, The primate malarias, 1971, G . R. Coatney135. Similar illustrations 
by G. H. Nicholson for 26 other plasmodium species available from Images from the History of Medicine136. 
Potential problems visible in blood smears 
Previously in our lab we have had problems with airborne yeast infections which were not 
visible in stained blood smears. I was fortunate to avoid these problems and since 
thoroughly disinfecting the sterile culture extraction hood these problems have not 
returned. 
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Many problems in culturing can be diagnosed from examining blood smears, in particular 
bacterial infection as shown in figure 51. Bacteria quickly kill the parasites within a 
culture but can be tolerated at very low levels. Infections can often be removed if they are 
caught early by adding gentomycin and are less likely to occur if gentomycin is used 
continually. Although gentomycin has no known effect on P. falciparum metabolism it is 
often preferable to take great care to keep sterile when handling cultures rather than add 
a further variable to an experiment. The cultures for all the metabolomics experiments 
reported in this thesis were cultured without gentamycin in strictly aseptic conditions. 
  
Figure 51: left: Rod-shaped bacteria are clearly visible in a Giemsa stained blood smear.  
right: A healthy ring-stage parasite in an infected culture shows that  minor infections are not always fatal. 
Optical fluorescence microscopy 
Optical fluorescence microscopy was used only to confirm that acridine orange dyed 
infected RBCs selectively. Slides were prepared according to the following protocols. 
Unfixed fluorescent slides 
1. Start with 100µl of mixed culture (5% haematocrit, 95% growth medium). 
2. Add 1µl of acridine orange dye at 50µg/ml (diluted x200 from stock at 10mg/ml) 
to a final dilution of 0.5µg/ml. 
3. Place on a glass microscope slide and cover with a glass cover slip. 
Hybrid fixed fluorescent slides (limited success) 
1. Start with 100µl of mixed culture (5% haematocrit, 95% growth medium). 
2. Add 1µl of acridine orange dye at 50µg/ml (diluted x200 from stock at 10mg/ml). 
3. Incubate for 3 minutes in the dark. 
4. Make long smears (slowly push the dyed culture over a slide), dry in the dark and 
fix with methanol. 
5. Stain with Giemsa. 
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Flow cytometry 
Preliminary experiments using flow cytometry were performed on a PRS III flow 
cytometer which proved effective but extremely unreliable. All reported experiments were 
performed on a BD FACSCalibur flow cytometer from Beckton Dickinson Biosciences. 
Acquired data was analysed at the time using the software supplied with the relevant flow 
cytometer as set up by Gareth Howell, director of the FBS flow cytometry facility. Post-
acquisition analysis, and the preparation of figures for this thesis, was performed using the 
Cytomation Summit 4.2 software from Dako. 
The development of a technique to measure parasitemia by flow cytometry is discussed in 
detail in the next chapter. Although we had limited success it seems likely that with the 
right experimental setup the technique would be more successful. Our experiments 
suggest the following protocol is most likely to yield good results. 
1. Start with 40µl of mixed culture (5% haematocrit, 95% growth medium). 
2. Add 1µl of acridine orange dye at 50µg/ml (diluted x200 from stock at 10mg/ml) . 
3. Incubate in the dark for 3 minutes. 
4. Add 1.5ml PBS (phosphate-buffered saline) and acquire. 
If an accurate and reliable system for counting parasites using flow cytometry could be 
developed it should be possible to use fluorescence-assisted cell sorting (FACS) to create 
extremely high parasitemia cultures for — amongst other potential uses — high-precision 
metabolomics. The drawback of this technique is that the effects of the intercalating 
acridine orange dye on metabolism are unknown and the technique seems considerably 
more complex than the magnetic isolation technique of parasite concentration which I 
discovered late in my project and describe later in this chapter. 
Synchronisation of cultures 
Female Anopheles mosquitoes typically bite in the evening and for this reason it would 
seem advantageous for P. falciparum to time the production of gametocytes so they were 
at their highest population within the bloodstream at that time. Some support for this 
hypothesis is provided by recent studies137 showing that Plasmodium parasites in mice (P. 
chabaudi) grow best when their 48-hour circadian rhythm is synchronised with the 24-
hour circadian rhythm of their host.  
No mechanism for this possible host-parasite circadian rhythm synchronisation has been 
proved but is clear that whether or not such a system exists in vivo it does not exist in 
vitro. Cultured parasites show no natural synchronicity of life stages and life-stage-
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synchronised cultures return to this state in a matter of weeks. Most studies are 
performed on synchronised cultures where the majority of parasites are at the same stage 
in their 48-hour life cycle together. 
Synchronisation presents advantages in two major areas for study. Firstly, when trialling 
new drugs or growth conditions, it allows the stage-specific impacts of any perturbations 
to be observed. Secondly, if metabolite exchange between the growth medium and the 
parasites is being measured it is possible to minimise contamination of the growth 
medium with the contents of lysing RBCs by ensuring measurements are not taken during 
parasite release. 
There are many ways to synchronise parasite cultures and excellent reviews on the 
subject exist138,139. Here I include details on the sorbitol incubation method we use in the 
lab and on a magnetic isolation method which we have not used but which holds 
considerable promise for further research. 
Sorbitol incubation 
The sorbitol incubation method as described by Lambros and Vandenburg in 1979140 
works by selectively killing schizonts and late-stage trophozoites by submitting them to 
the high osmotic pressure of otherwise non-toxic high concentrations of sorbitol. For short 
periods, early-stage trophozoites (rings) can withstand this osmotic pressure. Sorbitol 
synchronisation is performed according to the following protocol. 
1. Transfer the whole culture to be synchronised to a 50ml falcon tube. 
2. Centrifuge at 30-45k RPM in a benchtop centrifuge for 5 minutes. 
3. Remove and discard the supernatant. 
4. Add half the volume of the removed medium of 5% w/w sorbitol solution in water 
to the compacted RBCs. 
5. Incubate for exactly 5 minutes at room temperature. 
6. Add excess growth medium to restore osmotic pressure. 
7. Centrifuge the falcon tube at 30-45k RPM in a benchtop centrifuge for 5 minutes. 
8. Remove supernatant and replace with growth medium for continued culture. 
9. Transfer the mixture back to a culture flask and treat as usual (gas and incubate). 
Synchronisation typically kills slightly over half the parasites in a mixed culture and 
parasitemia will not increase until around 40 hours later, at which point it will increase by 
the usual daily growth-rate squared. Further synchronisations, as shown in figure 52 can 
produce a tighter synchronisation window at the cost of the extra time needed to achieve a 
high parasitemia. 
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Figure 52: a) A second synchronisation performed 36 hours after the first leads to a tighter final synchronisation 
profile as shown in (b). 
Objectively re-assessing sorbitol synchronisation 
Initial observations by Lambros and Vandenburg on what proportion of — and at 
precisely what times in the life-cycle — parasites are killed by sorbitol incubation are 
vague, 
Cultures examined immediately after sorbitol treatment consisted almost entirely of single and multiple 
ring-form infections, and uninfected RBCs. 
Lambros and Vandenburg140 
That paper later suggests a second synchronisation 34 hours after the first as the best time 
to fine tune and achieve a narrower synchronisation window, suggesting that they 
experienced survival of parasites up to 16-20 hours post invasion. Since the existing 
literature is unclear on this I decided to make a more accurate estimation based on a large 
experiment I conducted in December 2010. Seven identical cultures were grown in 
parallel and synchronised at       hours, and       hours. Blood smears of all cultures 
were taken approximately 24, 46 and 86 hours later with a selection of cultures being 
examined at times in between. The parasitemias of the cultures was measured and the 
proportion of each life-stage — rings, late-stage trophozoites or schizonts — was 
determined. 
The results of these tests are shown in figure 53 and the results are consistent — as shown 
by the dashed-line fits — with the combination of the two synchronisations killing the 
majority of parasites outside of a 14-hour window as shown in figure 54a. Since the 
second synchronisation took place 46 hours after the first synchronisation the 14-hour 
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period is consistent with a single synchronisation window being approximately 16 hours, 
at the low end of the range suggested in Lambros and Vandenburg140. 
The dashed-line fits in figure 53 are particularly interesting to me as an example of a 
biological system that seem complicated but whose behaviour can be explained with 
extremely simple rules. These dashed lines are just the convolution of the two functions 
shown in figure 54a and figure 54b performed using a simple script and the         
function in Matlab. The convolution function exactly represents the progress through time 
of an applied synchronisation window. The following parameters in the source functions 
started with a sensible guess and were adjusted by hand to provide a good fit of the data, 
 Duration of the synchronisation window, 
 Smoothness of the edges of the synchronisation window representing the 
imperfection of the synchronisation technique, 
 Time at which the transition between each of the four distinguished life stages 
occurs. 
It is likely that a slightly better fit could be made by further refining the parameters but 
within the uncertainties of the measurements this would provide us with no useful 
information. In addition to letting us elegantly quantify the progression of a population of 
P. falciparum through its life stages and giving us a more accurate measurement of the 
effectiveness of sorbitol synchronisation these results provide an objective measure of 
what times in a parasite’s life I have classified them to each named stage. 
Life-stage Visible period 
Merozoites* 0-1 hours 
Rings 2-16 hours 
Trophozoites  17-37 hours 
Schizonts 38-47 hours 
 
Table 5: Age of parasites since infection at which I have classified them at each distinct stage. 
*We know that merozoites re-invade extremely quickly after they are released so this 2 
hour period is actually best interpreted as the time after successful invasion but at which 
the ring form is not yet sufficiently mature to be visible in a blood smear. 
After exiting the host, merozoites recognize, attach, and enter RBCs, and this process occurs rapidly, 
probably on the order of 60s. 
Cowmann and Crabb141 
 
110 
 
 
Figure 53: Progression of life stages for seven identical cultures in AlbuMAX I 100% growth medium synchronised at 
    hours and       hours. Lines modelling life stage progression are the convolution of figure 54a and figure 
54b. 
 
 
Figure 54: a) Mathematical representation of a 14-hour synchronisation pulse killing 90% of the targeted life-stages. 
b) 48 hours of the idealised life-stage progression that best fits results in figure 53. This figure would continue 
infinitely in both directions. 
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Synchronisation and concentration of parasitised red blood cells using magnetic 
isolation 
I was introduced to the magnetic isolation method as described in Ahn et al. 2008142 by 
PhD student Murad Mubaraki and his supervisor Giancarlo Biaggini at the Liverpool 
School of Tropical Medicine. The technique works because the crystallised haem groups 
(haemozoin) formed as a by-product of haemoglobin digestion by the parasites at their 
later life stages is paramagnetic120 and therefore late-stage trophozoites and schizont 
infected RBCs respond differently to an applied magnetic field than uninfected  RBCs and 
early-stage trophozoite infected RBCs. 
Magnetic isolation is particularly interesting because in addition to creating a highly 
synchronous culture it can also concentrate infected RBCs up to a parasitemia of around 
90%. At this parasitemia cultures are liable to crash quickly but the increased 
concentration of parasites allows for more sensitive measurements of parasite 
metabolism. I do not include a protocol for this procedure beyond the reference to Ahn et 
al. as I have not used it and mention it only for completeness and because it may be useful 
for future experiments. 
Saponin lysis and parasite biomass isolation 
Parasite biomass must be separated from red blood cell biomass before any analysis of it 
can be performed. This process — as described in Ashong et al.143 — consists broadly of 
three steps, lysing the red blood cells using saponin, centrifuging the resultant mix at very 
high speed to separate parasite biomass and then washing away the red blood cell 
membrane components. Tubes were made RNA-safe by washing with phosphate-buffered 
saline (PBS) with 0.1% diethylpyrocarbonate (DEPC) added, the tubes were then 
autoclaved to ensure sterility and deactivate the DEPC before use. The following protocol 
was used. 
1. Place culture to lyse in a 50ml RNA-safe falcon tube and spin at 4500RPM on the 
benchtop centrifuge for 5 minutes. 
2. Remove the growth medium and re-suspend the pellet in 5 times the pellet’s 
volume of Tris-buffered Saline (TBS). 
3. Add stock saponin (15% w/w in water) to a final dilution of 1 in 100 and agitate 
for ⋍30s until the culture goes from a red colour to a deep purple, signifying lysis 
has occurred. 
4. Centrifuge for 10 minutes at 10k RPM in the large Beckmann centrifuge cooled to 
4°C using RNA-safe tubes. 
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5. Remove supernatant and discard. 
6. Add a small amount of TBS and gently wash away the white-coloured red blood 
cell ghosts, remove supernatant and discard. 
7. Resuspend all remaining parasite components in a small amount of TBS and 
transfer to RNA-safe 2ml micro-centrifuge (eppendorf) tubes. 
8. Centrifuge eppendorf tubes containing parasite biomass at 10k RPM for 10 
minutes in the benchtop centrifuge. 
9. Remove supernatant and any remaining red blood cell ghosts. 
10. Add ten times the pellet volume of RNAlater®(Invitrogen) and freeze at -80°C 
immediately. 
Problems working with large culture volumes 
Initially I planned to measure biomass components using the adapted TRI REAGENT 
(Sigma) protocol described in Daniel Opi’s masters thesis144. It seems likely that a large 
reason why he was unable to make accurate measurements of the RNA, DNA and protein 
content of the total parasite biomass was because the quantities of biomass he was 
measuring were too small. To overcome this problem I started examining options for 
culturing with up to 1 litre total culture volume and around 180ml in each culture flask. 
The principal problems I encountered with culturing in very large flasks were, 
 Tilting flasks to separate haematocrit and growth medium took a long time and I 
often removed cultures from their flasks and centrifuged them to ensure that 
growth medium was properly changed without accidentally removing haematocrit. 
 The gassing procedure — where air with only 3% oxygen is injected into flasks to 
replace atmospheric air — took much longer and seemed less successful. 
 Infections seemed more likely, probably due to the greater difficulty in dealing 
with the cultures and the longer times they were manipulated for. 
 Growth seemed to slow even further, from a 1.6 daily growth-rate to closer to 1.4. 
 Preparing and filtering large quantities of growth medium required special 
equipment including a pump-attached filtration bottle. 
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Measurements techniques 
Used growth medium assays 
Collection of samples 
My usual technique for taking used growth medium samples was as follows, 
1. Shake flask to homogenise the culture. 
2. Remove 0.5-1.0ml of culture. The precise amount depends on the number of time 
points and the volume of the culture. As little as 0.1ml of culture could easily be 
used now that the techniques for sample analysis are established. Gas the culture 
and place back in the incubator. 
3. Centrifuge to separate pellet from supernatant whilst avoiding precipitating any 
supernatant contents. Usually 5k RPM for 3 minutes on a small benchtop 
centrifuge will do this but higher speeds for higher durations are unlikely to cause 
any dissolved contents to fall out of the supernatant. 
4. Remove the supernatant and freeze at -80°C ready for later analysis. 
5. Re-suspend the pellet in the remaining supernatant and make a blood smear. 
6. If required, saponin lyse the pellet to isolate parasite biomass and freeze at -80°C 
for HPLC analysis of biomass components. 
Special case for Sara metabolomics set of experiments 
The above technique has the advantage of maintaining the same haematocrit 
concentration throughout but involves disturbing the culture every time a sample is 
collected. In the Sara metabolomics set of experiments — see table 20 on page 157 for a 
full summary of metabolomics experiments — I modified the technique to increase 
sensitivity and avoid disturbing the culture. In this modified technique, at each time point 
the culture flask was tilted for 15 minutes to allow the haematocrit and supernatant to 
fully separate before 1ml of growth medium was carefully removed without disturbing the 
haematocrit. From that point the technique continued as previously described. 
There is no evidence that leaving the culture separated and thus the haematocrit 
undisturbed made any difference but this technique did increase sensitivity as the 
percentage haematocrit increased over the course of the experiment. The difficulty came 
when adjusting the results to take into account of this. The most elegant solution to this 
problem was to assume a constant exchange rate of metabolites and substitute the 
haematocrit at each time point where a sample was taken with the mean haematocrit of all 
previous time points as shown in table 6. 
114 
 
 
Table 6 : Haematocrit correction table for the "Sara metabolomics" set of experiments. 1ml of growth medium was 
removed every 3 hours during the experiment. 
This method has the drawback that where the change in a metabolite’s concentration 
stops being constant it can produce strange results. There are examples of this which I 
deal with in the experimental results chapter, notably figure 76 on page 170 and figure 78 
on page 171. 
Chemical assays to measure lactate and glucose levels 
We hoped to measure glucose and lactate levels in used growth medium immediately after 
acquiring it and as part of Jennifer Lake’s Masters thesis145 we developed protocols to do 
so. The results of our preliminary tests and our reasons for choosing not to pursue the 
techniques are summarised here and described more fully in that Masters thesis. In all 
cases measurement were made according to the suggested protocols and calibration 
routines included with the kits. The glucose and lactate levels of samples of growth 
medium were either acquired immediately or thawed from -80°C  immediately prior to 
testing. 
The (SIGMA GAGO-20) glucose oxidase kit was used for most glucose level measurement, 
some tests were run using the glucose hexokinase assay (SIGMA GAHK-20). The 
absorptions, at 540nm and 340nm respectively, of the samples from both kits were 
acquired using an Ultrospec 2100 pro spectrophotometer. 
Hour of 
experiment
Medium (ml) RBCs (ml) Haematocrit
Mean haematocrit 
up to now
0 25 1.25 5.0% 5.0%
3 24 1.25 5.2% 5.0%
6 23 1.25 5.4% 5.1%
9 22 1.25 5.7% 5.2%
12 21 1.25 6.0% 5.3%
15 20 1.25 6.3% 5.5%
18 19 1.25 6.6% 5.6%
21 18 1.25 6.9% 5.7%
24 17 1.25 7.4% 5.9%
27 16 1.25 7.8% 6.0%
30 15 1.25 8.3% 6.2%
33 14 1.25 8.9% 6.4%
36 13 1.25 9.6% 6.6%
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The chosen lactate assay kit (Source BioScience AutoGen ABE2467) measured ʟ -Lactate 
as this has been reported as accounting for 93-94% of the total lactate produced by 
P. falciparum94. 
 
NMR Analysis of used growth medium 
The results from NMR were much better than from the chemical assay kits we used and 
those results are described in the chapter dedicated to experimental results. 
Sample preparation 
Samples of used growth medium for NMR analysis were thawed from -80°C storage and 
prepared as follows, 
 270 µl sample 
 27 µl D2O 
 3 µl TSP 
These amounts were placed in NMR tubes, either open topped (Julie Fisher lab) or sealed 
with a glass stopper meaning there was no interface between the air in the tube and the 
sample (FBS NMR service) as shown in figure 55. By reducing edge effects, the glass 
stopper increased the sensitivity of the measurements with the drawback that sample 
preparation was more difficult. 
 
Figure 55: An example of a glass stoppered NMR tube with no interface between the sample and the air as used in 
the FBS NMR service machines. 
Analysis in the Julie Fisher lab, Chemistry, The University of Leeds 
The machine used was a Varian Unity Inova 500 spectrometer operating at 499.97 MHz 
proton frequency. All NMR reported in this thesis was proton (1H) NMR. 
The Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence was used: [RD – 90°x - (t – 180°y - 
t)n – acq] with the following parameters; 
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relaxation delay (RD)  3 seconds 
t = 1.5 ms 
n = 150 
During the relaxation delay the decoupler was applied to selectively irradiate the water 
resonance 
Decoupler power = 4  
Spectral width = 6499.84 
Acq time = 1.26034s 
Acquired complex points = 8192 
Transients = 256 
Power = 57 
Samples were run at 20°C. 
Analysis by the NMR service, Faculty of Biological Sciences, The University of Leeds 
Minor adjustments to the protocol developed in chemistry were made by Arnout Kalverda 
at the NMR service in FBS. These attempted to account for the slightly different machines 
used for acquisitions but the general protocol remained the same. 
Data extraction from *.fid files 
Analysis of *.fid files produced by the spectrometers was performed using the freeware 
ACD/NMR Processor Academic Edition available at acdlabs.com/resources/freeware/ . 
The protocol for analysis was broadly similar for the *.fid files produced by each machine, 
1. Load *.fid file. 
2. Apply a Lorentzian-Gaussian window function with the following parameters 
Julie Fisher lab machine = (LB = -0.3, GF = 0.25), 
FBS NMR service machine = (LB = -0.3, GF = 0.1). 
3. Zero-fill the spectrum to increase the number of acquired points. 
Julie Fisher lab machine = 8192  32768, 
FBS NMR service machine = 8192  65536. 
4. Perform a Fourier Transform of the data. 
5. Adjust phase, first using the auto function and then manually using the central 
water peak at around 4.80ppm for reference. 
6. Apply a baseline correction. 
Julie Fisher lab machine = Auto simple, 
FBS NMR service machine = Auto simple, followed by manual adjustments and 
then a further automatic baselining is usually required. 
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7. Reference to TMS at 0ppm chemical shift. 
8. Manually integrate the HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid) signal (5 overlapping peaks) at 3.15ppm and reference to 100. 
These prepared spectra were saved as ACD/labs *.esp format files. Their further analysis 
is described in the experimental results chapter. 
Biomass analysis 
Biomass component extraction 
Extraction of biomass components from the biomass pellet was performed by manually 
disrupting/grinding the pellet within the eppendorf tube and vortexing the mixtures in the 
selected solvent for as long as necessary (often 5-10 minutes) to achieve as homogeneous 
a solution as possible. This solution was always a dark grey colour with fine — but clearly 
visible — suspended black particles. 
Samples were clarified by either centrifugation or spin filtration using the 40 micron spin 
filters supplied with the PARIS™ kit (AMBION). 
Determining protein concentration 
Protein content of biomass extractions was determined using the Bradford assay with a 
known concentration of bovine serum albumen (BSA) at seven x2 serial dilutions in the 
extraction solvent starting at 4mg/ml for calibration. 190µl of Bradford reagent was added 
to 10µl of sample in a well of a 96-well plate and incubated for at least 10 minutes before 
the absorption at 595nm was measured in a Spectramax 340 pc microplate reader 
(Molecular Devices).  
Determining DNA and RNA concentration 
DNA and RNA concentrations were measured using a nanodrop photometer blanked with 
Tris-Buffered Saline following the same extraction and purification steps described for 
protein content determination. 
NMR analysis of biomass components 
1H-NMR (Proton-NMR) analysis of parasite biomass components extracted in Tris-
buffered saline was attempted but produced no useful results. We lacked the NMR time to 
perform a thorough investigation of different extraction techniques and peak 
identification methods and once Teng et al.146 published a thorough 1H-NMR analysis in 
2009 no further efforts were made in this area. A full analysis of the findings of Teng et al. 
(appendix IV) suggests that repeating their techniques on a solubilised biomass pellet may 
yield good results in the future. 
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Analysis of lactate and glucose in biomass using chemical assays 
Analysis of parasite biomass components extracted in Tris-buffered saline using the 
glucose and lactate kits described for used growth medium analysis was attempted but 
produced no useful results. 
HPLC analysis of biomass components 
A fuller description of the development of the HPLC techniques used for biomass analysis 
— as reported briefly in figure 75 on page 168 — are contained within Sara Zakutansky’s 
Masters thesis147. This section contains only those details required to repeat the 
experiments.  
Sample preparation 
All HPLC extractions were performed on parasite biomass pellets that had been frozen at -
80°C in either RNAlater™ (AMBION) or PBS. 
Thaw sample, remove supernatant and remove any remaining red-blood cell ghosts. 
Transfer the parasite pellet to a pre-weighed eppendorf tube, reweigh the tube and 
calculate the pellet mass. 
Add 500µl of 60% methanol, disrupt the pellet manually with a pipette tip and vortex until 
the pellet is as dissolved as possible. 
Speed vac the pellet until dry. 
--------------Steps 5 and 6 are required only if alkaline phosphatase digestion is required. 
Re-suspend the pellet in 200µl restriction endonuclease buffer (NEB) and pass through a 
40micron spin filter to clarify (PARIS kit spin filters used).* 
Add 50U alkaline phosphatase and incubate at room temperature for 2 hours. 
-------------- 
Dilute in Ammonium Acetate HPLC running buffer to volume required (typically 500µl 
final volume). 
Samples were frozen at -20°C if they could not be acquired immediately. 
HPLC calibration 
Tests were performed on a Dionex 3000 series liquid chromatograph with a 200 mm × 4.6 
mm Thermo Scientific Hypersil GOLD column with 5 µm particle size and 175 Å pore size. 
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The column eluate was measured at 254 nm and the resulting chromographs were 
analysed in the Chromeleon software package. 
To calibrate the column, Sara Zakutansky measured the retention times and peak sizes of 
dihydroorotate, orotate, guanine, guanidine, uracil, uridine, deoxyuridine, hypoxanthine, 
xanthine, thymine, thymidine, inosine, and adenosine run both separately and as a mixture 
at concentrations ranging from 0.5 to 50 µM.  
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Accurate determination of P. falciparum 
growth-rate  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The parasite culturing for the fluorescence microscopy and flow cytometry in this chapter 
was performed by a Masters student, Cheng Ma. All reported experiments were designed and 
performed together. All the analysis reported in this section is my own. 
Cheng Ma’s Master’s thesis148 is available from the University of Leeds and offers a broadly 
similar, though perhaps more optimistic, analysis of our results. I am indebted to him for his 
efforts.  
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Do we need a better way of measuring growth-rate? 
Well-parameterised genome-scale metabolic models of model organisms like E. coli and 
S. cerevisiae are able to accurately predict changes in a population’s growth-rate in 
response to perturbations149,150 including changes in available nutrients. These model 
organisms are typically grown in chemostats where conditions are precisely controlled, 
with population, and thus growth-rate, measured via the dilution rate required to keep the 
growth medium’s optical density constant.  This approach also works for more challenging 
organisms such as M. tuberculosis but there is currently no widely-used equivalent test for 
any species of Plasmodium. The closest equivalent, the substantially more difficult 
technique of measuring the uptake of radioactive hypoxanthine151, is described in the final 
section of this chapter where I argue that it is not suitable for the experiments in this 
thesis. 
Measuring P. falciparum growth-rate in vitro using blood smears 
The parasitemia of cultures is determined using optical microscopy of stained blood 
smears and the growth-rate of a culture can be calculated from the rate at which 
parasitemia increases. When measuring changes in the growth-rate of cultures an 
additional complexity must be considered.  
P. falciparum is notoriously difficult to culture outside of live animals and so it is difficult 
to make changes to the growth medium without killing the parasites. When measuring a 
change in growth-rate due to a change in growth conditions — such as the addition of a 
known inhibitor or the restriction of a required nutrient — we have to balance the need 
for the change in growth-rate to be big enough to be measurable and small enough not to 
kill the cultures. Work on this compromise is not well reported in the literature and the 
basic background measurements to make that assessment are required. 
Uncertainty in the parasitemia of a single blood smear 
The uncertainty in a measurement of the parasitemia of a culture from a single blood 
smear can be estimated by taking a number of blood smears from the same sample and 
comparing the parasite counts.  
 
 
 
Parasites counted in ten 
fields of seven slides 
Mean Standard Deviation Implied percentage 
error in a single slide 
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95, 99, 95, 87, 77, 76, 110 91 12 13% 
Table 7: The number of parasites counted in ten fields of seven slides each made from the same sample. The 
standard deviation rather than the standard error is calculated because during the experiment only a single slide 
(   ) is counted and     √ . 
In the example shown in table 7 the parasitemia is 3.6±0.2%* taking into account all 7 
slides with the uncertainty increasing to ±0.5 if just a single blood smear were read. As a 
percentage, uncertainty in the measurement of a single slide is at least 10%.  To improve 
the readability of the graph in figure 56, and other graphs in this thesis, I have not 
included these large errors on individual measurements. This is because once a sufficient 
number of measurements has been taken over time the uncertainties on the 
measurements at each time point become unimportant. 
Uncertainty in the growth-rate over multiple readings 
I grew a standard culture of P. falciparum for two weeks, splitting the parallel cultures as 
necessary so that the parasitemia stayed in the safe range between 0.5% and 6%.  I 
measured the parasitemia of the cultures each day using thin blood smears and scaled up 
the recorded parasitemias according to how diluted with respect to the culture at the start 
of the trial the cultures had become. This meant that by the end of day 14 the average 
parasitemia of the 5 final parallel cultures was 4.6% but reported as 1251.1% after 
applying the dilution factor on day 5 with respect to day 0 of 303.5.  
                                                             
* the error here is an absolute value and not a percentage. The % refers to parasitemia which is 
always reported as the percentage of red-blood cells that are infected. 
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Figure 56 : Growth-rate of a population of P. falciparum grown in 100% AlbuMAX I media for two weeks as measured 
using Giemsa’s stain on thin blood smears under an optical microscope. Here the natural logarithm of the 
parasitemia is plotted so that the exponential growth curve becomes linear. Shaded areas show the error in a least 
squares linear fit of the data after 4 (dark), 7 (lighter) and 10 (lightest) days. 
Growth, as shown in figure 56, is exponential, with the population increasing by a factor of 
about 1.55 per day (d-1). At day 14 all cultures were harvested and the parasite biomass 
extracted and separated from red blood cells (RBCs) and frozen for further analysis. 
The blue shaded areas in figure 56 show the maximum and minimum possible growth-rate 
calculated by a least-squares fit and associated error calculations as provided by the linest 
function in Microsoft Excel after four days, seven days and ten days respectively. The 
results are as we would expect with the error on the best fit line decreasing as the 
experiment progresses. As the error decreases we can see that we would able to 
distinguish between two samples with ever closer growth-rates but we need to look at the 
lines in a numerical form, as in table 8, to see this most clearly. 
Experiment 
duration 
Number of 
measurements 
Calculated growth-rate 
(per day/ d-1) 
Error in 
growth-rate 
4 days 5 1.44 ±0.12 
7 days 8 1.55 ±0.05 
10 days 11 1.55 ±0.025 
Table 8 : Best-fit growth-rates for the three time periods depicted in figure 56. 
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Looking at the numbers in table 2 we see that if we aim to measure a change in growth 
from 1.55 to 1.45 d-1 then we would need to maintain the two cultures for 10 days to be 
sure that they are different (after 7 days 1.45+0.05 d-1 is not distinguishable from 1.55-
0.05 d-1). This is certainly possible but every extra day of culturing introduces a possibility 
that a culture could be affected by an unknown factor such as infection by bacteria or yeast 
or an unexpected crash. 
The advantages of making more frequent measurements 
These results give us a rough idea of the duration of an experiment needed to measure a 
change in growth-rate if measurements of parasitemia are taken every day during normal 
culture maintenance. If we assume that growth-rates remain exponential whatever their 
magnitude — sensible for an organism with no resource limits and that reproduces 
through asexual fission — we can use these results as a guide to the number of 
measurements required to accurately determine growth-rate over a shorter period.  
Taking more frequent measurements of a culture has a direct advantage, the growth-rate 
can be determined in less time, but also a secondary advantage, samples can be taken to 
observe properties of the culture on a shorter timescale. My work on the metabolism of 
P. falciparum over a single life-cycle relied on taking a minimum of five measurements 
over a period of around 40 hours. 
Note on the reproducibility of growth-rates across experiments and laboratories 
The reproducibility of growth-rates has been a problem throughout this project. 
Asynchronous cultures grown in growth medium containing over 10% human serum have 
been measured to have a typical growth-rate of around 2 d-1 (parasitemia doubling each 
day), in keeping with previous experience and the literature.  
In contrast, almost all my experiments with parasites grown in 100% AlbuMAX medium 
show a growth-rate of nearer 1.55 d-1. The work of a 2008 Master’s degree student, Cheng 
Ma148, reproduced a growth-rate of around 1.6 in 90% AlbuMAX I although previous 
experiments by both myself and Daniel Opi144 have achieved growth-rates of 2 in 90% 
AlbuMAX I. Considerable efforts to ensure that all components of the growth medium were 
prepared properly have been unable to solve this problem and in more recent 
experiments I too have seen a growth-rate of around 1.6 d-1 in 90% AlbuMAX I growth 
medium.  
These observations are worrying but not completely unexpected as slower growth-rates in 
AlbuMAX growth medium have been reported previously128. Since we are typically 
interested in measuring changes — rather than absolute values — of the metabolic 
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activity and the growth-rate of cultures submitted to perturbations, we can work around 
this issue. 
It is also of note that variability in growth-rate is widely reported, with early attempts at 
optimising growth conditions152 achieving a near doubling of parasite growth-rate by 
making small changes to the growth medium. 
Development of flow cytometry 
Thin blood smears are often time consuming to stain and clumsy to store and counting 
parasites by hand introduces large errors on individual readings. My finding that — with 
daily culture maintenance and observation — it would take two weeks of culturing to 
measure a change in growth-rate from 1.55 to 1.45 d-1 led me to think about better ways of 
measuring parasite growth-rate. After reading the review “Cytometry in malaria: moving beyond 
Giemsa” by Shapiro et al.153, I decided to investigate flow cytometry as a way to improve the 
measurement of growth-rate. 
Selection of a suitable fluorescent dye 
Flow cytometry works by staining cells with a dye that selectively binds to only those cells 
we want to count. In this case any DNA-binding dye will bind only to parasites as human 
RBCs contain no DNA. A quick review of the literature provided us with three dyes to 
consider, Hoescht153,154, Acridine Orange155,156 and syto-16157. Our discussions with 
Dr. Gareth Howell in the Astbury centre at The University of Leeds led us not to consider 
using the technique described in the paper using syto-16 and preliminary tests with 
Hoescht dye led to an unexplained sedimentation in our samples. Acridine orange became 
the best option for continued study and we set ourselves the goal of repeating the results 
found in “Re-Evaluating acridine orange for rapid flow cytometric enumeration of parasitemia in malaria-
Infected rodents” by Bhakdi et al.156. 
Fluorescence microscopy to confirm selective staining of infected RBCs 
Our first task was to test that acridine orange selectively stained infected RBCs by 
examining a stained sample of live cells under a fluorescence microscope. Unfortunately 
the only fluorescence microscope available to us has a broken lens at maximum 
magnification which caused us some of the following problems. 
 The illumination of the sample area was uneven, meaning that some areas within 
each field of view were harder to see than others. 
 Each field contained around 1500 RBCs making it hard to count the cells.  
 The cells were not fixed and thus tended to move slightly. 
126 
 
 Cells tended to stick to either the glass slide or the coverslip but the microscope 
could only focus on one plane at a time. 
Despite these difficulties we were able to confirm that acridine orange was selectively 
staining parasite-infected RBCs from our cultures. Figure 57 is a typical capture of the 
centre of a field of infected RBCs with a known parasitemia of 3.8%, as measured by 
Giemsa staining a thin blood smear under an optical microscope. Within this picture we 
found it useful to define two different types of fluorescent spots. Type 1 spots are clearly 
inside RBCs and of a similar size to a parasite whereas the type 2 spots are outside RBCs 
and often appear smaller. I have also highlighted a single stain with 2* which looks like it 
may be either part of the nearby cell or a parasite in a cell in another focal plane.  
Table 9 shows the results of counting the cells in figure 57 and we see that type 1 stains 
imply a parasitemia of around 4%, the same as determined by reading the blood smear, 
suggesting that type 1 stains are infected parasites.  
  
*estimate based on number of cells crossing the field edges (17x11) 
Table 9 : Counts of the different types of fluorescent spots in figure 57. 
The presence of the type 2 stains is unfortunate since it seems possible that they could be 
falsely counted as positive in a flow cytometer if the threshold of fluorescence were not 
adequately set. These spots could be aggregates of waste products and dead parasites in 
solution that have been stained by acridine orange or aggregates of dye particles. The 
tempting explanation that they are due to auto-fluorescence of unstained RBCs as 
described later in this chapter seems unlikely given their high frequency and the fact that 
they seem to occur outside of the RBCs.  
My original tests were carried out with a dye concentration of 4.0 µg/ml whereas future 
test were carried out at around 0.5-1.0 µg/ml. At these lower dye concentrations, fewer 
type 2 stains are visible under the fluorescence microscope suggesting that the problem of 
type 2 staining may be reduced at the concentrations we use in flow cytometry. 
Nevertheless, we still need to consider these staining artefacts when interpreting results 
from flow cytometry. 
 Number Inferred parasitemia 
Red blood cells 187* - 
Type 1 stains 8 4.3% 
Type 2 stains 15 8.0% 
Combined 23 12.3% 
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Figure 57: Fluorescence microscope image of RBCs stained with Acridine Orange at 4.0 µg/ml *. Green spots are 
areas of peak fluorescence under white light and are labelled as described.  
The fluorescent layer and the background layer were aligned in Photoshop due to a problem with the microscope 
optics. 
 
Having confirmed that acridine orange was able to stain infected RBCs whilst leaving 
uninfected cells unstained we moved on to seeing whether stained and unstained cells 
could be distinguished within a flow cytometer.  
                                                             
* Bhakdi et al.20 quote their dye concentrations after samples have been diluted by half in PBS. As a 
result a dye concentration of 4.0 µg ml is defined as being 2.0 µg ml in their paper. My results are 
completely equivalent as long as this factor of 2 is taken into account. 
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Single-channel flow cytometry 
The simplest type of flow cytometry is single-channel analysis, in our case using the green 
channel. This uses the confirmed property that acridine orange fluoresces green under 
illumination once bound to DNA and sets a cut-off intensity of fluorescence above which a 
cell is considered infected and below which a cell is considered uninfected. In order to test 
this method we prepared serial dilutions of a culture with an optically measured 
parasitemia of 4.6%. These assays were prepared by adding acridine orange to a final 
concentration of 1.25 µg/ml and then diluting with 1.5ml of phosphate-buffered saline 
solution (PBS) before acquisition. The threshold above which cells would be considered 
infected was set by running a control of stained uninfected cells through the flow 
cytometer and setting the gate to count a minimum of these cells. 
 
Figure 58 : Comparison of my results and published results for single-channel flow cytometry. a. Sample result from 
Bhakdi et al.156 with M1 gate denoting uninfected cells and M2 denoting infected cells. Parasitemia ≈30-50%. b. My 
equivalent result for a sample with a known parasitemia of 4.6%. Gate R1 denotes infected cells. 
Figure 58 shows an example of gate-setting to distinguish infected and uninfected 
populations. The excerpt in section a shows an idealised case where the distinction is easy 
to make whereas section b shows my real results with the gated area defining infected 
cells. In the ideal case the histogram for a control population (known parasitemia of 0.0%) 
would be identical to the histogram seen in b but with no counts in the section gated as R1. 
Any counts in the R1 gated section of this histogram for this control population should be 
discounted from all other samples and discarded as background noise. 
The very different parasitemias of the samples in figure 58 are a result of the limitation 
caused by culture “crashes” if culturing above 8% parasitemia. As Bhakdi et al.’s samples 
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came from living hamsters infected with Plasmodium berghei they were not constrained by 
this limitation. 
Determining an ideal dye concentration 
With a gate threshold set we moved on to trying to determine ideal parameters to use 
before sample acquisition. To this end we ran extensive tests to examine the effects on the 
measured parasitemia of, 
 the time the sample was left to incubate with the acridine orange before dilution in 
PBS, 
 keeping the samples in the dark during incubation, 
 the amount of PBS the sample was diluted with before acquisition, 
 the time the sample was left to incubate with the acridine orange after dilution 
 the concentration of acridine orange used. 
An example of the results from the last of these tests is shown below in figure 4 and shows 
a large variation between the measured parasitemia of samples stained with slightly 
different concentrations of acridine orange. 
 
Figure 59: FACS-determined parasitemia versus parasitemia determined by microscope inspection of Giemsa-
stained blood smears. Removal of counts from un-dyed control samples means some FACS-determined 
parasitemias are below 0%. 
Calibration issues 
The effects of varying the acridine orange concentration on the results of flow cytometry 
were not encouraging and the results for the other variables were no better. Further tests 
showed that part of our problems came from the raw data coming from the flow 
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cytometer. A clear example of one of these problems, setting a threshold for distinguishing 
infected from uninfected cells, is shown in figure 60 .  
These are histograms for two sequential runs using identical parameters on the same flow 
cytometer. The control sample consists of uninfected RBCs in media with 1.25 µg/ml 
(before dilution in PBS) of acridine orange added. The 0.18% parasitemia sample is 
identical but 2% of the total volume was from a culture at 4.6% parasitemia. Clearly this 
addition of a tiny amount of culture to an identical sample should not move the whole 
fluorescence peak since the peak in both cases corresponds to uninfected RBCs from an 
identical source. 
 
Figure 60: Comparison of raw single-channel output from BD FACSCalibur acquisition of a control sample (0% 
infected RBCs in media dyed with 1.25 µg/ml of acridine orange) versus a sample with a known parasitemia of 
0.18%. Overlapping section is darker. R1 shows gating optimal for control which is clearly not optimal for 0.18% 
case. 
This peak-shifting made it extremely difficult to set a gate that could consistently 
distinguish infected and uninfected cells. In our preliminary tests we never saw — no 
matter what the dye concentration used — as distinct a separation between the 
fluorescence of infected and uninfected RBCs as shown in figure 58a. This closeness in the 
magnitude of the fluorescence of the two populations meant that the placement of the gate 
had a big influence on the results. 
I had some success in overcoming the problems with the raw output of the flow cytometer 
by setting the gate position in different ways for different experiments as I will now 
explain. Where I have set a single gate and applied it to all samples I have called this gating 
technique “global and constant”.  
Where peak-shifting meant that a threshold could not be set this way I was forced to set a 
gate for each sample by eye. This meant estimating the position of the edge of the peak for 
each result and manually drawing a gate. I have called this gating technique “custom and 
variable” since the gate is different for each sample.  
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Figure 61 shows the results of a test to measure the parasitemia of samples by flow 
cytometry using global and constant gating where the parasitemia had already been 
determined by optical microscopy. The results appear impressive, with a good linear 
response and the flow cytometer picking up over a third of the parasites. Unfortunately 
the results are not nearly as positive when we look at them in detail. The control sample 
— uninfected RBCs stained with acridine orange — has a parasitemia of 2.10%, far higher 
than expected. Furthermore, even a tiny and insignificant change in the preparation of the 
samples, adding 2.0ml of PBS instead of 1.5ml of PBS before running the samples, causes a 
large and unpredictable change in the results. 
  
Figure 61 : Parasitemia measurements by single-channel flow cytometry using global and constant gating versus 
measurements by optical microscopy of Giemsa-stained blood smears. Samples were identical and prepared as 
described in the methods chapter and diluted with either 1.5ml or 2.0ml of PBS before acquisition. The point in red 
belongs to the 1.5ml dataset but is not included in the best fit line. 
 
Figure 62: Parasitemia by single-channel flow cytometry using custom and variable gating versus optical microscopy 
of Giemsa-stained blood smears. 
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Figure 62 shows the results from analysing exactly the same raw data from the flow 
cytometer as used to create figure 61 but instead determining by eye a custom gate for 
each sample. The combined numerical results from figure 61 and figure 62 are 
summarised below in table 10. 
Gating PBS added before 
acquisition (ml) 
Gradient Intercept Parasitemia 
of control 
Global and constant 1.5 0.37 0.78 2.10% 
Custom and variable 1.5 0.38 0.65 0.67% 
Global and constant 2 0.19 0.93 0.95% 
Custom and variable 2 0.13 1.33 0.81% 
Table 10 : Summary of the gradient and intercepts of best-fit lines for points in figure 61 and figure 62. 
Summary of single-channel flow cytometry 
Table 4 raises some issues that are very difficult to resolve. The measured relation 
between optical parasitemia and parasitemia as measured by flow cytometry seems 
erratic, possibly owing to tiny changes in sample preparation but more probably owing to 
instabilities within the flow cytometer. The peak-shifting issue highlighted in figure 60 
means we are forced to analyse samples by hand but even this does not give us a reliable 
technique for analysis. Custom and variable gating has a further drawback in that it 
removes the speed and objectivity of the process and thus both main advantages of flow 
cytometry over optical microscopy. Our failure to develop a better method for counting 
parasites using single-channel flow cytometry is perhaps not surprising given that 
examples in the literature have only proved the technique for the very high parasitemias 
found in in vivo infections. 
Dual-channel flow cytometry 
Acridine orange has a very useful property, it not only fluoresces green when bound to 
DNA and but it also fluoresces red when bound to RNA. Instead of a histogram of counts 
against intensity of fluorescence in a single colour axis, dual-channel flow cytometry 
produces a three dimensional plot with each measured cell placed according to the 
intensity of its fluorescence in the two different colours. By extracting this information 
from our samples we hoped to overcome the problems we experienced using single-
channel analysis. 
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Figure 63 is the output of dual-channel flow cytometry from exactly the same raw data as 
shown in figure 58. In other words, if we projected all the points in figure 63 onto the x-
axis and counted them to produce a histogram we would exactly reproduce figure 58. The 
peak shifting that meant we had to use a different gate for the control than for the rest of 
the samples in the single-channel case is also the case in dual-channel analysis and so this 
technique cannot offer any improvement in this regard and custom and variable is still 
likely to be required. 
 
Figure 63 : Dual-channel flow cytometry (red and green) for the same sample as shown in figure 58b. The gated area 
shown is a naïve attempt to select infected cells. Samples were dyed with acridine orange to a final concentration of 
1.25 µg/ml, left for at least 3 minutes, then diluted with 1.5ml of PBS before acquisition. 
A more advanced application of dual-channel flow cytometry is to specify zones of the plot 
which may correspond to different features of the cells measured. An excellent example of 
this can be found in Grimberg et al.158 where the authors were able to distinguish between 
all life stages of Plasmodium falciparum with a two-dye technique using Hoescht and 
thiazole orange and dual-channel flow cytometry. Whilst this technique certainly warrants 
further investigation, neither of the flow cytometers I have been able to use at Leeds have 
working filters to measure Hoescht fluorescence. We would also have to overcome a 
problem we had during our preliminary experiments with precipitates forming in our 
samples after adding Hoescht to them. We are still unsure what caused this precipitation 
but it seems likely that it was due to some reaction between the solvent used in our 
Hoescht stock and components within the growth medium. 
In Bhakdi et al.156 the zoning technique described in Grimberg et al. 158  for distinguishing 
life stages was used only to distinguish between cells that were fluorescing due to parasite 
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infection and those exhibiting simple auto-fluorescence. With acridine orange this seems 
likely to be our only option. Figure 64 is in an illustration of the zones in a dual-channel 
plot that we might suggest are due to these two different types of fluorescence.  
The significantly increased number of points in the infected fluorescence zone where 
parasitemia is high (3.5%) versus low (0.18%), as in figure 8, support this distinction. That 
the number of points in the auto fluorescence section of the plot goes down is in keeping 
with the observations of Bhakdi et al. 156 but is hard to explain. 
 
Figure 64 : Dual-channel output of a sample of known parasitemia of 3.5% showing the two distinct zones where it is 
suggested that fluorescence is the result of parasite infection or auto-fluorescence of an uninfected RBC. The zoning 
technique seems hard to justify as discussed in the thesis body. 
The idea that measuring auto-fluorescence can be eliminated using this method is very 
interesting but we have to remember that our results from single-channel flow cytometry 
already measured too few parasites rather than too many. Another worry for me is that 
Bhakdi et al. 156 does not fully justify the applied zoning technique or adequately explain 
why different types of fluorescence should occur in the different zones. The position of the 
infected fluorescence zone would suggest that more RNA is present in infected RBCs, 
which would make sense, but Bhakdi et al. 156  makes no mention this. These issues are 
particularly troubling given that Grimberg et al.158 makes no mention of auto-fluorescence 
in unfixed cells and makes no effort to filter out these cells in their paper.  
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A further reason that splitting the zone of higher fluorescence into two distinct sections 
may not be useful comes from inspecting the dual-channel plot in figure 63. Here we see 
that almost all the fluorescence in this plot would be counted as auto-fluorescence even 
though the known parasitemia is 4.6%. Experience with single-channel flow cytometry 
makes it clear that any technique that attempts to remove auto fluorescence from results 
must be calibrated using a negative control or dyed uninfected RBCs. When we consider 
the peak-shifting effect that we noticed in the green channel of the available equipment, 
and is likely to also exist in the red channel, we see that this is far from easy. 
Despite these problems, when dual-channel flow cytometry works it can give us good 
results. Figure 65 shows that at least some of our results do seem to agree with the results 
in Bhakdi et al. 156 and the results shown in figure 66 show that flow cytometry using this 
method can measure over half of the true number of parasites. 
 
Figure 65 : A. Stained uninfected cells from Bhakdi et al. (known parasitemia =0.0%, observed parasitemia = 0.09%) 
B. Stained mouse RBCs infected with P. berghei from Bhakdi et al. 156 (known parasitemia ≈* observed parasitemia = 
1.79%) C. Stained uninfected cells from my experiments. (known parasitemia =0.0%, observed parasitemia = 0.1%)  
D. Stained infected cells from my experiments. (known parasitemia = 3.5%, observed parasitemia = 2.0%) 
                                                             
* This measurement by Giemsa stain optical microscopy is not given in the paper but a later figure shows a 
near perfect 1:1 correspondence between optical measurements and measurements using flow cytometry.  
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Figure 66 : Parasitemia by dual-channel flow cytometry as demonstrated in figure 64 versus optical microscopy of 
Giemsa-stained blood smears. Samples prepared as in the methods chapter. Results are extremely variable across 
different runs. 
Disruptive variables 
We carried out a huge number of tests whilst trying to develop a robust protocol for 
measuring parasitemias of samples using flow cytometry. Many of our problems in the 
beginning were caused by machine issues but we also noticed that the results of flow 
cytometry were extremely difficult to predict and tiny changes in protocol — or just 
different runs of the same machine with the exact same settings — seemed to lead to 
massively different outcomes. We can see this in figure 66 where samples run in exactly 
the same conditions by the same machine give very different results.  The peak shifting 
effect I have described for single-channel flow cytometry is also visible in dual-channel 
flow cytometry with the peak in the green channel in very different positions in figure 63 
and figure 64. 
These problems meant that calibration of the output from the machines we used was 
almost impossible and required manual adjustments which removed many of the 
advantages of the technique. Even after rigorous calibration results were unpredictable. 
An interesting example of the variability of the experiments is shown below in figure 67. 
We noticed that at lower concentrations of acridine orange the two zones of fluorescence 
described previously became more and more distinct. At first we were very excited by this 
until we counted the number of cells in the infected fluorescence zone and saw that it 
accounted for less than a quarter of the known parasitemia, even fewer than measured at 
normal dye concentrations. 
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Figure 67 : Dual-channel output of a sample of known parasitemia of 3.3% dyed with 0.25 ug/ml acridine orange. The 
infected fluorescence zone contains 0.78% of the cells counted. 
Summary of flow cytometry 
Flow cytometry could have given us a quicker and more accurate way to measure the 
parasitemia of a culture and helped to more easily and objectively measure growth-rates 
of large cultures of P. falciparum grown in parallel under different conditions. In the end 
we have struggled to reproduce the published results as we would have liked to, only 
picking up between a quarter and a half of the infected cells as detected by Giemsa staining 
and optical microscopy. The unreliability of the equipment casts further doubt on the 
technique as despite a huge number of tests we were never able to isolate or eliminate 
sources of variability. It is an interesting hypothesis that we measure only a proportion of 
the true parasitemia because we are picking up only infections where the parasite is at its 
largest stage (schizont) but our experiments with a synchronised culture failed to show 
this*. My feeling is that the results of Bhakdi et al.156 were idealised and not ready for 
integration into a lab setting. That the paper was published in a flow cytometry journal 
rather than a parasitology journal, and the knowledge that Barbara Kappes and her group 
in Heidelberg have also tried and failed to use flow cytometry for parasitemia 
measurements†, supports this view. It seems possible that with the freedom to more 
accurately control and calibrate the flow cytometer many of the problems we had could be 
overcome but this was not possible within the restrictions of this project. 
Useful applications of flow cytometry to studies of Plasmodium falciparum using both dual-
channel and dual stain techniques have recently been published by Jiménez-Díaz et al. in 
2009157 and, most applicably to my project and already mentioned, by Grimberg et al. in 
2008158. 
                                                             
* These tests were carried out on the PRS III machine and should not be considered reliable. They 
are not reported. 
† Discussed in private communications with Glenn McConkey. 
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The inherent limits of “growth-rate” measurements in P. falciparum cultures. 
The final section of this chapter is a common point of discussion at all conferences on 
metabolism; what does growth-rate really mean?  
The growth-rate of an organism can mean either the rate at which biomass is produced, or 
the rate at which the population of the organism increases. In batch cultures of ideal 
organisms like E. coli and S. cerevisiae these two definitions are interchangeable since the 
population times the average mass of a single organism — which is constant — is equal to 
the biomass. This simplification no longer holds when the rate at which biomass is 
accumulated is no longer related to the rate at which the population of the organism 
increases and this is exactly the case with Plasmodium grown in culture. This discrepancy 
arises because, before bursting out of their containing RBCs, mature schizonts appear to 
have between 8 and 16 (16 - 32 according to Keeley et al.159) separate nuclei that will 
become merozoites upon lysis. Since only between 2 and 4 (equivalent to a daily growth-
rate of between 1.4 and 2.0) of these merozoites will successfully invade a new RBC as 
much as 7/8 of the accumulated biomass is lost with every life cycle thus breaking the link 
between biomass created and current population. 
In this example, all the processes of metabolism were still needed to create the biomass 
that was lost. However, since determining the exact proportion lost is extremely difficult, 
the simplification between the organism’s population, which we can easily measure, and 
the rate at which biomass is produced, which we cannot easily measure but which is most 
important for flux-balance analysis, is lost. The simplest solution to this problem is to only 
study biomass accumulation within a single life cycle and most my work has thus been 
limited to the 40-hour period in highly synchronised cultures where no RBC lysis occurs. 
This also requires the assumption that the biomass of the invading merozoites was 
negligible compared to the biomass of the final mature schizonts which seems sensible in 
comparison to other larger sources of uncertainty. 
A further discussion of this complexity and how it relates to the units of flux in my final 
model forms the first section of the chapter on metabolic modelling. 
Limits of the radioactive hypoxanthine assay 
As briefly mentioned at the start of this chapter, a standard objective method for 
measuring Plasmodium growth-rate is the radioactive hypoxanthine assay. In this assay 
parasites are cultured with radioactive hypoxanthine in the growth-medium and the 
resulting radioactivity of haematocrit is used to calculate the amount of hypoxanthine 
incorporated by the parasites and thus their growth-rate. 
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The assay works because the parasite is unable to perform de novo synthesis of purines 
which must be imported from the growth medium and/or the host cell. Given a selection 
of purines it has been shown that hypoxanthine is taken up preferentially160 and we know 
— both from personal experience and the literature — that it can be extremely difficult to 
maintain cultures in the absence of hypoxanthine40. Furthermore, in the presence of 
known inhibitors hypoxanthine uptake is reduced the least of the alternative purine 
sources: adenine, guanine, inosine, adenosine and guanosine160. More recent work agrees 
that hypoxanthine is taken up in preference to other purine sources161 but confusingly 
notes that, 
“the rate of adenosine uptake was considerably higher than the rate of hypoxanthine uptake in infected 
human RBCs” 
Quashie et al. 2010161 
More worryingly for the assumption that hypoxanthine uptake is a proxy for growth-rate, 
“In both uninfected and P. falciparum-infected erythrocytes, hypoxanthine uptake was completely blocked 
in the presence of 1 mM adenine.” 
 Quashie et al. 2010161 
These findings must be treated with caution and considerable doubt is cast on the 
conclusions of Quashie et al. 161 relating to purine uptake by Kirk et al.162. This 
disagreement leaves me with the impression that we do not yet fully understand the 
mechanism of hypoxanthine uptake or the effect on it of changing growth conditions. 
Despite these complexities I think that it is probably reasonable to presume that as long as 
the growth medium contains an excess of hypoxanthine and there are no major changes to 
metabolism or growth conditions, then the amount of hypoxanthine incorporated by the 
parasites is likely to be more or less proportional to biomass formation. This linear 
relationship has indeed been shown over extremely short (⋍10s) time periods161 and 
periods up to five days151. 
Still, we need to think carefully about what hypoxanthine uptake assays measure and how 
that might be affected by changes to metabolism not linked to growth-rate.  If we want to 
perform experiments on the metabolism of the malaria parasite in response to 
perturbation that may change the behaviour of purine salvage — and they are areas of 
interest in this thesis and its possible expansions — I would suggest that the hypoxanthine 
uptake assay is not an acceptable measurement of growth-rate.  
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Experimental results 
No account of the biochemistry of Plasmodium would be complete without some 
mention of the inherent pitfalls and problems encountered. 
Biochemistry of Plasmodium (Malarial Parasites), I. W. Sherman106, 1979 
 
Towards a biomass function for malaria 
Beyond a gap-free metabolic network, FBA requires both a biomass function and some 
constraints on the rate of exchange of compounds between the organism and its 
environment to accurately simulate metabolism. P. falciparum has been shown to be 
adaptable to different nutrient sources, and a minimal controllable growth medium160 is 
used to reduce the variability between experimental repeats. Nevertheless, the 
requirement to use human RBCs — necessarily of different ages or from different donors 
across experiments — introduces an uncontrollable variability into all experiments. This 
variability is visible later in my measured exchange fluxes and is also reported in a large 
body of knowledge on human RBCs. 
There is no published experimentally measured biomass function for P. falciparum. In 
explaining this, and perhaps light-heartedly, Giancarlo Biagini once suggested to me that a 
lot of the basic biochemistry was never done on malaria parasites because it couldn’t be 
cultured when such experiments were in fashion, and by the time Plasmodium could be 
cultured people were no longer interested in publishing basic biochemistry.  Irwin 
Sherman’s106 1979 publication in Microbiological Reviews remains the most 
comprehensive general work but is not comprehensive enough to build a biomass function 
from. More recently a number of more specialised papers have been published which fill in 
some gaps in our knowledge about free nucleotide and amino acid composition146 and 
fatty acid composition99 but these papers still do not reliably report the whole-organism 
concentrations for the key biomass components: protein, DNA, RNA, lipids and 
carbohydrates. 
At a push we could use existing data to build a biomass function for our own FBA analysis 
and in fact Chavali et al.’s 2008 analysis of Leishmania Major108 includes a biomass 
function adapted from E. coli using published information on essential components of 
growth media for other species of Leishmania. This is not a reason to ignore the 
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predictions of that model and even for model organisms such as E. coli, debates continue 
as to the importance and relevance of an accurate biomass function163.  
Still, for P. falciparum none of the existing solutions to the biomass problem are attractive. 
There are good reasons to think that the biomass function of a human parasite would be 
very different to that of a bacterium and in any case the biomass functions of different 
species of bacteria vary enormously164,165. Furthermore, even though the biomass function 
is probably not the most representative objective function of real metabolism76 I think it 
remains — within an experimentally constrained model — a reasonable approximation of 
“life” and in any case the best available tool. 
A first effort to measure the biomass of parasites grown in our own minimal media was a 
Masters project carried out in the year I started my PhD by Daniel Opi144. We worked 
together to convert his results into a preliminary biomass function but in addition to 
solving some early problems this served as a warning that biomass measurement would 
be much more difficult than expected. At the time, the lab’s technique for measuring 
parasite biomass components was to use Sigma’s Tri-Reagent system to separate the 
components of a large amount of biomass in different solvents and then dry and weigh 
each solvent separately. This method returned negligible amounts of DNA and RNA and a 
protein concentration of 89% of total biomass in the best case and over 100% in the worst 
case.  
By repeating the difficult large-batch cultures that Daniel had used for his experiments I 
was able to gather the large amounts of biomass needed to develop the techniques in this 
thesis. Ultimately, the new extraction technique I describe in this chapter can accurately 
determine the composition of the biomass extracted from small cultures and large-batch 
culturing is not required. 
The best place to start in this discussion of my experimental results is with table 11 which 
summarises the major wet-lab experiments that led to the final biomass function 
calculations I report in this thesis. The majority of the culturing in these experiments was 
performed by the person whose name is written first in the experiment name and I am 
extremely grateful to Cheng Ma, Sara Zakutansky and Jennifer Lake for their work and 
achievements in their Masters degree projects.
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A summary of experiments performed 
 
 
 
Table 11 : Summary of major growth-rate and biomass experiments conducted in 2008 and 2009. The growth-rate experiments used to produce figure 56 on page 123 were performed up to 22/12/2008 
and are not included in this summary chart but are present in my lab book. 
 
  
Growth-rate and Biomass Experiments (2008 - 2009)
Name Tom Biomass 1 Cheng FACS Tom Biomass 2 Tom Biomass 3
Culture End Date 22nd December 2008 July 2009 18th November 2009 2nd December 2009
Extracted Culture Volume (ml) - 540 1080
Extracted Parasitemia - 3.2% 1.7%
Extracted Pellet Volume (ml) - 18 30
Biomass Extracted Yes - Yes Yes
Description
Biomass samples used for preliminary 
experiments on biomass measurement (NMR 
metabolomics, glucose measurements by 
biochemical kit, Bradford Assay, RNA/DNA 
measurement).
21/03/09  fluorescence microscropy.                    
I did not do this culturing.
Extraction 18/11/2009. Culturing continued to 
December 2009, Biomass samples used for Sara 
Masters Project technique development and 
calibration of HPLC.
Extraction  02/12/2009 used for final biomass 
measurements. Cultures were saponin-lysed 
together then the lysate split by four and 
centrifuged and isolated to 4 eppendorf tubes 
labelled "1/4"
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Sources of uncertainty in biomass recovery 
As summarised in table 11 — and table 20 in the metabolomics section later — biomass 
was recovered from a number of experiments. The development of the techniques for 
measuring biomass components, also part of Sara Zakutansky’s and Jennifer Lake’s 
Masters dissertations, used the biomass samples from the experiments named Tom 
Biomass 1 and Tom Biomass 2. The extracted samples from Tom Biomass 3 — all of which 
had been RNA-safe acquired and stored at -80°C with RNAlater® (Ambion) — were 
acquired at the late schizont stage before lysis and were used to gain the final results 
reported in this section. 
Preliminary experiments allowed methods for determining biomass content to be 
improved with particular attention paid to four key areas, 
Separating parasite biomass from RBC biomass 
A key step in the isolation of parasite biomass is the separation of parasite and RBC 
components after the saponin lysis described in the methods chapter. The pellet visible 
after high-speed centrifugation of a lysed culture consists of a black core with a white 
covering. The black core is the parasite biomass, the white covering is formed of the 
remnants of the lysed red-blood cells and is called the RBC ghost. That the protein, DNA 
and RNA concentrations measured in table 13, table 14 and table 15 are within the 
expected range suggests that the separation of largely intact parasites and lysed red-blood 
cells is effective but it still seems likely that the two components of the pellet are not 
completely distinct. A more significant source of uncertainty in the isolated biomass 
weight is the process of separating the black and the white pellet section. RBC ghosts are 
“washed away” gently in TBS but this process is an inherently variable one with too much 
washing discarding some parasite biomass and too little leaving RBC ghosts in the parasite 
pellet. 
There is an elegant method for quantifying the scale of this uncertainty. Following saponin 
lysis of the infected RBC pellet from the Tom Biomass 3 experiment the homogenous 
lysate was split equally into four centrifuge tubes for parasite isolation. The measured 
weights of the dried parasite biomass from each of these tubes (1,2,3,4) should be 
identical but we see in table 12 (page 145) that they are not. This variance lets us calculate 
a mean dry biomass of 13.4mg with a standard error (  √   of 1.7mg: most easily 
expressed as a percentage error of 13%. 
One suggestion that is often made for simplifying the process of getting the P. falciparum 
biomass function is that the metabolic model for P. falciparum is inserted into the existing 
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FBA-ready metabolic model for a human RBC166. In this case, the biomass function for the 
RBC on its own would be substituted for the biomass composition of the RBC and the 
parasite together. Whilst this avoids the difficult step during biomass measurement of 
lysing RBCs and purifying the released parasites I suspect that this idea would not work. It 
is well documented94,113,127,167–170 that infected RBCs have massively altered metabolism 
and it has not yet been shown that any existing model for RBC metabolism is capable of 
reproducing these changes. 
Weighing pellets 
Two problems frustrated my first attempts at the simple task of weighing parasite 
biomass pellets. Firstly, I did not at first consider that eppendorf tubes vary considerably 
in mass; using one empty tube to tare a set of scales used to weigh another tube containing 
a biomass pellet produced highly misleading and useless results. As an example, some of 
the empty tubes used in the extractions summarised in table 12 weighed 0.8671g, 
0.9005g, 0.8937g and 0.8996g, a considerable variation when compared to the biomass 
pellet weight. Secondly, I did not at first consider that the vigorous vortexing needed to re-
suspend the isolated biomass pellet would grind away an appreciable amount of plastic 
from each eppendorf tube. 
Careful weighing at every step of biomass handling solved these problems and any 
remaining uncertainty is included in the 13% error described in the previous 
consideration of parasite and RBC biomass separation. 
Clarifying solutions before photometric assays 
All the successful techniques for measuring the composition of parasite biomass have been 
photometric but these techniques are made impossible by the dark grey colour of the re-
suspended parasite biomass. For each of the four samples and corresponding extraction 
methods I attempted, I clarified the samples before acquisition by two methods, a and b. 
Samples labelled a — and sample 4 — were clarified by centrifugation in a 2ml eppendorf 
tube at 5000RPM for 5 minutes except for 3a which was clarified by centrifugation at 
13000RPM for 5 minutes. No noticeable change in protein or nucleotide concentration 
arose from this change. Samples labelled b were clarified by passing through the 40 
micron filter cartridges provided with the PARIS(Ambion) kit in a benchtop centrifuge at 
13000RPM for 5 minutes. 
Solutions were visibly slightly clearer after filtration but the statistically indistinguishable 
results for samples 3a and 3b suggests that both techniques of clarification are equivalent. 
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Extracting biomass components from parasite pellets 
In part because of the overestimation of protein content in Daniel Opi’s thesis I wanted to 
avoid extraction of parasite biomass components using sodium dodecyl sulfate (SDS) as a 
detergent. The results reported in Teng et al.146 made me hopeful that simple extraction 
techniques such as vigorous agitation in methanol followed by drying and re-suspension 
in TBS (methanol/TBS, sample 1) would be sufficient. I also wanted to try extracting 
biomass components through vigorous agitation in TBS alone (sample 2). Extraction using 
phenol/chloroform and perchloric acid were not performed partly because they did not 
perform well in Teng et al. 146 and partly because I felt uncomfortable performing them.  A 
further extraction technique I tried was the cell lysis buffer component of the PARIS kit ( 
sample 3 and sample 4). 
A summary of the samples and their various treatments is shown in table 12 and the 
following results show that the PARIS kit’s cell lysis buffer proved a simple and effective 
method for isolating biomass components. 
 
Table 12 : Extraction methods and biomass weights of the four samples labelled “1/4” isolated at the end of the Tom 
Biomass 3 experiment. 
How much biomass is recovered 
In total, 30ml of haematocrit at a parasitemia of 1.7% was extracted from the Tom 
Biomass 3 experiment. The dry weight of the total parasite biomass was            
with this mass coming from an RBC pellet of 30ml at 1.7% parasitemia. 
From this — and the known concentration of RBCs in haematocrit (           ) — we 
can calculate   , the total number of parasites, to be, 
              
                                 
The dry weight per parasite            is thus, 
           
         
       
                           
  
Extraction Method Methanol/TBS TBS PARIS cell lysis buffer PARIS cell lysis buffer
Sample names 1a and 1b 2a and 2b 3a and 3b 4 (no filtration)
wet biomass weight (mg) 47.4 54.5 35.1 52.6
dry biomass weight (mg) 17.1 15.5 10.0 11.0
dry weight/wet weight 36% 28% 28% 21%
volume of extraction solvent (ml) 2 2 2 1
dry biomass concentration (mg/ml) 8.6 7.8 5.0 11.0
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Protein content 
The typical method of determining protein content with the Bradford assay is to create a 
calibration curve using a protein standard, BSA in my case, and then determine the protein 
content of a sample by comparing it to this curve. Preliminary tests with this technique 
were less accurate than I hoped and I settled upon another method — most clearly shown 
in figure 68 — where serial dilutions of both the BSA standard and the samples prepared 
by each method were measured for absorbance at 595nm. 
 
Figure 68 : Serial dilutions of BSA standard and samples 3b (from 5mg/ml of pure biomass) and 4 (from 11mg/ml of 
pure biomass) in Bradford reagent. Note the bubbles in the second row for sample 3b; this data-point was excluded 
from analysis. 
Figure 69 shows the results of these measurements for sample 4 and the BSA standard 
with the gradient of lines of best fit shown. The graph is illustrative only and the points at 
4mg/ml were discarded during numerical analysis because they were outside of the linear 
range of the assay. 
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Figure 69 : Determination of protein concentration for sample 4 (see table 12) by the Bradford assay. There are two 
points at each concentration for each sample corresponding to acquisition at 15 minutes and 90 minutes. 
Given the following algebraic identities, 
                                                     
                                                               
                                        
                                    (
                 
   
) 
                    (
              
   
) 
The percentage protein can be calculated because the ratio of the lines of best fit is equal 
to the inverse of the ratios of the protein concentrations in the two samples, thus, 
  
    
    
 
Error in protein content determination 
Errors for   and    (             are calculated by the LINEST least-squares 
regression function in Microsoft Excel; also available in most other spreadsheets (eg. 
Libreofffice). The error in      is 13% as previously shown (             and the error 
in    is negligible and therefore ignored. These component errors are combined according 
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to the standard formula for the propagation of uncertainty from multiple sources*171 to 
give an uncertainty in the final protein content. In this case this combination is, 
   √(
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Or explicitly, 
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The resulting protein content determinations and associated percentage-point errors for 
the seven samples are shown in Table 13. 
 
Table 13 : Protein concentration of biomass samples extracted using the techniques summarised in table 12 
Because of the bubbles visible in the second row of the 3b sample, see Figure 68, this point was omitted from 
analysis. Extractions by the methods used for samples 1 and 2 were clearly unsuccessful. 
The three separate samples, 3a, 3b, and 4 have the same protein content within the 
uncertainties of the experiment and can be combined to create a single best estimate of 
the protein content of P. falciparum’s late-stage schizont biomass. The uncertainties in this 
measurement are the combination — according to the previously described general 
formula for combining uncertainties — of the component percentage-point errors and the 
standard error (  √ ) arising from the variance of the three constituents. This gives a 
final best-estimate of the protein proportion of late-stage schizont biomass of 
P. falciparum to be, 
        
It is important to remember that the quoted uncertainty is a percentage-point error and 
not a percentage error, in this case meaning that the protein content has been measured to 
lie somewhere between 39% and 57%. 
  
                                                             
* If z is a function of x and y (with uncertainties  𝑥      𝑦), the uncertainty in z ( 𝑧  is given by, 
 𝑧   √(
 𝑧
 𝑦
  𝑦)
 
 (
 𝑧
 𝑥
  𝑥)
 
 ⋯ 
with the … representing the continuation of the pattern for all further variables. 
1a 1b 2a 2b 3a 3b* 4
% Protein 4% 4% 0% -1% 54% 46% 43%
percentage-point error 1% 1% 1% 1% 8% 7% 7%
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DNA and RNA content 
The DNA and RNA contents of the biomass extractions were measured using a nanodrop 
spectrophotometer and calculated as follows. 
Given the algebraic identities, 
                                                 
                                                               
                                                  
The DNA as a percentage of total biomass by weight is given by, 
  
    
  
 
And — following the same formula for combining errors as for proteins — the error in D is 
given by, 
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The resulting DNA content determinations and associated percentage-point errors for the 
seven samples are shown in table 14. 
 
Table 14 : DNA concentration of biomass samples. Extractions by the methods used for samples 1 and 2 were 
clearly unsuccessful. 
Applying exactly the same treatment for the RNA measurements gives us table 15. 
 
Table 15 : RNA concentration of biomass samples. Extractions by the methods used for samples 1 and 2 were 
clearly unsuccessful. 
Like with the protein level determination it is clear that the DNA and RNA content of 
samples 3a and 3b are the same within the uncertainties of the experiment but in this case 
it is unclear that sample 4 is part of the same set. To check that this was not because 
1a 1b 2a 2b 3a 3b 4
% DNA 0.4% 0.4% 0.2% 0.1% 7.6% 8.3% 4.1%
percentage-point error 0.2% 0.1% 0.1% 0.0% 1.3% 1.1% 0.7%
1a 1b 2a 2b 3a 3b 4
% RNA 0.5% 0.7% 0.1% 0.1% 7.4% 6.6% 3.6%
percentage-point error 0.5% 0.6% 0.1% 0.1% 1.1% 0.9% 0.5%
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sample 4 had a nucleotide concentration above the range of the nanodrop 
spectrophotometer I tested dilutions of the raw sample. These scaled correctly, showing 
that this was not the cause of the issue. Despite this I can see no reason not to combine the 
nucleotide determinations from samples 3a, 3b and 4 into a single reading. In calculating 
the error in this estimate the percentage-point errors reading was combined with the 
standard error (  √ ) arising from the variance of the three constituents. This gives a 
final best-estimate of the DNA (D) and RNA (R) proportion of late-stage schizont biomass 
of P. falciparum to be, 
           
           
As with the protein figure, the quoted uncertainty is a percentage-point error and not a 
percentage error. 
Best guesses and sanity checks 
One of the difficult but interesting parts of moving to a new scientific field is that you lack 
some very basic knowledge of techniques and expected outcomes. It is frequently 
disappointing, sometimes exciting and always very useful to check that results seem 
sensible. I made biologically sensible comparisons in the following four areas. 
Wet weight/Dry weight ratio 
Haemoglobin makes up around 92% of the dry weight172 of an RBC and around 35% of the 
wet weight of an RBC173 thus inferring a dry weight/wet weight ratio of 38%. The 
equivalent figure for E. coli is around 30%164. By comparison, the average dry weight/wet 
weight ratio for my parasite biomass extractions — see table 12 — is 28%: which seems 
sensible. 
Nucleotides as a percentage of dry weight 
Martin et al.116 report a final RNA mass of                      but do not report the 
mean dry weight of parasites in their study. If we use the dry weight I have measured, this 
figure corresponds to an RNA percentage of around 4%. The biomass function of Arvind 
Chavali’s L.major model (sup. 1)108 contains 1.6% DNA and 11% RNA as a percentage of 
dry weight. The biomass function of the S. cerevisiae in Förster et al. (sup. 3)174 contains 
0.4% DNA and 6.3% RNA as a percentage of dry weight. 
My measured RNA figure of          seems within the expected range but my DNA 
measurement of          initially seems very high. Once we remember that the biomass 
was harvested from synchronised cultures at the most mature stage of schizogeny my 
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results are more sensible. Since merozoites have been formed, the total amount of DNA 
will have increased by a factor of 8-3236 from the level before schizogeny began. The lower 
DNA content as a percentage of dry weight of the L. major biomass function is despite a 
larger genome of 32.8 million base pairs. This is to be expected in part because individual 
amastigotes of that species reproduce by simple division to produce two daughter cells 
and in part because the host macrophage is substantially larger meaning the minimum 
required amount of DNA represents a smaller percentage of total dry weight. 
To try and see if this difference in number of daughter cells explains the amount of DNA I 
have measured I have performed a basic calculation to calculate the number of complete 
genomes the measured DNA mass represents. 
The total DNA (        ) in the parasite’s biomass is formed of two components, free DNA 
nucleotides (       ) and chromosomal DNA (         ) which add up to give the total 
DNA measured by my assays. 
                           =              
An approximation of the amount of free DNA can be calculated from Teng et al.146 (table 36 
in appendix IV) giving a total of                      of free nucleotides of which it 
seems reasonable to assume that around a third* are/were intended for DNA synthesis. 
             
              
We know that the P. falciparum nuclear genome ( ) is 22,853,764 base pairs. Taking the 
mass of an average base pair to be (             ) we can calculate the total mass of 
DNA in a single parasite genome (    ) to be, 
      
     
  
 
     
            
         
                    
The genome is haploid in all of the erythrocytic life-stages so the total mass of 
chromosomal DNA is given by multiplying the mass of a single genome by the number of 
genomes (        ) to give, 
                        
                                                             
* Here I split DNA, RNA and energy (ATP, ADP etc…) populations equally for a very rough calculation. 
Free DNA is a small enough proportion of total DNA that any error in this figure should have only a 
small effect on these calculations. 
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Combining all these formulas and rearranging for the number of genomes gives us,  
         
(            )         
    
 
                           
          
       
This means that the best-estimate measurement of DNA content is within the maximum 
sensible figure of 32 genome copies per late-stage schizont. My feeling is that the most 
accurate figure is towards the lower end of the estimate for   with the equivalent 
calculation giving an average of 17.5 genome copies per late-stage schizont but the optical 
microscopy and staining techniques described in this thesis cannot reliably distinguish 
between 8, 16 and 32 nuclei in schizonts so I have little evidence either way.  
Protein as a percentage of dry weight 
The biomass function of Arvind Chavali’s L. major model (sup. 1)108 contains 45% protein 
as a percentage of dry weight, exactly the same as in Förster et al.’s S. cerevisiae model. 
This is in good agreement with my measurement of a 48% protein content. 
Dry weight per parasite 
The dry weight per parasite            is, 
           
         
       
                       
By comparison the dry mass of an RBC is given as               in Mysliwski and 
Korczak175 and               in Williams Hematology173. My measurements and these 
figures suggest that the dry weight of a mature P. falciparum schizont is around 20-30% of 
the dry weight of a human RBC. 
As previously noted, 92% of the dry weight of a human RBC is composed of haemoglobin. 
The principal source of amino acids in mature P. falciparum schizonts is from the digestion 
of the host erythrocyte’s haemoglobin100 and the best independent estimate from Krugliak 
et al. 2002103 is that 65% of the infected RBC’s haemoglobin is digested by the parasite of 
which up to 16% is retained. Multiplying these three percentages suggests that the protein 
mass of a mature P. falciparum schizont is around 10% of the RBC mass.  My 
measurements show that protein makes up around half of the parasite’s biomass and so 
the expected total biomass is just over 20% of the RBC mass; within the measured range of 
20-30% of RBC mass. 
Combining information from so many sources and confirming that my measurements are 
sensible is extremely pleasing but it raises a more serious point. I intended to use the 
biomass components from Teng et al.146 to provide information on relative proportion of 
amino acids and nucleotides in my biomass function but it is clear from the total mass 
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returned in their paper that their techniques measure only free metabolites, not those 
incorporated in polymers. A better solution is required. 
Details breakdown 
In order to create a detailed biomass function the measured amounts of DNA, protein and 
RNA need breaking down into their constituent nucleotides and amino acids and the lipids 
and carbohydrates need to be added to the biomass composition to make it up to 100%.  
Amino acid frequencies could naïvely be measured from the composition of translated 
proteins but a more complex analysis where the relative abundance of each protein is 
considered is already provided by Chanda et al.176 and adapted as table 16. 
 
Table 16 : Amino acid frequency in the Plasmodium falciparum proteome, from Table 1 in Chanda et al.176. 
Frequencies sum to 99% due to rounding in the original paper. 
DNA nucleotide composition is easy to add since we know that the majority of DNA 
nucleotides are incorporated in the chromosomes and we know the exact proportion of 
DNA nucleotides from the genome sequence47. 
Amino Acid Frequency (%)
Aspartate 12.2%
Lysine 11.6%
Isoleucine 9.3%
Leucine 8.1%
Glutamate 7.0%
Serine 6.3%
Aspartate 6.0%
Tyrosine 5.5%
Phenylalanine 4.6%
Threonine 4.2%
Valine 4.1%
Glycine 3.1%
Arginine 2.9%
Glutamine 2.8%
Alanine 2.4%
Proline 2.2%
Histidine 2.2%
Methionine 2.2%
Cysteine 1.8%
Tryptophan 0.5%
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Table 17 : DNA nucleotide frequency in the P. falciparum genome. 
Another contribution to total RNA comes from gene transcripts in the form of messenger 
RNA (mRNA) and from Gardener et al.47 we know that around 76.3% of the nucleotides in 
introns are A or T meaning the mRNA composition should be about 76.3% T and U, giving 
the final RNA nucleotide composition shown in table 18 . 
 
Table 18 : RNA nucleotide frequences are calculated by taking into account both the ribosomal RNA nucleotide 
composition and the likely composition of mRNA from gene transcription. The rRNA:mRNA ratio is set at 1:1. 
A complexity that I have omitted in my final model with regard to the RNA content of the 
biomass function is that, in quickly growing cells, ribosomal RNA makes up the major part 
of the total RNA; typically 85% in E. coli and 81% in S. cerevisiae165. From Vezza et al.177 we 
know that the ribosomal RNA (rRNA) of P. falciparum has around a 35-37% G-C content 
and the AMP and UMP composition of the biomass may well we correspondingly lower. I 
have not made this correction since the proportion of RNA which is ribosomal is unknown. 
In any case, making such a change results in negligible changes to the model’s behaviour 
and predictions. 
No serious attempts were made to quantify the carbohydrate and lipid composition of the 
biomass and so these remaining components were added in the same ratio (carbohydrate 
27:15 lipids) as they are including the L. major biomass function of Chavali et al.108. The 
breakdown of lipid and carbohydrate components of the biomass function are discussed in 
the next chapter of this thesis as the pathways that generate are considerably simplified in 
the final model. 
 
 
 
 
 
 
DNA nucleotide Frequency (%)
dAMP 40.3%
TMP 40.3%
dGMP 9.7%
dCMP 9.7%
RNA nucleotide Frequency (%)
AMP 38.7%
UMP 38.7%
GMP 11.3%
CMP 11.3%
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All of this gives the final biomass composition shown in table 19 and figure 70. 
 
Table 19 : The components of the final biomass function as a percentage of dry weight. 
 
Figure 70 : The components of the final biomass function as a percentage of dry weight. 
  
Component % dry weight
DNA 6.7%
RNA 5.9%
Protein 48.0%
Lipids 14.1%
Carbohydrate 25.3%
Total 100.0%
DNA
7% RNA
6%
Protein
48%
Lipids
14%
Carbohydrate
25%
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Measuring exchange fluxes 
What started as an idea to extend Jennifer Lake’s Masters project evolved into a key part of 
my thesis when I spoke at the White Rose Doctoral Training Centre internal conference in 
Sheffield in late 2009. I was pitching my ideas to perform metabolomics on the malaria 
parasite using liquid chromotagraphy linked to mass spectrometry (LC-MS) techniques as 
described widely for many other organisms. The specialisms and experience at Leeds were 
not ideal for trying these types of experiments but Cassey McRae and Hayley Fenton in 
Julie Fisher’s group in Chemistry at Leeds said that was I was looking to do was very 
similar to the work they were doing on the metabolomics of cancer patients, looking at the 
composition of body fluids. 
Jennifer had been measuring the rate at which glucose was taken up by the parasite and 
the rate at which lactate was produced using biochemical kits which were inaccurate and 
unreliable*. Preliminary tests we performed using 1H-NMR (Proton NMR) metabolomics 
proved to be more reliable and were additionally able to distinguish more metabolites. A 
summary of these preliminary trials and the three major metabolomics experiments that 
followed are contained in table 20. In this section I will explain the results and the 
techniques I have developed. 
The methods and data analysis are identical for all compounds and so I start with a 
detailed description of the techniques. The results are then split into carbon compounds 
and amino acids. Glutamine is considered as a carbon compound rather than an amino 
acid due to its recently clarified role as the principal carbon source — via conversion to 
oxoglutarate — driving the mitochondrial TCA cycle95 as shown earlier as figure 33 on 
page 73. The magnitude and direction of the exchange fluxes measured also supports 
glutamine being primarily considered as a carbon compound.  
Splitting the metabolites this way makes sense because the exchange fluxes measure two 
different things. The exchange fluxes for carbon compounds primarily tell us how the 
parasite produces the energy it needs to survive, with the magnitude and choice of 
pathway providing further information in areas such as redox metabolism. The amino acid 
exchanges tell us how the parasite acquires the amino acids it needs to synthesise proteins 
and the way it deals with the haemoglobin it digests. 
Hypoxanthine exchange fluxes are included with the amino acid analysis simply because 
the magnitudes of the fluxes are similar. The NMR assignment of hypoxanthine is unclear 
and the results should be treated with even greater caution than their high uncertainties 
and wider variability suggest.
                                                             
* Protocols are in the methods section, a full evaluation is contained in Jennifer’s thesis145. 
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Table 20 : Summary of metabolomics and biomass experiments performed in 2010 and 2011. 
Metabolomics and Biomass Experiments (2010-2011)
Name Jenny Metabolomics Tom repeat of Jenny Metabolomics Sara Metabolomics of Inhibition
Tom repeat of Sara Metabolomics of 
Inhibition
Culture End Date July 2010 17th November 2010 June 2011 22nd December 2011
Extracted Culture Volume (ml) 120 2 x 13 8
Extracted Parasitemia
4.1%
3.5% (uninhibited)                                                
4.5% (inhibited)
2.6%
Haematocrit volume at extraction (ml) 3.75 2 x 1.25 0.32
Biomass Extracted Successfully No Partially Yes No
NMR Acquisition Month 29/07/2010 21/02/2011 July and August 2011 January 2012
Time Points Harvested (including fresh 
medium)
2 11 13 5
Time Points Measured 2 11 5 5
End Time 24 41
Blood Nulls No Yes, insufficient Yes, sufficient No
Notes Ethanol production detected.
Methanol sterilisation. No ethanol production 
detected.
Full set of blood nulls both with and without 
atovaquone inhibition, Normal growth and 
sublethal atovaquone inhibition time course of 
parasitised red blood cells
No blood nulls. Significantly lower base 
metabolism.
Description
Fresh Albumex growth medium was measured 
for the first time. Three biological replicates of 
used growth medium harvested after 24 hours 
were measured.
Single blood null at 14.50 hours not accurate 
enough. Ethanol production result from Jenny's 
results not reproduced. 11 time-points taken for 
one sample. 1 time-point taken at 31.58 hours 
for a biological replicate largely agrees with main 
sample
Strange experimental technique means changing 
haematocrit percentage. Abnormally high 
haematocrit at end of experiment may affect 
results. Strange technique has advantage of 
increasing sensitivity. Sample B is uninhibited. 
Sample A is inhibited with atovaquone at 3.2nM.
Sample 1 is uninhibited. Samples 2 is inhibited 
with atovaquone at 3.2nM
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Collecting spectra 
I create spectra for each growth medium sample using the 1H-NMR techniques described 
in the methods section. These spectra are then grouped by experiment like in the example 
shown in figure 72 for the Sara A set from the “Sara metabolomics of inhibition, June 
2011” set of experiments summarised in table 20.  
The exact position of peaks is not constant across different experiments even if the data 
processing is identical. It is therefore extremely important to align each peak manually in 
the ACD/labs software to ensure that the range of integration is consistent across spectra 
and for this reason it is best to integrate spectra that will later be compared in sets. 
An example of the visual alignment required — in this case the prominent α-Glucose 
doublet at 5.25ppm — is shown in figure 71 and each peak requires its own alignment. 
This figure also gives an excellent visual example of how glucose is consumed by the 
parasite over time, leading to a large decrease in its concentration in the growth medium. 
A final note on this image is that whilst the sizes of the peaks in this case largely 
correspond to the concentration of glucose in the medium this is often misleading due to 
the visual normalisation techniques in the ACD/labs software. Although this kind of visual 
inspection can be useful for peak identification, the reported area under each curve — and 
not the visual representation of the area — is the only reliable way to assess the 
concentration of each metabolite. 
 
Figure 71 : 1H-NMR spectra for the α-Glucose doublet at 5.25ppm from the Sara A set. (left) Positions as referenced 
to TMS at 0ppm. (right) Positions once manually aligned. Colours blue, green, grey, pink, red, correspond to t = 0, 
9.2 18.5, 27.0, 36.5 hours and show the clear decrease in glucose concentration in the growth medium over time. 
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Figure 72 : The four 1H-NMR spectra in the Sara A set. Here the integrals for the selected spectrum (red, 30/06_00h20_A, t = 9.2 hours) are shown. The two symmetrical HEPES multiplets at 2.86 and 
3.15 (integral referenced to 100) are visible. Colours green, grey, pink, red, correspond to t = 9.2 18.5, 27.0, 36.5 hours.   
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Picking peaks  
With the spectra of all the acquired samples collected into sets for each experiment we 
need to identify the peaks within the spectra that correspond to metabolites of interest. 
Initially we drew heavily on the time and experience of Cassey McRae, a PhD student in 
Julie Fisher’s lab who showed us how to identify and interpret spectra. My method for 
identifying peaks has evolved but in my final full review of my results was as follows. 
1. Visually move through the set of spectra and note the positions and forms (singlet, 
doublet, multiplet, etc…) of visible peaks. In total 34 peaks or sets of peaks were found. 
2. Look for peaks at the same position in Cassey’s suggested reference paper, “750 MHz 
1H and 1H-13C NMR spectroscopy of human blood plasma” by Nicholson et al.178. 
3. Search for other peaks using the human metabolome database179 (HMDB) available at 
www.hmdb.ca and the Biological Magnetic Resonance Data Bank (BMRDB) at 
http:  www.bmrb.wisc.edu . 
4. Verify proton assignments for each peak using the interactive 1H-NMR viewer at 
http:  mmcd.nmrfam.wisc.edu , part of the Madison Metabolomics Consortium  
Database180 (MMCD). 
With a large number of the peaks identified I downloaded the reference spectra from 
HMDB for the following metabolites, 
Malate, leucine, isoleucine, ethanol, glucose, glycerol, histidine, hypoxanthine, alanine, 
glutamate, glutamine, valine, lactate, NAD, NADP, phenylalanine, tyrosine. 
These reference spectra, as shown separately in figure 73 and combined in figure 74, were 
used to check that the peaks identified in my samples were at the correct position and of 
the same shape as expected. Metabolites that were known to be present in the growth 
medium were not included in the reference set of spectra where the only measurable 
peaks overlapped with other strong signals. For example asparagine is present in RPMI 
medium but its principal peaks at 2.8–3.0 ppm are obscured by a HEPES peak at 2.84–2.90 
ppm. Arginine’s triplets at 3.23ppm and 3.76ppm are obscured by glucose and 
glucose/glutamate/glutamine respectively. There are techniques to separate overlapping 
signals in NMR spectra but they introduce considerable error into the results130, especially 
when used by someone with no experience of them and when one signal is considerably 
stronger than the other. 
 
161 
 
 
Figure 73 : Collection of 1H-NMR reference spectra used as a guide to peak identification displayed separately. From 
the top, spectra are of NADP, NAD, Leucine, Lactate, L-Valine, L-Glutamine, L-Glutamate, L-Alanine, Isoleucine, 
Hypoxanthine, Histidine, Glycerol, Glucose, Ehtanol, Isoleucine (included twice in error), Leucine (included twice in 
error), Malate. 
 
 
Figure 74 : Collection of 1H-NMR reference spectra used as a guide to peak identification displayed together. Other 
reference spectra were downloaded and examined individually but determined not to be present in any spectra. 
A total of 21 peaks represent 12 unique metabolites (counting α and β-glucose together*) 
were identified and are summarised in table 21 with the majority of these metabolites 
visible in all 42 spectra acquired. The glycerol assignments and associated results should 
be treated with caution and I discuss this further at the end of this chapter. 
                                                             
* The α and β isomers of glucose interconvert spontaneously and the distinction between the two 
forms within my model could be removed without affecting my results. Restrictions on glucose flux 
in the modelling section of this thesis are always on the combined flux of both forms. 
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Table 21 : NMR peak assignment table ordered by observed peak position (ppm). The two unobserved malate peaks 
and the HEPES peak used as a concentration reference are included in addition to the 21 metabolite peaks 
representing 12 unique metabolites that were observed in at least some spectra. The hypoxanthine assignment is not 
very clear and should be treated with caution. In all cases the Madison Metabolomics Consortium  Database180 was 
used as the definitive source of hydrogen counts for each peak. 
With the peaks identified, the area under each of them was integrated within the ACD/labs 
software with the integral expressed as a percentage of the HEPES peak at 3.15ppm. 
Converting metabolite integrals to metabolite concentrations 
At the level of NMR analysis used in this thesis, the integral of a peak (  ) is proportional to 
the number of molecules in solution (proportional to the milliMolar concentration ([ ]  ) 
times the number of hydrogen atoms (  ) in each molecule that produce the integrated 
peak. For all metabolites in solution, 
       [ ]   
And thus 
  
  [ ]  
          
Observed 
Position (ppm)
Peak Type
Nicholson 
Position (ppm)
Hydrogens
Molecular 
Weight (g/mol)
Isoleucine 0.95 t 0.93 3 131.17
Leucine 0.97 t 0.97 6 131.17
Valine 0.99 d 0.97 3 117.15
Isoleucine 1.02 d 1.00 3 131.17
Valine 1.05 d 1.02 3 117.15
Ethanol 1.16 t - 3 46.07
Lactate 1.33 d 1.34 3 90.08
Alanine 1.46 d 1.46 3 89.09
Glutamine 2.13 m - 2 146.14
Glutamine 2.45 m - 2 146.14
HEPES 3.15 m - 2 238.30
Glycerol 3.56 dd 3.56 2 92.09
Glycerol 3.66 dd 3.64 2 92.09
Lactate 4.12 q 4.12 1 90.08
β-Glucose 4.65 d 4.66 1 180.16
α-Glucose 5.24 d 5.24 1 180.16
Tyrosine 6.90 m 6.87 2 181.19
Tyrosine 7.20 m 7.17 2 181.19
Phenylalanine 7.33 m 7.33 2 165.19
Phenylalanine 7.38 m 7.38 1 165.19
Phenylalanine 7.43 m 7.43 2 165.19
Hypoxanthine 8.20 d - 2 136.11
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From this relationship we can calculate the milliMolar concentration of a metabolite from 
the known concentration of any other metabolite. Often an external concentration 
standard is added to samples before acquisition but this requires extremely accurate 
pipetting and sample preparation at the small acquisition volumes (⋍ 300µl) of our NMR 
system. Instead we make use of the extremely clear peaks of the HEPES* buffer used at 
very high concentration (see table 35 in appendix III) in RPMI 1640 medium. In particular 
I have chosen to use the multiplet at 3.15ppm produced by two hydrogens.  
  
  [ ]  
  
      
      [     ]  
  
Isolating [ ]   gives us, 
[ ]    
          [     ]  
         
 
This milliMolar concentration can be converted to the more useful mg/ml using the molar 
mass of the metabolite (  ), 
[ ]       [ ]   
  
    
 
The integrals of different peaks within the reference spectra for each metabolite available 
from the human metabolome database179 show that small deviations from this basic 
theory occur but applying these corrections is difficult and unnecessary since the 
uncertainties are small compared to biological variance. 
HEPES as a concentration reference 
Using HEPES as an internal concentration reference is not completely new130 but it is rare 
enough that documentation is not widely available. Indeed the technique has its 
drawbacks, namely that, 
… the use of protonated, organic buffers (e.g., Tris, MOPS or HEPES) should be 
avoided. Signals from these additives can mask important metabolite resonances 
or can be mistaken as ‘‘unknown’’ endogenous metabolites. 
Quantitative metabolomics using NMR, David. S. Wishart, 2008181 
Since HEPES exists in the growth medium already there is no easy way to avoid this 
problem and it makes sense to use the HEPES signals if possible. 
                                                             
* 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid. 
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The NMR spectrum of HEPES is strange in that it changes considerably with concentration* 
and is extremely poorly predicted by the best commercial NMR spectrum prediction 
software (MestReNova®, analysis performed in collaboration with a fellow doctoral 
student, Simon England at the University of Sheffield). The BMRDB assignment table for 
HEPES points to there being five distinct peaks, of various multiplicity, at 2.851, 2.936, 
3.056, 3.151 and 3.851ppm with hydrogen assignments of 4, 2, 2, 6 and 2 respectively and 
in light of this Cassey McRae assigned the peak at 3.15ppm to 6 hydrogens. 
The problem with these assignments is that the peaks I observe in my samples, table 22,   
do not agree with them.  
 
Table 22 : Chemical shifts and integrals of the four HEPES peaks in my samples. Integrals are referenced to the 
clearest and most reliable peak at 3.15ppm. 
My observed four peaks with equal integrals are far more consistent with the HEPES 
spectrum in MMCD (Madison Metabolomics Consortium  Database180). In that spectrum 
the four peaks are the same shape as I observe but only the 3.15ppm peak is in the same 
position. That the peaks are in different positions is not ideal but it seems reasonable 
given the way the reference spectra vary with HEPES concentration. 
There is a second concern with using the 5958mg/L (25.03mM) of HEPES in RPMI 1640 
growth medium as a concentration reference. In Teng et al.146 it is reported that HEPES 
accumulates in the parasite biomass to a final concentration of at least 
                                 . This is the highest concentration of any 
measured metabolite accumulated in the parasite biomass and significantly higher than 
the three next most significantly accumulated metabolites: glutamate at around 30 g/1015 
parasites and glutathione and ATP at around 20 g/1015 parasites. This high absorption of 
HEPES by the parasite will lower its concentration in the used growth medium and could 
thus falsely suggest an increase in the concentrations of the other metabolites. An estimate 
of the percentage error that this problem could introduce can be calculated as follows. 
                                                             
* The spectra on the Biological Magnetic Resonance Data Bank (BMRDB) at 
http:  www.bmrb.wisc.edu  show this very clearly. 
Chemical shift (ppm) Peak type Integral
2.72 t 88.7
2.86 m 92.2
3.15 m 100.0
3.78 t 105.2
Mean 96.5
St. dev. 6.4
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The initial concentration of HEPES in the growth medium and the amount absorbed by the 
parasites is roughly, 
[     ]                
[     ]                     
                               
Assuming a typical haematocrit of 5%, parasitemia of 5% and packed RBC density of 
            of haematocrit182 we can calculate the number of parasites per litre of 
culture. 
[         ]                                          
The total amount of HEPES absorbed by these parasites is thus, 
                [     ]               [         ] 
                     
                             
The percentage change in HEPES concentration in the growth medium due to absorption 
by parasites is thus, 
                            
              
[     ]       
      
A 0.3% underestimation of metabolite concentrations is tiny compared to other 
uncertainties and can be ignored. Accumulation of HEPES by uninfected RBCs has not been 
reported as a major concern. The effect of HEPES absorption may become an issue in 
experiments conducted at higher haematocrit concentrations and higher parasitemias. 
A further concern using HEPES as the stated reference concentration of 5958mg/L is that 
it is diluted by 5-10% when the RPMI medium is combined with the haematocrit for 
culturing. It might be sensible to make a correction to account for this but for the 
unrelated finding in Lewis et al.130 that metabolite concentrations calculated from 1H-NMR 
spectra and referenced to HEPES were typically underestimated by a similar amount. 
  
166 
 
A note on the graphs and axes 
I am convinced that the graphs on the next few pages are the best way to show my results 
but I am also aware that they are heavy on information and require detailed explanation. 
The four sets of experiments summarised in table 20 are all displayed on the same graphs 
(figure 76 — figure 79 and figure 82 — figure 88) with the experiments grouped 
according to shape of marker; 
 Diamonds — Jenny preliminaries. 
 Dots — Tom repeat of Jenny. 
 Squares — Sara metabolomics.  
(Set A is inhibited with sub-lethal dose of atovaquone, Set B is grown in normal 
growth medium, Sets C and D are uninfected blood nulls for set A and B respectively.) 
 Triangles — Tom repeat of Sara. 
The colour of each series is different except for blood nulls — parallel cultures of identical 
but uninfected RBCs — which are always shown in blue. 
The y-axes of the graphs have units of mg per 10 billion RBCs which is a product of the 
measured concentration of the metabolites in the growth medium in mg/ml and the 
volume of homogenous culture containing an average of 10 billion RBCs (ml/10 billion 
RBCs). For metabolites such as lactate and glycerol that are not present at detectable 
levels in the growth medium at     this is a perfect unit for the y-axis. For other 
metabolites with a significant concentration at     the choice of y-axis can be confusing. 
This is because an equal concentration will have a different value depending on the 
haematocrit concentration in the culture. The major upside of the choice of y-axis unit is 
that gradients are directly comparable across all experiments and correspond to the 
exchange rates of the compound between the growth medium and the population of 
infected and uninfected RBCs. 
A final explanation needs to be made of the starred points present in figure 76, figure 77 
and figure 78. As described on page 114 of the methods chapter the Jenny metabolomics 
set of experiments used a complex technique that required an equivalent haematocrit to 
be calculated for each measured point. These calculations assume a constant exchange of 
metabolites but in the case of the Sara A set the glucose in the growth medium was 
exhausted and could no longer be absorbed by the parasite. This had a knock-on effect on 
lactate and glycerol entering the growth medium and the assumption of constant exchange 
rate in the haematocrit correction no longer held. 
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Although figure 76 appears to show lactate being reabsorbed by the RBC population in the 
final time step the actual levels in the growth medium increased over this period, from 
4.65mg/ml to 4.67mg/ml. Likewise with glycerol, figure 78 greatly exaggerates the 
reduction in glycerol concentration. In the last three time points the concentrations of 
glycerol in the growth medium were 2.25mg/ml, 3.14mg/ml and 2.82mg/ml. Whilst the 
idea that glycerol produced from glucose may be reabsorbed by the parasite once it the 
glucose is exhausted is fascinating — and in keeping with models of E. coli metabolism76 — 
it is impossible to suggest this based on a single point in a single experiment with such 
large underlying uncertainties. 
The experimental setup used to get the results in the Sara metabolomics set of results is 
undoubtedly complex and in appendix IX to this thesis I discuss much simpler ways to 
achieve even better results. Despite its many drawbacks this overly complex system 
allowed high sensitivity assays to be conducted and has produced some fascinating 
results. 
Atovaquone inhibition 
Two of the sets of experiments, Sara metabolomics and Tom repeat of Sara metabolomics, 
had one time series where the growth medium contained 3.2nM of the known inhibitor 
atovaquone in addition to an experiment in normal conditions. This was the concentration 
of the compound measured by Sara Zakutansky in her Masters thesis to reduce the 
parasite population’s growth-rate to 1; no increase or decrease in population over time. 
We choose a sub-lethal concentration of the inhibitor in the hope of observing not the 
death of a culture — which could lead to the complete breakdown of metabolism — but 
rather a highly stressed but still functional version of metabolism. 
The mechanism of action of atovaquone is well known, with precise details in Olliaro126 
amongst others. At its most simple it is an inhibition of the enzyme dihydroorotate 
dehydrogenase which catalyses reaction R01867 as shown in figure 75. Dihydroorotate 
(DHO) is primarily produced from aspartate and the conversion of glutamine to glutamate. 
Orotate goes on to form pyrimidine nucleotides. The results shown in figure 75 show that 
with a 3.2nM concentration of atovaquone in the growth medium the flux through R01876 
is slowed, leading to an accumulation of dihydroorotate before the reaction and a 
reduction of the amount of orotate after the reaction. 
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Figure 75 : HPLC measurements of dihydroorate and orotate concentrations in the parasite biomass pellets extracted 
at the end of the Sara metbolomics set of experiments suggest that sub-lethal atovaquone inhibition (sample A) was 
successful in reducing the flux through R01867 leading to accumulation before, and reduced concentration after, the 
reaction. 
The results in figure 75 are presented briefly because the parasite biomass extractions in 
these experiments were performed using the methanol/water technique I later found to 
be ineffective in freeing the contents of isolated biomass pellets*.  
Uncertainties on individual points 
The graphs in the remainder of this chapter are already full of information so I have not 
included estimates of the errors in individual readings even though I have made efforts 
estimate these. As I discuss later, no two batches of RBCs have the same metabolic 
properties so I cannot calculate errors by comparing results from different experiments; 
the variability of RBC metabolism across different experiments is far greater than the 
technical error in each of my measurements. 
One way of estimating the technical uncertainties in individual points is by making use of 
the multiple measurements of fresh growth medium since these samples have never been 
in contact with RBCs or parasites. 
                                                             
* A more complete set of results and detailed methods are contained in Sara Zakutansky’s Masters 
thesis147 but are the subject to the same caveat. 
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Table 23 : Mean and standard deviation for eight different metabolite concentrations for the five different t = 0 fresh 
medium samples across all experiments. 
The result of this error analysis is in table 23 but we need to be wary of the results. My 
feeling is that a large part of the uncertainty calculated in this measurement is actually 
variability in the growth medium across experiments from differing amounts of AlbuMAX I 
powder used in preparation, different composition of any remaining serum not washed 
from the RBCs, etc…  
A better way to estimate the size of the uncertainty in single readings is suggested when 
examining table 21. Many metabolites have multiple peaks identified and since these are 
merely different reports of the same metabolite’s concentration any variance in the results 
gives an idea of the uncertainty in calculations of metabolite concentration from the NMR 
results. By calculating the standard deviations from the two — or three for phenylalanine 
— integrals for each of these metabolites and expressing this is a percentage of the 
average concentration for the metabolite in that spectrum we produce the uncertainty 
estimates in table 24. 
 
Table 24 : Average standard deviation as a percentage of metabolite concentration for the six metabolites with 
multiple measurable peaks. *Lactate measurements at      were ignored as the standard deviation of the two 
measurements at 4.12(q) and 1.33(d) was extremely high as a percentage of the mean concentration at    . 
Whilst this method is only possible for the few metabolites where multiple peaks are 
available for measurement it makes more sense to me as a way to quantify the technical 
error in the NMR method of measuring metabolite concentrations. 
The errors derived from this technique are used later in the numerical analysis of the 
“Tom Repeat of Jenny Blood Null” series where an error in the straight line fit cannot be 
returned from the linear regression as there are only two points. The error is instead 
calculated by assuming an error of 10% in both directions for both points and propagating 
this error to the calculated gradient. This assumed error is the average of  table 24 if 
lactate is ignored and is in keeping with other studies of HEPES-normalised quantitative 
NMR130 for isolated peaks. 
Valine Leucine Isoleucine Tyrosine Phenylalanine Glutamine Glucose Hypoxanthine
Mean Concentration (mg/ml) 0.02 0.03 0.04 0.03 0.02 0.25 1.85 0.24
Standard Deviation 0.002 0.009 0.004 0.006 0.006 0.05 0.48 0.05
Standard Deviation as percentage 
of mean concentration
10% 30% 9% 22% 28% 20% 26% 21%
Valine Isoleucine Tyrosine Phenylalanine Glutamine Lactate*
Average standard deviation as a 
percentage of concentration
7% 10% 5% 17% 10% 24%
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We are now ready to look at the next four graphs (figure 76 — figure 79) which show how 
the concentrations of carbon compounds change within the growth medium over the 
course of an approximately 40 hour experiment. In all cases the cultures are synchronised 
and the     point of the experiment is just after the merozoites have infected their host 
cells. The end of the experiments is just before the first late-stage schizonts start to lyse 
and exit their host cells. 
 
Carbon compound results 
 
Figure 76 : The concentration of lactate in growth medium over time. The starred red point was not used during 
numerical analysis and does not suggest reabsorption of lactate from the growth medium*. 
                                                             
* see page 112 for a complete explanation of the origin of this misleading point and why it is omitted 
from further analysis. 
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Figure 77 : The concentration of glucose (α + β) in growth medium over time. The starred red point was not used 
during numerical analysis. Points at t =0 are only reported for blood nulls as discussed later. 
 
Figure 78 : The concentration of glycerol in growth medium over time. The starred red point was not used during 
numerical analysis and does not suggest reabsorption of glycerol from the growth medium. 
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Figure 79 : The concentration of glutamine in growth medium over time. Points at t =0 are only reported for blood 
nulls as discussed later. 
We can make some important observations from these graphs which I list in the same 
order as the graphs. 
 Lactate is not detectable in fresh growth medium (at    ) and is produced at a 
constant rate in all experiments, including by blood nulls. 
 The rate of lactate production varies considerably across different experiments 
with blood nulls (uninfected RBCs) in one experiment producing more lactate than 
infected RBCs in other experiments. 
 In experiments with paired blood null series we see that infected RBCs produce 
more lactate than blood nulls. 
 Glucose is consumed at a constant rate which is similar to the rate at which lactate 
is produced. 
 The rate of glucose consumption varies considerably across different experiments. 
 Glucose is consumed more quickly by infected RBCs than uninfected RBCs. 
 Glycerol is not detectable in fresh growth medium (at    ) and is produced at a 
constant rate by infected RBCs. It is not produced by uninfected RBCs. 
 Glycerol production was only detected in the highest sensitivity experiment and 
even this assignment is not without controversy. 
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 Glycerol production is at a rate about a tenth of the rate of lactate production. 
 Glutamine appears to be consumed at a constant rate although this rate is 
considerably slower (       times) than glucose. 
 The observed production of glutamine by the blood null series in the “Tom repeat 
of Jenny Blood Null” experiment seems unlikely and is an example of why multiple 
measurements of blood null series are required. 
Numerical analysis of carbon compound exchange 
Whilst looking at the graphs of how carbon source concentrations in the growth medium 
change over time gives us a good feeling for what is happening, a more rigorous numerical 
analysis is required to extract numbers that we can use with our metabolic model as 
constraints for flux-balance analysis. Since the blood nulls show significant and variable 
levels of metabolism we can only make calculations of parasite metabolism for those 
experiments where we have a parallel blood null. In these case we calculate for each 
metabolite a least-squares linear regression using the LINEST function which returns a 
gradient (  ) and an associated error (  ) in that gradient. A gradient (    ) and an 
associated error (    ) for the blood null was similarly calculated. 
The blood null gradient is subtracted from metabolite gradient to give the gradient caused 
by infected RBCs (  ) whilst being careful to remember that parasites replace, in the 
same proportion as the culture’s parasitemia ( ), rather than add to the number of 
uninfected RBCs. 
      (          ) 
The uncertainties combine to give   , 
   √  
      
   
The gradient   is the result of the small percentage ( ) of the RBCs that are infected and 
so to calculate the exchange flux in units of mg/10 billion infected RBC/hour or more 
sensibly           per parasite (  ) 
   
  
 
  
   (          )
 
 
The results of this analysis for the three series with associated blood nulls is summarised 
table 37, table 38 and table 39 in appendix V but shown most easily in figure 80 below. 
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Figure 80 : Exchange fluxes of carbon compounds. Differences between the glycerol excretion and glutamine 
absorption rates in Sara A and Sara B sets are not significant. No glycerol was measured in the “Tom Repeat of 
Jenny” experiment. 
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Amino acids and hypoxanthine results 
A key complexity of working with malaria parasites is the interplay between RBC host and 
the parasite itself. This is important in many areas but nowhere as strongly as with regard 
to amino acid metabolism since the parasite does not synthesise amino acids itself47 but 
rather obtains them from haemoglobin digestion or from the host cell. Measuring the 
content of the growth medium tells us the exchange of metabolites between the infected 
RBC (including the internal parasite) and the extracellular space. Putting aside for a 
moment the significant changes to RBC metabolism provoked by parasite invasion we can 
safely subtract the background effect of the RBC’s metabolism for carbon compounds. This 
is because the quantities of glucose, lactate and glycerol contained within the RBC at the 
moment of parasite infection are insignificant compared with the amounts exchanged with 
the growth medium over the subsequent 40 hours of parasite growth. The same cannot be 
said for amino acids because — as mentioned when considering the biomass function 
measurements earlier — around 92% of an RBC’s dry weight172 at the moment of parasite 
infection is protein: almost exclusively haemoglobin. 
 
Figure 81 : Amino acid sources and fates in a cultured infected RBC are more complex than with carbon sources due 
to the abundant proteins provided by haemoglobin digestion. It is unclear whether the free amino acid pool in the 
RBC is large enough to affect measured amino acid exchange fluxes between the parasite and growth medium 
significantly. 
In the case of amino acids we only measure the exchanges between the infected RBCs and 
the extra-cellular space even though only the exchange of isoleucine — an essential amino 
acid not present in haemoglobin — is required for growth*. Furthermore, the dynamics of 
amino acid exchange are already known to be extremely complex with the parasite known 
                                                             
* Parasites cannot grow without isoleucine and enter a state of hibernation until isoleucine is 
adequately provided124. 
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to digest more haemoglobin than it needs for growth, export excess amino acids103 and, 
bizarrely, to grow more slowly if certain amino acids that should be adequately supplied 
by the digestion of haemoglobin are not present in the growth medium100. Finally, because 
the fluxes of amino acids are smaller than for the carbon compounds the relative size of 
the internal pool within the RBC but not within the parasite may no longer be insignificant 
as a buffer between a compound entering/leaving the parasite and entering/leaving the 
growth-medium. 
These issues, displayed in figure 81, make the meaning of measured amino acid exchange 
fluxes between the infected RBC and the growth medium more challenging to interpret 
than with carbon compounds. The data from which these exchange fluxes are calculated is 
shown on this and the next three pages as figure 82 — figure 88. 
 
 
Figure 82 : The concentration of valine in the growth medium over time. 
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Figure 83 : The concentration of alanine in the growth medium over time. 
 
Figure 84 : The concentration of leucine in the growth medium over time. 
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Figure 85 : The concentration of isoleucine in the growth medium over time. 
  
Figure 86 : The concentration of tyrosine in the growth medium over time. 
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Figure 87 : The concentration of phenylalanine in the growth medium over time. 
 
Figure 88 : The concentration of hypoxanthine in the growth medium over time. 
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As with the carbon compounds it is useful to make some general observations from the 
graphs. 
 Valine, alanine and phenylalanine are clearly exported from the infected RBC into 
the growth medium. 
 Valine seems to be exported more quickly in the second half of the life cycle. 
 Alanine may be exported more quickly in the second half of the life cycle but the 
low concentration of alanine at early time points means it cannot be reliably 
detected by NMR metabolomics. 
 Leucine seems to be exported into the growth medium but it is not clear. 
 Isoleucine and tyrosine seem to be exchanged at the same rate between RBCs and 
the growth medium in both parasite-infected cultures and the uninfected blood 
null series. 
 The considerably lower exchange fluxes measured for the amino acids and 
hypoxanthine make the accurate quantification of the fluxes more difficult. 
 The considerable variability of the two blood null sets makes the interpretation of 
results difficult and increases the uncertainty in my findings. 
A more complex but extremely important point to make is that the series of infected 
cultures when traced back to     frequently do not seem to start at the same 
concentration as the blood nulls. This is not something we see in the carbon source graphs 
and is a particular problem for the Sara metabolomics experiments because 
measurements were only taken at five time points.  
I haven’t been able to uncover the origins of this discrepancy but the possible 
interpretation that in the first time point a large exchange of amino acids occurs between 
infected RBCs and the growth medium that does not occur between uninfected RBCs and 
the growth medium is not plausible. Without a good suggestion for why this incongruity 
might be occurring I am forced to deal with it as well as possible. In this case I have done 
so by ignoring the     points when calculating the gradients of the infected RBC lines of 
best fit. In the Sara metabolomics set of experiments this makes a considerable difference. 
In the case of the ”Tom Repeat of Jenny” metabolomics set of experiments this makes 
almost no difference as a sufficient number of time points are sampled to make a single 
point relatively unimportant. 
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Numerical analysis of amino acid exchange 
With the exception of this change the numerical analysis of the amino acid exchange fluxes 
is identical and produces table 40, table 41 and table 42 in the appendix V and as figure 89 
below. 
 
Figure 89 : Amino acid and hypoxanthine exchange fluxes from infected RBCs. Positive values indicate the 
metabolite is released into the growth medium, negative values indicate that it is absorbed. 
 
Carbon balance 
Examining figure 80 showing carbon compound exchange fluxes we see that, within error, 
carbon compounds are balanced within the system. The phrase “within error” is very 
important because in each case the glucose consumption is higher than the lactate 
production and when averages of the three experiments are taken the uncertainties 
reduce such that the difference becomes significant. This incomplete conversion of glucose 
to lactate has been observed before with Krugliak et al.103 stating that, 
Most of the glucose consumed (60–70%) by Plasmodium falciparum is 
incompletely oxidized to lactic acid and excreted although the exact percentage 
varies between different Plasmodium species and the atmospheric culture 
conditions used. This glucose consumption contrasts with the >90% glucose-to-
lactate conversion observed in uninfected RBCs and reflects the increased flux of 
glucose carbon into biomass (nucleic acids, lipids, glycosylated proteins) required 
for proliferating parasites. 
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The first part of this agrees with my results as summarised in table 25 with a measured 
glucose flux to lactate flux mass ratio* of between 1.38:1.00 (72% conversion) and 
1.71:1.00 (58% conversion). My results agree far less well with Krugliak et al.’s 103 second 
finding, with the only reliable blood null experiment I conducted showing a glucose flux to 
lactate flux mass ratio for uninfected RBCs  of 1.76:1.00 (56% conversion). 
 
Table 25 : Ratios of glucose uptake and lactate excretion (          ) from uninfected RBC and infected RBC 
populations in the three experiments with blood nulls. Results from the ”Tom Repeat of Jenny” experiment should be 
treated with caution as the blood null line of best fit was calculated from only two points. 
My results also do not completely agree with the suggestion that the origin of the 
incomplete measured conversion of glucose to lactate is extra biomass formation from 
carbon compounds. The mean carbon accumulation I have measured in parasites across 
all three experiments is                            so over 40 hours the unaccounted 
mass of carbon compounds is                     . This is twice the average parasite 
dry weight of                         showing that biomass formation cannot fully 
explain the imbalance. 
It is known that P. falciparum can produce acetate and experiments with other species of 
Plasmodium have measured the production of formate and other volatile carbon 
compounds183,184 though there are reasons discussed in Krugliak et al. to think that this 
may not occur in P. falciparum cultured in more modern conditions. It is known that D-
lactate is additionally produced at a rate of around 5% that of L-lactate and this is not 
measured. It is important to note that precise carbon balance is not achieved at the most 
best estimate for the carbon compound fluxes but that carbon balance is achieved well 
within the uncertainties in those measurements. 
                                                             
* Glucose to lactate mass ratio of 2:1 (180.16:90.08) is exactly equivalent to the carbon mass ratio of 
2:1 (6:3). 
Sara A Glucose Lactate Ratio
uninfected RBCs -0.79 0.45 1.76
infected RBCs -18.2 13.2 1.38
Ratio 23.0 29.3
Sara B Glucose Lactate Ratio
uninfected RBCs -0.79 0.45 1.76
infected RBCs -8.2 4.8 1.71
Ratio 10.4 10.7
Tom repeat of Jenny Glucose Lactate Ratio
uninfected RBCs* -0.26 0.68 0.38
infected RBCs -16.7 10.0 1.68
Ratio 64.4 14.7
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In summary, my measured carbon compound fluxes achieve carbon balance but not at 
their most likely rates. It is likely that a combination of biomass formation, retention of 
lactate and glycerol within the parasite and the RBC, the production of carbon compounds 
that I have not measured, and most importantly uncertainties in my measured fluxes can 
explain what might seem to be a carbon imbalance. My metabolic model confirms this, 
The absence of malate 
I cannot measure some metabolites which I know to present in the medium at visible 
concentrations because they are obstructed by other peaks. A good example of this is L-
arginine whose principal peaks at 3.23(t) and 3.76(t) are both overwhelmed by glucose 
peaks at the same position. 
This does not seem to be the case for malate, which is important because one of the most 
interesting results in malaria metabolism since I started this project was published in 
Nature in August 2010 by Olsewzski et al.95. One of the many findings — figure 3 in their 
manuscript — shows that P. falciparum parasites produce and export malate to the growth 
medium using a highly adapted version of the TCA cycle fed with glutamine. In the paper, 
extracellular concentrations of malate reach a concentration of about 60µM 40 hours after 
synchronisation. This compares with the 90µM concentration of L-phenyalanine and the 
110µM concentration of L-tyrosine that NMR analysis of my growth medium can detect, 
giving me hope that we too would measure malate production. The possibility that we 
might be able to detect malate and confirm this result seems even more likely when we 
examine the experimental technique in the paper in more detail. 
Olszewksi et al.’s95 experiments continued to hour 40 (    ) and were conducted at an 
unusually low haematocrit (    ) of 0.4% and at 6% parasitemia (    ). My equivalent 
experiments named “Tom repeat of Jenny Metabolomics” were conducted at a final 
measured haematocrit concentration of 3.1% (   ) and a parasitemia of 4.1% (   ).  From 
this we can calculated the expected final concentration of malate in my used growth 
medium, [ ]   from the concentration in Olsewksi et al. [ ]   . 
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From this predicted concentration we can calculate the expected integral value for each of 
malate’s three single proton (      ) peaks with reference to a single (      ) HEPES 
peak defined as having an integral of 100. 
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The set of experiments named “Sara Metabolomics” which were conducted to a final time 
of 36.5 hours at an average haematocrit of 7.5% and a parasitemia of 4.5% giving an 
equivalent predicted concentration of 770µM and a predicted integral of 1.53. For 
comparison, integrals for phenylalanine and tyrosine are registered in all samples with 
magnitudes typically between 0.20 and 0.40 so we would expect to see malate signals at 
this predicted intensity. 
Before we can try to find malate we need to know what we’re looking for. The principal 
multiplet peaks of the malate NMR spectrum, as shown in figure 90, are summarised in the 
human metabolome database (HMDB)179 in the following order of maximum relative 
intensity, 
 A double-doublet produced by a single proton with a maximum relative intensity 
of 1.00 at 2.66ppm referenced to TSP at 0.00ppm. 
 A double-doublet produced by a single proton with a maximum relative intensity 
of 0.91 at 2.36ppm referenced to TSP at 0.00ppm. 
 A double-doublet produced by a single proton with a maximum relative intensity 
of 0.25 at 4.29ppm referenced to TSP at 0.00ppm. 
 
Figure 90 : The three peaks of the experimental 1H-NMR spectrum of malate from HMDB179. There are no significant 
peaks outside of this range. The peak to the right is TSP at a chemical shift of zero. 
Of the three malate peaks the one at 2.66ppm is close to the HEPES signal at 2.72ppm 
making it difficult to identify and the one at 2.36ppm is obscured by an unreliable, but 
present, glutamate multiplet at the same location. The peak at 4.29ppm is flanked by two 
larger unidentified signals making the assignment unclear. There is a small signal at 
4.29ppm in the Sara metabolomics set of experiments but  if this is malate then it is not 
visible in the ”Tom Repeat of Jenny” set of experiment and its integral of 0.07 (35µM, 
185 
 
0.005mg/ml) in the final time point is around one twentieth of the production measured 
in Olszewksi et al.95. Furthermore, the shape of the peak at 4.29ppm is not convincingly 
malate. 
A clue to explaining this discrepancy between our results is given in another paper by the 
same group, in which they suggest why malate may be exported, 
“in cell culture, aspartate levels are relatively high and this flux [from oxaloacetate 
to aspartate] may be redirected to malate, which is then excreted due to overflow 
metabolism” 
Central carbon metabolism of Plasmodium parasites, Olszewski et al.88 
To consider this idea we need to look at three things we know about aspartate, 
1. It is present at 20mg/L (0.15mM) in RPMI medium (see appendix III). I cannot 
measure changes in its concentration with my NMR technique since the three 
double doublets at 2.66, 2.80 and 3.89ppm are obscured by HEPES, HEPES and 
glucose respectively.  
2. It is present in haemoglobin at about the same level as phenylalanine and makes 
up a similar proportion of the proteome composition. We know that phenylalanine 
is exported from the parasite due to excess haemoglobin digestion but we need to 
remember that phenylalanine does not have the additional roles of aspartate in 
metabolism so aspartate is unlikely to be in excess simply due to haemoglobin 
digestion. 
3. It is produced instead of lactate by a branch of glycolysis at phosphoenolpyruvate 
and additionally, according to Olszewksi et al.95, from glutamine in the 
mitochondrial TCA cycle*. Furthermore, it is consumed by both nucleotide and 
amino acid synthesis. We do not know what percentage of the aspartate consumed 
comes from each possible source but it seems unlikely that the requirement is 
exceeded by haemoglobin digestion and the branched TCA cycle. If the glycolytic 
flux were channelled to aspartate production this would easily produce a large 
excess of the metabolite. 
The system that Olszewski proposes as to why malate may be produced and exported is 
plausible but to me it seems odd. Malate is most likely produced in part because of an 
overflow from the main branch of glycolysis and yet lactate is clearly the main overflow 
metabolite. Channelling glycolysis to malate seems to offer no advantage over the 
                                                             
* The figure showing this in Olszewski et al. is reproduced earlier in this thesis as Figure 33. 
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production of lactate and costs a molecule of ATP in comparison to lactate production and 
export. 
I revisit the malate issue in the final chapter with respect to a fuller metabolic model 
which provides some answer, and yet more questions. Certainly we can say that we have 
not measured the same malate production and efflux as previously reported. 
Sanity checks and discussion of results 
Absolute metabolite concentration 
The composition of RPMI 1640 is very accurately known — see table 35 in appendix III —, 
and our only additions are AlbuMAX I, sodium bicarbonate and hypoxanthine as described 
in the methods chapter. This provides an excellent benchmark with which to test the 
metabolite concentrations measured by our unusual HEPES-referenced NMR technique. 
We can also compare this technique with the results of Massimi et al. (sup. 1)185 who used 
a similar quantitative NMR approach to measure the components of  a growth medium 
consisting of RPMI 1640 medium (Sigma) supplemented with 10% foetal calf serum (FCS) 
and 2 mM (0.29mg/ml) L-glutamine. A final check of the measured concentrations is 
provided by the biochemical assays of fresh growth medium we  performed and which are 
reported fully in Jennifer Lake’s Masters dissertation145. All these sources of information 
and the equivalent averages from all my NMR measurements of fresh growth medium are 
shown for the overlapping metabolites in table 26. 
 
Table 26 : Concentration of six metabolites in RPMI 1640 (manufacturer’s definitions) and the equivalent 
measurements for fresh growth medium (t=0) by 1H-NMR in Massimi et al.185, in my NMR results and for glucose as 
reported in Jennifer Lake’s Masters dissertation145. 
The higher amino acid concentrations in Massimi et al. 185 could be explained by their use 
of unprocessed FCS unlike my use of AlbuMAX which has the majority of free amino acids 
removed. but their observation of a far lower glucose and glutamine level than would be 
expected in RPMI supplemented with 0.29mg/ml L-glutamine is more puzzling and 
RPMI 1640 Massimi et al. Biochemical assays
Concentration 
(mg/ml)
Concentration 
(mg/ml)
Concentration 
(mg/ml)
Standard 
Deviation
Concentration 
(mg/ml)
Isoleucine 0.050 0.10 0.042 0.004 -
Valine 0.020 0.04 0.022 0.006 -
Alanine 0.000 0.02 0.002 0.010 -
Glutamine 0.300 0.38 0.245 0.15 -
Glucose 2.000 1.03 1.853 1.44 2.33
Phenylalanine 0.015 0.05 0.020 0.017 -
My measured mean concentrations, 
fresh growth medium
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suggests that my HEPES-referenced method is in many ways superior to their more 
complex techniques. My results vindicate the decision to assign the reference peak of 
HEPES to 2 hydrogens as the concentrations of the comparable metabolites are in good 
agreement with the composition of RPMI 1640 and the independent measurement of 
glucose levels by a biochemical assay. The underestimation of metabolite concentration at 
higher concentrations is in keeping with the results in Wishart181. 
The composition of AlbuMAX I is unknown but from these results we can broadly suggest 
that it is principally albumen with a considerable amount of fatty acids and/or lipids and 
negligible free amino acids and carbohydrates.  
Known fluxes and stage specificity 
Lactate production by infected RBCs has been reported previously, with Pfaller et al.186 
measuring a mean lactate production rate of    -                       * with a 
higher rate of     -                        at the schizont stage.  Vander Jagt 
et al.94 report higher but comparable L-lactate production rates† for ring stages of 
                       and                        for trophozoite/schizont 
stages. 
My results seem reasonable in comparison to these previously reported results with the 
best estimate of lactate production in the range                              . The 
slightly lower figure that I measure is likely due to the RBC population variability I discuss 
later and my observed slower growth-rate in AlbuMAX-based medium as opposed to the 
10% serum medium used in Pfaller et al. 186  and presumably used in Vander Jagt et al.‡. 
The stage specificity of lactate production in these two papers is presented — as far as I 
can see — without a statistical test and in the case of Vander Jagt with an experimental 
technique my results show to be unreliable; two different experiments were used to 
calculate early and mature stage lactate production rates meaning background RBC 
metabolism was different in each experiment. Of my experiments the “Tom Repeat of 
Jenny” set is the one where enough time points were sampled to make observing stage-
specificity most likely. Taking time points before 17h to be early stage (ring) and those 
after 17h to be late stage (trophozoite/schizont) — these times are accurately derived on 
page 110 of this thesis — I calculated the stage-specific exchange fluxes for glucose, lactate 
                                                             
* The normal equivalent unit (Eq) used in the paper is rare and for lactate 1nEq = 1nmol. 
† D-lactate is produced at a rate about 5% of L-lactate. The D-lactate NMR peak at 1.40ppm (d) is 
not visible or obscured by the 1.33(d) L-lactate peak so I have not measured it. 
‡ Culture details are in referenced paper to which I do not have access. 
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and valine as shown in figure 91. For all three metabolites the exchange flux is higher in 
the latter life stage but only in the case of valine is this statistically significant. 
 
Figure 91 : Exchange fluxes of the three metabolites potentially showing stage-specificty at the ring stage (early) and 
the trophozoite/schizont stages (late). The valine exchange flux and associated uncertainty is shown at 100 times 
real scale to be visible. 
It is worth noting that in figure 91 the exchange fluxes of glucose and lactate are higher 
when life stages are split than they are for the whole series. This is because the two lines 
of best fit are not forced to meet at      ; the origins of this strange result can be seen 
by examining figure 76 and figure 77. Forcing the two lines of best fit to meet near       
does not change the results; the gap between early and late life stage exchange fluxes 
reducing slightly but the gap in valine emission remains statistically significant. 
Glycerol production 
The metabolism and exchange of glycerol by P. falciparum is an area of considerable 
disagreement. Lian et al.46 measured production and export of glycerol by the infected RBC 
and Olszewksi et al.109 measured absorption and use of glycerol by the parasite. 
Absorption of glycerol would be impossible to measure with my NMR technique since the 
growth medium contains no NMR-measurable free glycerol but this does not make the 
findings of Olszewski et al. implausible. Firstly, their measurements are more sensitive —
though less accurate — and secondly it is possible that some glycerol becomes available to 
the parasite due to some degradation of the glycerophospholipids likely to be present in 
the growth medium and the host RBC. 
Nevertheless, if my NMR assignments to glycerol are correct then production and export 
of glycerol was seen clearly in the “Sara A” and “Sara B” metabolomics experiments with 
no measurable background production of glycerol by uninfected RBCs. The only doubt I 
have with these results is that the glycerol peaks are close to glucose peaks and I saw no 
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Valine (x100)
Lactate
Glucose
Early life stages (before 17h)
Late life stages (after 17h)
<—— Absorbed by parasite Emitted by parasite ——>
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measurable production of glycerol by infected RBCs in the other less sensitive 
experiments*. Since this result is of such importance I have spent a considerable amount of 
time examining the NMR glycerol assignment which I justify here. 
Figure 92 shows glycerol’s two principal peaks and how the double-doublet at 3.56ppm 
overlaps slightly with a distinctive glucose signal. Apart from this interference, this 
glycerol peak is not affected by any other identified metabolites. 
 
Figure 92 : Glycerol (red) and glucose (blue) peaks overlap slightly at 3.50ppm affecting the otherwise clear glycerol 
peak assigned to 3.56ppm. Spectra are from HMDB references and manually aligned with the TMS peak at 0ppm. 
 
Figure 93 : Ethanol and isoleucine are both strong peaks that obscure the glycerol peak at 3.66ppm. Spectra are 
from HMDB references and manually aligned with the TMS peak at 0ppm. 
As we can see in figure 93, the same cannot be said for the glycerol peaks (dd) at 3.66ppm. 
These peaks are obscured by isoleucine and ethanol, both known to exist in the growth 
medium at high concentrations and clearly seen in the experimental results shown in 
figure 94. 
I am confident enough to make the glycerol assignment at 3.56ppm but it is clear that only 
the left two peaks of the double-doublet are isolated enough to be reliably measured. In 
                                                             
* The Sara metabolomics set of experiments were more sensitive because of the higher parasitemia, 
higher average haematocrit and because the spectra were acquired by the FBS NMR service with 
the improvement in sensitivity mentioned in the methods chapter on page 115. 
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the reference spectra for glycerol the integrals of the left pair of peaks and the right pair of 
peaks have integrals in the ratio 3:2 and so in all cases I have measured the left pair of 
peaks and multiplied by 5/3 to estimate the true integral. 
 
Figure 94 : Spectra for the “Sara A” set annotated to show the set of peaks I assign to glycerol. Colours blue, green, 
pink, red, corresponds to t = 9.2 18.5, 27.0, 36.5 hours. Glucose concentration at the final time point is almost zero 
meaning the glycerol peak of the double doublet becomes visible. Due to the normalisation techniques used in 
ACD/labs the visual size of each peak is only a guide to its integral. 
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Amino acid fluxes 
As mentioned previously, the amino acid fluxes cannot be understood without a 
substantial amount of background information. An essential tool for helping with the 
interpretation of these results is the amino acid composition of the haemoglobin protein 
as calculated from the amino acid sequences  of haemoglobin subunit α (P69905) and 
haemoglobin subunit β (P68871) in UniProt187 and shown for selected amino acids in table 
27. 
 
Table 27: Amino acid composition of 2 α-subunits + 2 β-subunits of the human haemoglobin molecule ordered by 
total weight per mole of haemoglobin for selected amino acids of interest, The full table is reproduced in Appendix VI 
as table 43. 
The composition of haemoglobin gives us the ratios of amino acids that the parasite 
acquires through haemoglobin digestion. The next important quantity is the ratio of amino 
acids that the parasite uses to create its biomass; already extracted from Chanda et al.176 as 
table 16 on page 153. Here, the same table for the selected amino acids of interest is 
reproduced as table 28. 
 
Table 28 : Amino acid use in the P. falciparum proteome, adapted from Chanda et al.176 for selected amino acids of 
interest, The full table is reproduced in Appendix VI as table 44. 
We’ve measured the exchange fluxes between the infected RBC and the growth medium 
and so referring back to figure 81 outlining the sources and fates of amino acids we see 
Name
Molecular 
Weight (g/mol)
Count
Weight per mole 
of haemoglobin (g)
Percent by 
Weight
Percent by amino 
acid count
Leucine 113 72 8142 13.0% 12.5%
Valine 99 62 6142 9.8% 10.7%
Alanine 71 72 5115 8.2% 12.5%
Phenylalanine 147 30 4412 7.1% 5.2%
Aspartate 115 30 3451 5.5% 5.2%
Tyrosine 163 12 1957 3.1% 2.1%
Glutamine 128 8 1024 1.6% 1.4%
Isoleucine 113 0 0 0.0% 0.0%
Amino Acid Percent by weight
Percent by amino 
acid count
Isoleucine 8.5% 9.3%
Glutamate 8.3% 7.0%
Leucine 7.4% 8.1%
Tyrosine 7.3% 5.5%
Aspartate 6.5% 6.0%
Phenylalanine 5.5% 4.6%
Valine 3.3% 4.1%
Glutamine 2.9% 2.8%
Alanine 1.4% 2.4%
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that we now have the three key fluxes in the system. If we temporarily ignore the pool of 
free amino acids in the RBC*, and the possibility of conversion between amino acids, we 
can calculate some very interesting conclusions from our results. 
Figure 95 shows how these three factors balance when it is assumed that 40% — the 
amount required to achieve an average net balance of the six amino acids to the left of the 
dotted line — of the haemoglobin in the host RBC is digested by the parasite. 
 
Figure 95 : Stacked bar charts showing the fluxes of amino acids to (negative) and from (positive) the pool of free 
amino acids (shown in figure 81) for the”Tom Repeat of Jenny”experiment. The blue bars represent the quantity of 
each amino acid freed from haemoglobin digestion (assuming 40% of the host cell’s haemoglobin is digested). Red 
bars represent the quantity of each amino acid used for protein synthesis by the parasite. Green bars represent the 
measured fluxes of amino acids out of the parasite (into the parasite in the case of glutamine). The total mass of 
amino acids is conserved in this figure. 
We can see clearly in this figure that glutamine is used in a way quite unlike the other 
amino acids, confirming that it is better considered as a carbon source. We can also clearly 
see the problem we face in explaining why no isoleucine uptake flux from the growth 
medium was measured. A possible explanation for the problem with the isoleucine result 
is suggested by Elford et al.188 who report that isoleucine is taken up equally by uninfected 
and infected red blood cells. More recent work at higher precision than my method and 
that employed by Elford et al.188 has measured an increase in isoleucine uptake by infected 
red blood cells189. 
A drawback of this amino acid balancing approach is that the solution does not provide 
enough tyrosine, alanine or phenylalanine to explain the amounts incorporated into 
proteins within the organism and exported by the infected RBC. Figure 96 shows the result 
                                                             
* There is some evidence103 that infected RBCs are made extremely permeable by the parasite and 
thus unable to retain a significant free amino acid pool. 
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of a different calculation, ensuring that the amino acids tyrosine and phenylalanine are 
supplied from haemoglobin digestion in adequate amounts. This calculation suggests that 
at least 55% of the host RBC’s haemoglobin is digested by the parasite. 
 
Figure 96 : Stacked bar charts showing the fluxes of amino acids to (negative) and from (positive) the pool of free 
amino acids (shown in figure 81) for the ”Tom Repeat of Jenny” experiment. The blue bars represent the quantity of 
each amino acid freed from haemoglobin digestion (assuming 55% of the host cell’s haemoglobin is digested). Red 
bars represent the quantity of each amino acid used for protein synthesis by the parasite. Green bars represent the 
measured fluxes of amino acids out of the parasite (into the parasite in the case of glutamine). The total mass of 
tyrosine and phenylalanine is conserved in this figure. 
 
As always I am interested in checking that my measurements and calculations are 
reasonable and these results let us calculate a figure to compare with the unexpected 
haemoglobin digestion strategy employed by P. falciparum, specifically that, 
 “The parasite digested up to 65% of the host cell’s haemoglobin but utilized only 
up to about 16% of the amino acids derived from haemoglobin digestion.” 
Krugliak et al.103 
Our minimum figure of 55% of haemoglobin being digested to supply adequate amounts of 
phenylanine and tyrosine to explain protein formation and the measured excretion fluxes 
agrees well with this figure, deduced through a very different method. For the amino acids 
for which I have flux information — alanine, leucine, phenylalanine, tyrosine and valine — 
I calculate that 16% of the amino acids obtained through haemoglobin digestion are 
incorporated into the parasite’s proteins. If isoleucine and glutamine are included then 
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this number increases to 23%: still in good agreement with the previous measurements by 
Krugliak et al.103. 
Lastly I should note that figure 95 and figure 96 are presented for the ”Tom Repeat of 
Jenny” set of experiments because the larger number of acquired time points makes the 
amino acid exchange flux figures from this experiment more reliable. Similar results are 
observed for the Sara A and Sara B set of experiments but are not shown. 
Possibility of stress response 
In treating the Sara A set of experiments with a sub-lethal but active dose of atovaquone 
we might have expected to observe a slow-down in carbon use and haemoglobin 
digestion amino acid excretion in keeping with the predicted slowing of the culture’s 
growth-rate to zero. Instead we observe the opposite. Similar stress responses have been 
observed in other organisms and recently in P. falciparum grown in large-scale cultures 
where a similar stress response was observed, 
“Once a continual decline in parasitemia was observed, however, glucose 
consumption and lactate production per parasite increased”  
Preechapornkul et al.129  
It is tempting to imagine that a sensing mechanism within the parasite — perhaps similar 
to the distributed metabolic sensing observed in E. coli76 — might allow the parasite to 
respond to the inhibited production of pyrimidines caused by atovaquone treatment by 
increasing other fluxes to try and force more flux through the affected reaction. 
Disappointingly the repeat of this experiment, “Tom repeat of Sara”, shows the opposite 
with less growth and less metabolism in response to the same atovaquone inhibition. 
Hypoxanthine 
There is considerable discussion on the role and importance of hypoxanthine to parasites 
at the very of my chapter on measuring P. falciparum growth-rates and we expect to 
observe hypoxanthine being taken up by infected RBCs from the growth medium.  
The NMR metabolomics techniques that I have used are good at detecting large changes in 
metabolite concentration caused by large carbon source fluxes due to their use as energy 
sources and large amino acid fluxes in considerable part due to excess haemoglobin 
digestion and the disposal of surplus amino acids. In comparison the calculations in this 
chapter on HEPES absorption show us that the NMR techniques I have used are not 
particularly well suited to measuring the smaller amounts of metabolite uptake caused by 
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the simple accumulation of a metabolite as is the case for hypoxanthine. A further 
complexity in interpreting the hypoxanthine results is that the assignment is unclear. In 
table 21 I assign a doublet at 8.20ppm to hypoxanthine but the shape of this doublet is 
variable within my spectra and often not convincingly in keeping with the reference 
spectra’s shape. 
The uncertainty around the hypoxanthine fluxes is reflected in the wide variability and 
extremely large errors for hypoxanthine exchange shown in figure 89. Clearly the results 
are not exactly what we would have expected but the issues I have just mentioned and a 
closer inspection of the time-series data in figure 88 suggests that measurements of 
hypoxanthine being produced and excreted from infected RBCs in the Sara metabolism set 
of experiments are incorrect. In the ”Tom Repeat of Jenny” set of experiments where a 
larger number of time-points were acquired a considerable hypoxanthine uptake is 
measured albeit with a very large error in the best fit line. 
False starts and dead ends 
Measuring metabolism using kits 
The use of biochemical assays to measure glucose consumption and lactate production by 
infected RBCs was largely a failure and is fully reported in Jennifer Lake’s Masters 
dissertation145. It was however a failure in the right direction and the glucose 
measurements were useful in confirming the validity of the NMR technique we moved on 
to and which has been very successful. 
Fermentation of glucose to ethanol in P. falciparum 
All metabolomics experiments — except “Tom repeat of Jenny metabolomics” where 
methanol was used instead of ethanol in the spray used to maintain sterility in the culture 
hood — show a steady accumulation of ethanol in the growth medium. When we first 
observed this it was very interesting because ethanol production could play a significant 
role in achieving a more satisfactory carbon balance. It would also be a completely new 
observation in Plasmodium although not completely unbelievable since the metabolism of 
glucose to ethanol has been observed in other apicomplexan parasites such as 
Cryptosporidium parvus190.  
Section 4.4 of Jennifer Lake’s Masters dissertation145 details the possible genes required to 
allow this and how we found some evidence for most of these within the P. falciparum 
genome. Figure 97 below is included as an example of the role of FBA in assessing the 
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metabolic changes that can result from small changes to a metabolic network and a first 
introduction to the tools and visual representation in the final chapter. 
 
Figure 97: FBA-predicted fluxes through my early 2010 model of glycolysis, the pentose phosphate cycle and the 
TCA cycle using minimum and maximum constraints for glucose, lactate, glycerol and ethanol fluxes. Low energy 
small molecules are provided free. The objective function consumes high energy molecules or precursors (ATP, 
NADH, NADPH etc…) and is maximised up to a top limit. 
(left) with no flux allowed through additional ethanol generating reactions.  
(right) with flux allowed through additional ethanol generating reactions. 
Ultimately, the much reduced and variable ethanol content of the growth medium when 
methanol was used as the sterilising agent strongly argued against fermentation occurring 
in P. falciparum and the experience serves as a warning that when you want to find genes 
coding for reactions in an organism they are worryingly easy to find and justify. 
Variability of RBC metabolism 
If you had asked me at the beginning of this project what metabolic processes were 
performed by an RBC I would have guessed that — apart from exchange of CO2 and O2 — 
they did nothing. This is very clearly not the case and I have measured considerable 
exchanges of many different metabolites between uninfected RBCs and their environment. 
Perhaps more forgivably I felt that the background metabolism of isolated and washed 
human RBCs would be largely constant across different experiments as long as the 
conditions were kept the same. For this reason — and largely because of the extreme 
difficulty in getting the time to acquire samples using the NMR machines — I have made 
poor use of much of my experimental time by not running sufficient blood nulls in parallel 
with my experiments with infected RBCs. 
The variability of RBC metabolism, as shown most clearly in the wide variation of 
gradients in figure 76, still surprises me. Looking into RBC variability further it quickly 
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becomes clear that tiny changes in temperature172, age of donor175, diet of donor191 and 
other unidentified or random sources of variability182 all lead to RBCs with very different 
metabolic profiles. A further complication is that the malaria parasite does not just feed on 
the RBC it infects, it changes its metabolism to its own requirements, digests and disposes 
of haemoglobin and the toxic haem group, and provides nutrients to sustain its host. Not 
only does the background metabolism of uninfected RBCs change considerably from 
experiment to experiment but so too does the parasite’s ability and approach to adapting 
these variable hosts to its own metabolic requirements.  
It is always dangerous to assume that anything can be left unmeasured and uncontrolled 
for between experiments with malaria. 
Finally, as if the variability of RBCs was not enough of a challenge, there is even some good 
evidence in Mehta et al.131 that “malaria parasite-infected erythrocytes inhibit glucose utilization in 
uninfected red cells”. 
Solving the RBC variability problem? 
Discussions with Prof. D. Fell have suggested some possibilities for avoiding the worst of 
the RBC variability problems that are worth considering. It is known that storage of RBCs 
leads to the depletion of internal metabolites — notably ATP and 2,3-
Bisphosphoglycerate192,193 — and it seems likely that the variable storage times of RBCs 
before use makes this a significant source of variability. Additionally, degradation of RBC 
morphology is known to occur during storage194.  
As reported in Watanabe et al.194, incubation in inosine restores ATP to near pre-storage 
concentrations and incubation with glucose and citrate restores RBC morphology to close 
to normal. Incubation in all three compounds restores both morphology and ATP levels, 
though less effectively than when performed separately. 
No previous studies of P. falciparum metabolism report using any of these techniques to 
standardise the host RBCs’ metabolic properties before experiments began and 
discussions with Dr. Glenn McConkey suggest this is not widely, if ever, used. It would be 
worth conducting further experiments using metabolically restored RBCs to see whether 
some of the variability observed in my work can be reduced. If this technique could allow 
experiments conducted at different times to be compared it would greatly increase the 
scope of comparative metabolomics of the malaria parasite. 
Two precautions would need to be taken if following these RBC preparation techniques. 
Firstly, the impact of adding additional glucose to the system would need closely 
monitoring but should cause no problems as long as the glucose level was constant, or low 
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enough to be insignificant, at the time the RBCs were used. Secondly, the addition of 
inosine to the system — and to some extent the restoration of erythrocytic ATP —
provides a supplementary purine source to hypoxanthine and further casts doubt on the 
applicability of radioactive hypoxanthine methods of growth-rate measurement. Assuming 
erythrocytic ATP was restored to the same level across all experiments this should cause 
no problems. 
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Metabolic modelling 
 
Figure 98 : Final annotated model with live flux projections of the optimal flux distribution given the applied 
experimentally derived constraints. Annotations in red show key pathways and features of the network. Flux weights 
are not linear and greatly exaggerate smaller fluxes. For example the three exchange fluxes at the top-left, α-D-
glucose β-D-glucose and glutamine import have fluxes of 19.24, 19.24 and 0.98 respectively but appear much closer 
in width. Calculated using SurreyFBA87. 
The above figure shows the final result of all my modelling; it is my best representation of 
the metabolic fluxes in P. falciparum. This chapter describes how I combined everything 
I’ve described in the rest of this thesis to arrive at this answer and then explores what the 
model tells us about the parasite. 
Creating the above model has taken four years and has been a process of trying, failing and 
improving as often as possible. The constraints, objectives and simplifications described in 
this chapter were developed alongside the development of the model rather in stark 
contrast to the way they are presented alone at the end of this thesis. The final results are 
heavily influenced by many layers of earlier results. This iterative process was made 
possible because of the technique of visual representation I have developed and use 
heavily in this chapter; I believe it is an important technique in metabolic modelling. 
I will begin with a description of some of the key concepts, constraints and objectives that 
define the model.  
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Units of biomass and exchange fluxes 
The problem of units in my metabolic model can be best outlined in the following two 
statements. 
 In idealised batch-cultures of E. coli the rate of biomass production, the amount of 
biomass, and the fluxes in the system are all proportional. 
 In synchronised cultures of P. falciparum the rate of biomass production is 
proportional to the fluxes in the system but neither of these is proportional to the 
amount of biomass. We know this because, as shown in figure 91 on page 188, no 
metabolite except valine shows a strong stage-specificity/time dependency of 
exchange flux even though biomass increases by a factor of 8-32 during the life 
cycle. 
This key difference makes comparing the flux-balance analysis solutions of my model with 
other organisms very difficult and requires further explanation so that possible solutions 
to the problem can be fully understood. The results in this thesis are presented in units 
that are understood throughout the FBA community and a full understanding of these 
additional complexities is not necessary to appreciate my results. 
The goal of my metabolic model is to simulate the creation of biomass and thus the growth 
of the parasite. Any units for flux and biomass formation can be defined within the SBML 
model but the convention is to express biomass creation in grams of dry weight per hour 
(ΔgDW/hour) and fluxes in units of millimoles per hour per gram of dry weight of biomass 
(mmole/hour/gDW) usually rearranged as mmole/gDW/hour.  
These units work well for unsynchronised cultures of bacteria or yeast in chemostats 
where the rate of consumption of nutrients and thus the rate of biomass formation is 
proportional to the biomass of the subject organism in the system and where no mass is 
lost from the system at the moment of replication. This condition is met for E. coli, S. 
cerevisiae and even Leishmania major where reproduction produces daughter cells which 
all survive. In these systems the rate of biomass production by the subject organism is 
equal to the rate at which the biomass of the system increases. 
The cultures of P. falciparum that I have worked with are more complex than this. Since 
the majority of merozoites released when the schizont lyses its host do not successfully 
infect a new RBC the majority of biomass accumulated by the parasite over the 48 hour life 
cycle is lost to the system. We can estimate this since we know that the doubling time of a 
culture is around 24 hours and thus after 48 hours the biomass of an unsynchronised 
culture will have increased by a factor of 4. In this same time a single parasite starting a 
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merozoite and bursting out from a red blood cell at the 48th hour will have increased its 
biomass by a factor of between 8 and 32 depending on the number of daughter cells it 
produced. We can see that in an unsynchronised culture this means that the rate of 
biomass creation is far greater than the rate at which the biomass of the system increases 
and the condition described in the previous paragraph is no longer met.  
A second complexity with P. falciparum is that my cultures are synchronised and remain 
synchronised far more strongly than batch cultures of bacteria or yeast. Although some 
variability of fluxes in line with life-stage has been observed elsewhere I measure little or 
none for the majority of the exchange fluxes I have been able to measure.  
Since the biomass of the system is expanding rapidly over the life cycle — a schizont 
presumably weighs 8-32 times as much as a merozoite — the fluxes, if measured in units 
of mmole/gDW/hour with the gDW representing the dry weight of biomass at that 
moment, decrease by a factor of 8-32 over the course of the life cycle. Because of this it 
makes much more sense to measure fluxes with respect to the rate at which biomass is 
formed rather than the overall biomass of the system. This means that the unit of flux 
within the network is (mmole/hour)/( ΔgDW/hour) = mmole/ΔgDW with the fluxes 
defined in proportion to the rate of biomass accumulation. 
Using these units would be fine except for the fact that all the tools for model analysis and 
the assumptions of all researchers in the field are set up differently. Thankfully there is an 
elegant hack that lets us pretend we’re using the usual unit of flux.  
We just have to imagine that we are examining a system with a mass equal to the amount 
of biomass produced in one hour. At this point the biomass of the system (gDW) is equal to 
rate of change of the biomass (ΔgDW/hour) and the flux values are identical whether in 
units of mmole gDW hour or mmole ΔgDW. This simplification is the one that I have 
made throughout this chapter and that I use to report all of my results. 
Where comparisons need to be made with other organisms we ignore the problem of lost 
biomass at reproduction and consider an unsynchronised culture with an average parasite 
age of 24 hours. Assuming this and dividing all the fluxes in my model — except the 
biomass flux — by 24 gives us absolute fluxes in mmole/gDW/hour for comparison with 
other flux-balance models. Following discussions with Prof. David Fell this is the system of 
units I will use for publishing and sharing my final model. 
Within the final model fluxes are scaled and the biomass function calculated such that a 
flux through the biomass function of 1 gDW/hour is equal to the experimentally measured 
rate of biomass production. 
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Defining the final biomass function 
The calculations in the experimental results chapter provide the percentages of dry weight 
that are used to calculate the biomass function. In these calculations the proportion of 
each component by dry weight (amino acids, DNA nucleotides, RNA nucleotides, fat, 
carbohydrate) is broken down into a proportion by stoichiometry and then further to 
stoichiometries of each of the subcomponents. 
Amino acid stoichiometries are calculated as per Chanda et al.176 (table 44 in appendix VI) 
and for each amino acid in the biomass function 2 molecules of GTP and one molecule of 
ATP are converted to 2 molecules of GDP and 1 molecule of AMP plus 2 molecules of 
orthophosphate and one molecule of diphosphate. This energy cost of protein formation 
makes up for the simplifications in my model whereby amino acids are not attached to 
tRNA molecules nor is the process of polymerisation modelled. 
Nucleotides, both DNA and RNA, are included in the biomass function in the cytosol as the 
nucleus is not modelled. For each nucleotide consumed by the biomass function a 
molecule of diphosphate is released back into the system. 
The carbohydrate composition of P. falciparum is unclear. In the distantly related parasite 
L. major, 90% of the carbohydrate content is known to be mannan195, a polymer of 
mannose. In my model GDP-mannose (C00096) forms 90% of the carbohydrate 
component of the biomass function, with GDP-L-fucose (C00325) making up the 
remainder and acting as a surrogate for all glycosylation within the cell. For each molecule 
of GDP-mannose or GDP-L-fucose incorporated into the biomass function a molecule of 
GDP is returned to the system. 
Fatty acids are incorporated into the biomass function according to the observations in 
Tarun et al.196 and Mi-ichi et al.104.  
… Plasmodium parasites depend on de novo fatty acid synthesis only for liver-
stage development. 
A. Tarun et al.196 
… the parasite’s overall fatty acid composition reflects that of the medium, 
although the parasite has a limited capacity to desaturate and elongate serum-
derived fatty acids.  
Mi-ichi et al.104 
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Table 2 in Mi-ichi et al.104 lets us calculate that the vast majority of fatty acids in the final 
parasite are unchanged from those absorbed from the growth medium and only 0.64%  
are elongated by a single C2H4 unit and 10.8% are desaturated.  Elongation is modelled by 
the reaction ‘single fatty-acid elongation’ (SFAE) which is the simplification and 
generalisation of KEGG reactions R01626, R04952, R04953, R04954 and R04955 to create 
the custom compound ‘FAC2H4unit’ which is incorporated into the biomass function. 
Desaturation is modelled by ‘R02222_generalised’ and included in the biomass function as 
a custom compound ‘DesatFA’. Whilst de novo synthesis of fatty acids is left in the model it 
is not included in the biomass as per Tarun et al.196. 
Figures on the process of fatty acid absorption and incorporation in P. falciparum are not 
available and the energy costs of this process are considered only as part of the ATP 
maintenance function. The general acetylation purpose of the branched-TCA cycle as 
described in Olszewksi et al.95 is modelled by the inclusion of ‘Acetylated generic 
compound’ (AcCmpd) in the biomass function at a stoichiometry equal to 10% of the fatty-
acids portion of the biomass function. 
Applying constraints 
The largest number of constraints applied to the network are thermodynamic in origin 
and applied to the reversibility and direction of reactions. These restrictions were 
determined iteratively: by performing FBA, projecting the results onto the network map 
and then examining reactions where fluxes were far higher than reasonable. Where loops 
occurred that produced free ATP, NADPH or NADH, they were removed by adding 
constraints on the direction of reactions or limited to sensible fluxes in the case of arginine 
and proline conversion. In cases where reactions in pairs formed loops but the net flux 
direction for the pair of reactions was unclear one of the reactions was restricted to zero 
flux.  Reaction R04125 — part of glycine and serine interconversion — was restricted to 
zero flux because it increased amino acid influx and efflux without improving biomass 
production. This was only a problem when using the SurreyFBA software for network 
analysis and could be removed if another solver were used. 
Exchange flux constraints for measured carbon sources were applied to limit the model to 
the experimentally determined solution space. During model development constraints 
were applied to amino acid fluxes to try and match them to experimental parameters but 
this was not necessary in the final model. 
A breakdown of the number of reactions to which constraints are applied and the reasons 
for those constraints is provided in table 29 with their locations represented on the visual 
map in figure 99. 
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Table 29 : A summary of the constraints applied to the reactions within the final model. The biomass is constrained in 
a forward direction until simulations are performed at which point it becomes the optimisation goal and is no longer 
constrained. 
 
Figure 99 : A visual representation of the constraints applied to the final model during flux-balance analysis. The 
biomass function is not shown as it is the optimisation goal and not constrained in the final model. 
 Green = direction constrained, Red = experimentally measured or literature reported flux constraint applied, Blue = 
flux set to zero, Orange = flux limited to a reasonable rate that could not be measured (arginine, proline, glutamate 
exchange). 
Restriction on purine sources 
The decision to restrict adenine and adenosine uptake as purine sources to zero is 
justifiable given the findings of Quashie et al. that, 
“Hypoxanthine was taken up with 12-fold higher efficiency than adenosine.” 
Quashie et al.197 
However, there are a number of papers including the appropriately named “Erythrocytic 
Adenosine Monophosphate as an Alternative Purine Source in Plasmodium falciparum” by Cassera 
249 total reactions
194 unconstrained and reversible reactions
35 non-reversible reactions (zero in one direction, unconstrained in the other)
9 exchange fluxes limited to known values (glucose uptake, glutamine uptake, etc…)
4 internal fluxes set to zero to stop thermodynamically unlikely cycles
3 limited to sensible fluxes where fluxes were not measured (arginine, proline, aspartate)
2 Adenine and adenosine fluxes set to zero to force hypoxanthine uptake
1 ATP maintenance
1 biomass function
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et al.198 that suggest purine uptake may be more complex than previously discussed. The 
reactions allowing the uptake of the alternative purine sources are left in the model and 
the restrictions on the fluxes through them can be loosened if desired. 
NADH/NADPH interconversion 
The importance of NADH fates within the parasite46 means that NADH/NADPH 
interconversion could play an important role in the parasite’s metabolism. Direct 
interconversion via R00112 (NADPH:NAD+ oxidoreductase, EC number 1.6.1.1 and/or 
1.6.1.2) is part of the network but a limited additional capacity may also be provided by 
two loops betwen Glutathione and GSSG (reduced glutathione) and between 
Ferricytochrome B and Ferrocytochrome B. So that NADH/NADPH interconversion can be 
monitored by observing a single flux these loops are disallowed in the network and then 
provided for by R00112, with a precautionary note placed in the SBML file. 
Alternatives to internal constraints 
Applying constraints to stop loops and to limit thermodynamically unfeasible reactions 
works but requires a judgement to be made on what the behaviour of the system would 
be. Since the model is designed to show us the behaviour of the system this clearly reduces 
the objectivity of the model’s predictions. 
Two ways that similar restrictions can be placed on the model without a subjective 
decision being made are to consider the thermodynamic cost and to couple reactions. 
The thermodynamic consideration involves calculating the free energy change of each 
reaction within the model and adding an optimisation condition to the analysis such that 
the system as a whole is thermodynamically balanced. This condition would limit fluxes 
through costly reactions — such as loops that create free ATP — without absolutely 
stopping them and a discussion of how to implement a system like this is found in Henry 
et al.199.  
A simpler solution to the problem is to link the direction of pairs or groups of reactions 
that may cause an unnatural loop such that net flow in either direction is allowable but the 
thermodynamically unacceptable creation of free ATP is disallowed. This is an approach 
adopted in Feist et al.200 and elsewhere. 
Adopting either of these — or other similar — approaches can improve the predictive 
power and objectivity of the metabolic model but has the side effect of requiring more 
complex analysis, often using custom software which makes the resulting model hard to 
re-use and its predictions hard to reproduce. 
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ATP maintenance function 
It is an inconvenient fact that FBA of even the best current metabolic models for model 
organisms like E. coli predicts far higher growth-rates than are experimentally measured. 
The solution to this problem is to add an ATP maintenance function to the final model that 
reduces the growth-rate to an experimentally measured or expected rate in ideal 
conditions. The ATP maintenance is typically split into two parts with the majority of the 
ATP flux integrated with the biomass function and called the growth-associated 
maintenance function and a lesser part added to the network as a standalone reaction 
converting ATP and H20 to ADP and orthophosphate and called the non-growth-associated 
maintenance function. 
Since all the fluxes in my network are proportional to growth the distinction between non-
growth associated and growth-associated maintenance is unnecessary and I have 
implemented it as a separate reaction (ATPmaint_c) within my final network. Figure 100 
shows the effect of varying the flux forced through the ATP maintenance function on 
biomass production and justifies my choice of 30 mmole/gDW/hour to limit the biomass 
production in optimal conditions to close to the measured rate of 1 gDW/hour. 
 
Figure 100 : The effect of an increasing ATP maintenance flux on the rate of biomass formation. Calculated using 
SurreyFBA87. 
If the ATP maintenance function is integrated into the biomass function it changes the 
growth-rate predicted by my model by less than 5% and makes no difference to other 
fluxes. Given the cost in terms of lost flexibility of incorporating the ATP maintenance 
function into biomass function and the limited physiological ranges of P. falciparum 
growth-rates I have chosen to keep the ATP maintenance function separate from the 
biomass function for all the results discussed in this thesis. 
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The ATP maintenance function is the “least bad” solution to the problem that growth-rates 
are otherwise over estimated and in conversations with Pedro Mendes at the University of 
Manchester and Fiona Achcar at the University of Glasgow it is clear that in the majority of 
metabolic models there is very limited experimental justification for the value eventually 
chosen. My chosen ATP maintenance flux of 30 mmole/gDW compares to 59.81mmol 
 gDW in Adam Feist’s 2007 E. coli reconstruction200, 32.26mmol/gDW in Chavali’s L. major 
reconstruction108 and 60.01mmol gDW in Plata’s P. falciparum reconstruction58. The 
Huthmacher P. falciparum model implements the ATP maintenance reaction separately 
from the biomass function in the same way as I do but the flux forced through it is not 
included in the SBML model as a non-standard analysis technique is used. 
I prefer to keep the ATP maintenance function completely separate from any identifiable 
use of ATP but this is not the case in many other models. If the ATP maintenance flux is 
integrated with the biomass function and added to the identified ATP and GTP costs of 
amino acid polymerisation the final ATP/GTP growth-associated maintenance flux is 
42.31mmole/gDW; even closer to that of the similar models I have just mentioned. 
Malaria-specific ATP exchange complexities 
There are additional difficulties and distractions in the literature when considering the 
ATP drains in the malaria parasite. In Choi et al.201, isolated parasites — freed from their 
hosts RBC by saponin lysis —import ATP from their surroundings. This result should be 
considered with caution since freed parasites may well have extremely perturbed 
metabolism. An intriguing result in Kanaani et al. 1989117 suggests that during the RBC 
stage of its life cycle the parasite exports ATP to its host, presumably to stop the host from 
dying. I have considerable doubts about this finding given that the paper relies on the 
assumption that mitochondrial inhibitors reduce the amount of ATP production in the 
parasite. Significant research, most notably Fry et al.202 and Painter et al.119, strongly 
suggest that the mitochondrion does not play a significant role in ATP production in 
P. falciparum. 
The uncertainty and complexity of the ATP exchange between parasite and host is such 
that I have not included it in my final model and the ATP maintenance reaction is sufficient 
to contain any intriguing ATP transfer behaviour performed by the parasite that I have not 
added to my model. 
Adding an additional cost to haemoglobin digestion 
My final model’s considerably simplified haemoglobin digestion pathway within the food 
vacuole serves its primary purposes of supplying amino acids to the system but presents a 
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problem. This problem is shown most clearly in the graph on the left of figure 101 where 
we see that a higher rate of biomass formation occurs where more haemoglobin is 
digested. An upper bound on this effect is only imposed by limiting proline efflux to an 
acceptable rate*. 
  
Figure 101 : The growth-rate predicted by FBA on the final model for a range of haemoglobin digestion fluxes. 
Calculated using SurreyFBA87. 
(left) The formation of haemozoin from haem incurs no cost and the optimal solution is for the parasite to digest ever 
more haemoglobin. A reduction in the maximum allowed efflux of proline from the system places an upper limit on 
the haemoglobin digestion flux. 
(right) The addition of a 10 ATP cost for each molecule of haem incorporated into haemozoin moves the optimal 
haemoglobin digestion flux lower but still allows a large range of haemoglobin digestion fluxes that give a biomass 
production rate close to optimal. 
The solution to the problem of non-convergent haemoglobin digestion is to add an ATP 
cost to the process of crystallising the haem molecules released by haemoglobin digestion 
to haemozoin. We can justify this cost as representing what we know is a metabolically 
expensive process but its magnitude is chosen for no other reason than that it moves the 
solution space of the model to give the graph on the right of figure 101. Here the system’s 
optimum rate of haemoglobin digestion does not require limiting by an arbitrary 
constraint on proline efflux. 
At the maximum haemoglobin digestion flux of 0.075 mmole/gDW/hour shown in figure 
101 the 10 ATP/mmole of haem crystalised as haemozoin (40 ATP/mmole of haemoglobin 
digested) represents an addition of 3 mmole/gDW/hour to the total ATP maintenance. 
 
  
                                                             
* see Figure 105 for a justification of this rate. 
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Results 
The creation, parameterisation and constraint of my metabolic model has taken up the 
majority of this thesis and the majority of my time over the past four years. Getting the 
results from the final model was a considerably shorter and more instantly rewarding 
experience. I report the main findings here. 
The model accurately predicts the growth-rate of P. falciparum 
The carbon-source flux constraints in my model are set from my experimental values such 
that the experimentally measured biomass production rate is 1 gDW/hour. Before the 
addition of the ATP maintenance function my model produces a biomass production rate 
of around 2.5 gDW/hour which — whilst higher than what is experimentally measured — 
is of the same magnitude. If the predicted growth-rate was an order of magnitude higher 
than what we had measured we would be able to infer that the parasite had an energy 
source other than that included in the model, presumably either the pathways required for 
aerobic respiration or a direct uptake of ATP from the host RBC. 
That the predicted growth-rate is reduced to the experimental growth-rate when the ATP 
maintenance function is set to a value close to that of other similar organisms is further 
evidence that the model accurately predicts growth-rate. 
Measured glucose influx and lactate efflux rates achieve carbon balance and optimal 
growth 
We know that the primary energy source for P. falciparum is the creation of lactate from 
glucose via the glycolysis pathway and therefore the influx of glucose is closely linked to 
the efflux of lactate. Figure 102 shows how biomass production varies for the model’s final 
allowed efflux rate of lactate of -60 mmole/gDW/hour and has some very interesting 
features. At low levels of glucose uptake the model produces no biomass at all as the 
organism’s ATP maintenance requirements are not met. This is entirely in keeping with 
widespread knowledge that P. falciparum parasites die extremely rapidly in low glucose 
environments. Once the maintenance requirements of the parasite are met growth is 
highly dependent on glucose influx until a peak is reached where no further lactate efflux 
is allowed. The flexibility of the model means that carbon balance can be achieved at no 
cost to growth for a brief plateau of increasing glucose influx before the glucose is used 
inefficiently by the parasite and leads to reduced growth. 
The shaded region in the graph is centred on the measured glucose influx rate for the Tom 
Metabolomics set of experiments and extends as far as the uncertainty on that 
measurement in either direction. 
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Figure 102 : Biomass production response to glucose uptake. The shaded region shows the measured glucose influx 
and its associated error (38.48±14mmole/gDW/hour). The lactate efflux of -60 mmole/gDW/hour is slightly higher 
than the best measured value (56) but well within the error on that measurement. Calculated using SurreyFBA87. 
Figure 103 is the equivalent for lactate of figure 102 with the shaded region this time 
centred on the final lactate efflux rate of -60 mmole/gDW/hour and extending as far as the 
uncertainty on that measurement in either direction. The dependency of biomass 
formation rate on the increasing lactate efflux shows that energy produced by glycolysis is 
a primary restriction on the growth-rate of the parasite. 
 
Figure 103 : Biomass production response to lactate efflux for three glucose uptake rates corresponding to the best-
guess (38±14 mmole/gDW/hour), minus and plus the associated error (24, 56). The shaded region shows the final 
lactate efflux and its associated error (60±11 mmole/gDW/hour). Calculated using SurreyFBA87. 
What we see from these two graphs is that my measurements of glucose and lactate fluxes 
accurately predict growth-rate — the experimentally measured growth-rate given the 
glucose and lactate flux constraints is 1gDW/hour — and achieve carbon balance well 
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within the uncertainties in their measurements. Optimal growth-rates of the model are 
achieved within the measured ranges of glucose influx and lactate efflux. 
I experimented with displaying the dependency of the rate of biomass formation as a 
function of allowed lactate efflux and glucose influx on a three-dimensional plot but found 
these hard to interpret once printed. 
The model accurately predicts internal fluxes 
Large-scale quantitative measurements of internal metabolic fluxes in P. falciparum has to 
my knowledge been limited to the work of Olszewski et al.109 focusing on the TCA cycle. A 
far more limited resource is provided by Atamna et al.167 which measures the diversion of 
the glycolytic flux towards the oxidative pentose-phosphate cycle* (PPC) and towards 
nucleotide metabolism through the formation of ribose sugars. 
This provides an excellent opportunity to compare the predictions of my metabolic model 
with experimentally measured fluxes and the agreement shown in table 30 is encouraging. 
 
Table 30 : Fluxes in mmole/gDW/hour of glucose towards the pentose phosphate cycle and nucleotide sugar 
formation. Figures from Atamna et al. 167 are converted to equivalent units for comparison. Calculated using 
SurreyFBA87. 
Whilst glucose and oxidative PPC fluxes are in excellent agreement. my model predicts a 
higher flux to nucleotides than reported in Atamna et al.. This is consistent with my 
suspicion that the true DNA content of my biomass function should be towards the lower 
end of the uncertainties in the values I’ve measured. 
Another explanation for some of the discrepancy in the glucose to nucleotide flux is that 
that my model forces the exclusive use of hypoxanthine as a purine source. This requires a 
glucose flux to nucleotides in the form of PRPP (C00119) or Ribose 1-phosphate (C00620) 
whereas an uptake of adenosine — as known to be possible from Cassera et al.198 —would 
not require this diversion of flux as PPC-synthesised ribose sugars would only be required 
for pyrimidine synthesis. 
                                                             
* The hexose-monophosphate shunt (HMS) is referred to in the paper. These are the same thing. 
Path Taken Flux from Atamna 1994 FBA predicted Flux
(mmole/gDW/hour) (mmole/gDW/hour)
Glycolysis 41.90 37.54
Oxidative PPC 1.50 1.42
Nucleotide 0.06 0.24
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The model accurately predicts the low-oxygen metabolism of P. falciparum. 
Another area in which the model accurately reproduces the known metabolism of 
P. falciparum is in relation to oxygen consumption. Oxygen and carbon dioxide are both 
taken up from the environment but neither O2 nor CO2 exchange is essential for parasite 
growth. If exchange of oxygen is limited to zero, growth continues but is slowed to 67% of 
the optimal growth-rate, consistent with the knowledge that P. falciparum’s optimum 
culturing conditions  are a low — but not zero — oxygen environment. 
The optimal growth-rate is achieved when the parasite takes in CO2 at 
0.009 mmole/gDW/hour and O2 at 0.178 mmole/gDW/hour. This compared with the 
Adam Feist et al.200 E. coli model which takes up 18.2 mmole/gDW/hour of oxygen. If the 
factor of 24 correction discussed at the start of this chapter is applied then P. falciparum 
has an oxygen requirement for optimal growth of just 0.074 mmole/gDW/hour of oxygen: 
around 250 times less than E. coli. 
By comparison, Adam Feist’s E. coli model has a glucose import flux of 8-11 
mmole/gDW/hour compared to the glucose import flux of my P. falciparum model of 38.4 
mmole/gDW/hour, or at the 24th hour of the life stage, 1.6 mmole/gDW/hour.  That the 
comparable glucose uptake rate of E. coli is six times higher (8-11 compared to 1.6) than 
P. falciparum but its oxygen use is 250 times higher (0.178 compared to 0.074) shows how 
inefficiently P. falciparum uses glucose by relying on anaerobic respiration whilst E. coli 
can perform aerobic respiration. 
The model accurately predicts measured amino acid exchange rates 
Although loose constraints are placed on proline and arginine exchange fluxes these are 
not reached in the model unless the rate of haemoglobin digestion would lead to more 
haemoglobin being digested than is available*. None of the other amino acid efflux rates 
are constrained in the final model and so the predicted amino acid exchange fluxes are the 
result of the model’s haemoglobin digestion rate, amino acid use for the protein synthesis 
part of the biomass and any interconversion of amino acids within the model. 
The FBA-predicted exchange fluxes and my NMR-measured fluxes for the five amino acids 
plus hypoxanthine I was able to measure are shown in table 31. 
                                                             
* see Figure 105 for a justification of this rate. 
213 
 
 
Table 31 : Measured exchange fluxes of the six measured amino acids and hypoxanthine compared with the fluxes 
predicted by the optimal solution of my final model. Calculated using SurreyFBA87. 
The agreement of these two sets of results can be best seen as a graph as in figure 104 
where a linear fit shows predicted fluxes to be on average 1.26 times larger than measured 
fluxes. If we scale this figure to take into account the discrepancy between the measured 
growth-rate of 1 gDW/hour and the predicted growth-rate of 1.15 gDW/hour the gradient 
of the line of best fit becomes 1.10: an excellent agreement between the model and 
experimental results. 
    
Figure 104 : Measured flux of amino acids and hypoxanthine against FBA-predicated fluxes at the optimal FBA 
solution of my final model. Best fit line is forced through the origin. 
 
As a result of the complex nature of my final model the relationship between the rate of 
haemoglobin digestion and the rate of biomass formation is complicated, but flux-balance 
analysis easily calculates it. From these two pieces of information and knowledge of the 
haemoglobin content of an uninfected red blood cell and the mass and protein content of a 
mature parasite we can calculate — for a single parasite — the percentage of the host 
Compound Measured flux FBA predicted Flux
(mmole/gDW/hour) (mmole/gDW/hour)
Valine 0.63 1.16
Leucine 0.35 1.18
Isoleucine 0.00 -0.44
Alanine 1.25 1.46
Tyrosine 0.13 0.26
Phenylalanine 0.54 0.44
Hypoxanthine -0.45 -0.13
y = 1.26x
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RBC’s haemoglobin that is digested and the percentage of the freed amino acids that are 
integrated into the parasite’s proteins as in figure 105. 
 
Figure 105 : The relationship between the haemoglobin digestion flux and the percentage of the host’s haemoglobin 
that is digested (blue line) and the percentage of the freed amino acids that are integrated into the parasite’s proteins 
(red line). 
At the optimal solution — giving the numbers in table 31 — the haemoglobin digestion 
flux of 0.022 mmole gDW hour is equivalent to the digestion of 30% of the host’s 
haemoglobin and incorporation of 40% of the freed amino acids into the parasite’s 
protein. The upper limit on haemoglobin digestion set by a limit on proline efflux 
approximately limits haemoglobin digestion to the amount present in the host red blood 
cell. 
A haemoglobin digestion flux of 0.046 mmole/gDW/hour is equivalent to digestion of 65% 
of the host’s haemoglobin and incorporation of 19% of the freed amino acids into the 
parasite’s protein and is closer to the maximum equivalent values measured by  rugliak 
et al.103 of 65% digestion and 21% incorporation respectively. As previously shown in 
figure 101 the range of haemoglobin digestion fluxes possible whilst only slightly reducing 
the predicted growth-rate is considerable and so Krugliak et al.’s results are consistent 
with my model. However, it is important to note that this level of haemoglobin digestion, 
whilst energetically possible, does not agree with my measured NMR exchange fluxes as 
shown in table 31. 
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Flux variability analysis (FVA) at the optimal growth-rate 
I have shown how the level of haemoglobin can vary considerably whilst still producing a 
near-optimal growth-rate but it is informative to perform flux-variability analysis on all 
the reactions in the network. 
Figure 106 shows the reactions that can vary whilst still producing the optimal growth-
rate where the thickness of each edge corresponds to the range of fluxes allowed through 
the corresponding reaction. The four futile loops that produce and consume nothing in a 
complete cycle are noted in the figure’s caption and are not interesting except to note that 
the fluxes through these reactions are not informative in the optimal solution. 
Of more interest in figure 106 is to notice that the variances of the amino acid 
interconversions at the bottom right of the figure and the variances of the reactions in 
glycolysis are the same, suggesting that the two are linked.  L-malate export is variable 
between zero and its maximum allowed valued for the optimal solution meaning that both 
the measured malate efflux in Olszewski et al.95 and my measured lack of a malate efflux 
are consistent with the predictions of my model. 
 
Figure 106 : The variability of fluxes that still give 100% of the optimal growth-rate. The very thick lines are three 
cycles that are futile and can have any value as they ultimately produce and consume nothing. The three exchange 
reactions involved in a futile cycle are H2O, Orthophosphate and Diphosphate which combine with an internal 
reaction that converts Diphosphate to 2 Orthophosphate + H2O to form a futile cycle. Aspartate, proline and arginine 
exchange fluxes are all variable within the optimal solution space and aspartate and proline exchange fluxes are 
constrained to a sensible maximum value in the final model. Calculated using the COBRA toolbox v1.3.3203. 
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Flux variability analysis (FVA) for a solution producing at least 99% of the optimal 
growth-rate 
FVA at the 99% level, shown in figure 107, shows the range of values that each flux can 
take within a solution that can still produce biomass at 99% of the optimal rate. The 
interesting progressions from the 100% FVA solution are that 
 The flux though the branched TCA cycle via succinate becomes highly variable, 
suggesting that this branch plays a minimal role in any modelled aspect of growth. 
The proposed role of this branch of the branched TCA cyle in Olszewski et al.95 is 
not completely clear and needs further investigation. 
 The pentose-phosphate cycle (PPC) and NADPH:NADH interconversion (R00112. 
X-shape at the top-right of figure 107) become variable, suggesting that changes in 
NADPH production by the oxidative PPC can be compensated for by R00112 
without significantly affecting growth. 
 Haemoglobin digestion rate becomes variable, as expected from the results in 
figure 101. 
 
Figure 107 : The variability of fluxes that still give 99% of the optimal growth-rate. The flux through the mitochondrion 
via succinate becomes variable as does haemoglobin digestion and the pentose-phosphate cycle. Calculated using 
the COBRA toolbox v1.3.3203. 
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Flux variability analysis (FVA) for a solution producing at least 70% of the optimal 
growth-rate 
The range that each flux can take and still form a solution that produces biomass at 70% of 
the optimal rate — shown in figure 108 — is extremely large and covers almost all the 
network. The reactions that are least variable in this solution are those that are not 
capable of carrying any flux and those that produce a component of the biomass along a 
metabolic pathway for which there are no alternative routes. For example, adenine and 
adenosine uptake and the subsequent reactions required to use these purine sources for 
nucleotide synthesis have no flux variability because they are disallowed in the model and 
thus always have a flux of zero. The uptake of isoleucine and the branch of the TCA cycle 
via citrate has a low variability since isoleucine and the general acetylation product 
produced in the mitochondrion are made available only through a set of non-redundant 
reactions. 
With relation to earlier observations of the low oxygen and carbon dioxide uptake rates of 
the model it is interesting to note that the parasite is much more able to deal with changes 
to oxygen uptake than with changes to carbon dioxide uptake. At the FVA 70% level, 
oxygen absorption ranges between 0.009 — 0.202 mmole/gDW/hour whilst carbon 
dioxide absorption ranges between 0.006 — 0.009 mmole/gDW/hour. 
 
Figure 108 : The variability of fluxes that still give 70% of the optimal growth-rate. Calculated using the COBRA 
toolbox v1.3.3203.  
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Essential reactions and predicted lethal and sub-lethal single-gene deletions 
Out of 249 reactions in the network, 220 are capable of carrying some flux. Of these “live 
reactions” 117 are essential and reduce growth-rate to zero if removed. The location of 
these reactions within the network is shown in figure 109. 
 
Figure 109 : The location of essential reactions in the network. Calculated using SurreyFBA87. 
Since more than one gene, or indeed no gene, can be linked to a reaction and more than 
one reaction can be linked to a gene the 117 essential reactions correspond to 79 lethal 
gene deletions. A further 19 gene deletions cause a reduced growth-rate but are not lethal 
with these genes largely associated with the oxidative PPC cycle and the succinate branch 
of the TCA cycle. These are, as expected, the parts of metabolism that show considerable 
flux-variability within the FVA 99% result shown in figure 109. 
Another interesting group of genes that cause a reduced growth-rate but that are not 
lethal are those associated with the oxidative stress response. This set of genes includes 
those coding for reactions that oxidise hydrogen peroxide via the reduction of glutathione 
and genes associated with the maintenance of NADPH/NADH levels needed to restore 
glutathione to its oxidised state. 
A summary of the genes whose deletions affect growth-rate is provided in the table 
making up appendix VII. Of these genes it is interesting to note that of the 98 predicted 
lethal or growth-reducing single-gene deletions only 22 are predicted as lethal in Plata 
et al.58. More worryingly, of the 45 genes whose deletion has no effect on growth-rate, 8 
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are predicted as lethal in Plata et al.58. All single gene-deletion simulations were carried 
out in the COBRA toolbox v1.3.3203. 
Lethal and sub-lethal double-gene deletions 
Any double gene deletion involving a gene that is lethal when deleted on its own is also 
lethal and the vast majority of double-gene deletions are trivially lethal in this way and 
therefore uninteresting. The second largest group of double-gene deletions are those 
where both genes are non-lethal when deleted singly and non-lethal when deleted in pairs. 
The most interesting set of double-gene deletion behaviours are those where both genes 
when deleted singly are not-lethal but that are lethal when deleted together. The predicted 
growth-rate — as a proportion of the optimal growth-rate — for fifteen genes and thus 
105 gene pairs is shown in figure 110. Full details on these genes is presented in table 32. 
 
Figure 110 : Predicted growth-rate as a proportion of optimal forall pairwise deletions of fifteen genes that give 
interesting growth-rate predictions. The metabolic role of each gene within the network is shown at the right Growth-
rate predictions made using COBRA toolbox 1.3.3203. 
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Role
PFE0730c 0.99 Oxidative PPC/NADPH creation
PF14_0511 0 0.99 Oxidative PPC/NADPH creation
PF14_0520 0 0.99 0.99 Oxidative PPC/NADPH creation
PF14_0508 0 0 0 0.99 NADPH:NAD oxidoreductase
PFL0960w 0 0 0 0.95 0.99 Non-oxidative PPC
PFF0530w 0 0 0 0.95 0.99 0.99 Non-oxidative PPC
MAL3P2.24 0 0 0 0 0.78 0.78 0.98 Glycerol metabolism (creates FAD for TCA cycle)
PF08_0045 0 0 0 0 0.78 0.78 0.98 0.98 TCA cycle (right side, via succinate)
PF10_0334 0 0 0 0 0.78 0.78 0.98 0.98 0.98 TCA cycle (right side, via succinate)
PF13_0070 0 0 0 0 0.78 0.78 0.98 0.98 0.98 0.98 TCA cycle (right side, via succinate)
PF13_0120 0 0 0 0 0.78 0.78 0.98 0.98 0.98 0.98 0.98 TCA cycle (right side, via succinate)
PF13_0121 0 0 0 0 0.78 0.78 0.98 0.98 0.98 0.98 0.98 0.98 TCA cycle (right side, via succinate)
PF14_0295 0 0 0 0 0.78 0.78 0.98 0.98 0.98 0.98 0.98 0.98 0.98 TCA cycle (right side, via succinate)
PFI1340w 0 0 0 0 0.78 0.78 0.98 0.98 0.98 0.98 0.98 0.98 0.98 0.98 TCA cycle (right side, via succinate)
PFL0630w 0 0 0 0 0.78 0.78 0.98 0.98 0.98 0.98 0.98 0.98 0.98 0.98 0.98 TCA cycle (right side, via succinate)
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Table 32 : Details on the 15 interesting double-deletion genes whose pair-wise deletions are lethal or growth-reducing (see figure 110) but whose deletions singly are not lethal.
Gene
Associated 
Reaction(s)
Reaction Name(s)
Associated 
EC number
Role
PFE0730c R01056 D-ribose-5-phosphate aldose-ketose-isomerase 5.3.1.6 Oxidative PPC/NADPH creation
PF14_0511
R02035
R02736
6-Phospho-D-glucono-1,5-lactone lactonohydrolase
beta-D-Glucose-6-phosphate:NADP+ 1-oxoreductase
3.1.1.31
1.1.1.49
Oxidative PPC/NADPH creation
PF14_0520 R01528 6-phospho-D-gluconate:NADP+ 2-oxidoreductase (decarboxylating) 1.1.1.44 Oxidative PPC/NADPH creation
PF14_0508 R00112 NADPH:NAD+ oxidoreductase 1.6.1.1 NADPH:NAD oxidoreductase
PFL0960w R01529 D-Ribulose-5-phosphate 3-epimerase 5.1.3.1 Non-oxidative PPC
PFF0530w
R01641
R01830
Sedoheptulose-7-phosphate:D-glyceraldehyde-3-phosphateglycolaldehyde transferase
beta-D-Fructose 6-phosphate:D-glyceraldehyde-3-phosphateglycolaldehyde transferase
2.2.1.1
2.2.1.1
Non-oxidative PPC
MAL3P2.24 R00848 sn-Glycerol-3-phosphate:(acceptor) 2-oxidoreductase 1.1.5.3 Glycerol metabolism (creates FAD for TCA cycle)
PF08_0045
R00621
R03316
NO NAME
NO NAME
1.2.4.2
1.2.4.2
TCA cycle (right side, via succinate)
PF10_0334
R00408
R00432
Succinate:(acceptor) oxidoreductase
Succinate:CoA ligase (GDP-forming)
1.3.99.1
6.2.1.4
TCA cycle (right side, via succinate)
PF13_0070
R00621
R03316
NO NAME
NO NAME
1.2.4.2
1.2.4.2
TCA cycle (right side, via succinate)
PF13_0120 R02570 succinyl-CoA:enzyme N6-(dihydrolipoyl)lysine S-succinyltransferase 2.3.1.61 TCA cycle (right side, via succinate)
PF13_0121 R02570 succinyl-CoA:enzyme N6-(dihydrolipoyl)lysine S-succinyltransferase 2.3.1.61 TCA cycle (right side, via succinate)
PF14_0295 R00405 Succinate:CoA ligase (ADP-forming) 6.2.1.5 TCA cycle (right side, via succinate)
PFI1340w R01082 (S)-malate hydro-lyase (fumarate-forming) 4.2.1.2 TCA cycle (right side, via succinate)
PFL0630w R00408 Succinate:(acceptor) oxidoreductase 1.3.99.1 TCA cycle (right side, via succinate)
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Conclusions 
The final model contains more information than would be useful to present in this thesis. I 
have taken great care to ensure that questions that future researchers may wish to pose of 
the model can be asked easily and the answers understood. A number of further findings 
are, 
 D-lactate is not produced by the model unless forced to but the measured level as 
presented in Vander Jagt et al.94 contributes to the carbon balance of the model. 
 Glycerol is produced by the model but not at the rate I have measured unless 
forced. The consumption of FAD in the succinate half of the branched TCA cycle is 
met by the production of glycerol and its efflux from the parasite. See additional 
note on the next page. 
 Forcing glycerol and D-lactate efflux, combined with the level of carbohydrate 
accumulation from Chavali’s108 L. major metabolic model and the level of fatty acid 
modification in Mi-ichi et al.104 creates a carbon-balanced model if the L-lactate 
efflux is raised slightly from the best estimate of 56 mmole/gDW/hour to 60 
mmole/gDW/hour. 
 L-malate is produced only if the allowed lactate efflux is not sufficient to achieve 
carbon balance. Flux-variability analysis (FVA) shows that any value of L-malate 
efflux between 0 and the maximum allowed can form part of a solution that give 
the optimal growth-rate so both my experimental results and those in Olszewski 
et al.95 are in agreement with my model. 
 Aspartate is similarly variable within the optimal solution, strongly supporting the 
view presented in Olszewski et al.88 that L-malate and aspartate exchanges are 
balanced by the parasite to achieve carbon balance. It is likely that the different 
culture conditions used by me and Olszewski et al.95 led me not to measure L-
malate production where they did. 
 The predicted flow of glucose around the pentose-phosphate cycle matches 
measurements in the literature and the predicted flow to nucleotides is close to 
measurements in the literature. 
 The ATP maintenance cost that gives the measured growth-rate is in keeping with 
both Chavali et al.108’s L. major and Plata et al.58’s P. falciparum model. 
 My model predicts that — over the complete life cycle — between 31% and 100% 
of the host RBC’s haemoglobin can be digested whilst remaining within 95% of the 
optimal growth-rate. The predicted percentage of the digested amino acids used by 
the parasite at these two extremes is 40% and 13% respectively. At the maximum 
65% digestion suggested in Krugliak et al.103 my FBA model predicts that the 
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parasite uses 21% of the available amino acids compared to the 16% measured in 
that paper: an excellent agreement within the uncertainties of the model and the 
measurements. 
 For the optimal solution of my model, corresponding to digestion of 31% of the 
RBC’s haemoglobin, the amino acid exchanges predicted by my model are 
consistent are within 10% of those measured by NMR metabolomics: an excellent 
agreement. 
 The branched TCA-cycle reported in Olszewksi et al.95 is the optimal flux solution 
although FVA shows that the behaviour of the cycle can vary considerably and still 
produce a growth-rate of 99% of optimal. 
 
The complexities of glycerol metabolism 
With respect to the second of my conclusions on the previous page a clarification is 
required. The role of protein complexes is not always elegantly contained within the KEGG 
LIGAND ontology and my network only contains the first of the reactions performed by the 
succinate dehydrogenase (SDH) enzyme complex (Complex II) shown in figure 111. The 
FADH2 produced by the conversion of succinate to fumarate is retained within the enzyme 
complex and is oxidised back to FAD by the reduction of Coenzyme Q10 (Q) (ubiquinone) to 
ubiquinol (QH2), both of which are free within the inner mitochondrial space — a 
compartment which, for simplicity and due to the limited function of the mitochondria in 
P. falciparum, I omit from my model. 
The mitochondrial glycerol-3-phosphate dehydrogenase (GPDH-M) complex works 
similarly via Coenzyme Q10 but in the opposite direction and whilst the two enzyme 
complexes cannot in reality exchange FAD or FADH2 directly as they do my model, they 
can do so in effect via the intermediate Coenzyme Q10. This means that the simplification in 
my model of allowing FAD and FADH2 to be exchanged between the SDH complex and the 
GPDH-M complex is unrealistic but also unlikely to have any effect on the predictions of 
my model. 
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Figure 111 : The succinate dehydrogenase (SDH) complex (left) and the mitochondrial glycerol-3-phosphate 
dehydrogenase (GPDH-M) complex (right) cannot share FAD/FADH2 since neither ever leaves the enzyme complex. 
Both enzyme complexes restore their FAD/FADH2 balance via external Coenzyme Q10 (Q/QH2) in the mitochondrial 
membrane space. Both images from Wikipedia (user: Johnhfst. user: Boghog2). 
 
The functioning of these complexes is additionally interesting because of the unusual role 
of Coenzyme Q10 in P. falciparum — as reported on page 89 of Painter et al119.  
“erythrocytic stages of the human malaria parasite Plasmodium falciparum seem to 
maintain an active mitochondrial electron transport chain to serve just one 
[essential] metabolic function: regeneration of ubiquinone [Coenzyme Q10] required 
as the electron acceptor for dihydroorotate dehydrogenase, an essential enzyme 
for pyrimidine biosynthesis”.  
Within my model, the action of dihydroorotate dehydrogenase (DHODH) is simplified to 
completely remove the complexity of including the electron transport chain (ETC) in my 
model. I have justified this because the flux through the ETC is tiny compared to that in an 
aerobically respiring organism. The DHODH reaction in my model instead represents the 
combined role of the ETC/ubiquinone interaction with a conversion of water to hydrogen 
peroxide simulating the ETC’s creation of superoxide ions leading to oxidative stress. 
The Coenzyme Q10 that is regenerated by P. falciparum’s ETC could be used to drive the 
succinate dehydrogenase enzyme complex in the citrate cycle but there are good reasons 
why this might not be the case. Painter et al119. state that, 
“maintenance of mitochondrial membrane potential,… was essential in these 
parasites”  
and that, 
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“maintenance of electropotential across the mitochondrial inner membrane is a 
critical function of the electron transport chain”.  
Typically electropotential is maintained largely by ATP synthase and yet despite the 
recent discovery of a P. falciparum ATP synthase204 it remains unclear what function it 
serves given that any ATP derived in this way has not been observed to play any role in 
the energy metabolism of the parasite in the RBC life stages.  
These results further convince me that the unusual — and disputed — metabolic fate of 
glycerol in P. falciparum plays an important role in explaining the role of the mitochondria 
in RBC metabolism.  Returning to Lu-Yun Lian et al.46’s findings about glycerol.  
“it is hypothesized … that glycerol production by the malaria parasite is the result 
of a metabolic adaptation to growth in O2-limited (and CO2 elevated) conditions by 
the operation of a glycerol-3-phosphate shuttle for the re-oxidation of assimilatory 
NADH.”  
The results of my model and experimental results agree with this hypothesis but make a 
key addition. Since the glycerol-3-phosphate shuttle in this instance is unbalanced — with 
excess glycerol exported rather than used to re-oxidise NADH — thus maintaining 
mitochondrial membrane potential, it might be not be wholly useful to refer to it as a 
shuttle, but rather a partially branched shuttle. 
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Final comparison of my final model to similar models 
At the end of this chapter I want to make one final comparison between by model, the two 
other leading malaria metabolic models and the model and work which has served as my 
example for much of this thesis: Arvind Chavali’s Leishmania major metabolic model108. I 
already referred to the problem with orphaned reactions in the Huthmacher et al.59 and 
Plata et al. 58 models on page 72 but I want now to focus on another two problems: 
unconserved metabolites and reproducibility of modelling results. 
Unconserved metabolites 
Consider two reactions, A <=> B + C and A <=> B. Individually these reactions may seem 
reasonable but together they allow the infinite creation, or destruction, of the metabolite 
C. In this example we refer to C as an unconserved metabolite. The mathematical solution 
to this problem is to assign compound C a mass of zero but in more complex loops a 
solution to similar problems can sometimes be found by assigning to the same compound 
a negative mass in some reaction and a positive mass in other reactions. Indeed, the 
documentation of SurreyFBA87 describes unconserved metabolites as, “those whose molecular 
masses cannot be simultaneously assigned positive values”. A more formal definition of an 
unconserved metabolite, including this basic example and algorithms for detecting them 
within networks, is found in Nikolaev205 with significant development in Gevorgyan89.  
The importance of unconserved metabolites is that whilst mathematical solutions to these 
problems exist it is never biochemically acceptable to create or destroy mass. 
Unconserved metabolites are almost always a symptom of stoichiometric inconsistencies 
within a metabolic network. 
In light of the impact unconserved metabolites can have on the accuracy of a model I used 
SurreyFBA87 to search for them in the three models of interest. 
As a result of the balanced reactions checker in MetNetMaker and my visual model 
assembly process my final model contains no unconserved metabolites. In comparison the 
Huthmacher et al.59 P. falciparum model has 7 unconserved metabolites and the Chavali 
et al.108 L. major model has 319 unconserved metabolites. The Plata et al.58 P. falciparum 
model could not even be loaded into SurreyFBA and checked for unconserved 
metabolites*. 
                                                             
* I tried searching for unconserved metabolites by first manually parsing the model and SurreyFBA 
reported none but it is unclear whether the manually parsed model was analysed correctly. 
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Reproducibility of results 
A second area for comparison between models is on the reproducibility of results. Since all 
models are constraints-based reconstructions designed for metabaolic analysis using at 
least FBA it is reasonable to expect that opening the models in commonly used FBA 
software and running a simple simulation to maximise biomass production would yield a 
result. I tried this with all three models. 
The Huthmacher et al.59 model cannot produce biomass in SurreyFBA87 or COBRA 
v1.3.3203. Constraints are not included in the model and since the analysis techniques used 
to create the published results are implemented in custom software that is not distributed 
they are almost impossible to reproduce. There are a huge number of reactions and no 
visual model, which — combined with the almost unreproducible computational results — 
makes the model less useful than it could be. 
The Plata et al.58 model produces biomass in COBRA v1.3.3203 but cannot load into 
SurreyFBA87. The model seems to contain no constraints which may limit the biological 
accuracy of its predictions. The very large number of reactions and lack of a visual model 
makes it hard to examine this network. 
The Chavali et al.108 model cannot produce biomass in SurreyFBA or COBRA 1.3.3203. The 
visual model is excellent and is clearly produced in Simpheny which may provide excellent 
analysis and visualisation tools*. In speaking with Arvind Chavali at ICSB 2010 in 
Edinburgh he mentioned that he was continuing to use his model but that a considerable 
amount of information had not made it across from Simpheny to the SBML format model 
he published.  
                                                             
* I am told that the software has matured since then but seems effectively restricted to former PhD 
students of Bernhard Palsson. 
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Summary and future directions 
 
 
 
… in 10 human metabolic pathway databases, none of the descriptions (of TCA) is 
entirely correct and consensus exists on only 3 reactions. 
Stobbe et al.206 via Ben Heaver* 
 
 
 
 
 
I have drawn conclusions on my results in each chapter and this final section does not 
repeat them. Instead I look at some of the larger issues and recent advances in systems 
biology and how these have affected and could improve my work. It is likely that many of 
the opinions in these final few pages will turn out to be wrong. 
Whilst all the ideas are my own they have often come about from discussions, largely on 
twitter, with people including, but not limited to, Fiona Achcar at the University of 
Glasgow, Natalie Stanford at the Humboldt University of Berlin, Christian Priesnitz at the 
University of Saarbrucken, Nicolas le Novère at the European Bioinformatics Institute, 
Cambridge, Mark Hucka at the California Institute of Technology, Ben Heaver at the 
Institute for Systems Biology, Seattle and Pedro Mendes, Neil Swainston and Kieran 
Smallbone all at the University of Manchester. I find twitter increasingly valuable for both 
engaging in, and observing at a distance, discussions between systems biologists all 
around the world.  
                                                             
* Postdoctoral fellow at the Institute for Systems Biology (Price group), Seattle 
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The utility of my model 
I have been stunned by the agreement between the predictions and my model and 
experimentally measured knowledge of P. falciparum metabolism. That internal fluxes, 
amino acid exchange fluxes and growth-rate are all accurately reproduced by a relatively 
simple model analysed by a simple technique still amazes me. This is true even though the 
technique has been shown to work in many other organisms. 
In both cases where my experimental measurements disagree with literature — on malate 
efflux and haemoglobin digestion rate — the model shows that differences that seem 
considerable are found in areas of high variability within the modelled metabolism of 
P. falciparum. It is very possible that even where my measured results and previously 
published results do not agree, they are both correct; they certainly both agree with my 
model of malaria metabolism. 
There’s a lot more that can be learned from my model as long as the limit of its utility is 
appreciated. I am hopeful that the work of the ParaMet consortium* will build on my 
model by using Carbon-13 fluxomics — directly measuring more internal fluxes to refine 
and confirm the predictions of the model — and by adding a model of gene activity and 
regulation similar to that reported in Chandrasekaran and Price75.  A promising avenue for 
further research is the possibility of building upon my preliminary studies of the metabolic 
response to known inhibitors of P. falciparum that I reported on page 168 with respect to 
atovaquone inhibition. An application for funding which I wrote to continue these 
metabolomics studies and improve their integration with an ever improving metabolic 
model is included as appendix IX and gives some further details on this. 
The limits of existing models 
The observation from Stobbe et al.206 on the previous page is an excellent condensation in 
136 characters of the greatest weakness and the greatest strength of current tools in 
metabolic systems biology. Existing metabolic models are often excellent for their 
designed purpose but poor in other situations and frequently in complete disagreement 
with other models of the same system built for a slightly different purpose. 
I am not convinced that enough care is being taken with existing models to explore the 
limits of their usefulness and I hope that by ensuring that a visualisation of each reaction, 
connection and connection within my network is provided, an idea of my network’s limits 
can also be appreciated. Much more rigorous work on the limitations of models and the 
                                                             
* project descriptions at http:  bit.ly SOv7HE 
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impact of uncertainty on the conclusions that can be drawn from their analysis is being 
done by Fiona Achcar207 at the University of Glasgow. 
Standards beyond SBML, ensuring models can be reused 
SBML has been a great achievement in systems biology, allowing the wide interchange and 
re-use of metabolic models. But as I have shown in this thesis it is a step forward rather 
than a solution to the problems of model re-use. The goal of the MIRIAM25 (Minimum 
Information Required In The Annotation of Models) project and the associated 
identifiers.org208 project is to allow ontologies for reactions, compounds and simulation 
parameters of biological models to be defined such that the models can be re-used and 
their results reproduced. In the words of the Wikipedia page, “MIRIAM is a community-level 
effort to standardize the annotation and curation processes of quantitative models of biological systems.” 
My model is not MIRIAM compliant and as shown in the following tweets the worthy goal 
of MIRIAM is, as yet, unrealised. 
 “MIRIAM support is really hard. I just annotated a large model and what was hard 
was to find the sources to annotate.” 
“Good #sbml annotation has to be done carefully, and the ontologies were far from 
optimal: lots of elements missing.”  
“Software tools (mine included) have a long way to go to really help with MIRIAM 
annotation... many cannot even do it.” 
Tweets from Pedro Mendes to Mike Hucka and  
Neil Swainston in 2012 on the subject of model re-use. 
Tools for FBA and FVA are unreliable; higher level analysis is hard to trust 
One of the most worrying findings in this PhD has been that basic tools that large amounts 
of published work are based upon are not reliable. The basic techniques of FBA and FVA 
are well-established and a simulation run on one piece of software should give the same 
result on another piece of software. This is not the case! 
The development of my final model took place largely in combination with analyses 
conducted in SurreyFBA87, with constraints added to the model to improve the results of 
FBA in that software. SurreyFBA is an excellent piece of software in that it can be run 
either from the command line or from an excellent small user interface called JyMet. It has 
a further considerable advantage of being free so I could install and run it easily on any 
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computer. The final flux-variability analysis and gene deletion predictions were performed 
in the COBRA toolbox v1.3.3 as these types of analysis were difficult to perform in 
SurreyFBA. 
It was by using two pieces of software on the same model that I noticed some problems. As 
shown in figure 106 a large number of fluxes can vary and still give the optimal solution 
and there is no reason that two different programs should give the same solution to a 
problem as long as all fluxes lie within the allowed variabilities. The problem is that the 
COBRA toolbox v1.3.3 actually predicts a slightly (<2%) higher growth-rate than 
SurreyFBA when analysing the same model. Upon closer inspection the model was able to 
grow without any flux through the purine salvage pathways, a prediction that was clearly 
incorrect. The complexity of installing the COBRA toolbox v1.3.3 and its dependencies was 
such* that I have not tried using a newer version of the COBRA toolbox to see if this 
problem still exists. In discussions with members of John Pinney’s group at Imperial 
College London I have heard that they too have got strange results from the COBRA 
toolbox, this time with COBRApy v2.0.5. In this case the exact same problem would give a 
different optimal growth-rate each time it was solved.  
My point in raising these concerns is not to criticise existing software but to re-iterate a 
feeling I have had throughout my PhD. Systems biology is already very complex and 
advances like the Mycoplasma genitalium whole-cell model209 signal a future where 
currently separate models of different processes in organisms are joined together. Since 
errors in biological simulations have a tendency to multiply rather than fade away when 
scaled up and joined together the success of these systems may hinge on these small 
details. 
For this reason I have made considerable efforts — as discussed frequently in this thesis 
— to ensure that my model is re-usable and that the predictions it makes are both 
reproducible and, through visualisation, easy to understand and play with. I have also 
tried hard to get some idea of the uncertainties in many of the measurements I have made 
to ensure that the conclusions I have drawn are reasonable. 
Sharing ideas as well as models 
When I started my PhD the Wikipedia pages on computational biology didn’t exist and 
those on malaria were largely limited to the human impact rather than the science of the 
parasite. Since then these great introductory resources have improved markedly, in part 
thanks to the efforts of people like Alex Bateman at the Sanger Institute who have outlined 
                                                             
* I spent nearly 4 months trying to get Matlab installed, compiling and installing dependencies and 
testing the final installation before I could perform any simulations. 
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areas for improvement and encouraged researchers to engage with the platform. Pages on 
metabolic engineering, isotopic labelling and synthetic biology have all been created and 
improved in the last 18 months and are now valuable starting points for students and 
cross-disciplinary scientist like me to start exploring new fields. On a personal level I am 
extremely happy that the page I wrote on flux-balance analysis is viewed at least 120 
times a month compared to 30 times per month before I rewrote it and that is now 
available in three languages. I am very glad that the complete dismissal of tools for online 
learning and sharing of knowledge that I experienced six  years ago as an undergraduate 
has given way to an appreciation of their advantages and limitations. 
Better metabolic visualisation 
I’ve shown how combining mathematical and visual approaches to network 
reconstruction can help avoid errors that are hard to see when a reconstruction is 
performed predominantly in one of those two ways. I hope I have also caused the reader 
to pose the same questions that I have in trying to understand the behaviour of these 
networks. I am convinced that the simplification of metabolism to the pathway metaphor 
in biochemistry risks obscuring the highly connected nature of metabolism but I am also 
convinced that software tools could solve that problem and let scientists see and play with 
the complex interactions within metabolic networks. I have made efforts to solve this 
problem with my MetNetMaker software and my visual metabolic reconstruction but I 
think that outside help from the world of design will be needed to really solve the 
problem. I have tried to get this assistance via synthetic aesthetics, without success, and 
via the Wellcome Trust, with more success. 
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Synthetic aesthetics 
In 2010 I submitted a letter of interest for funding and support from the Synthetic 
Aesthetics project led by the University of Edinburgh and Stanford University whereby 
scientists would be paired with designers to try and solve similar problems. I include the 
full letter of interest, which includes my ideas on how we might fix these problems, as 
appendix IX to this thesis but three sentences of the letter provide a good summary, 
In the exciting and rapidly progressing new fields of synthetic biology and systems 
biology people are saving time by using old network design principles, often taken 
from electronic engineering, rather than thinking about the real requirements of the 
problems they face. My fear is that by reusing these existing design tools in the 
world of biology we risk obscuring a truer understanding of biological systems. To 
put it simply, I think that we are drawing biological networks just like we draw 
electronic networks not because the two are similar but because we haven’t taken 
the time to design a better way of doing things.  
Extract from my Letter of Interest for Synthetic Aesthetics210 funding 
Simalaria 
Although my application for synthetic aesthetics funding was unsuccessful many of the 
concepts were re-used in an application for funding from the Wellcome Trust which was 
successful. This short project put me in touch with a Bristol based games development 
company called MobilePie to develop a game based on my PhD research. The game is a 
scientifically accurate representation of flux-balance analysis where the user must balance 
energy creation via glycolysis and glucose consumption — and the associated energy cost 
— of DNA, Fat and Protein synthesis by the control of flux gates shown as multi-coloured 
nodes in figure 112. In two days we were unable to create more than a basic 
representation of the malaria parasite but I’m very pleased with the game’s role of proving 
that many of my ideas for better metabolic network visualisation are achievable. 
The best way to understand SIMALARIA is to play it, currently at 
http://media.mobilepie.com/simalaria/simalaria.html (currently the second hit on google 
for ‘similaria’) and playable through a web browser on Mac and Windows. 
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Figure 112 : (left) glycolyis, oxidative pentose-phosphate pathway, purine base synthesis and fatty acid elongation in 
the apicoplast in a simplified version of the complete final model. Haemoglobin digestion to scavenge amino acids is 
shown separately in the bottom-right. (right) the same model in SIMALARIA, glycolysis in orange, ribose sugar 
synthesis via the oxidative pentose phosphate cycle in green, nucleotide base synthesis via the purine synthesis 
pathway in light blue, fatty acid elongation in pink. Haemoglobin digestion requires no glucose flux but consumes 
energy in the game. 
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Appendix I : Dead-end compounds algorithm and implementation 
The algorithm behind the functioning of the dead-end compounds button can be expressed 
either as a diagram as in figure 116 or as code as in figure 113. As mentioned in chapter 2 : 
MetNetMaker the SQL queries are run and the query results output to files and displayed 
on screen using VBA code. The full code of the ExComps() subroutine that does this is 
included as figure 115 with a simplified version in figure 114 more suitable for 
understanding how the code works. 
 
Figure 113 : The six queries composing the SQL portion of the dead-end compounds algorithm. All queries refer 
either to each other or to tables in MetNetMaker’s central database shown in figure 20. Nested SQL queries break 
the algorithm down into distinct levels as shown in figure 116. 
ReactantsQuery 
SELECT DISTINCT [REACTIONS-PRODUCTS LINK].[Compound ID], [Selected Reactions].Compartment 
FROM [Selected Reactions] , [REACTIONS-PRODUCTS LINK] 
WHERE [Selected Reactions].[Reaction ID] = [REACTIONS-PRODUCTS LINK].[Reaction ID]  
AND [Selected Reactions].Rev=False 
UNION 
SELECT DISTINCT [REACTIONS-REACTANTS LINK].[Compound ID], [Selected Reactions].Compartment 
FROM [Selected Reactions] , [REACTIONS-REACTANTS LINK]  
WHERE [Selected Reactions].[Reaction ID] = [REACTIONS-REACTANTS LINK].[Reaction ID] 
AND [Selected Reactions].Rev=True 
 
ProductsQuery 
SELECT DISTINCT [REACTIONS-PRODUCTS LINK].[Compound ID], [Selected Reactions].Compartment 
FROM [Selected Reactions] , [REACTIONS-PRODUCTS LINK] 
WHERE [Selected Reactions].[Reaction ID] = [REACTIONS-PRODUCTS LINK].[Reaction ID]  
AND [Selected Reactions].Rev=True 
UNION 
SELECT DISTINCT [REACTIONS-REACTANTS LINK].[Compound ID], [Selected Reactions].Compartment 
FROM [Selected Reactions] , [REACTIONS-REACTANTS LINK]  
WHERE [Selected Reactions].[Reaction ID] = [REACTIONS-REACTANTS LINK].[Reaction ID] 
AND [Selected Reactions].Rev=False 
 
CompoundsInOnly 
SELECT ReactantsQuery.[Compound ID], ReactantsQuery.Compartment 
FROM ReactantsQuery  
LEFT JOIN ProductsQuery ON ReactantsQuery.[Compound ID] = ProductsQuery.[Compound ID] 
WHERE ProductsQuery.[Compound ID] Is Null 
 
CompoundsOutOnly 
SELECT ProductsQuery.[Compound ID], ProductsQuery.Compartment 
FROM ProductsQuery  
LEFT JOIN ReactantsQuery ON ProductsQuery.[Compound ID] = ReactantsQuery.[Compound ID] 
WHERE ReactantsQuery.[Compound ID] Is Null 
 
CompoundsInOutputQuery 
SELECT CompoundsInOnly.[Compound ID], CompoundsInOnly.[Compartment],  
[PREFERRED COMPOUND NAME].[Compound Name]  
FROM CompoundsInOnly , [PREFERRED COMPOUND NAME]  
WHERE CompoundsInOnly.[Compound ID] = [PREFERRED COMPOUND NAME].CompoundID 
 
CompoundsOutOutputQuery 
SELECT CompoundsOutOnly.[Compound ID], CompoundsOutOnly.[Compartment],  
[PREFERRED COMPOUND NAME].[Compound Name]  
FROM CompoundsOutOnly , [PREFERRED COMPOUND NAME]  
WHERE CompoundsOutOnly.[Compound ID] = [PREFERRED COMPOUND NAME].CompoundID 
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Figure 114 : Simplified version of the VBA code to run the SQL queries in figure 113 and output the results to a text 
file which is then opened with Notepad. 
 
Simplified Export Subroutine (no screen display, no formatting, no error handling) 
Sub ExComps() 
 OutputPath = Application.CurrentProject.Path & "\excompstemp.txt"  
 Open OutputPath For Output As #5 
 
 Set ta20 = CurrentDb.OpenRecordset(CompoundsInOutputQuery, dbOpenSnapshot) 
 While Not ta20.EOF 'Compounds that only enter the network 
  Print #5, ta20.[Compound ID] & Chr(9) & ta20.[Compartment] & Chr(9) & ta20.[Compound Name] 
  ta20.MoveNext 
 Wend 
 
 Set ta21 = CurrentDb.OpenRecordset(CompoundsOutOutputQuery, dbOpenSnapshot) 
 While Not ta21.EOF 'Compounds that only exit the network 
  Print #5, ta21.[Compound ID] & Chr(9) & ta21.[Compartment] & Chr(9) & ta21.[Compound Name] 
  ta21.MoveNext 
 Wend 
  
 Close #5 
 VBA.Shell ("Notepad.exe " & Application.CurrentProject.Path & "\excompstemp.txt") 'Opens the file in notepad 
End Sub 
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Figure 115 : Full version of the VBA code to run the SQL queries in figure 113 and output the results to a text file 
which is then opened with Notepad and displays the results as an on-screen notification. 
Full Export Subroutine 
Sub ExComps() 
 Dim SQLstring As String 
 Dim ta20 As Object 
 Dim OutputPath As String 
 Dim MessageText As String 
 Dim CompartmentHolder As String 
 Dim IDHolder As String 
 
 Forms("Reaction Picker").Requery 'Refresh before 
 
 MessageText = "This list may be truncated, a full copy has been opened in Notepad. Copy into a spreadsheet for correct formatting."  + vbNewLine + vbNewLine 
 
 OutputPath = Application.CurrentProject.Path & "\excompstemp.txt" 
 Open OutputPath For Output As #5 'The numbers here shouldn't matter, chosen to avoid any chance of conflict 
 SQLstring = "SELECT CompoundsInOnly.[Compound ID], CompoundsInOnly.[Compartment], [PREFERRED COMPOUND NAME].[Compound Name] FROM 
CompoundsInOnly INNER JOIN [PREFERRED COMPOUND NAME] ON CompoundsInOnly.[Compound ID] = [PREFERRED COMPOUND NAME].CompoundID;" 
 Set ta20 = CurrentDb.OpenRecordset(SQLstring, dbOpenSnapshot) 
 Print #5, "Compounds that only enter the network" 
 MessageText = MessageText + "Compounds that only enter the network" + vbNewLine 
 Print #5, "-------------------------------------" 
 MessageText = MessageText + "-------------------------------------" + vbNewLine 
 Print #5, "" 
 MessageText = MessageText + "" + vbNewLine 
 Print #5, "ID" & Chr(9) & "Compartment" & Chr(9) & "Name" 
 MessageText = MessageText + "Compound ID" & Chr(9) & "Compartment" & Chr(9) & "Compound Name" + vbNewLine 
  
While Not ta20.EOF 
  CompartmentHolder = ta20.[Compartment] 
  IDHolder = ta20.[Compound ID] 
  If Len(CompartmentHolder) < 10 Then 'Hack to double the number of tabs if compartment is short to make the output align 
   CompartmentHolder = CompartmentHolder + Chr(9) 
  End If 
  If Len(IDHolder) < 10 Then 
   IDHolder = IDHolder + Chr(9) 
  End If 
  Print #5, ta20.[Compound ID] & Chr(9) & ta20.[Compartment] & Chr(9) & ta20.[Compound Name] 
  MessageText = MessageText + IDHolder & Chr(9) & CompartmentHolder & Chr(9) & ta20.[Compound Name] + vbNewLine 
  ta20.MoveNext 
 Wend 
 
 Print #5, "" 
 MessageText = MessageText + "" + vbNewLine 
 SQLstring = "SELECT CompoundsOutOnly.[Compound ID], CompoundsOutOnly.[Compartment], [PREFERRED COMPOUND NAME].[Compound Name] FROM 
CompoundsOutOnly INNER JOIN [PREFERRED COMPOUND NAME] ON CompoundsOutOnly.[Compound ID] = [PREFERRED COMPOUND NAME].CompoundID;" 
 Set ta20 = CurrentDb.OpenRecordset(SQLstring, dbOpenSnapshot) 
 Print #5, "Compounds that only exit the network" 
 MessageText = MessageText + "Compounds that only exit the network" + vbNewLine 
 Print #5, "------------------------------------" 
 MessageText = MessageText + "-------------------------------------" + vbNewLine 
 Print #5, "" 
 MessageText = MessageText + "" + vbNewLine 
 Print #5, "ID" & Chr(9) & "Compartment" & Chr(9) & "Name" 
 MessageText = MessageText + "Compound ID" & Chr(9) & "Compartment" & Chr(9) & "Compound Name" + vbNewLine 
 
 While Not ta20.EOF 
  CompartmentHolder = ta20.[Compartment] 
  IDHolder = ta20.[Compound ID] 
  If Len(CompartmentHolder) < 10 Then 'Hack to double the number of tabs if compartment is short to make the output align 
   CompartmentHolder = CompartmentHolder + Chr(9) 
  End If 
  If Len(IDHolder) < 10 Then 
   IDHolder = IDHolder + Chr(9) 
  End If 
  Print #5, ta20.[Compound ID] & Chr(9) & ta20.[Compartment] & Chr(9) & ta20.[Compound Name] 
  MessageText = MessageText + IDHolder & Chr(9) & CompartmentHolder & Chr(9) & ta20.[Compound Name] + vbNewLine 
  ta20.MoveNext 
 Wend 
 
 MsgBox MessageText, vbDefaultButton1, "Dead-End Compounds"  
Close #5  
VBA.Shell ("Notepad.exe " & Application.CurrentProject.Path & "\excompstemp.txt") 'Opens the file in notepad 
End Sub 
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Figure 116 : Visual representation of the algorithm for returning dead-end compounds as represented as a set of SQL queries in figure 113. 
  
[Selected Reactions]
Reaction ID Com partm ent Rev
[REACTIONS-REACTANTS LINK] Reaction ID Com pound ID Reaction ID Com pound ID [REACTIONS-PRODUCTS LINK]
[ReactantsQuery] Com pound ID Com partm ent Com pound ID Com partm ent [ProductsQuery]
[CompoundsInOnly] Com pounds ID Com partm ent Com pounds ID Com partm ent [CompoundsOutOnly]
[PREFERRED COMPOUND NAME] Com pound ID Preferred Name
[CompoundsInOutputQuery] Com pounds ID Com partm ent Compound Name Com pounds ID Com partm ent Compound Name [CompoundsOutOutputQuery]
Rev = true
Rev = falseRev = false
Rev = true
If not in other 
table
Distinct
Distinct
Distinct
Distinct
[  
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Appendix II : Example reconstruction and evidence checker spreadsheet 
 
Table 33 : Reactions for pyrimidine metabolism in P. falciparum in the evidence checker spreadsheet ready for import back into MetNetMaker for export and manipulation. 
Reaction Id Compartment EC Number
Max +ve 
Flux
Max -ve 
Flux
Objective
Map 
Number
Gene Rev SharkHunt PlasmoDB BRENDA KEGG Direction Notes
R00156 Cytosol 2.7.4.6 500 -500 FALSE 00240 PF13_0349, PFF0275c FALSE 4.2E-58 yes BRENDA reversible
R00158 Cytosol 2.7.4.14 500 -500 FALSE 00240 PFA0555c FALSE 0.001 yes BRENDA reversible
R00512 Cytosol 2.7.4.14 500 -500 FALSE 00240 PFA0555c FALSE 0.001 yes BRENDA reversible not in MPMP
R00570 Cytosol 2.7.4.6 500 -500 FALSE 00240 PF13_0349, PFF0275c FALSE 4.2E-58 yes BRENDA reversible
R00571 Cytosol 6.3.4.2 500 -500 FALSE 00240 PF14_0100 FALSE 0 yes DIRECT EVIDENCE forward not in MPMP
R00573 Cytosol 6.3.4.2 500 -500 FALSE 00240 PF14_0100 FALSE 0 yes DIRECT EVIDENCE forward
R00575_balanced Cytosol 6.3.5.5 500 -500 FALSE 00240 PF13_0044 FALSE 0.0000019 yes BRENDA not in MPMP
R00965 Cytosol 4.1.1.23 500 -500 FALSE 00240 PF10_0225 FALSE 2.8E-14 yes DIRECT EVIDENCE forward
R01665 Cytosol 2.7.4.14 500 -500 FALSE 00240 PFA0555c FALSE 0.001 yes BRENDA forward not in MPMP
R01867 Cytosol 1.3.3.1 500 -500 FALSE 00240 PFF0160c FALSE 2E-88 yes DIRECT EVIDENCE reversible
R01870 Cytosol 2.4.2.10 500 -500 FALSE 00240 PFE0630c FALSE 5.5E-32 yes DIRECT EVIDENCE reversible
R01993 Cytosol 3.5.2.3 500 -500 FALSE 00240 PF14_0697 FALSE 1.9E-45 yes DIRECT EVIDENCE reversible
R02016 Cytosol 1.8.1.9 500 -500 FALSE 00240 PFI1170c FALSE 0.036 yes DIRECT EVIDENCE forward
R02018 Cytosol 1.17.4.1 500 -500 FALSE 00240 PF10_0154, PF14_0053, PF14_0352 FALSE 0 yes DIRECT EVIDENCE forward
R02024 Cytosol 1.17.4.1 500 -500 FALSE 00240 PF10_0154, PF14_0053, PF14_0352 FALSE 0 yes DIRECT EVIDENCE forward
R02093 Cytosol 2.7.4.6 500 -500 FALSE 00240 PF13_0349, PFF0275c FALSE 4.2E-58 yes BRENDA reversible
R02094 Cytosol 2.7.4.9 500 -500 FALSE 00240 PFL2465c FALSE 1.4E-48 yes DIRECT EVIDENCE reversible
R02098 Cytosol 2.7.4.9 500 -500 FALSE 00240 PFL2465c FALSE 1.4E-48 yes DIRECT EVIDENCE reversible
R02100 Cytosol 3.6.1.23 500 -500 FALSE 00240 PF11_0282 FALSE 3.2E-19 yes DIRECT EVIDENCE forward
R02101 Cytosol 2.1.1.45 500 -500 FALSE 00240 PFD0830w FALSE 6E-61 yes DIRECT EVIDENCE forward
R02326 Cytosol 2.7.4.6 500 -500 FALSE 00240 PF13_0349, PFF0275c FALSE 4.2E-58 yes BRENDA reversible
R02331 Cytosol 2.7.4.6 500 -500 FALSE 00240 PF13_0349, PFF0275c FALSE 4.2E-58 yes BRENDA reversible
R00132 Cytosol 4.2.1.1 500 -500 FALSE 00240 PF11_0410 FALSE 3.8E-10 yes BRENDA
R01397 Cytosol 2.1.3.2 500 -500 FALSE 00240 MAL13P1.221 FALSE 3.9E-89 yes no forward
R02325 Cytosol 3.5.4.13 500 -500 FALSE 00240 PF13_0259 FALSE no yes no forward
R00945 Cytosol 2.1.2.1 500 -500 FALSE 00240 PF14_0534, PFL1720w FALSE 9E-146 yes DIRECT EVIDENCE
CarbonicAcid_disoc Cytosol spontaneous 500 -500 FALSE 00240 FALSE
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Table 34 : Evidence summary from the ECinfo database as presented in the evidence checker spreadsheet and used to help judge the existence of the reactions in table 33 and populate them with 
additional information for SBML export. 
  
Reaction Id By EC number -> Gene
By Reaction ID -> 
EC
By EC number 
(best)
By Reaction ID 
(best)
By EC 
number
By Reaction ID 
(best)
By EC number By Reaction ID
Balanced
R00156 4.2E-58 PF13_0349, PFF0275c 2.7.4.6 R00156 BRENDA BRENDA PF13_0349, PFF0275c PF13_0349 reversible True
R00158 0.001 PFA0555c 2.7.4.14 R00158 BRENDA BRENDA MAL1P2.40 MAL1P2.40 reversible True
R00512 0.001 PFA0555c 2.7.4.14 no BRENDA BRENDA MAL1P2.40 MAL1P2.40 reversible True
R00570 4.2E-58 PF13_0349, PFF0275c 2.7.4.6 R00570 BRENDA BRENDA PF13_0349, PFF0275c PF13_0349 reversible True
R00571 0 PF14_0100 6.3.4.2 no DIRECT EVIDENCE DIRECT EVIDENCE PF14_0100 PF14_0100 forward True
R00573 0 PF14_0100 6.3.4.2 R00573 DIRECT EVIDENCE DIRECT EVIDENCE PF14_0100 PF14_0100 forward True
R00575_balanced 0.0000019 PF13_0044 no no BRENDA no PF13_0044 #N/A #N/A
R00965 2.8E-14 PF10_0225 4.1.1.23 R00965 DIRECT EVIDENCE DIRECT EVIDENCE PF10_0225 PF10_0225 forward True
R01665 0.001 PFA0555c 2.7.4.14 no BRENDA BRENDA MAL1P2.40 MAL1P2.40 forward True
R01867 2E-88 PFF0160c 1.3.3.1 R01867 DIRECT EVIDENCE DIRECT EVIDENCE PFF0160c PFF0160c reversible True
R01870 5.5E-32 PFE0630c 2.4.2.10 R01870 DIRECT EVIDENCE DIRECT EVIDENCE soluble soluble PFE0630c PFE0630c reversible True
R01993 1.9E-45 PF14_0697 3.5.2.3 R01993 DIRECT EVIDENCE DIRECT EVIDENCE PF14_0697 PF14_0697 reversible True
R02016 0.036 PFI1170c 1.8.1.9 R02016 DIRECT EVIDENCE DIRECT EVIDENCE PFI1170c PFI1170c forward True
R02018 0 PF10_0154, PF14_0053, PF14_0352 1.17.4.1 R02018 DIRECT EVIDENCE DIRECT EVIDENCE PF10_0154, PF14_0053, PF14_0352 PF10_0154 forward True
R02024 0 PF10_0154, PF14_0053, PF14_0352 1.17.4.1 R02024 DIRECT EVIDENCE DIRECT EVIDENCE PF10_0154, PF14_0053, PF14_0352 PF10_0154 forward True
R02093 4.2E-58 PF13_0349, PFF0275c 2.7.4.6 R02093 BRENDA BRENDA PF13_0349, PFF0275c PF13_0349 reversible True
R02094 1.4E-48 PFL2465c 2.7.4.9 R02094 DIRECT EVIDENCE DIRECT EVIDENCE PFL2465c PFL2465c reversible True
R02098 1.4E-48 PFL2465c 2.7.4.9 R02098 DIRECT EVIDENCE DIRECT EVIDENCE PFL2465c PFL2465c reversible True
R02100 3.2E-19 PF11_0282 3.6.1.23 R02100 DIRECT EVIDENCE DIRECT EVIDENCE intracellular intracellular PF11_0282 PF11_0282 forward True
R02101 6E-61 PFD0830w 2.1.1.45 R02101 DIRECT EVIDENCE DIRECT EVIDENCE PFD0805w PFD0805w forward True
R02326 4.2E-58 PF13_0349, PFF0275c 2.7.4.6 R02326 BRENDA BRENDA PF13_0349, PFF0275c PF13_0349 reversible True
R02331 4.2E-58 PF13_0349, PFF0275c 2.7.4.6 R02331 BRENDA BRENDA PF13_0349, PFF0275c PF13_0349 reversible True
R00132 3.8E-10 PF11_0410 4.2.1.1 R00132 BRENDA BRENDA no #N/A True
R01397 3.9E-89 MAL13P1.221 2.1.3.2 R01397 no no MAL13P1.221 MAL13P1.221 forward True
R02325 no PF13_0259 3.5.4.13 R02325 no no no #N/A forward True
R00945 9E-146 PF14_0534, PFL1720w 2.1.2.1 R00945 DIRECT EVIDENCE DIRECT EVIDENCE cytosol cytosol MAL13P1.67, PFL1720w MAL13P1.67 True
CarbonicAcid_disoc
KEGG pfa KEGG directionSharkHunt PlasmoDB MPMP BRENDA HIT BRENDA Localisation
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Appendix III : RPMI components 
 
Table 35 : Components of RPMI 1640 growth medium211. 
COMPONENTS Molecular Weight Concentration (mg/L) mM
Glycine 75 10 0.133
L-Arginine 174 200 1.15
L-Asparagine 132 50 0.379
L-Aspartic acid 133 20 0.15
L-Cystine 240 20 0.0833
L-Glutamic Acid 147 20 0.136
L-Glutamine 146 300 2.05
L-Histidine 155 15 0.0968
L-Hydroxyproline 131 20 0.153
L-Isoleucine 131 50 0.382
L-Leucine 131 50 0.382
L-Lysine hydrochloride 146 40 0.274
L-Methionine 149 15 0.101
L-Phenylalanine 165 15 0.0909
L-Proline 115 20 0.174
L-Serine 105 30 0.286
L-Threonine 119 20 0.168
L-Tryptophan 204 5 0.0245
L-Tyrosine 181 20 0.11
L-Valine 117 20 0.171
Biotin 244 0.2 0.00082
Choline chloride 140 3 0.0214
D-Calcium pantothenate 477 0.25 0.000524
Folic Acid 441 1 0.00227
Niacinamide 122 1 0.0082
Para-Aminobenzoic Acid 137 1 0.0073
Pyridoxine hydrochloride 206 1 0.00485
Riboflavin 376 0.2 0.000532
Thiamine hydrochloride 337 1 0.00297
Vitamin B12 1355 0.005 3.7E-06
i-Inositol 180 35 0.194
Calcium nitrate (Ca(NO3)2 4H2O) 236 100 0.424
Magnesium Sulfate (MgSO4-7H2O) 246 100 0.407
Potassium Chloride (KCl) 75 400 5.33
Sodium Bicarbonate (NaHCO3) 84 2000 23.81
Sodium Chloride (NaCl) 58 5500 94.83
Sodium Phosphate dibasic (Na2HPO4) anhydrous 142 800 5.63
D-Glucose (Dextrose) 180 2000 11.11
Glutathione (reduced) 307 1 0.00326
HEPES 238 5958 25.03
Phenol Red 376.4 5 0.0133
Amino Acids
Vitamins
Inorganic Salts
Other Components
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Appendix IV : Free components of the biomass function 
In my analysis of Table 1 in Teng et al.146 I took the maximum measured concentration of 
each metabolite from each of the extraction methods and converted from a milliMolar 
concentration to        parasites. The total mass measured in their experiment is 
536.8        parasites, around a twentieth of the total mass that I have measured of total 
biomass per parasite. It is clear that the paper only reports free metabolites, not the 
composition of the biomass. It is possible that digesting the proteins and DNA/RNA 
polymers to monomers and repeating their analysis techniques could accurately 
determine the biomass composition of P. falciparum. 
 
 
Table 36 : Table created from calculations based on Table 1 in Teng. et al. Reported concentrations of metabolites 
have been converted from milliMolar concentration to       parasites. Note the very high standard deviations 
showing the inherent variability in the biology of the system. 
Metabolite Best estimate Standard Deviation
Alanine (Ala) 5.2 2.0
GABA 6.6 1.4
Arginine (Arg) 20.5 5.4
Asparagine (Asn) 9.6 4.8
Aspartate (Asp) 7.5 1.9
Glutamate (Glu) 45.3 16.5
Glutamine (Gln) 7.0 1.6
Glycine (Gly) 3.4 1.3
Histidine (His) 2.6 1.0
Isoleucine (Ile) 4.0 2.2
Leucine (Leu) 10.3 4.0
Lysine (Lys) 13.9 4.9
Methionine (Met) 1.8 1.2
Phenylalanine (Phe) 4.2 1.9
Serine (Ser) 4.4 2.4
Threonine (Thr) 6.0 3.0
Tyrosine (Tyr) 4.1 1.5
Valine (Val) 4.6 1.6
Total amino acids 160.9 58.6
Reduced (GSH) 46.5 10.3
Oxidised (GSSG) 29.2 12.0
myo-Inositol (Ins) 1.2 0.4
Phosphocholine (PC) 7.7 1.6
Phosphoethanolamine (PE) 17.8 5.9
AMP 5.3 3.2
ADP 13.2 4.8
ATP 28.4 12.8
UMP, CMP, (U/C MP) 11.8 7.3
UDP, CDP, UTP, CTP, (U/C D/T P) 31.7 10.2
NAD+ 53.9 9.3
Acetate 1.3 0.8
Formate 0.3 0.1
Fumarate 0.7 0.2
alpha-Ketoglutarate (alpha-KG) 2.0 1.6
Lactate (Lac) 2.8 2.0
Malate (Mal) 6.8 1.9
Succinate (Succ) 1.4 0.2
Ethanol 0.6 0.4
HEPES 80.1 13.3
Putrescine (Put) 7.2 2.0
Spermidine (Spd) 23.2 6.5
Spermine (Spm) 2.9 0.6
Total 536.8 224.8
  𝑥                      
                  
Colours refer to extraction methods used,
perchloric acid (n=13)
methanol/water (n=12)
methanol/chloroform/water (n=10)
Notes:
* Ethanol results are not reported as they were determined to 
be the result of contamination during preparation.
* The following met bolites were not measurabl ,
* No reliable method of measuring any lipids was found.
Glycerophosphocholine (GPC), Glycerophosphothanolamine (GPE), 
GMP, GDP, GTP, Hypoxanthine, IMP, NADP+, Citrate, Pyruvate.
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Appendix V : Measured exchange fluxes 
Carbon source exchange flux calculations 
 
Table 37 : Sara A carbon source flux calculations. 
 
Table 38 : Sara B carbon source flux calculations. 
 
Table 39 : Tom repeat of Jennifer carbon source flux calculations.  
No glycerol production was detected.  
Value Glucose Lactate Glycerol Glutamine
-0.79 0.45 0.00 -0.06
-1.57 1.03 0.04 -0.08
0.13 0.02 0.00 0.02
0.39 0.06 0.01 0.01
0.41 0.06 0.01 0.02
-0.82 0.60 0.04 -0.02
-18.2 13.2 0.8 -0.4
50% 10% 14% 125%
-1010 1470
Units
    
  
    
  
  
  
  
  
  
     mg/RBC/hour
     mg/infected RBC/hour
    nmol/infected RBC/hour
Value Glucose Lactate Glycerol Glutamine
-0.79 0.45 0.00 -0.06
-1.05 0.60 0.02 -0.07
0.13 0.02 0.00 0.02
0.23 0.01 0.00 0.00
0.27 0.02 0.00 0.02
-0.29 0.17 0.02 -0.01
-8.2 4.8 0.7 -0.2
92% 13% 5% 302%
-458 530
Units
    
  
    
  
  
  
  
  
  
     mg/RBC/hour
     mg/infected RBC/hour
    nmol/infected RBC/hour
Value Glucose Lactate Glutamine
-0.26 0.68 0.04
-0.93 1.06 -0.05
0.22 0.07 0.03
0.10 0.03 0.01
0.25 0.07 0.03
-0.69 0.41 -0.09
-16.74 9.97 -2.14
36% 18% 38%
-929 1107
Units
    
  
    
  
  
  
  
  
  
     mg/RBC/hour
     mg/infected RBC/hour
    nmol/infected RBC/hour
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Amino acid exchange flux calculations 
 
Table 40 : Sara A amino acid flux calculations.  
Hypoxanthine is listed last as its NMR assignment is unclear. 
 
Table 41 : Sara B amino acid flux calculations.  
Hypoxanthine is listed last as its NMR assignment is unclear. 
 
Table 42 : Tom repeat of Jennifer amino acid flux calculations.  
Hypoxanthine is listed last as its NMR assignment is unclear. 
  
Value Valine Leucine Isoleucine Alanine Tyrosine Phenylalanine Hypoxanthine
0.000 -0.001 -0.003 0.000 -0.005 -0.001 -0.016
0.007 0.001 0.001 0.014 -0.001 0.002 -0.004
0.002 0.002 0.002 0.000 0.001 0.001 0.002
0.002 0.003 0.001 0.002 0.002 0.003 0.001
0.002 0.004 0.002 0.002 0.002 0.003 0.002
0.008 0.002 0.004 0.014 0.003 0.004 0.012
0.21 0.06 0.11 0.41 0.10 0.10 0.33
31% 184% 47% 13% 53% 86% 16%
Units
    
  
    
  
  
  
  
  
     mg/RBC/hour
     mg/infected RBC/hour
Value Valine Leucine Isoleucine Alanine Tyrosine Phenylalanine Hypoxanthine
0.000 -0.001 -0.003 0.000 -0.005 -0.001 -0.016
0.003 0.000 -0.002 0.004 0.001 0.002 -0.006
0.002 0.002 0.002 0.000 0.001 0.001 0.002
0.001 0.001 0.004 0.002 0.002 0.001 0.004
0.002 0.002 0.005 0.002 0.002 0.001 0.004
0.003 0.001 0.001 0.004 0.005 0.004 0.009
0.07 0.03 0.01 0.08 0.12 0.09 0.21
56% 198% 721% 67% 45% 32% 48%
Units
    
  
    
  
  
  
  
  
     mg/RBC/hour
     mg/infected RBC/hour
Value Valine Leucine Isoleucine Alanine Tyrosine Phenylalanine Hypoxanthine
0.002 -0.002 0.002 0.007 0.001 0.002 0.000
0.011 0.003 0.002 0.019 0.003 0.011 -0.006
0.002 0.003 0.005 0.001 0.003 0.003 0.012
0.002 0.002 0.001 0.002 0.001 0.003 0.008
0.003 0.003 0.005 0.002 0.004 0.004 0.014
0.009 0.005 0.000 0.012 0.002 0.010 -0.007
0.22 0.12 0.00 0.29 0.06 0.24 -0.16
35% 67% 12088% 21% 147% 37% 211%
Units
    
  
    
  
  
  
  
  
     mg/RBC/hour
     mg/infected RBC/hour
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Appendix VI: Key amino acid compositions 
Key amino acid compositions, full tables 
 
Table 43 : Amino acid composition of 2 α-subunits + 2 β-subunits of the human haemoglobin molecule ordered by 
total weight per mol of haemoglobin. The molecular weights given are those of the amino acid after it has formed a 
protein. 
Name
Molecular 
Weight (g/mol)
Count
Weight per mole 
of haemoglobin (g)
Percent by 
Weight
Percent by amino 
acid count
Leucine 113 72 8142 13.0% 12.5%
Valine 99 62 6142 9.8% 10.7%
Lysine 128 44 5636 9.0% 7.6%
Histidine 137 38 5208 8.3% 6.6%
Alanine 71 72 5115 8.2% 12.5%
Phenylalanine 147 30 4412 7.1% 5.2%
Aspartate 115 30 3451 5.5% 5.2%
Threonine 101 32 3234 5.2% 5.5%
Glutamate 129 24 3097 5.0% 4.2%
Serine 87 32 2785 4.5% 5.5%
Proline 97 28 2717 4.4% 4.8%
Asparagine 114 20 2281 3.7% 3.5%
Glycine 57 40 2281 3.7% 6.9%
Tyrosine 163 12 1957 3.1% 2.1%
Arginine 156 12 1873 3.0% 2.1%
Methionine 131 10 1310 2.1% 1.7%
Tryptophan 186 6 1116 1.8% 1.0%
Glutamine 128 8 1024 1.6% 1.4%
Cysteine 103 6 618 1.0% 1.0%
Isoleucine 113 0 0 0.0% 0.0%
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Table 44 : Amino acid use in the P. falciparum proteome, adapted from Chanda et al.176. The molecular weights 
given are those of the amino acid after it has formed a protein. 
  
Amino Acid Percent by weight
Percent by amino 
acid count
Asparagine 13.1% 12.2%
Lysine 12.0% 11.6%
Isoleucine 8.5% 9.3%
Glutamate 8.3% 7.0%
Leucine 7.4% 8.1%
Tyrosine 7.3% 5.5%
Aspartate 6.5% 6.0%
Phenylalanine 5.5% 4.6%
Serine 4.4% 6.3%
Arginine 4.1% 2.9%
Threonine 3.4% 4.2%
Valine 3.3% 4.1%
Glutamine 2.9% 2.8%
Histidine 2.8% 2.2%
Methionine 2.7% 2.2%
Proline 2.0% 2.2%
Glycine 1.9% 3.1%
Cysteine 1.8% 1.8%
Alanine 1.4% 2.4%
Tryptophan 0.8% 0.5%
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Appendix VII : Single gene deletions that affect growth-rate 
 
Gene
Relative 
Growth
Associated 
Reaction(s)
Reaction Name(s)
Associated EC 
number
MAL13P1.221 0 R01397 carbamoyl-phosphate:L-aspartate carbamoyltransferase 2.1.3.2
MAL13P1.40 0 R01512 ATP:3-phospho-D-glycerate 1-phosphotransferase 2.7.2.3
MAL8P1.156 0 R01819 D-mannose-6-phosphate aldose-ketose-isomerase 5.3.1.8
PF07_0072 0 R04779 ATP:D-fructose-6-phosphate 1-phosphotransferase 2.7.1.11
PF08_0062 0 R00127 ATP:AMP phosphotransferase 2.7.4.3
PF08_0066 0
R03815
R07618
R07618
dihydrolipoylprotein:NAD+ oxidoreductase
enzyme N6-(dihydrolipoyl)lysine:NAD+ oxidoreductase
enzyme N6-(dihydrolipoyl)lysine:NAD+ oxidoreductase
1.8.1.4
1.8.1.4
1.8.1.4
PF08_0071 0 R00275 superoxide:superoxide oxidoreductase 1.15.1.1
PF08_0077 0 R00888 GDP-mannose 4,6-hydro-lyase(GDP-4-dehydro-6-deoxy-D-mannose-forming) 4.2.1.47
PF10_0086 0 R00127 ATP:AMP phosphotransferase 2.7.4.3
PF10_0123 0 R01231 Xanthosine-5'-phosphate:L-glutamine amido-ligase (AMP-forming) 6.3.5.2
PF10_0137 0 R05692 GDP-L-fucose:NADP+ 4-oxidoreductase (3,5-epimerizing) 1.1.1.271
PF10_0154 0
R02017
R02018
R02019
R02023
R02024
2'-Deoxyadenosine 5'-diphosphate:oxidized-thioredoxin2'-oxidoreductase
2'-Deoxyuridine 5'-diphosphate:oxidized-thioredoxin2'-oxidoreductase
2'-Deoxyguanosine 5'-diphosphate:oxidized-thioredoxin2'-oxidoreductase
2'-Deoxyuridine 5'-triphosphate:oxydized-thioredoxin2'-oxidoreductase
2'-Deoxycytidine diphosphate:oxidized-thioredoxin 2'-oxidoreductase
1.17.4.1
1.17.4.1
1.17.4.1
1.17.4.1
1.17.4.1
PF10_0155 0 R00658 2-phospho-D-glycerate hydro-lyase (phosphoenolpyruvate-forming) 4.2.1.11
PF10_0169 0 R01818 D-Mannose 6-phosphate 1,6-phosphomutase 5.4.2.8
PF10_0218 0 R00351 acetyl-CoA:oxaloacetate C-acetyltransferase (thioester-hydrolysing) 2.3.3.1
PF10_0225 0 R00965 orotidine-5'-phosphate carboxy-lyase (UMP-forming) 4.1.1.23
PF10_0363 0
R00200
R00200
ATP:pyruvate 2-O-phosphotransferase
ATP:pyruvate 2-O-phosphotransferase
2.7.1.40
2.7.1.40
PF10_0407 0 R02569 acetyl-CoA:enzyme N6-(dihydrolipoyl)lysine S-acetyltransferase 2.3.1.12
PF10_0409 0
R00742_balanced
R04386_balanced
Acetyl-CoA:carbon-dioxide ligase (ADP-forming)_balanced
Acetyl-CoA:carbon-dioxide ligase (ADP-forming)_balanced
6.4.1.2
6.4.1.2
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Gene
Relative 
Growth
Associated 
Reaction(s)
Reaction Name(s)
Associated EC 
number
PF11_0145 0 R02530 (R)-S-Lactoylglutathione methylglyoxal-lyase (isomerizing) 4.4.1.5
PF11_0157 0 R00842 sn-Glycerol-3-phosphate:NAD+ 2-oxidoreductase 1.1.1.8
PF11_0208 0 R01518 2-Phospho-D-glycerate 2,3-phosphomutase 5.4.2.1
PF11_0256 0
R00014
R03270
pyruvate:thiamin diphosphate acetaldehydetransferase(decarboxylating)
NO NAME
1.2.4.1
1.2.4.1
PF11_0294 0 R04779 ATP:D-fructose-6-phosphate 1-phosphotransferase 2.7.1.11
PF13_0044 0
R00149
R00575_balanced
Carbon-dioxide:ammonia ligase(ADP-forming,carbamate-phosphorylating)
hydrogen-carbonate:L-glutamine amido-ligase (ADP-forming,carbamate-phosphorylating)_balanced
6.3.4.16
6.3.5.5
PF13_0141 0 R00703 (S)-Lactate:NAD+ oxidoreductase 1.1.1.27
PF13_0143 0 R01049 ATP:D-ribose-5-phosphate diphosphotransferase 2.7.6.1
PF13_0144 0 R00703 (S)-Lactate:NAD+ oxidoreductase 1.1.1.27
PF13_0157 0 R01049 ATP:D-ribose-5-phosphate diphosphotransferase 2.7.6.1
PF13_0229 0
R01325
R01900
citrate hydro-lyase (cis-aconitate-forming)
isocitrate hydro-lyase (cis-aconitate-forming)
4.2.1.3
4.2.1.3
PF13_0242 0 R00267 Isocitrate:NADP+ oxidoreductase (decarboxylating) 1.1.1.42
PF13_0269 0 R00847 ATP:glycerol 3-phosphotransferase 2.7.1.30
PF13_0349 0
R00124
R00156
R00330
R00570
R01137
R01857
R02093
R02326
R02331
ATP:ADP phosphatransferase
ATP:UDP phosphotransferase
ATP:GDP phosphotransferase
ATP:CDP phosphotransferase
ATP:dADP phosphotransferase
ATP:dGDP phosphotransferase
ATP:dTDP phosphotransferase
ATP:dCDP phosphotransferase
ATP:dUDP phosphotransferase
2.7.4.6
2.7.4.6
2.7.4.6
2.7.4.6
2.7.4.6
2.7.4.6
2.7.4.6
2.7.4.6
2.7.4.6
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Gene
Relative 
Growth
Associated 
Reaction(s)
Reaction Name(s)
Associated EC 
number
PF14_0053 0
R02017
R02018
R02019
R02023
R02024
2'-Deoxyadenosine 5'-diphosphate:oxidized-thioredoxin2'-oxidoreductase
2'-Deoxyuridine 5'-diphosphate:oxidized-thioredoxin2'-oxidoreductase
2'-Deoxyguanosine 5'-diphosphate:oxidized-thioredoxin2'-oxidoreductase
2'-Deoxyuridine 5'-triphosphate:oxydized-thioredoxin2'-oxidoreductase
2'-Deoxycytidine diphosphate:oxidized-thioredoxin 2'-oxidoreductase
1.17.4.1
1.17.4.1
1.17.4.1
1.17.4.1
1.17.4.1
PF14_0100 0 R00573 UTP:L-glutamine amido-ligase (ADP-forming) 6.3.4.2
PF14_0341 0
R02739
R02740
R03321
alpha-D-Glucose 6-phosphate ketol-isomerase
alpha-D-Glucose 6-phosphate ketol-isomerase
beta-D-Glucose 6-phosphate ketol-isomerase
5.3.1.9
5.3.1.9
5.3.1.9
PF14_0352 0
R02017
R02018
R02019
R02023
R02024
2'-Deoxyadenosine 5'-diphosphate:oxidized-thioredoxin2'-oxidoreductase
2'-Deoxyuridine 5'-diphosphate:oxidized-thioredoxin2'-oxidoreductase
2'-Deoxyguanosine 5'-diphosphate:oxidized-thioredoxin2'-oxidoreductase
2'-Deoxyuridine 5'-triphosphate:oxydized-thioredoxin2'-oxidoreductase
2'-Deoxycytidine diphosphate:oxidized-thioredoxin 2'-oxidoreductase
1.17.4.1
1.17.4.1
1.17.4.1
1.17.4.1
1.17.4.1
PF14_0378 0 R01015 D-glyceraldehyde-3-phosphate aldose-ketose-isomerase 5.3.1.1
PF14_0425 0 R01070 beta-D-fructose-1,6-bisphosphate D-glyceraldehyde-3-phosphate-lyase(glycerone-phosphate-forming) 4.1.2.13
PF14_0441 0
R00014
R03270
pyruvate:thiamin diphosphate acetaldehydetransferase(decarboxylating)
NO NAME
1.2.4.1
1.2.4.1
PF14_0534 0 R00945 5,10-Methylenetetrahydrofolate:glycine hydroxymethyltransferase 2.1.2.1
PF14_0598 0 R01061 D-glyceraldehyde-3-phosphate:NAD+ oxidoreductase (phosphorylating) 1.2.1.12
PF14_0664 0
R00742_balanced
R04385
R04386_balanced
Acetyl-CoA:carbon-dioxide ligase (ADP-forming)_balanced
biotin-carboxyl-carrier-protein:carbon-dioxide ligase (ADP-forming)
Acetyl-CoA:carbon-dioxide ligase (ADP-forming)_balanced
6.4.1.2
6.3.4.14
6.4.1.2
PF14_0697 0 R01993 (S)-dihydroorotate amidohydrolase 3.5.2.3
PF14_0774 0 R00885 GTP:alpha-D-mannose-1-phosphate guanylyltransferase 2.7.7.13
PFA0530c 0 R00127 ATP:AMP phosphotransferase 2.7.4.3
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Gene
Relative 
Growth
Associated 
Reaction(s)
Reaction Name(s)
Associated EC 
number
PFA0555c 0 R00158 ATP:UMP phosphotransferase 2.7.4.14
PFC0170c 0
R02569
R00621
R03316
acetyl-CoA:enzyme N6-(dihydrolipoyl)lysine S-acetyltransferase
NO NAME
NO NAME
2.3.1.12
1.2.4.2
1.2.4.2
PFC0275w 0 R00842 sn-Glycerol-3-phosphate:NAD+ 2-oxidoreductase 1.1.1.8
PFC0831w 0 R01015 D-glyceraldehyde-3-phosphate aldose-ketose-isomerase 5.3.1.1
PFD0311w 0 R01736 (R)-S-Lactoylglutathione hydrolase 3.1.2.6
PFD0660w 0 R01518 2-Phospho-D-glycerate 2,3-phosphomutase 5.4.2.1
PFD0755c 0 R00127 ATP:AMP phosphotransferase 2.7.4.3
PFD0830w 0
R00939
R02101
5,6,7,8-Tetrahydrofolate:NADP+ oxidoreductase
5,10-Methylenetetrahydrofolate:dUMP C-methyltransferase
1.5.1.3
2.1.1.45
PFE0555w 0 R02222_generalised Generalised Single Unit Fatty Acid Desaturation 1.14.19.1
PFE0605c 0 R00497 gamma-L-glutamyl-L-cysteine:glycine ligase (ADP-forming) 6.3.2.3
PFE0630c 0 R01870 Orotidine-5'-phosphate:diphosphatephospho-alpha-D-ribosyl-transferase 2.4.2.10
PFF0160c 0 R01867 (S)-Dihydroorotate:oxygen oxidoreductase 1.3.3.1
PFF0230c 0 R02530 (R)-S-Lactoylglutathione methylglyoxal-lyase (isomerizing) 4.4.1.5
PFF0275c 0
R00124
R00156
R00330
R00570
R01137
R01857
R02093
R02326
R02331
ATP:ADP phosphatransferase
ATP:UDP phosphotransferase
ATP:GDP phosphotransferase
ATP:CDP phosphotransferase
ATP:dADP phosphotransferase
ATP:dGDP phosphotransferase
ATP:dTDP phosphotransferase
ATP:dCDP phosphotransferase
ATP:dUDP phosphotransferase
2.7.4.6
2.7.4.6
2.7.4.6
2.7.4.6
2.7.4.6
2.7.4.6
2.7.4.6
2.7.4.6
2.7.4.6
PFF0455w 0 R00351 acetyl-CoA:oxaloacetate C-acetyltransferase (thioester-hydrolysing) 2.3.3.1
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Gene
Relative 
Growth
Associated 
Reaction(s)
Reaction Name(s)
Associated EC 
number
PFF0895w 0
R00342
R00342
(S)-malate:NAD+ oxidoreductase
(S)-malate:NAD+ oxidoreductase
1.1.1.37
1.1.1.37
PFF1130c 0 R00275 superoxide:superoxide oxidoreductase 1.15.1.1
PFF1155w 0
R01326
R01600
R01786
ATP:D-mannose 6-phosphotransferase
ATP:beta-D-glucose 6-phosphotransferase
ATP:alpha-D-glucose 6-phosphotransferase
2.7.1.1
2.7.1.1
2.7.1.1
PFF1300w 0
R00200
R00200
ATP:pyruvate 2-O-phosphotransferase
ATP:pyruvate 2-O-phosphotransferase
2.7.1.40
2.7.1.40
PFI0755c 0 R04779 ATP:D-fructose-6-phosphate 1-phosphotransferase 2.7.1.11
PFI0925w 0 R00894 L-glutamate:L-cysteine gamma-ligase (ADP-forming) 6.3.2.2
PFI1020c 0 R01130 IMP:NAD+ oxidoreductase 1.1.1.205
PFI1105w 0 R01512 ATP:3-phospho-D-glycerate 1-phosphotransferase 2.7.2.3
PFI1140w 0
R08539_balanced
R00100
NADPH:ferricytochrome-b5 oxidoreductase
NADH:ferricytochrome-b5 oxidoreductase
1.6.2.4
1.6.2.2
PFI1170c 0 R02016 NADPH:oxidized-thioredoxin oxidoreductase 1.8.1.9
PFI1420w 0 R00332 ATP:GMP phosphotransferase 2.7.4.8
PFL0285w 0 R01736 (R)-S-Lactoylglutathione hydrolase 3.1.2.6
PFL0595c 0 R00274 glutathione:hydrogen-peroxide oxidoreductase 1.11.1.9
PFL0675c 0 R00885 GTP:alpha-D-mannose-1-phosphate guanylyltransferase 2.7.7.13
PFL0780w 0 R00842 sn-Glycerol-3-phosphate:NAD+ 2-oxidoreductase 1.1.1.8
PFL1550w 0
R03815
R07618
R07618
dihydrolipoylprotein:NAD+ oxidoreductase
enzyme N6-(dihydrolipoyl)lysine:NAD+ oxidoreductase
enzyme N6-(dihydrolipoyl)lysine:NAD+ oxidoreductase
1.8.1.4
1.8.1.4
1.8.1.4
PFL1720w 0 R00945 5,10-Methylenetetrahydrofolate:glycine hydroxymethyltransferase 2.1.2.1
PFL2465c 0
R02094
R02098
ATP:dTMP phosphotransferase
ATP:dUMP phosphotransferase
2.7.4.9
2.7.4.9
PF14_0334 0.9665 R00093 L-glutamate:NAD+ oxidoreductase (transaminating) 1.4.1.14
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Gene
Relative 
Growth
Associated 
Reaction(s)
Reaction Name(s)
Associated EC 
number
MAL3P2.24 0.982 R00848 sn-Glycerol-3-phosphate:(acceptor) 2-oxidoreductase 1.1.5.3
PF08_0045 0.982
R00621
R03316
NO NAME
NO NAME
1.2.4.2
1.2.4.2
PF10_0334 0.982
R00408
R00432
Succinate:(acceptor) oxidoreductase
Succinate:CoA ligase (GDP-forming)
1.3.99.1
6.2.1.4
PF13_0070 0.982
R00621
R03316
NO NAME
NO NAME
1.2.4.2
1.2.4.2
PF13_0120 0.982 R02570 succinyl-CoA:enzyme N6-(dihydrolipoyl)lysine S-succinyltransferase 2.3.1.61
PF13_0121 0.982 R02570 succinyl-CoA:enzyme N6-(dihydrolipoyl)lysine S-succinyltransferase 2.3.1.61
PF14_0295 0.982 R00405 Succinate:CoA ligase (ADP-forming) 6.2.1.5
PFI1340w 0.982 R01082 (S)-malate hydro-lyase (fumarate-forming) 4.2.1.2
PFL0630w 0.982 R00408 Succinate:(acceptor) oxidoreductase 1.3.99.1
PF14_0192 0.9861
R00094
R00115
glutathione:NAD+ oxidoreductase
glutathione:NADP+ oxidoreductase
1.8.1.7
1.8.1.7
PFE0730c 0.9874 R01056 D-ribose-5-phosphate aldose-ketose-isomerase 5.3.1.6
PF14_0511 0.9893
R02035
R02736
6-Phospho-D-glucono-1,5-lactone lactonohydrolase
beta-D-Glucose-6-phosphate:NADP+ 1-oxoreductase
3.1.1.31
1.1.1.49
PF14_0520 0.9893 R01528 6-phospho-D-gluconate:NADP+ 2-oxidoreductase (decarboxylating) 1.1.1.44
PFF0530w 0.9903
R01641
R01830
Sedoheptulose-7-phosphate:D-glyceraldehyde-3-phosphateglycolaldehyde transferase
beta-D-Fructose 6-phosphate:D-glyceraldehyde-3-phosphateglycolaldehyde transferase
2.2.1.1
2.2.1.1
PFL0960w 0.9903 R01529 D-Ribulose-5-phosphate 3-epimerase 5.1.3.1
PF14_0508 0.9934 R00112 NADPH:NAD+ oxidoreductase 1.6.1.1
MAL13P1.146 0.9975 R00181 AMP aminohydrolase 3.5.4.6
PF13_0259 0.9994 R02325 dCTP aminohydrolase 3.5.4.13
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Appendix VIII : Application for Synthetic Aesthetics funding 
The synthetic aesthetics project was run by the University of Edinburgh and the University 
of Stanford and aimed to bring together designers and scientists to solve problems with 
design in synthetic biology. More details on the project and some of the results of the 
funding are online at www.syntheticaesthetics.org. My proposal, as outlined in the letter of 
interest below, was not funded but remains an interest of mine. 
 
 
Letter of interest, 
For me, synthetic biology is all about networks. From standardising biological building 
blocks to creating new organisms, it is the interactions rather than the components that 
are most fascinating. In the exciting and rapidly progressing new fields of synthetic 
biology and systems biology people are saving time by using old network design 
principles, often taken from electronic engineering, rather than thinking about the real 
requirements of the problems they face. My fear is that by reusing these existing design 
tools in the world of biology we risk obscuring a truer understanding of biological 
systems. To put it simply, I think that we are drawing biological networks just like we 
draw electronic networks not because the two are similar but because we haven’t taken 
the time to design a better way of doing things. 
Recently, I took pictures of all the networks that were printed on posters at the Systems 
Biology of Microorganisms conference in Paris. There were reaction networks, regulatory 
networks, gene expression networks and protein interaction networks galore. Almost 
without exception the aesthetics of the network drawings were poor but the real problem 
in the drawings was their underlying design. I saw that all the networks were drawn with 
large components connected by identical thin lines even though the components were 
largely unimportant and the connections were both critical and varied. 
My specialism is metabolism but all biological networks are similar in that they are rarely 
static collections of connected components. The flows within them are changeable and the 
networks themselves reorganise far more dynamically than their electrical counterparts. 
Biological networks pulse with life, they adapt to changes and most importantly they grow 
and shrink with time. All of these properties can conceivably be described in terms of 
statically connected components within highly connected networks but they could be 
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much more meaningfully described by concentrating more on the connections and less on 
the components. 
I am confident that my vision as outlined on the next page can be realised, but I know from 
experience that it will not be easy. Recently I completed a full reconstruction of the 
metabolic network of human malaria but found the task frustrating and unnecessarily 
difficult. In talking with other people I found that the problems I had were common and as 
a newcomer to the field of systems biology I was surprised that many of the problems had 
not been resolved. I decided to try and help by designing MetNetMaker, probably the first 
metabolic network model creator with an easy to use interface and no enormous nested 
menus or command prompts. In doing this I met with a surprising amount of resistance. I 
was frequently told, “it would be quicker to just design your network” or asked “why do 
you want the tool to look nice? You’re the only one who’ll use it” and occasionally mocked 
for “wasting my PhD” spending more of my time designing the tool than doing what 
systems biologists consider to be real work. 
The Synthetic Aesthetics project offers me a chance to show that good design in science is 
worth spending time on. I firmly believe that time spent on good design will repay itself 
many times over but it is rare to get the opportunity to try and prove that conviction. I am 
well aware that my vision has large gaps as well as unseen problems; it needs a fresh input 
of ideas and someone to look at it who can ask the questions I haven’t thought of yet. I’d 
like help to find someone with new ideas and a different perspective on design and science 
and I’d really like to grasp this rare opportunity to justify design within science as 
something more than just an eccentric passion. I have friends who are designers who 
might be interested to work with me on this project but I think it might be more creative 
and original to take advantage of the skills and interests of the designers who are applying 
for this project so that together we can look at these problems and change how we think 
about, and design, metabolic networks. I’m not proposing that we create the software to 
do this, but I would certainly like to create a compelling visual template for building such a 
system that we could use to tempt students, amateur coders and funding bodies into 
helping make our improved vision a reality. 
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Vision 
I imagine metabolic networks where the consumption of a metabolite is shown as a visible 
whirlpool draining from the system and the production of a metabolite is shown as a 
pulsing fountain. Currency metabolites flow in different coloured streams between their 
multiple occurrences and feedback, both negative and positive, visually impedes or 
magnifies flow within the network. In this vision, dead-end metabolites are immediately 
visible as obstructions to flow, redundant reactions stick out like rocks in a river, the role 
of cellular compartments as barriers to flow is clear and the effects of changes in the 
structure of the network are immediately reflected in the flows within it. The network 
itself would be largely static, in keeping with existing design principles in SBML (sbml.org) 
and SBGN (sbgn.org), and efforts would be made to preserve recognisable design elements 
such as the layout of the KEGG metabolism map and the shapes of the TCA cycle, glycolysis 
and fatty-acid metabolism. The goal must be to move networks away from mathematical 
abstraction and towards living entities that designers of biological systems can play with 
and explore. 
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Appendix IX : Application for Gates Foundation funding 
 
Section I 
The genetic origins of emerging drug resistance in malaria are being uncovered 
more quickly but our understanding of how existing drugs and drug-candidates 
work has not kept pace. We propose a mix of computation and experiment to 
improve existing models of P. falciparum metabolism with the aim of discovering 
how anti-malarial compounds kill parasites. 
There is no published process for finding out how existing anti-malarial drugs affect 
parasite metabolism. Even for those drugs with a known mechanism of action, the wider 
metabolic affects — and thus areas of metabolism where synergistic drug combinations 
could be targeted — have not been systematically explored. We think a process we have 
developed and have good plans to improve can address this problem. 
Existing models of malaria metabolism (Plata et al. 2010; Huthmacher et al. 2010) lack key 
links with experimentally measured properties of malaria metabolism and lack the 
associated tools and simplicity needed to keep them flexible, up-to-date, and accessible to 
wet-lab scientists. Significant recent advances that move us closer to an accurate biomass 
composition for P. falciparum are not integrated with these models nor have 
measurements of metabolite exchange between parasite, host and growth medium. 
Using our MetNetMaker software (Forth et al, Bioinformatics, 2010) we have created a 
simple and adaptable metabolic model of P. falciparum that allows flux-balance analysis 
(FBA) and similar analysis to be performed on an improved version of the most widely 
used, most frequently updated and most discussed metabolic network for malaria 
(Ginsburg 2006). This manually curated model has not previously been available for 
computational analysis. As a proof of concept we have conducted an initial trial comparing 
the metabolism of parasites grown in normal culture conditions and those grown in 
growth medium containing a sub-lethal dose of atovaquone, a widely used prophylactic 
anti-malarial. NMR analysis of the used growth medium in this trial was able to quantify 
the exchange flux of metabolites between the growth medium and parasitised red blood 
cells for the four principle carbon sources (Glucose, Lactate, Glycerol, Glutamine) and a 
further six amino acids (Valine, Isoleucine, Leucine, Alanine, Tyrosine, Phenylalanine) over 
forty hours. HPLC analysis of parasites isolated at the end of this period confirmed that the 
critical step in pyrimidine synthesis was partially inhibited and provided information to 
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update the nucleotide portion of the biomass function for the parasite under these 
conditions. 
 
 
Production (up) and consumption (down) of metabolites by malaria parasites in normal conditions 
(black) and when inhibited by atovaquone (gray). Amino acids (left) are on a different scale to carbon 
sources (right). 
 
Exchange fluxes between the parasites and their growth medium largely agree with 
existing knowledge and, with the exception of lipids, cover all major metabolite 
destinations branching from the most accurate current model of P. falciparum central 
carbon metabolism. Applying these measured fluxes as constraints on the metabolic model 
and performing flux-balance analysis shows that inhibition of a single reaction involved in 
pyrimidine synthesis significantly affects pathways as distant as glycerol metabolism. 
Currently atovaquone is used in combination with pro-guanyl and marketed by GSK as 
Malarone®, but the clear effect it has on glycerol metabolism suggests a new possibility 
for synergy that could overcome developing resistance. 
Significant issues have been resolved and we feel ready to apply our process to a larger 
number of known anti-malarial compounds and candidate compounds with the aim of 
proving that the effects on core metabolism of many of these drugs can be systematically 
deduced. The limited success that we have had to date suggests that this is possible and 
we are keen to see if this technique can be useful with no prior knowledge of a drug’s 
mechanism of action. 
Section II 
In phase 1 we will study 20% of the drug-like compounds in the open-access malaria box, 
choosing the forty with the lowest EC50 concentration, plus the antimalarials atovaquone, 
artemesinin and doxycycline. Each round of experiments will analyse the metabolism of 
parasitised red blood cells in the presence of the EC50 concentration of six compounds. An 
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identically treated culture of red blood cells and another of parasitised red blood cells in 
growth medium without an anti-malarial compound added act as the required controls. 
1. 0 hours — synchronise 200ml of high parasitemia (≈5%) culture by soribitol 
incubation. 
2. 24 hours — concentrate schizonts to the ≈90% parasitemia by magnetic isolation. 
3. 24 hours — create 6 parallel 6ml cultures at 10% parasitemia and 10% 
haematocrit by diluting with red blood cells and standard growth medium 
supplemented with extra glucose and the relevant test compound. Also prepare 
the two controls. 
4. 34, 44, 54 hours — remove 0.25ml of culture and centrifuge to isolate the growth 
medium. 
5. 54 hours — isolate the resultant parasite biomass for HPLC analysis. 
Extracted growth medium samples and biomass samples will be stored at -80°C and 
retained for future analysis by LC-MS or other techniques at a later date or by another 
research group. We aim to acquire NMR spectra, calculate exchange fluxes and measure 
biomass components by HPLC for the forty-three compounds in six batches over the 
course of the year. Integration with our metabolic model will be ongoing and may extend 
slightly after this. 
 British Pounds US Dollars  
Grade 7 postdoctoral researcher salary 
+ pension + NI + University costs (10%) 
31 591 + 5 055 + 2 441 + 3 
908  
= £42 995 
$69 214 
NMR acquisition costs £12 000 $19 317 
Malaria culturing costs £5 000 $8 050 
HPLC running costs £1 000 $1 609 
Total  $98 190 
 
